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Abstract 
There is growing evidence that neural network disruption has a major contribution to 
Traumatic Brain Injury (TBI) morbidity. Understanding more about the impact of TBI 
on synaptic structure and function may help elucidate post-injury neural network 
disturbance. In this thesis we aimed to achieve this by studying two postsynaptic 
density proteins: post-synaptic density protein 95 (PSD95) and Synapse Associated 
Protein 102 (SAP102). These proteins are major scaffold proteins that assemble 
neurotransmitter receptors, channels and enzymes into multi-protein signalling 
complexes. We aimed to pursue the hypothesis that TBI disrupts the levels and 
location of PSD95 and SAP102 and thereby impairs synapse function contributing to 
post-injury neural network disruption.  
 
In this thesis, we aimed to investigate mild TBI as it constitutes over three quarters of 
cases, patients can suffer from a range of symptoms and a substantial number do not 
get back to their pre-injury function. To do this, we validated a model of mild TBI using 
the Lateral Fluid Percussion Injury (LFPI) device. In wildtype mice, we found that a 
single mild LFPI led to an increased righting time (a simple behavioural assay) in the 
injury cohort. Histopathological analysis showed evidence of dysmorphic cortical cells 
and traumatic axonal pathology in the corpus callosum. Coupled to this, there was a 
significant inflammatory response within the injury cohort with elevated numbers of 
astrocytes and microglia. Together, this data showed evidence of behavioural, axonal 
and inflammatory changes after a mild LFPI. 
 
The project utilized mice that had enhanced green fluorescent protein (eGFP) fused 
with the C-terminus of the endogenous PSD-95 protein and kusabira orange (mKO2) 
fused to SAP102. Male PSD95-eGFP and mKO2-SAP102 mice aged 8-16 weeks 
were randomised to a mild LFPI or sham and followed up to 7 or 28 days. Using high 
resolution confocal microscopy and machine learning approaches, PSD95 and 
SAP102 synaptome maps for puncta density, size and intensity were created. We 
found a significant reduction in synaptic puncta density at 28 days post-injury. This 
was evident in brain regions distal to the injury site including the contralateral cortex 
and hippocampus. We also observed evidence of synapse density recovery in the 
ipsilateral cortex between 7 and 28 days indicating synaptic recovery following a 
traumatic insult. There were differential patterns of change between PSD95 and 
SAP102 with evidence of more pronounced PSD95 puncta loss and recovery 
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suggesting SAP102 is less vulnerable to TBI. We found evidence of a chronic 
inflammatory response with elevated numbers of microglia at 28 days. There was a 
negative association between puncta density and microglia numbers which may 
indicate a role for microglia in synapse removal post-TBI. 
 
In conclusion, using a brain-wide unbiased synaptic mapping approach, we 
interrogated the impact of a mild traumatic injury on the postsynaptic density proteins 
PSD95 and SAP102. We observed a reorganization of the synaptome following injury 
which was progressive and involved brain regions distal from the injury site. Our study 
also highlighted the capacity for synaptic recovery post-injury and pointed towards a 
potential role of chronic inflammation on post-TBI synaptopathy.  
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Lay Summary 
Synapses, the connections between neurons, are essential to all behaviours. Recent 
studies have shown that subtle damage to synapses may cause a range of brain 
diseases such as autism and schizophrenia. Traumatic Brain Injury (TBI) is a major 
health problem for which there are currently no known drug therapies. It can lead to 
significant long-term morbidity while even mild injuries, which constitute over three 
quarters of TBI cases, can cause a range of symptoms that negatively impact patients’ 
lives. The focus of TBI research has primarily been at the level of the neuron and very 
little is known about the effects it has on synapses. In this thesis, we describe the use 
of a novel mouse model that has been engineered so that its synapses are fluorescent 
and therefore readily examined with a microscope. This permitted us to ask if TBI 
damages synapses and how they recover after injury. We used state-of-the-art 
microscopes that allowed us to survey the entire mouse brain. The data generated 
was then analysed with a machine learning approach which provided detailed 
information about synapse numbers, size and brightness. In our experiments, we 
found that an experimental TBI led to a delayed reduction in the number of synapses 
a month after the injury and that brain regions distant from the injury site lost 
synapses. In mice that sustained a TBI, we found that the cortex recovered synapses 
after the injury suggesting that the brain has the capacity to recover lost connections 
between neurons. We also found a reduction in synapses in brain regions with high 
numbers of infiltrating microglial cells (immune cells) suggesting that these cells may 
play a role in synapse loss after TBI. The next steps for this research is to understand 
the impact of TBI on different subtypes of synapses and then use imaging techniques 
to examine synapses in humans who have suffered a TBI. 
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1.1 TRAUMATIC BRAIN INJURY 
Traumatic Brain Injury (TBI) is a temporary or permanent impairment of brain function 
due to an external mechanical force to the head. It is a leading cause of death and 
disability around the world. TBI can occur due to a wide range of mechanisms 
including falls, road traffic accidents (RTA), assaults and sports or military-related 
injuries. It encompasses a heterogeneous and broad set of pathologies that overlap 
and vary in their severity and patient outcomes.  
 
1.1.1 Epidemiological patterns and trends  
Traumatic brain injury is a critical public health problem. Estimates vary widely across 
countries which in part is due to the varying quality and robustness of the 
epidemiological data (Roozenbeek et al. 2013). There are several reasons for the lack 
of robust population-based data in TBI. The lack of a clear definition of TBI 
(particularly mild injuries) has led to variation in the literature. The International 
Classification of Disease (ICD) definition in emergency department (ED) admissions 
can lead to false negatives and positives (Bazarian et al. 2006). The second limitation 
is under-reporting, patients – particularly those with mild injuries – do not routinely 
present to ED which can lead to under-estimation of the true burden of TBI. Taking 
these limitations into account, it is estimated that 7.7 million people are living with TBI-
related disabilities in the European Union (Tagliaferri et al. 2006). In the USA, the 
Centre for Disease Control and Prevention monitor TBI incidence and have 
standardized definitions. Between 2002-2006, there were 1.7 million TBIs in the USA 
leading to 1.4 million ED visits. This included 275000 hospitalizations and 52000 
deaths (Faul et al. 2010). Incidence of TBI is rising globally due to increased use of 
motor vehicles in low and middle income countries (Maas et al. 2008). Differences in 
low and high-income country TBI injury patterns are present. Analysis of MRC 
CRASH trial data showed that patients from low and middle income countries were 
younger and more likely to be injured in a RTA (MRC CRASH Trial Collaborators et 
al. 2008). Though historically seen as a disease of the young there has been an 
upward shift in the median age of patients sustaining a TBI in developed countries 
(Roozenbeek et al. 2013). This is explained by greater life expectancy, improvement 
in road safety and motor vehicles which have seen a reduction in RTA-related TBIs. 
CDC data has shown that the leading cause of TBI was falls (35.2%) followed by 
RTAs (17.3%) (Faul et al. 2010). This demographic shift towards older patients with 
TBIs due to falls has led to a shift from diffuse injuries to contusional injuries. Elderly 
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patients with TBI pose a particular challenge due to the presence of multiple 
comorbidities and the use of anticoagulant medication. Mortality in TBI appears to 
have remained static since 1990 compared to a period of improvement between 1970-
1990 (Stein et al. 2010). The static mortality since 1990 may be due to the 
epidemiological shift to an older patient population. Societal costs of TBI are 
significant – not only related to the medical care but also the associated economic 
impact of the ensuing disability. In Europe, TBI is among the top three causes of 
injury-related medical costs (Polinder et al. 2007). While in the USA, the annual 
economic burden of TBI is estimated at $60 billion (Maas et al. 2008).  
 
1.1.2 Classification of TBI 
Due to the broad and heterogonous nature of TBI, there are several ways to classify 
it. Traditionally, classification has centred around three main areas: penetrating injury, 
structural damage on computerized tomography and clinical severity as measured by 
the Glasgow Coma Scale (Figure 1.1). 
 
 
Figure 1.1: Schematic of classification systems for TBI demonstrating the three 
main classification systems: skull integrity, structural damage and clinical severity.  
 
1.1.2.1 Penetrating injury 
Whether the skull is breached is an important classifying factor for TBI. Penetrating 
TBI occurs due to gunshot wounds, stabbings or blast projectiles. It is far less common 
than closed TBI, however patient outcomes are significantly worse. Within the civilian 
population, particularly in the USA, gunshot wounds are a major cause of penetrating 
head injuries. Aarabi and colleagues found that over a 24 month period, patient 
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mortality in the state of Maryland from gunshot wounds to the head was 91% (Aarabi 
et al. 2014). 
 
1.1.2.2 Structural damage 
Assessment for structural damage using neuroimaging has become a principle form 
of TBI classification (Figure 1.2). The introduction of Computerized Tomography (CT) 
revolutionized the management of TBI as it provided a diagnostic tool to quickly 
differentiate between a range of intracranial injuries and guide management. Despite 
CT’s limitations, which include its inability to identify subtle injuries and the fact it is 
momentary snapshot of an evolving process, it has been an integral part of classifying 
TBI and guiding its management.  
 
1.1.2.2.1 Diffuse Axonal Injury 
Diffuse axonal injury (DAI) is a form of intra-axial brain injury that involves widespread 
damage to white matter tracts (Figure 1.2, A). It is a major cause of chronic disorders 
of consciousness after a severe TBI (Victoria E Johnson et al. 2013). However, there 
is growing evidence that a degree of axonal injury also occurs in even mild TBIs 
(Smith 2016). CT is not as sensitive as MRI in identifying DAI (Mittl et al. 1994). 
However, there is evidence that subtle early CT changes, including intraventricular 
haemorrhage, are associated with DAI (Mata-Mbemba et al. 2015).  
 
1.1.2.2.2 Intracranial hemorrhage 
Traumatic intracranial haemorrhages occur due to damage to blood vessels at the 
time of injury. The location and type of blood vessel determines the subtype of 
intracranial haemorrhage that is seen. Damage and rupture of intraparenchymal 
micro-vessels lead to intra-axial (within the brain substance) haemorrhage. While 
damage to bridging veins and arteries lead to extra-axial (out of the brain substance) 
haematomas.  
  
1.1.2.2.3 Cerebral contusions 
A cerebral contusion is defined as an intra-axial haemorrhagic lesion with necrotic 
tissue (Figure 1.2, B). Contusions occur at the time of injury due to physical disruption 
of micro-vessels and the extrusion of blood into the brain substance (Kurland et al. 
2012). They typically occur at the apex of the frontal and temporal lobes due to the 
relative motion of the brain compared to the bony cranium prominences. On CT, 
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contusions appear as hyperdense lesions within the parenchyma intermixed with 
normal (isodense) tissue. Contusive injury is associated with microvascular 
dysfunction due to vasoconstriction and thrombosis (Kurland et al. 2012). This can 
lead to worsening ischaemia, perilesional swelling and haemorrhagic progression. 
Contusions are typically seen in coup and contrecoup injuries. A coup injury occurs 
at the site of impact to the brain while contrecoup injuries occur at the site opposite to 
the area hit. The biomechanics of this process are due to the translation of the brain 
within the rigid skull leads to it colliding with the cranial vault after impact. 
 
1.1.2.2.4 Subdural haematoma 
Subdural haematoma (SDH) is a collection of blood situated underneath the dura 
mata but out of the brain substance (Figure 1.2, C). The two main causes of subdural 
haematomas are accumulation of blood from a parenchymal laceration (usually high 
impact injury) or disruption of bridging vessels from cerebral acceleration-deceleration 
(usually lower impact injury) (M. Greenberg 2017). On CT, subdural haematomas 
appear as a hyperdense crescentic mass that, if large, can cause compression of the 
underlying brain.  
 
1.1.2.2.5 Extradural haematoma 
Extradural haematomas (EDH) are collections of blood outside of the dura mata 
(Figure 1.2, D). They are not as common as subdural haematomas and are found in 
1% of head trauma admissions (M. Greenberg 2017). They are commonly attributed 
to disruption of the middle meningeal artery by a temporoparietal skull fractures. 
Compared to SDH, EDH occur due to lower impact forces and patients typically 
present with a lucid period before their conscious level deteriorates. On CT, EDH 
appear as a biconvex hyperdense lesion adjacent to the skull.  
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Figure 1.2: CT demonstrating TBI structural damage findings of (A) diffuse Axonal 
Injury [image reproduced under creative common licence from Ramalho and Castillo, 
(2015)] (B) traumatic cerebral contusions [image reproduced under creative common 
licence courtesy of Dr Jeremy Jones, Radiopaedia.org, rID: 8079] (C) acute subdural 
haematoma [image reproduced under creative common licence courtesy of A.Prof 
Frank Gaillard, Radiopaedia.org, rID: 35891]  (D) acute extradural haematoma [image 
reproduced under creative common licence courtesy of Dr Sandeep Bhutal, 
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1.1.2.3 Clinical Severity (Glasgow Coma Scale) 
The severity of TBI is determined clinically by measuring the patient’s conscious level 
using the Glasgow Coma Scale (GCS). The GCS is 15-point scale that looks at three 
areas: the patient’s eyes, motor and verbal response (Table 1.1). Patients can have 
a maximum aggregate score of 15 and a minimum of 3. The scale was first described 
by Teasdale and Jennett in 1974 and has been demonstrated as a strong predictor 
of mortality in TBI (Teasdale et al. 2014).  
 
Eye opening Verbal response Motor response 
1 None 1 None 1 None 
2 To stimulus 2 Sounds 2 Extension 
3 To speech 3 Words 3 Abnormal flexion 
4 Spontaneous 4 Confused  4 Normal flexion 
  5 Orientated 5 Localizing  
    6 Obeying commands 
Table 1.1: Glasgow Coma Scale with breakdown of the three components: eye, 
verbal and motor response 
 
1.1.2.3.1 Moderate and Severe TBI 
Based on the GCS, moderate TBI is considered a GCS 9-13 and severe TBI a GCS 
3-8. Epidemiological studies have indicated that moderate and severe TBI 
compromise approximately a fifth cases with an equal distribution between the two 
severities (Bruns & Hauser 2003). Traumatic intracranial haemorrhages occur in 25–
35% of patients with severe TBI and in 5–10% of moderate injuries (Maas et al. 2008). 
Outcome for patients following moderate and severe head injury can vary from death 
through to living independently. A multivariate analysis of 8686 patients’ data drawn 
from 8 RCTs, demonstrated that the strongest predictors of patient outcome was: 
motor component of the GCS, pupillary response, age and CT characterization 
(Murray et al. 2007). 
1.1.2.3.2 Mild Traumatic Brain Injury (mTBI) 
Mild TBI is estimated to account for the majority (80%) of all cases of TBI (Bruns & 
Hauser 2003). Mild TBI and concussion are terms that are used interchangeably. Both 
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terms point towards a disruption of brain function following a mechanical force to the 
cranium. For the purposes of consistency, the term mild TBI will be used in this thesis. 
One of the challenges surrounding the research and management of mild TBI is unity 
around the definition of the disease. The WHO collaborating Centre for Neurotrauma 
Task Force on Mild Traumatic Brain Injury undertook a major review of literature and 
recommended the below definition in Panel 1 (Carroll et al. 2004). Within this thesis, 
we define human mild TBI based upon the WHO taskforce definition.   
 
Mild TBI is an acute brain injury resulting from mechanical energy to the head from 
external physical forces. Operational criteria for clinical identification include: (i) 1 
or more of the following: confusion or disorientation, loss of consciousness for 30 
minutes or less, post-traumatic amnesia for less than 24 hours, and/or other 
transient neurological abnormalities such as focal signs, seizure, and intracranial 
lesion not requiring surgery; (ii) Glasgow Coma Scale score of 13–15 after 
30 minutes post-injury or later upon presentation for health care. 
These manifestations of mild TBI must not be due to drugs, alcohol, 
medications, caused by other injuries or treatment for other injuries (e.g. 
systemic injuries, facial injuries or intubation), caused by other problems 
(e.g. psychological trauma, language barrier or coexisting medical conditions) or 
caused by penetrating craniocerebral injury 
Panel 1.1: WHO Taskforce recommended definition of mild TBI 
 
Historically, mild TBI was deemed to be a benign process for which patients fully 
recovered. However, there is a growing body of evidence that mild TBI can lead to 
symptomology that can significantly affect patients’ quality of life. A recent large 
prospective study of patients with mild TBI found that almost a half did not achieve a 
complete recovery at 6 months post-injury (van der Naalt et al. 2017). There are a 
number of sequelae for mild TBI including: 
 
1.1.2.3.2.1 Post-concussional Syndrome 
Post-concussional syndrome (PCS) is a constellation of symptoms that occur in 
patients following a mild TBI. These include somatic symptoms (headache, blurred 
vision, dizziness), cognitive symptoms (difficulty concentrating, memory problems) 
and emotional symptoms (irritability, low moods) that, in most cases, gradually resolve 
during the 12 weeks after the injury (Levin & Diaz-Arrastia 2015) (Figure 1.3). 
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However, a proportion of patients have been found to develop persistent symptoms 
beyond 3 months. A prospective study of 107 patients found that 22% had persistent 
symptoms at 3 months (Hou et al. 2012). There is controversy surrounding PCS given 
the non-specific nature of the symptoms, particularly as these symptoms have also 
been identified in the general trauma population (King 2003; Meares et al. 2008). A 
number of studies have highlighted that a pre-morbid psychiatric history was a strong 
predictor of persistent PCS (Ponsford et al. 2011; Hou et al. 2012; Hellström et al. 
2017). There is therefore a growing view that early phase PCS show association 
between neurological symptoms and cognitive function which, subsequently, in 
patients with persisting symptoms becomes less clear with a growing psychosocial 
basis (Williams et al. 2010). A large prospective cohort study of mild TBI patients 
found that the strongest predictive factors of 6-month outcome were indicators of 




Figure 1.3: Schematic of constellation of post-concussional symptoms 
demonstrating the main categories of symptoms patient experience: somatic, 
cognitive and emotional.  
 
1.1.2.3.2.2 Cognitive impairment  
Several studies have attempted to map cognitive deficits in patients after a mild TBI. 
Karr and colleagues systematically reviewed the literature for meta-analyses of 
Headache 
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neuropsychological outcomes after mild TBI (Karr et al. 2014). The review showed 
that a broad range of cognitive domains (executive function, memory, visuospatial 
skills) had been assessed in the context of mild TBI. The range of studies showed a 
wide variation in the effect sizes seen across the reported studies. However, mild TBI 
patients appeared to have worse performance in executive function, memory and 
attention assessments. The review found evidence that patients saw a resolution of 
deficits by 90 days while, interestingly, those with sport-related mild TBIs recovered 
quicker with cognitive domains reaching non-significance by 7 days post-injury.  
 
1.1.2.3.2.3 Chronic Traumatic Encephalopathy 
In 1928, the pathologist Dr. Harrison Martland published a seminal paper describing 
‘punch drunk syndrome’; a constellation of chronic motor and neuropsychiatric 
symptoms in former boxers (Martland 1928). The term dementia puglistica was 
ascribed to the progressive neuropsychiatric condition that emerged after repetitive 
mild TBIs and a number of case series indicated a neuropathological basis to the 
syndrome (Corsellis 1989; Roberts et al. 1990). However, interest in the condition 
was limited until evidence of similar findings in non-boxing contact sports such as in 
American Football and in military personnel (Omalu et al. 2011; McKee et al. 2009). 
The term Chronic Traumatic Encephalopathy (CTE) was introduced to describe the 
clinicopathological condition emerging from a wide range of physical exposures. 
Examined brains have demonstrated gross findings including brain atrophy, cavum 
septum pellucidum and ventricular enlargement (Douglas H. Smith et al. 2013). One 
of the most consistent neuropathological findings in CTE is the presence of 
neurofibrillary tangles (McKee et al. 2009). These tangles are typically located within 
the superficial layers of the cortex and have a propensity to be found deep within sulci. 
The consistency of tau findings in CTE cases has led to it being described as a 
tauopathy. In contrast, Amyloid beta –an important finding in Alzheimer’s Disease- is 
a less consistent feature in CTE. A review of the literature, revealed that 66 (53%) of 
the 124 examined cases had evidence of amyloid pathology (Douglas H. Smith et al. 
2013). A range of other pathological findings have included neuronal loss, white 
matter degeneration and inflammation (Omalu et al. 2011; Omalu et al. 2006; McKee 
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1.1.3 Pathophysiology of Traumatic Brain Injury 
The pathophysiology of TBI is a complex, dynamic and multifaceted process. To best 
understand it, TBI pathophysiology can be divided into primary and secondary injury 
phases (Figure 1.4). 
 
 
Figure 1.4: Schematic of primary and secondary injury processes following TBI. 
A physical force to the head leads to tissue deformation during which neural, glial and 
vascular tissue is injured. Within minutes, this leads to the development of secondary 
injury pathways including glutamate neurotoxicity, oxidative stress, inflammation and 
mitochrondrial dysfunction. These pathways potentiate neuronal injury and contribute 
to functional deficit.  
 
1.1.3.1 Primary injury 
Primary injury TBI is the tissue damage and disruption caused to the brain at the time 
of the external force application. Due to the broad and heterogeneous nature of 
external causes of TBI this can differ in the extent and severity of the damage. Taking 
this into account, the best approach to understanding primary injury is to consider the 
forces applied which can lead to focal and diffuse injuries. At the macroscopic level, 
focal forces to the skull can cause skull fractures and intracranial hemorrhages (intra-
axial and extra-axial) due to disruption of blood vessels. While diffuse forces lead to 
shearing of white matter tracts. At the cellular level, diffuse forces particularly can lead 
to diffuse axonal injury and microhaemorrhages from disruption of small blood 
vessels. Ischaemic brain damage is usually superimposed on primary brain injury. 
This can be due to a multitude of causes including compression from extra-axial 
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haemorrhage, perilesional ischaemia around a contusion or due to focal 
microvascular disruption.  
 
1.1.3.2 Secondary injury 
Secondary injury results from ensuing pathophysiological mechanisms that begin 
within minutes of the primary injury and can last for months to years afterwards. The 
range and extent of these processes can vary according to the severity of the 
traumatic injury. Secondary injury pathways include:  
 
1.1.3.2.1 Glutamate excitotoxicity 
Following TBI, there is an increase in extraceullar excitatory amino acids including 
glutamate as cellular membranes rupture and cell content is released. Microdialysis 
studies in humans and preclinical models of TBI have demonstrated this early 
increase in glutamate (Folkersma et al. 2011; Chamoun et al. 2010). Surges in 
glutamate levels subsequently lead to ionic imbalances on the postsynaptic 
membranes. This includes the release of potassium (K+) for which levels correlate 
with injury severity (Katayama et al. 1990). In addition to perturbation in K+ levels, 
intracellular calcium (Ca2+) accumulation has also been observed following TBI 
(Osteen et al. 2001; Fineman et al. 1993). Ca2+ overloading has been shown to lead 
to mitochondrial dysfunction and induce oxidative stress (Peng & Jou 2010; Xiong et 
al. 1997). 
 
1.1.3.2.2 Oxidative stress 
Free radicals are molecules with an unpaired electron which are highly reactive and 
can lead to cellular damage. They include both reactive oxygen (ROS) and reactive 
nitrogen (RNS) species. Free radicals are produced as part of normal metabolic 
activity and are managed by antioxidant systems. TBI disrupts this system leading to 
increases in free radicals that overwhelm the scavenging system and causes 
oxidative stress (O’Connell & Littleton-Kearney 2013). Mitochondria are an important 
source of free radicals. After TBI, Ca2+ accumulation leads to the activation of several 
enzymes that increase ROS and RNS production (Lewén et al. 2000). Several studies 
have attempted to quantify free radical changes or its consequences (lipid 
peroxidation and protein nitration) in preclinical TBI models. Hydroxyl radical, a ROS, 
was found to increase by 250% which was maintained above baseline for 90 minutes 
in a rat model of TBI (Marklund et al. 2001). Lipid peroxidation occurs when fatty acids 
 Page | 14 
react with ROS leading to alterations in membrane permeability (Prins et al. 2013). 
Increases in markers of lipid peroxidation have been seen after preclinical models of 
TBI (Tyurin et al. 2000; Singh et al. 2006). 
 
1.1.3.2.3 Mitochondrial dysfunction and energy crisis 
Calcium accumulation and oxidative stress lead to mitochondrial dysfunction which in 
turns leads to reduced energy production. Preclinical studies have demonstrated 
reduction in ATP production and accumulation of mitochondrial calcium (Xiong et al. 
1997; Sullivan et al. 1998). Imaging approaches have also been used to measure 
brain metabolic activity. The commonest modality has been Positron Emission 
Tomography (PET) using [18F]Fluorodeoxyglucose. This method has been 
extensively utilized in mild TBI patients. A comprehensive review of the literature 
highlighted that, despite variation in the methodology and measurement approaches, 
a pattern of reduced glucose uptake or hypometabolism was clear in a variety of brain 
regions including the anterior cingulate, precuneus, anterior temporal lobe, superior 
parietal cortex and corpus callosum (Byrnes et al. 2014).  
 
1.1.3.2.4 Inflammation 
Following TBI, a complex and multifaceted inflammatory process develops which can 
be both beneficial and detrimental. Mechanical disruption of cells leads to the release 
of Damage Associated Molecular Patterns (DAMPs) which in turn leads to glial cells 
upregulating a range of cytokines including tumour necrosis factor (TNF) and 
interleukin-6 (IL-6) (Ransohoff & Brown 2012). A range of central and peripheral 
immune cells subsequently migrate to the trauma site. Initially, circulating neutrophils 
infiltrate followed by monocytes, dendritic cells and T lymphocytes (Clark et al. 1994; 
Jin et al. 2012). Microglia, resident immune cells, respond to injury by polarizing to 
two phenotypes as a response to differing cytokines (Colton 2009). The M1-like 
‘proinflammatory’, though initially considered beneficial, can become harmful if 
prolonged (Wang et al. 2013; Loane et al. 2014). The M2-like ‘alternative’ phenotype 
are associated with the production of anti-inflammatory cytokines (Colton 2009). 
Several studies have charted the temporal profile of microglia phenotypes following 
experimental TBI (Jin et al. 2012; Wang et al. 2013). They have shown a bimodal 
response with a M2-like peak at 7 days followed by an M1-like peak at 3-4 weeks. 
There is growing evidence of chronic neuroinflammation following TBI years after the 
initial injury. Examination of autopsy brains following TBI showed activated microglia 
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up to 18 years after injury (Victoria E. Johnson et al. 2013). The development of 
Translocator Protein (TSPO) radioligands, a marker of activated glial response, has 
allowed the in-vivo investigation of inflammation after a TBI (Vivash & OBrien 2016). 
Two studies have used PET imaging to quantify inflammatory changes in-vivo post-
TBI. Coughlin and colleagues undertook a case control study of NFL players who had 
experienced sport-related mild TBIs (Coughlin et al. 2017). The investigators 
observed a higher distribution of TSPO in 8 out of 12 brain regions within the NFL 
cohort. Similarly, Fujita and colleagues observed, in a mixed cohort of mild and 
moderate TBI, a global increase in TSPO signal across all brains in TBI patients 
(Fujita et al. 2017). Importantly, both these studies highlighted that inflammation was 
evident in patients months to years after the initial injury.  
 
1.1.3.2.5 Axonal injury 
Dynamic deformation of long white matter tracts at injury leads to disruption of axonal 
transport. This leads to progressive axonal dysfunction following the initial mechanical 
injury. Historically, traumatic axonal injury was determined using histological 
approaches such as haematoxylin and eosin (H+E) and silver staining (Douglas H 
Smith et al. 2013). However, the introduction of immunohistochemistry allowed for 
more specific targeting of axonally transported proteins. Amyloid Precursor Protein 
(APP) moves through the axonal cylinder by anterograde transport (Douglas H Smith 
et al. 2013). Mechanical perturbation of the axon leads to pooling of APP. 
Accumulation of this transported material leads to either varicosities along the length 
of the axonal or, in the event of complete disconnection, as a axonal bulb (Victoria E 
Johnson et al. 2013). Axons within a single specimen can be found in differing stages 
of degeneration and disconnection highlighting that it is an evolving pathology. The 
pathophysiology of this process is believed to be related to dysregulation of sodium 
channels leading to a calcium influx. This process leads to microtubular loss and 
energy failure secondary to microchondrial damage and ultimately impairs axonal 
transport (Wolf et al. 2001; Douglas H Smith et al. 2013). Preclinical histological 
studies have pointed towards evidence of diffuse axonal injury as an important 
pathological process in mild TBI (Spain et al. 2010; Mierzwa et al. 2015). However, 
histological confirmation of this in human beings is limited due to the low mortality rate 
after mild TBI. Advanced structural MRI modalities such as diffusion tensor imaging 
(DTI) provide detailed information on the ultrastructure of white matter tracts by 
measuring the random movement of water molecules through the brain tissues 
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(Alexander et al. 2007). Within this body of evidence, there is a great deal of variability 
in the imaging protocols however a meta-analysis of 13 studies of DTI following mild 
TBI demonstrated diffusion abnormalities within the corpus callosum, particularly its 
posterior arm (Aoki et al. 2012). A study assessing longitudinal DTI changes after a 
mild TBI revealed a dynamic pictures suggesting progressive axonal pathology that 
goes on for months post-injury (Veeramuthu et al. 2015). Importantly, a number of 
studies have demonstrated the predictive value of DTI changes on functional outcome 
following mild TBI (Yuh et al. 2014; Veeramuthu et al. 2015). 
 
1.2 PRECLINICAL MODELS OF TRAUMATIC BRAIN INJURY 
The heterogeneous nature of TBI has led to a wide array of preclinical animal models 
being developed over the years. Within the literature, there are two broad categories 
of TBI model: open and closed skull. Each of these models hold differing strengths 
and drawbacks in its ability to recapitulate aspects of the human disease (Table 1.2). 
Although larger animals (such as pigs) have closer neuroanatomy to humans which 
makes them better to model the biomechanics of human TBI, rodents are mostly used 
for a range of reasons. These include their small size, short life span, lower housing 
costs and the ability to utilize genetically modified mouse models. This section will 
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1.2.1 Fluid Percussion Injury 
 
 
Figure 1.5: Lateral fluid percussion injury model demonstrating mouse attached 
to fluid reservoir. Pendulum is released to create a pressure pulse which is applied to 
the intact dura [image reproduced from Xiong et al (2013) with permission from 
Springer Nature] 
 
The Fluid Percussion Injury model is a well-established and widely used open skull 
TBI model (Figure 1.5). It was initially developed in cats but then was modified for 
use in rodents (Thompson et al. 2005). Briefly, the mice undergo a craniectomy 
(removal of bone window) which can vary in location including: midline (centred over 
the sagittal suture), parasagittal (<3.5mm from the sagittal suture) or lateral (>3.5mm 
from the sagittal suture) (Xiong et al. 2013). The location of the craniectomy has been 
shown to be an important determinant of the extent and location of the brain lesion 
and functional motor outcome (Vink et al. 2001). In this thesis, we will focus on the 
lateral Fluid Percussion Injury (LFPI) model. The traumatic injury is inflicted by a fluid 
pressure pulse which is generated by release of a pendulum and is delivered to the 
surface of the intact dura causing brief deformation of the brain parenchyma. The 
severity of injury can be altered by the strength of the pressure wave by varying the 
height of the pendulum (Kabadi et al. 2010; McIntosh et al. 1989). Reflecting human 
TBI severity categories, the literature commonly refers to mild, moderate and severe 
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LFPI depending on the intensity of the pressure pulse. The LFPI model is considered 
to be a mixed focal and diffuse injury with histological findings akin to human disease 
including cortical contusion, white matter disruption and intraventricular haemorrhage 
(McIntosh et al. 1989; Xiong et al. 2013). There has been comprehensive cellular 
characterization of the LFPI with evidence of immediate (within minutes) neuronal 
injury which progresses to neuronal loss in the ipsilateral cortex and subcortical 
structures up to a week after the injury (Hicks et al. 1996). Mapping of inflammatory 
changes after LFPI have demonstrated a robust response including cytokine release 
and astroglial activation (Cao et al. 2012; Ambrosini et al. 2003; Vitarbo et al. 2004). 
Temporal-spatial axonal pathology has been characterized following LFPI which 
showed progressive cortical and subcortical axonal injury as indexed by accumulation 
of amyloid precursor protein (Pierce et al. 1996; Masumura et al. 2000). Importantly, 
evidence of progressive axonal injury was found in mild LFPI in the mouse (Spain et 
al. 2010). The behavioural sequelae of the LFPI have also been comprehensively 
investigated. This includes a transient loss of the righting reflex which has been used 
as a means to measure the severity of the injury (Carbonell et al. 1998; Schmidt & 
Grady 1995). A range of sensorimotor tests have been applied to rodents after LFPI 
(including beam balance, rota-rod and whisker test and acoustic startle) that 
demonstrated significant impairment in motor function in the injury groups (Hamm 
2001; Sackheim et al. 2017; Learoyd & Lifshitz 2012; Saatman et al. 1997). Cognitive 
testing with the Morris Water Maze have shown post-injury impairment in spatial 
memory in LFPI rodents (Spain et al. 2010). Due to the technical difficulties of a 
craniotomy and hub application, the LFPI model suffers from a high exclusion rate. 
Alongside this, the biomechanics of the injury and need to open the skull means there 
is limited generalizability to the human disease. Saying that, LFPI reproduces many 
aspects of human TBI from its histopathology and functional and behavioural deficits. 
It allows for variation in injury severity and can be used in rodents which afford the 
ability to test hypotheses using genetically modified animals. These strengths make 
it a relevant and useful TBI model. Within this thesis, we aim to utilise the ability to 
vary the severity of LFPI to induce a milder injury. We define this as an injury leading 
to an elongated right reflex with evidence of axonal injury and inflammatory response 
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1.2.2 Controlled Cortical Impact 
 
Figure 1.6: Controlled Cortical Impact injury model demonstrating the application 
of a rigid impact device into the mouse brain [image reproduced from Xiong et al 
(2013) with permission from Springer Nature] 
 
The Controlled Cortical Impact (CCI) model is a form of open skull TBI model (Figure 
1.6). Much like the LFPI model, it involves fashioning a craniectomy but then uses a 
rigid impact device to deform the cortical tissue (Dixon et al. 1991). The severity of 
the injury can be controlled by changing the depth, time and velocity of the impact 
device (Xiong et al. 2013). The ability to independently control these biomechanical 
parameters is an advantage over the LFPI. CCI leads to widespread cortical and 
subcortical neurodegeneration making it a mixed (focal and diffuse) injury model (Hall 
et al. 2005). The severity of cognitive deficit has been associated with the depth and 
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1.2.3 Weight Drop models 
 
Figure 1.7: Weight drop injury models showing the Feeney weight device (A) and 
the Marmarou device (B) [image reproduced from Xiong et al (2013) with permission 
from Springer Nature] 
 
Weight drop models inflict a TBI by dropping a free-falling weight onto the rodent’s 
head. The severity of the injury can be varied by altering the height in which the weight 
is dropped. There are several iterations of the weight drop model with differing 
procedures to the skull. The Feeney model delivers a weight to the intact dura after a 
craniotomy (Figure 1.7, A). The model produces cortical contusion which progresses 
to haemorrhage into the white matter (Feeney et al. 1981). Alternatively, the Shohami 
model is a closed skull variation where the weight is dropped onto the intact 
unprotected skull (Shapira et al. 1988). The injury leads to a combination of cerebral 
contusion and diffuse axonal injury (Albert-Weissenberger et al. 2012; Xiong et al. 
2013). In an attempt to model human diffuse axonal injury, Marmarou developed an 
impact acceleration model which involved attaching a stainless-steel disc to the 
exposed skull before releasing a guided weight to inflict the injury (Marmarou et al. 
1994) (Figure 1.7, B). The model is characterized by wide spread neuronal disruption 
and diffuse axonal injury throughout the corpus callosum, internal capsule and 
cerebellar peduncles (Abd-Elfattah Foda & Marmarou 1994). Weight drop models can 
recapitulate differing aspects of focal and diffuse human TBI. They are low cost 
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High exclusion rate, 















Need for craniotomy, 
















high mortality rate 
+ ++ 
Table 1.2: Comparative summary of different preclinical TBI models [adapted 
from Xiong et al (2013)] 
 
1.3 THE EXCITATORY SYNAPSE 
The mammalian brain is composed of a hugely complex network of neurons. How 
these neurons connect and communicate, referred to as the connectome, is 
increasingly seen as important to understanding the basis of cognition and behaviour 
(Oh et al. 2014). The synapse is the mode of communication between neurons. 
Information is transmitted via electrical impulse which is conducted down the neuron 
axon and then relayed to the dendritic tree of the next neuron. The junction between 
these two neurons is the synapse. Typically, the synapse is composed of a 
presynaptic axonal terminal and the dendritic postsynaptic density separated by the 
synaptic cleft. The existence of the synapse, a term coined by Sherrington in 1897, 
was a topic of debate for decades until electron microscopy (EM) studies confirmed 
their existence (De Robertis & Bennett 1955). 
 Page | 22 
 
1.3.1 Synapse classification 
1.3.1.1 Chemical versus electrical synapses 
The electrical impulse travelling from one neuron to the next can be conducted by two 
means: direct electrical or indirect chemical transmission (Figure 1.8). Electrical 
synapses allow for direct bidirectional cellular communication via gap junctions that 
consist of hemi-channels that permit the exchange of ions and small molecules 
(Figure 1.8, B). Electrical synapses allow for rapid communication and are important 
during development and are believed to be necessary for the subsequent formation 
of chemical synapses (Pereda 2014). Conversely, chemical synapses propagate 
unidirectional communication between neurons indirectly by the release of 
neurotransmitters from presynaptic vesicles (Figure 1.8, A). These neurotransmitters 
move across the synaptic cleft and bind to receptors on the postsynaptic density. This 
triggers a flow of charged molecules that, if sufficient, will leads to triggering of an 
action potential (AP) that propagates down the neuron. Though slower than electrical 
synapses, chemical synapses allow for greater modulation of signal propagation 
through changes in presynaptic vesicle and postsynaptic receptor numbers (Branco 
& Staras 2009). 
 
 
Figure 1.8: Schematic representation of chemical and electrical synapses. 
Image A demonstrates neurotransmitter release and inotropic receptors of chemical 
synapse. Image B demonstrates the hemi-channels of electrical synapses [image 
reproduced from Pereda et al (2014) with permission from Springer Nature] 
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1.3.1.2 Excitatory versus inhibitory synapses 
EM studies of chemical synapses by Gray led to observations that divided synapses 
into two types (Gray 1959). This classification was based upon the size and symmetry 
of the postsynaptic density and their location. Type 1 (axo-dendritic) typically have 
wide and pronounced postsynaptic thickening and are found on dendritic spines or 
shafts. Conversely, Type 2 (axo-somatic) synapses had smaller, less pronounced 
postsynaptic thickenings and were found on the soma. Subsequent immuno-labelling 
studies of different neurotransmitters led to classification of Type 1 synapse as 
‘excitatory’ and Type 2 synapses as ‘inhibitory’ (Harris & Weinberg 2012). Gray’s 
classification remains the most used to describe synapses however there is evidence 
that not all synapses fit neatly into these dichotomous categories (Klemann & Roubos 
2011).  
 
1.3.2 The excitatory postsynaptic density 
The postsynaptic density (PSD) is made up of a network of proteins that interact to 
receive, process and convey synaptic inputs. Scaffolding proteins are a major 
component of the PSD of which the Disc Large Homolog (DLG) family is the most 
abundant in excitatory synapses. 
 
1.3.2.1 The DLG protein family 
The DLG family is part of the Membrane-associated Guanylate Kinase (MAGUK) 
protein superfamily. In invertebrates, a single Dlg protein is encoded by a single Dlg 
gene. Conversely, in vertebrates, the DLG family is composed of four proteins coded 
by four different genes: Synapse Associated Protein 97 (SAP97) is encoded by Dlg1; 
Postsynaptic Density Protein 93 (PSD93) is encoded by Dlg2; Synapse Associated 
Protein 102 (SAP102) is encoded by Dlg3 and Postsynaptic Density Protein 95 
(PSD95) is encoded by Dlg4. In this thesis, we will focus on two DLG proteins: PSD95 
and SAP102. DLG proteins are expressed at cell-cell interfaces in epithelial and 
neuronal cells. In mammals, PSD95 is brain specific while SAP102 is mainly 
expressed within the brain (Müller et al. 1996; Cho et al. 1992). Distribution patterns 
of PSD95 and SAP102 messenger ribonucleic acid (mRNA) and proteins have been 
characterized in the mouse brain (Fukaya et al. 1999; Fukaya & Watanabe 2000). 
mRNA distribution was high within the Cornu Ammonis (CA) and Dentate Gyrus (DG) 
hippocampal regions and neocortical layers (Fukaya et al. 1999). There was 
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moderate expression of PSD95 and SAP102 mRNA within the thalamus, cerebellum, 
hypothalamus and midbrain. Immunohistochemical examination of PSD95 and 
SAP102 protein expression found similar patterns to the mRNA findings (Fukaya & 
Watanabe 2000). The same study also examined subcellular expression of the two 
proteins. The authors found that PSD95 appeared as small puncta within the dendrite 
closely apposed to synaptophysin-positive nerve terminals. Within the forebrain, 
PSD95 is restricted to the PSD however, it has been identified presynaptically in 
Pinceau synapses (basket cells in the cerebellum that synapse onto Purkinje cells) 
(Hunt et al. 1996; Fukaya & Watanabe 2000; Laube et al. 1996). PSD95 has also 
been reported to be found within the juxtaparanodes, however its exact role in this 
structure remains to be fully elucidated (Rasband et al. 2002; Rasband & Trimmer 
2001). 
 
1.3.2.2 Structure and protein networks within PSD 
The PSD usually lies within the distal end of the dendritic spine head. It measures 
300-400nm wide and 30-50nm thick (Carlin et al. 1980). Due to its abundance in the 
brain, the PSD has undergone comprehensive biochemical analysis. Proteomic 
studies have revealed that the PSD contains approximately 1000 proteins and that 
these are relatively conserved between humans and mice (Bayés et al. 2012; Bayés 
et al. 2011). These proteins have a myriad of differing functions including: scaffolding, 
signalling, receptors and cytoskeletal elements (Sheng & Hoogenraad 2007). Of 
these proteins, PSD95 is one of the most highly abundant with approximately up to 
300 PSD95 molecules per PSD (Cheng et al. 2006). PSD95 has been shown to form 
nanoclusters within the PSD (Broadhead et al. 2016). Within the PSD, SAP102 and 
PSD95 play a central role in organizing the differing proteins types (Kim & Sheng 
2004).  
 
1.3.2.3 PSD95 and SAP102 in receptor complexes 
A number of differing studies have shown conflicting results in the role of PSD95 with 
the NMDA receptor (NMDAR). PSD95 knock down has been shown to both affect and 
not affect NMDAR transmission (Elias et al. 2006; Ehrlich et al. 2007). A recent study 
using Blue Native Page revealed that the NMDARs form 1.5MDa complexes with 
PSD95 and PSD93 (Frank et al. 2016). Interestingly, NMDARs were not present in 
the complexes when either PSD95 or PSD93 were knocked out suggesting that both 
are required to recruit the receptors into the complex. The same study showed that 
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SAP102 and SAP97 formed smaller (0.2-0.4MDa) complexes (Frank et al. 2016). The 
role of DLG proteins has also been studied in the context of the AMPA receptor 
(AMPAR). PSD95 indirectly binds to AMPAR via Stargazin (Nicoll et al. 2000). 
AMPAR function has been shown to mirror increases and decreases in PSD95 
expression (Stein et al. 2003; Elias et al. 2008; Elias et al. 2006; Ehrlich et al. 2007). 
These observations are due to changes in the number of AMPAR clustering at the 
synaptic membrane (El-Husseini et al. 2000). Studies have also found that SAP102 
may be involved in AMPAR transmission (Elias et al. 2006; Elias et al. 2008). 
However, KO SAP102 mice have been found to have normal AMPAR-mediated 
transmission (Cuthbert et al. 2007). Interestingly, double KO mice for PSD95 and 
PSD93 were found to have overexpression of SAP102 potentially indicating a 
compensatory role (Elias et al. 2006). This highlights that the DLG proteins may have 
an overlapping function in transmitting AMPARs to the synaptic membrane surface.  
 
1.3.3 Function of PSD95 and SAP102 
1.3.3.1 Synaptic plasticity 
Synapses can strengthen or weaken over time in processes known as Long Term 
Potentiation (LTP) and Long Term Depression (LDP) respectively. The molecular 
mechanisms underlying LTP are believed to involve the activation of NMDAR which 
in turn increase the recruitment of AMPARs to the synaptic membrane. The role of 
the DLG proteins, particularly PSD95, have been extensively examined in the context 
of LTP. PSD95 KO mice have been found to have enhanced LTP (Migaud et al. 1998). 
While acute expression enhancement of PSD95 appears to dampen LTP (Ehrlich & 
Malinow 2004). In contrast, SAP102 KO mice show normal LTP when tested with high 
frequency stimulation protocols (Cuthbert et al. 2007). In the context of LDP, PSD95 
overexpression induced potentiation with protocols that were typically insufficient to 
do so (Stein et al. 2003). While knock down of PSD95 impaired LDP (Ehrlich et al. 
2007). Together, these data point towards a role of DLG proteins, particularly PSD95, 
in LTP and LDP.  
 
1.3.3.2 Role in behaviour and cognition 
Given the effect of manipulating PSD95 and SAP102 on synaptic plasticity, several 
studies have also assessed the impact of DLG mutations on the behavioural 
repertoire. Spatial learning, assessed using the Morris Water Maze, was severely 
impaired in mice with PSD95 KO (Migaud et al. 1998). While mice with SAP102 KO 
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showed impairments that could be overcome with additional training when compared 
to WT mice (Cuthbert et al. 2007). An elegant study using touchscreen cognitive 
testing comprehensively assessed the impact of PSD95 and SAP102 mutations on 
cognitive function (Nithianantharajah et al. 2013). The study assessed four domains 
of the cognitive repertoire: conditioning and simple learning, complex learning, 
cognitive flexibility and attention and response control. PSD95 KO showed marked 
simple learning deficits while SAP102 KO demonstrated comparable function to WT 
mice. In a visual discrimination test and extinction test assessing cognitive flexibility, 
SAP102 KO mice performed better than WT. Contrary to the SAP102 findings, PSD93 
KO mice were found to have decreased function in these cognitive tests. These data 
indicate that PSD95 has a fundamental role in simple learning while SAP102 and 
PSD93 are important for forms of higher cognitive function.  
 
1.3.3.3 Role in neurological disease 
Mutations within genes encoding for PSD proteome have been found to be associated 
with up to 133 neurological and psychiatric diseases (Bayés et al. 2011). De novo 
mutations in schizophrenic patients were found to be over-represented in PSD genes 
(Fromer et al. 2014). A further proteomic study looking at PSD95 interaction networks 
found a significant correlation with schizophrenia susceptibility proteins within 
glutamate receptor clusters (Fernández et al. 2009). Coupled to this, a schizophrenic 
patient was found to have a deletion in DLG2 (PSD93) (Walsh et al. 2008). 
Interestingly, similar cognitive deficits were identified in humans and mice with PSD93 
mutations (Nithianantharajah et al. 2013). Mutations within the gene that encodes 
SAP102 has also been associated with non-syndromic mental retardation (Zanni et 
al. 2010). Alongside evidence of the role of PSD mutations as the cause of a range 
of intrinsic brain disorders, synapses also appear to be part of the early 
pathophysiology of inflammatory and degenerative disorders such as multiple 
sclerosis and Alzheimer’s disease (S. Hong et al. 2016; Wegner et al. 2006).  
 
1.4 TRAUMATIC BRAIN INJURY AND THE SYNAPSE 
The vital role of the synapse makes it an interesting area of study in the context of 
TBI. In this section, we will focus on examining the evidence looking at synaptopathy 
following TBI and the central role the synapse plays in TBI secondary injury. 
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1.4.1 The postsynaptic density as an intersection of TBI secondary injury  
The postsynaptic density is a point where three major TBI secondary injury processes 
intersect and interact. These processes are: glutamate neurotoxicity, oxidative stress 
and inflammation: 
 
1.4.1.1 Glutamate neurotoxicity 
As previously discussed, TBI leads to a surge in glutamate which acts upon two main 
receptors within the postsynaptic density: NMDA and AMPA receptors (Figure 1.9, 
A). NMDA receptors consist of 3 subunits (NR1, NR2 and NR3). Glutamate is an 
NMDA receptor agonist and binding leads to an influx of Ca2+ which is critical for signal 
transduction (Figure 1.9, B). In TBI, elevated glutamate levels on the NMDA receptor 
leads to abnormal intracellular Ca2+ levels and contributes to neuronal death 
(Arundine et al. 2004; Arundine et al. 2003). AMPA receptors, which consist of 4 
subunits (GLuR1-4), constitute one of the primary transducer at the excitatory 
synapse (Luo et al. 2011). AMPA receptor subunit composition is an important 
determinant of the receptor function (Ju et al. 2004). Several studies have shown that 
TBI-related glutamate increases can lead to changes in AMPA receptors that 
perpetuate glutamate toxicity by exacerbating Ca2+ overload. Particularly the release 
of intracellular calcium leads to the expression of AMPA receptors lacking subunit 
GluR2 which are highly permeable to calcium (Bell et al. 2009; Spaethling et al. 2008). 
This shift in AMPA receptor subtype is an important factor in exacerbating excitotoxic 
neuronal death. PSD95 connects to PKCalpha - the kinase that phosphorylates 
AMPA GluR2 – which promotes GluR2-deficient AMPA receptors and exacerbates 
TBI neurotoxicity. Perturbation of this relationship attenuates this toxicity (Bell et al. 
2009) (Figure 1.9, C).  
 
1.4.1.2 Oxidative stress 
The postsynaptic density plays an important role in the convergence of glutamate 
toxicity and oxidative stress. The activation of the NMDA receptor and the influx of 
Ca2+ leads to the generation of reactive oxygen and nitrogen species (Szydlowska & 
Tymianski 2010). PSD95 binds to the NMDA receptor and neuronal nitric oxidase. 
This relationship plays an important part in oxidative damage and it has been 
observed that its disruption led to reduced cell death in an in-vitro model of TBI 
(Arundine et al. 2004) (Figure 1.9, F). PSD95 may not only have a role in mediating 
oxidative stress after TBI but also appears to be negatively impacted by it. A temporal 
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analysis of PSD95 found significant reductions in concentration of the protein at 24 
hours post-injury following an earlier depletion of antioxidant systems and increase in 
oxidants (Ansari et al., 2008 (1); Ansari et al., 2008 (2)). Interestingly, a study by Yu 
using system biology approaches to analyse gene expression data from multiple TBI 
animal models highlighted nitric oxidase synthase 1 as a potential protein indicator of 
TBI (Yu et al. 2015). 
 
1.4.1.3 Inflammation 
Inflammation is a well described process following TBI. However, there is growing 
evidence that the inflammatory process acts through the synapse to further 
perpetuate TBI-secondary injury. Tumour Necrosis Factor alpha (TNF-alpha) is a 
proinflammatory cytokine that infiltrates the injury site and has been found to reduce 
expression of AMPA GluR2 (Beattie et al. 2002; Stellwagen et al. 2005) (Figure 1.9, 
D). As described above, these changes in AMPA structure can worsen calcium 
overload and perpetuate cell death. More recently, Zhang and colleagues found in an 
in-vitro model of ischaemia and inflammation that microglial CR3 triggered long term 
depression by activation of NADPH oxidase and GluR2-mediate AMPA receptor 
internalisation (Zhang et al. 2014) (Figure 1.9, E). Both these data point towards a 
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Figure 1.9: TBI secondary injury and the postsynaptic density demonstrating 
surge of glutamate following TBI (A) which leads to influx of Ca2+ into the cell at the 
NMDA and AMPA receptors (B). PSD95 which is bound to PKCalpha promotes a 
GluR2-deficient AMPA receptors and exacerbates TBI neurotoxicity (C). The release 
of TNF-alpha also acts upon the AMPA receptors and reduces expression of GluR2 
which worsens neurotoxicity (D). Triggered by CR3, microglia lead to long term 
depression by activation of NADPH oxidase and GluR2-mediate AMPA receptor 
internalisation (E). PSD95 is bound to neuronal nitric oxidase plays a role in promoting 
oxidative stress after TB (F)I.  
 
1.4.2 Synaptic changes after TBI 
Early evidence on the impact of TBI on synaptic plasticity and function came from 
electrophysiological studies examining LTP and LDP. Preclinical studies consistently 
showed impairments in LTP following LFPI (Miyazaki et al. 1992; Reeves et al. 1995; 
Sanders et al. 2000; Sick et al. 1998). These deficits in LTP, however, have been 
found to recovery over time (Norris & Scheff 2009). Conversely, LDP appeared not 
be affected in preclinical models of TBI (D’Ambrosio et al. 1998).  
 
1.4.2.1 Synaptic loss following traumatic injury 
Early clues on the impact of neuronal death on synapses came from electron 
microscopy ultrastructural studies that monitored synapse changes after denervation. 
Commonly used models included intraventricular injections of kainic acid or electro-
ablation to injure neurons and subsequently analyze the impact on synaptic 
projections. Models using both of these approaches demonstrated a significant 
reduction in synaptic density between 3-4 days post-lesion (Marrone et al. 2004; 
Anderson et al. 1986). However, these approaches are limited in providing insights 
into TBI-related synaptopathy due to the differing mechanism. To overcome this, a 
number of studies have used biochemical and imaging approaches to quantify 
synaptic loss following various preclinical models of TBI (Table 1.3). Using a 
moderate CCI model, Scheff used electronic microscopy to examine synaptic 
changes in the CA1 region of the hippocampus (Scheff et al. 2005). At 2 days post-
injury, there was a 58% reduction in synapse numbers in the CA1 stratum radiatum 
in the injury group. A similar finding was found by Gao and colleagues who examined 
synaptic density in the dentate gyrus using immunohistochemistry against 
synaptophysin after a moderate CCI (Gao et al. 2011). At 3 days after the injury, the 
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density of synaptophysin-positive puncta was reduced by 30.77% compared to the 
sham mice. Biochemical approaches have also shown evidence of synaptic loss in 
TBI models. Using Western blotting in a CCI model, Wakade found a 46.6% reduction 
in hippocampal PSD95 in injury mice compared to sham 7 days after injury (Wakade 
et al. 2010). A similar study assessed a set of synaptic proteins (PSD95, Synapsin-I, 
SAP97 and GAP43) in the hippocampus at multiple time points post-CCI using 
Western blotting (Ansari et al., 2008 (1)). The authors found significant reductions in 
PSD95 and Synapsin-I compared to sham from 48 hours which persisted up till 96 
hours post-injury. System biological approaches have corroborated these findings. Yu 
et al analyzed high-throughput gene expression data from four different TBI animal 
models and found a suppressed network of proteins for which the proteins were 
associated with the synapse and centred around PSD95 (Yu et al. 2015). Though 
limited, there has been observations of synaptopathy in human cases of TBI. Castejon 
and colleagues undertook a small case series looking at human cortical tissue 
samples after TBI (Castejòn et al. 1995). Utilizing EM, the authors found evidence of 
swollen and shrunken presynaptic terminals and separation from the postsynaptic 
density. The authors also described dendritic swelling and evidence of synaptic 
phagocytosis by astroglial cells. This later observation opens questions regarding the 
underlying mechanism of synaptic loss. Axonal injury is an important part of TBI 
pathology. Canty and colleagues used two-photon microscopy and laser 
microsurgery to look at the effect of axotomy on synapses in-vivo at a single axon 
level (Canty, Teles-Grilo Ruivo, et al. 2013). The authors observed rapid reductions 
of synaptic density along the injured proximal axon within 6 hours.  
 
1.4.2.1.1 The role of astroglia in synaptic damage and loss after TBI 
A particularly important question is the role of astroglial cells in removing or ‘stripping’ 
synapses in disease. Several studies have made observations linking microglia to 
synapse removal in different disease models. Wake et al used two-photon microscopy 
and found that transient cerebral ischaemia led to more prolonged contact between 
microglia and presynaptic terminal, following which a number of boutons were noted 
to have disappeared (Wake et al. 2009). Similarly, Hong et al looked at a murine 
model of Alzheimer’s disease and observed early synapse loss that preceded plaque 
formation (S. Hong et al. 2016). The authors described microglia engulfment of 
synaptic elements which was not observed in mice with CR3 knock-out (a high affinity 
receptor expressed on macrophages) Subsequently, the authors observed a rescue 
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of synaptic loss using a microglia knockout model. They concluded that the 
complement cascade and microglia mediate early synaptic loss in Alzheimer’s 
disease. An in-vitro study that aimed to model inflammation and ischaemia (two 
important pathologies in TBI) found evidence that the two processes act 
synergistically through microglial CR3 to induce LTD (Zhang et al. 2014). These data 
point toward a potential role of microglia in synaptic pruning however there is a lack 
of conclusive mechanistic evidence, particularly in the context of TBI. The role of 
astrocytes has also been examined in TBI. Furman and colleagues examined the 
effect of blockading the astrocytic calcineurin/NFAT signalling pathway on 
hippocampal synaptic function and protein levels (Furman et al. 2016). Using an 
adeno-associated virus delivery system to deliver VIVIT (an NFAT inhibitory peptide), 
the authors found a prevention of injury-induced synaptic strength loss in CA1 and an 
associated reduction in synaptic protein loss (PSD95 and GluR1). Interestingly, these 
observations occurred without a significant change in the number of astroglia between 
the treated and control rodents indicating that the synaptoprotective effects of VIVIT 
do not require an associated reduction in glial activation. Astrocytes have also been 
implicated in propagating synaptic damage by the release of D-serine. Perez et al 
found a shift from neuronal to astrocytic D-serine release after CCI (Perez et al. 2017). 
The authors found that astrocyte-specific elimination of D-serine rescued synaptic 
plasticity.  
 
1.4.2.2 Synaptic recovery and circuit reorganization  
Alongside observing the degree of synaptic loss after injury, a range of studies have 
also looked at synaptic recovery and reorganization. Denervation studies described 
post-injury synaptogenesis after the initial loss. This process of recovery has been 
observed from as early as 6-10 days after the injury and has been followed up to 30-
60 days after the lesion injury (Marrone et al. 2004; Anderson et al. 1986). However, 
TBI involves a complex and interactive set of secondary injury processes which may 
impact synaptic recovery. A combination of deafferentation and central fluid 
percussion has been used to tease out the effect of TBI secondary injury on synaptic 
recovery. Reeves and colleagues found that a combination of CA1 deafferentation 
and central FPI led to persistent impairment of LTP and an associated reduction in 
NMDA receptor immunobinding compared to deafferentation alone (Reeves et al. 
1997). Two studies examined reactive synaptogenesis using EM in preclinical models 
of TBI (Table 1.3). Scheff and colleagues found a recovery of CA1 synapse density 
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at 10 days post injury which continued to day 30 and plateaued at 70% of control mice 
(Scheff et al. 2005). Semchenko used a rotatory head injury model in rats and found 
an increase in sensorimotor cortical synaptic density from day 7 to day 30 post-injury 
compared to control (Semchenko et al. 2006). Interestingly, another study by Canty 
using laser axotomy and two-photon microscopy observed regeneration in a subset 
of axons which then went on to form synaptic boutons to prelesional postsynaptic 
densities (Canty, Huang, et al. 2013).  
 
1.4.2.2.1 The role of astrocytes in synaptic circuit remodeling after TBI  
These observations point towards a degree of limited or maladaptive synaptic 
reorganization post-injury. The mechanisms underlying post-injury synaptogenesis 
have been investigated. Astrocytic Matrix Metalloproteinase-3 (MMP3), an enzyme 
involved with the breakdown of the extracellular matrix, has been implicated in 
maladaptive synaptic recovery after TBI (Huntley 2012). A study comparing 
deafferentation alone to deafferentation and FPI found persistent elevated increases 
in MMP3 for which there was significant colocalization to astrocytes in the combined 
injury group (Falo et al. 2006). Pharmacological inhibition of MMP3 led to increases 
in PSD thickening on EM and an improvement in spatial learning. Similarly, 
Nikolakopoulou found evidence of the involvement of astrocytic Ephrin-B1 in synaptic 
remodelling after a moderate CCI in mice (Nikolakopoulou et al. 2016). After injury, 
an upregulation of Ephrin-B1 was observed which coincided with a decrease in the 
presynaptic protein VGlut1. Ablation of Ephrin-B1 accelerated the recovery of VGlut1 
puncta. The authors linked Ephrin-B1 to STAT3 phosphorylation which they 
implicated in synaptic remodelling. A similar conclusion was reached by Tyzack and 
colleagues who examined the role of astrocytic STAT3 in synaptic remodelling in a 
facial murine nerve axotomy model (Tyzack et al. 2014). The authors implicated 
astrocytic STAT3-regulated release of thrombospondin-1 in post-injury synaptic 
remodelling. The study found that KO of thrombosopondin-1 led to impaired synaptic 
recovery which mirrored findings in a model of cerebral ischaemia which showed 
deficits in synaptic density and functional recovery with KO of thombospondin-1/2 
(Liauw et al. 2008). In TBI, there is evidence of thrombospondin upregulation in both 
in-vitro and in-vivo models (Tran et al. 2012). Plasma levels of thrombospondin-1 has 
also been found to be elevated in patients with TBI and may act as a prognostic 
biomarkers (Wang et al. 2016). Astrocytes may also play a role in post-injury circuit 
reorganisation by the secretion of Hevin, a synaptogenic protein (Singh et al. 2016). 
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Furnam and colleagues found an increase in Hevin levels in injury mice compared to 
sham which was further amplified by the blockade of the calcineurin/NFAT signalling 
pathway (Furman et al. 2016).  These data together suggest that astrocytes may play 
a double-edged role in synaptic reorganization post-TBI releasing enzymes and 
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Table 1.3: Summary of preclinical studies examining post-TBI synaptic changes  
 
1.4.2.3 Synapse subtypes and TBI 
As discussed in an earlier section, there is EM evidence of differing types of excitatory 
synapse. More recently, whole brain molecular synaptome mapping has shown there 
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to be huge heterogeneity in synaptic subtypes across the mouse brain (Zhu et al. 
2018). This degree of molecular phenotyping has not been described in the context 
of TBI, however there is some evidence to suggest that brain injury leads to changes 
to different synapses. Investigators have observed differing responses from synaptic 
subtypes to denervation (Marrone et al. 2004). Conversely, Scheff’s study which 
looked at CA1 synapses after CCI found no significant difference in synaptic size 
between the injury and sham groups over time (Scheff et al. 2005). A study using two-
photon microscopy and laser microsurgery found that newly formed terminaux 
boutons were preferentially lost after axotomy compared to older more established 
boutons (Canty, Teles-Grilo Ruivo, et al. 2013). This data, though limited, points 
towards differing vulnerabilities and responses to TBI from synaptic subtypes. 
 
1.5 SUMMARY AND RATIONALE  
In this section, we have examined the impact of TBI on a population level and 
highlighted that even mild injuries can have a significant impact on patients’ lives. The 
pathophysiology of TBI is a complex, interconnected process with a number of 
secondary injury pathways including glutamate neurotoxicity, oxidative stress and 
inflammation. The synapse appears to both play a role in and be directly affected by 
TBI. Preclinical studies looking at the impact of TBI on the synapse have shown early 
reduction in synaptic density in certain brain regions and there is evidence of 
maladaptive synapse reorganization thereafter. However, the approaches used in 
these studies were limited, both in the scope of the brain regions examined and the 
number of synaptic proteins. Therefore, our understanding of the impact of TBI on the 
synapse remains incomplete.  
 
1.6 THESIS AIMS AND HYPOTHESIS 
In this thesis, we aim to examine the whole-brain temporal spatial impact of a mild 
LFPI model on the synapse by studying two postsynaptic density proteins (PSD95 
and SAP102). To overcome the limitations of the literature, we aim to utilize a knock-
in model where two fluorescent proteins are tagged to PSD95 and SAP102. With the 
use of an in-house developed machine learning algorithm, we aim to create whole 
brain synaptome maps to examine the temporal spatial profile of PSD95 and SAP102 
after a mild TBI. We hypothesize that a mild LFPI will induce a progressive, dynamic 
and differential alteration in PSD95 and SAP102 levels.  
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Material and Methods 
 
  
 Page | 38 
  
 Page | 39 
2.1 ANIMALS 
All animal experimentation was undertaken in accordance with Home Office 
guidelines [Animal (Scientific Procedures) Act 1986] and was approved by The 
University of Edinburgh. Surgical experimental procedures were undertaken on the 
project license of Dr. Jonathan Rhodes (70/7984).  
 
2.1.1 Wild type C57BL/6 mice 
Adult male mice in experiment described in Chapter 3 were purchased from Charles 
River Laboratories. The mice were allowed to acclimatize in the animal unit for at least 
7 days prior to experimentation. They were aged 8-12 weeks at the time of the surgical 
procedure. The mice were kept in a 12-hour light/dark cycle and given free access to 
food and water before and after the experimental procedure.  
 
2.1.2 PSD95-eGFP and SAP102-mKO2 Knock-in (KI) mouse line 
Both the PSD95-eGFP and SAP102-mKO2 mouse lines were generated by Dr. Fei 
Zhu under the supervision of Dr. Noboru Komiyama and Prof. Seth Grant. The mice 
used in the LFPI experiments were male homozygous for PSD95-eGFP and 
hemizygous for SAP102-mKO2 and aged between 8-16 weeks at the time of surgery. 
The mice were kept in a 12-hour light/dark cycle and given free access to food and 
water before and after the experimental procedure.  
 
2.1.2.1 Generation of mouse line 
The generation of the mouse line is fully described in Dr. Fei Zhu’s PhD thesis. The 
gene targeting technique used for PSD95 and SAP102 has been described previously 
(Fernandez, 2009). Two mouse lines were generated, eGFP and mKO2 were inserted 
in-frame in the last coding exon of Dlg4 (PSD95) and Dlg3 (SAP102) respectively 
(Figure 2.1). Briefly, a targeting vector was created which contained the homologous 
DNA sequence for Dlg3 or Dlg4 linked to the corresponding fluorescent protein. The 
final vector contained a 5’ homology arm and a 3’ homology arm which, respectively, 
was 6.3kb and 2.9kb for Dlg4 and 2kb and 5.7kb for Dlg3. The vector contained 
neomycin-resistance gene sequence and was flanked by IoxP sites for future excision 
with Cre recombinase. Diptheria toxin A gene was inserted as a negative selection 
marker for random integration events. Sanger sequencing was used to confirm vector 
functions and PCR cloned fragments. Targeting vectors were separately 
electroporated into mouse embryonic stem cells (E14Tg2a). Cells with stable 
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integration of DNA were selected out with the use of G418 antibiotic – only cells 
expressing neomycin were selected through resistance to antibiotic. While cells with 
random integration would have diphtheria and therefore were less likely to survive. 
Subsequently, long range PCR was used to confirm correct targeting. From here, 
clones were then expanded and microinjected into a blastocyst and inserted into a 
recipient female. Male chimeras were then crossed with wild type mice from C57BL/6J 
strain and the resultant litters genotyped to confirm targeted allele transmission to the 
F1 generation. Heterozygous F1 generation mice were crossed with Cre-deleter mice 
to remove the IoXP flanked neo cassette. Finally, the reporter line mouse lines, were 
established by breeding heterozygote mice with C57BL/6J wild type mice before 
interbreeding to create the homozygous mice.  
 
 
Figure 2.1: Schematic representation of generation of PSD95-eGFP and 
SAP102-mKO2 mice. The wildtype genomic locus of PSD95 (Dlg4) and SAP102 
(Dlg3) are represented along with corresponding targeting vectors. These vectors 
contain DNA encoding for fluorescent proteins [eGFP = green bar and mKO2 = pink 
bar]. Alongside the fluorescence protein DNA, the targeting vector contained a 
neomycin positive selection cassette adjacent to a LoxP site and a Diptheria Toxin A 
(DTA) negative selection cassette. The target allele is shown before and after Cre 
recombination. Image reproduced from Zhu et al. (2018) under creative common 
licence.  
 
2.1.2.2 Characterization of mouse line 
Biochemical, electrophysical and imaging techniques were used to comprehensively 
characterize the transgenic knock-in mouse model. These experiments were 
performed by Dr. Fei Zhu, Dr. Maksym Kopanitsa, Dr. Zhen Qui and Dr. Melissa 
Cizeron. A detailed description can be found in Dr. Zhu’s and Dr. Cizeron’s theses 
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and in a recently submitted manuscript. A summary of their findings is described 
below: 
 
2.1.2.2.1 Biochemical characterization 
Western blots were used to measure the overall expression of PSD95 and SAP102. 
This experiment was undertaken by Dr. Fei Zhu. Briefly, mouse forebrains were 
homogenised in deoxycholate buffer and centrifuged. Proteins were then run through 
sodium dodecyl sulphate (SDS)-PAGE gel. Following this, they were transferred to a 
nitrocellulose gel and labelled with either anti-PSD95 or anti-SAP102 antibodies. The 
results showed that PSD95-eGFP and SAP102-mKO2 levels were similar to those of 
the endogenous proteins (Figure 2.2). 
 
Figure 2.2: Western blot of postsynaptic proteins demonstrating analysis from 
wildtype, heterozygous and homozygous forebrain homogenates for PSD95-eGFP 
(A) and SAP102-mKO2 (B). Molecular weight in kDA. Image reproduced from Zhu et 
al. (2018) under creative common licence. 
 
2.1.2.2.2 Electrophysiological characterization 
The functional impact of inserting the fluorescent proteins was assessed using 
electrophysiology. Dr. Maksym Kopanitsa undertook the experiments described 
below. Acute brain slices from the two mouse lines were collected and recordings 
from CA1 were taken as previously described (Kopanitsa et al. 2006). Input-output 
relationships, paired-pulse facilitation and theta burst stimulation were assessed. No 
significant differences were found between the knock-in and wildtype mice. 
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2.1.2.2.3 Imaging characterization 
Spatial expression patterns of the two proteins (PSD95 and SAP102) were also 
assessed with a number of experiments. Firstly, low magnification images of the 
knock-in mouse lines were examined and the distribution patterns compared to those 
described in the literature. Alongside this, qualitative comparisons were made 
between knock-in expression patterns and those using antibody staining. These two 
experiments were undertaken by Dr. Fei Zhu and are described in her thesis. 
Following from this, Dr. Melissa Cizeron and Dr. Zhen Qui used high resolution 
confocal microscopy (SDM) and machine learning algorithms (details of the 
methodology can be found below and in Dr. Melissa Cizeron’s thesis) to create whole 
brain synaptome maps of PSD95 and SAP102 expression at the single synapse 
resolution. Data on the density, intensity and size of the puncta was analysed. This 
demonstrated differential regional expression of the two proteins with unique patterns 
for the measured metrics (Figure 2.3). 
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Figure 2.3: PSD95 and SAP102 synaptome maps demonstrating (i) puncta density 
(puncta per 100 µm2) (ii) puncta intensity (16-bit grey scale) (iii) puncta size (µm2) and 
(iv) colocalisation (%) for PSD95 (above) and SAP102 (below). Image reproduced 
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2.2 GENOTYPING 
All genotyping was undertaken by either Mr. David Fricker or Ms. Rand Dahan. 
 
2.2.1 Tissue collection 
Every mouse had two samples of tissue collected for genotyping at two time-points. 
The first sample was an ear clipping taken at 3 weeks of age. This sample was used 
to provide an initial genotyping screen to allow mouse selection for experimentation. 
The second tissue sample included two tail samples approximately 2-3mm in length 
taken at the time of transcardial perfusion. A second round of analysis was 
undertaken using this sample to confirm the mouse was the correct genotype. If there 
was evidence of discrepancy, then a further analysis was done on the final sample if 
required. Therefore, all mice had at least two rounds of genotyping. 
 
2.2.2 Polymerase Chain Reaction (PCR) protocol 
DNA was extracted from tail or ear samples using MyTaq Extract-PCR kit (Bioline). A 
2µl sample of extracted DNA was mixed with 0.5µl of the specific primers (Table 2.1). 
For PSD95-eGFP allele, MyTaq HS (Bioline) was used. The DNA and primers were 
mixed with 4µl of 5X PCR buffer, 0.15µl Taq enzyme and 12.85µl of double distilled 
water to make a volume of 20µl. For the SAP102-mKO2 allele, two separate mixtures 
were created with the associated primers as outlined in Table 2.1. The DNA and 
primers were mixed with 2.5µl of 5X PCR buffer, 0.15µl Taq enzyme, 0.5 µl of 10mM 
deoxynucleotide triphosphate (dNTPs) and 18.35µl of double distilled water to make 
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Allele Name Sequence 





SAP102 mKOF3-1 GCCAGATGAAGACCACCTACAAG 
SAP102 UTR_R1 GGGACAAGAACAGTAGTCATTTG 
SAP102-mKO2 
(WT reaction) 
SAP102 ExonF2 CATCACAGGAGGGTCGTTACTAG 
SAP102 UTR_R1 GGGACAAGAACAGTAGTCATTTG 
Table 2.1: PSD95 and SAP102 primer sequences used for PCR protocol  
 
Allele PCR cycle conditions 
PSD95-eGFP 95°C            1mins 
 
95°C            15secs 
55°C            15min                        35 cycles 
72°C            45sec 
 
72°C            5mins (optional) 
4°C               Forever 
SAP102-mKO2 95oC            15 mins 
 
94oC             45 sec 
55oC             45 sec                       35 cycles  
72oC             1 min 
 
72oC             10 mins 
Table 2.2: Cycling conditions used for PSD95 and SAP102 reactions 
 
The mixtures were then placed in the PCR machine with reaction specific cycling 
condition as described in Table 2.2. A 2% agarose gel in Tris-Acetate-EDTA (TAE) 
containing 0.5% ethidium bromide was used to separate the PCR products. These 
were then visualized by UV transillumination (UVP GelDoc-It TS2 Imager). Table 2.3 
highlights the amplification products observed for the PSD95 and SAP102 reactions. 
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Allele Amplification product size 
PSD95-eGFP Wildtype 330bp 
 Mutant  514bp 
SAP102-mKO2 Wildtype 280bp 
Wildtype reaction Mutant 1.1kb 
SAP102-mKO2 Wildtype No band 
Mutant reaction Mutant 280bp 
Table 2.3: PSD95 and SAP102 amplification products  
 
2.3 LATERAL FLUID PERCUSSION INJURY MODEL 
The mice were anaesthetized with 5% isoflurane (Merial, UK) in 100% O2 prior to 
surgery for 2 minutes. The mice were then weighed and placed in stereotaxic frame 
(Model 900, David Kopf Instruments). A nose cone was used to maintain anaesthesia 
(Figure 2.4, A). During surgery, the mice’s’ body temperature was maintained at 
37±0.5oc using a heat pad and rectal thermometer probe (Homoeothermic blanket 
control unit, Harvard Apparatus). A razor was then used to shave a small patch of hair 
from the top of the mouse’s head and eye ointment (Xailin) was applied to the eyes. 
A midline scalp incision was fashioned and the skin flaps reflected using skin clips. A 
plastic guide was glued onto the skull using 3M Vetbond and a lateral 2mm circular 
craniectomy was then trephined (Miltex) midway between the bregma and lambda. 
Care was taken to not injure underlying dura. An injury hub was created by cutting off 
the female end of Luer-Loc needle hub. This was secured over the craniectomy site 
using glue (Loctite Power Flex Gel) and dental cement (Simplex Red, Associated 
Dental Products) (Figure 2.4, B). The mice were then removed from the stereotatic 
frame and the depth of anaesthesia reduced till they responded to tail pinch. The mice 
were then replaced in the anaesthetic box for 1 minute. Once complete, the injury hub 
was filled with normal saline and attached to the fluid percussion device (Custom 
Design and Fabrication, Virginia Commonwealth University) (Figure 2.4, C). When 
they showed response to tail stimulus (to standardize anaesthesia levels) had a mild 
to moderate injury (1.1-1.5 atm) was inflicted. This was determined by oscilloscope 
attached to the fluid percussion device (Figure 2.4, D). Sham mice had the exact 
same procedure except the release of the pendulum to inflict the percussion injury. 
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Following this, the mice were disconnected from the fluid percussion device and 
placed on their back to measure their righting time - a marker of the neurological 
severity of the injury. A righted animal was defined as having moved all four limbs 
onto the surface it was lying on. The righting reflex has been found to correlate with 
injury severity (Hamm 2001). Importantly, the righting reflex can be effected by 
anaesthesia necessitating a consistent experimental protocol (Eakin et al. 2015). 
Clear exclusion criteria were defined (Table 2.4). Following righting, the mice were 
then re-anesthetized and had the hub removed and the skin incision sutured using 5-
0 Vicryl (Ethicon). A 2mg/kg dose of Bupivicaine (AstraZeneca) was applied to the 
wound to manage pain. Mice were then placed in a heated recovery chamber kept at 
30oC (Lyon Electric Company) for 30 minutes prior to being returned to a cage. A 
range of time-points for recovery were used including: 24 hours, 7 days and 28 days. 
Mice were initially monitored daily for the 5 days postoperatively. Following this, they 
were assessed once a week till the end of the experiment. 
 
2.3.1 Randomization protocol 
Mice were randomized to the following four cohorts: 7 day injury, 7 day sham, 28 day 
injury and 28 day sham. When a group of mice became eligible for randomization, 
each mouse would be allocated a number from 1 – n. A random sequence generator 
(www.random.org) was used to produce the sequence 1 - n in random order. Using 
this random order, the mice would be sequentially allocated to the four cohorts in the 
following order: 7 day injury, 7 day sham, 28 day injury and 28 day sham. In the event 
that there were not enough mice to be randomized to all four cohorts, then the unfilled 
groups would be rolled over to the following experiment.  
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Figure 2.4: Lateral fluid percussion injury procedure demonstrating the major 
steps including craniectomy with dura intact (A) followed by hub fixation with dental 
cement (B) and subsequently attaching the mouse to the FPI device (C) and the 
oscilloscope readout (D) 
 
Exclusion Criteria 
Dural tear during craniectomy 
Dural rupture occurring following application of fluid pulse or removal of hub 
Post-injury paralysis lasting greater than 30 minutes 
Table 2.4: Exclusion criteria for fluid percussion injury experiments 
A B 
C D 
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2.4 TISSUE COLLECTION AND PROCESSING 
2.4.1 Transcardial perfusion and brain fixation 
Mice were administered a terminal dose of intraperitoneal injection of 0.1ml 20% 
phenobarbital sodium (Euthatal – Merial Animal Health Ltd). Once the mice were fully 
anaesthetized (not responding to tail pinch), they were pinned to a cork board and 
underwent a thoracotomy. The heart was fully exposed and a small knick was made 
in the right atrium. Subsequently, 10mls of phosphate buffered solution (PBS - Fisher 
Scientific) was injected slowly into the left ventricle. This was followed by 10mls of 4% 
paraformaldehyde (PFA - prepared by diluting 16% Alfa Aesar in 1:4 PBS). Following 
this, the mice were decapitated and the brain dissected free from the skull. It was 
subsequently post-fixed in 5mls of 4% PFA for 3-4 hours and then placed in a 30% 
sucrose solution (prepared by diluting VWR Chemicals sucrose in PBS) for 48 hours. 
The brains were then placed in a solution of 50:50 30% sucrose and Optimum Cutting 
Temperature medium (OCT - VWR International) for 1 hour before being embedded 
in a mould (Sigma-Aldrich) in OCT. This was achieved by immersing the moulds in a 
beak of isopentane (Sigma-Aldrich) which was then placed in liquid nitrogen. Once 
frozen, the brains were kept at -80oc till they were sectioned.  
 
2.4.2 Blinding 
After brains were removed and were being fixed in sucrose solution they were blinded 
by a member of the Grant lab (Sarah Lempriere - SL). SL applied a blinding code to 
each mouse and kept a central register of the mice and blinding codes which was 
inaccessible to the primary investigator (AJ). The blinding was unmasked after the 
generation of the raw subregional puncta data to allow for subgroup analysis. 
 
2.4.3 Cryosectioning protocol 
A NX70 Thermo Cryostat was used to cut coronal sections 18 microns in depth. A 
small drop of PBS was placed on a Superfrost Plus glass slide (Thermo Scientific) 
before sections were collected. A total of two sections were placed on each slide. 
Slides were left to dry at 4oc overnight following which they were stored at -80oc till 
further analysis. Sections were kept away from light as much as possible to minimize 
loss of fluorescence.  
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2.5 HISTOLOGY 
2.5.1 Haematoxylin and Eosin (H+E) staining 
Slides containing sections from the level corresponding to approximately -1.94mm 
from bregma according to Frankilin and Paxinos were selected for haematoxylin and 
eosin staining. Selected slides were washed in a 1% PBS bath for 5 minutes. After 
this, slides were hydrated through graduated ethanol concentrations followed by 
rinsing in running water for 5 minutes. The slides were then placed in filtered Shandon 
ready-made Harris Haematoxylin Acidified [ThermoFisher Scientific (#6765003)] for 
3 minutes followed by rinsing in running water. The haematoxylin was then 
differentiated in 1% acid alcohol for 10 seconds. After rinsing, the slides were then 
placed in Scott’s Tap Water substitute (1 litre distilled water, 20g MgSO4, 3.5g 
NaHCO3) for 2 minutes. From there, the slides were placed in Shandon EosinY 
Alcoholic [ThermoFisher Scientific (#6766007)]. Following rinsing in running water, 
the slides were dehydrated through increasing graduated alcohol concentrations. The 
slides were finally cover-slipped using DPX [Sigma (06522)]. All stages were 
performed at room temperature (RT).  
 
2.5.2 Immunohistochemistry 
2.5.2.1 Amyloid Precursor Protein (APP) immunostaining 
Sections were defrosted and the OCT was washed away by agitating in 1% PBS for 
5 minutes. After this, slides were hydrated through graduated ethanol concentrations. 
The Leica Novolink Max Polymer Detection system (406040647) was used. In 
summary, a peroxidase block was applied for 30 minutes. Following this, the sections 
underwent antigen retrieval in citric acid (1.05g in 500mls TBX at pH 6) in a pressure 
cooker up to 125oC. Subsequently, the sections were then treated with a protein block 
for 15 minutes. This was followed by application of 1:1000 anti-amyloid precursor 
protein A4 clone 22C11 (Millipore MAB348) antibody for 30 minutes. Subsequently, 
the post primary solution was applied for 30 minutes followed by a polymer for a 
further 30 minutes. Dab (1:200) was applied to the sections for 1 minute. The sections 
were then counterstained with Haematoxylin for 60 seconds followed by Scott’s Tap 
Water for 2 minutes. Following this, the sections were dehydrated through increasing 
concentrations of ethanol prior to immersion in xylene. Finally, the sections were 
cover slipped using DPX [Sigma (06522)]. All stages were performed at RT unless 
stated otherwise. For Chapter 4, block was for 30 minutes and primary antibody 
incubation was for 90 minutes.  
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2.5.2.2 Astroglial immunostaining 
Sections were washed of OCT in a 1% PBS bath for 5 minutes. After this, the sections 
were incubated with blocking solution (Triton 0.2%, Bovine Serum Albumin 5%) at RT 
followed by an overnight incubation of the sections with the primary antibody solutions 
at 4oC: Rabbit GFAP antibody (Abcam ab7260) (1:500) and Goat Iba-1 Polyclonal 
IgG antibody (Abcam ab5076) (1:150). After washing, secondary antibodies were 
applied: Donkey anti-rabbit Alexa Flour 546 IgG H&L (Abcam ab10040) (1:300) and 
donkey anti-goat Alexa Flour 647 IgG H&L (Abcam ab150079) (1:300) for 1 hour at 
RT. The secondary antibodies were then washed off with three 10-minute washes. 
DAPI (1:1000) was applied during the penultimate wash at RT. The slides were then 
cover-slipped using Mowiol. Evgenia Rusina assisted in the immunohistochemistry. 
For Chapter 4 there was a change in protocol: 10% BSA solution was applied for 1 
hours, we decreased the concentration of Goat Iba-1 Polyclonal IgG antibody (Abcam 
ab5076) and left it to incubate at RT for 90 minutes followed by TBS only washes and 
then incubation with donkey anti-goat Alexa Flour 647 IgG H&L (Abcam ab150079) 
(1:500) for 1 hour followed by three 5 minute TBS only washes.  
 
2.5.2.3 Synaptic vesicle glycoprotein 2A staining 
Evgenia Rusina performed this immunohistochemistry protocol under AJ’s 
supervision. The OCT was washed away from the sections by agitating in a 1% PBS 
bath for 5 minutes. A blocking solution (Bovine Serum Albumin 5%, Triton 0,5%) was 
applied for 1 hour. Following this, the sections were incubated with Rabbit anti-SV2A 
(Abcam ab32942) (1:1000) for 1 hour. Subsequently, sections were washed with five 
5-minute washes. After that, the secondary antibody Goat Anti-Rabbit Alexa Fluor 647 
(Abcam ab150079) (1:2000). Then five more 5-minute washes were performed with 
the application of DAPI (1:1000) with the third washing. Finally, the sections were 
cover-slipped using Mowiol [Sigma (4-88)]. All stages were performed at RT. 
 
2.5.2.4 4’,6-diamidino-2-phenylindole (DAPI) staining 
DAPI staining was applied to all sections except those stained with APP. Sections 
were incubated in 1:1000 4’,6-diamidino-2-phenylindole (Sigma) diluted in PBS. For 
sections with no other immunostaining, the slides were left to defrost then washed in 
a PBS bath for 5 minutes. Following this, DAPI was applied to the section for 15 
minutes followed by a 5-minute PBS bath. For sections undergoing other 
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immunostaining, the DAPI solution was applied as an alternative to the penultimate 
washing solution after the secondary antibody incubation.   
 
2.5.3 Mowiol preparation 
Mounting solution was prepared by dissolving 96g of glycerol (Sigma-Aldrich) and 
38.4g Mowiol (Calbiochem) in 192ml 0.2M Tris buffer at 8.5pH and 95ml MilliQ water. 
The mixture was then heated up to 50oc till clear. Following centrifuge at 8500rpm for 
15 minutes, the supernatant was collected and 2.5% 1,4-Diazabicyclo[2.2.2]octane 
(Sigma-Aldrich) added. Mowiol was stored at -20oc until used.  
 
2.5.4 Coverslip mounting 
For all sections (expect those stained for APP and H+E), 12µl of Mowiol was applied 
to each section and then covered using 1.5 thickness coverslips (VWR International). 
For APP and H+E staining, 20µl DPX (Sigma) was applied to each section and then 
covered using 1.5 thickness coverslips (VWR International). Efforts were made to 
remove air bubbles. 
 
2.6 IMAGING TECHNIQUES 
2.6.1 Wide field fluorescence microscopy 
The Zeiss Axioscan.Z1 was used for wide field microscopy of mouse brain sections. 
It allowed for high throughput automated scanning of up to 100 slides. Both 
fluorescence (DAPI, GFAP, Iba-1, SV2A) and bright field (APP, H+E) microscopy was 
used for the experiments in this thesis. Images were acquired at 20X using a Zeiss 
Plan-Apochromat lens with a numerical aperture (NA) of 0.8. Excitation light was 
emitted using a Light Emitting Diode (LED) with a range of 400-700nm. This light was 
then filtered with a band pass (BP) filter and split using Farb Teiler (FT) before being 
projected onto the sample. Emission light was also split using FT and filtered with the 
BP filter before being detected by a high sensitivity camera (Hamamatsu Orca-flash 
4.0 monocome camera). For image acquisition, Ring Aperture Contrast (RAC) at 2.5X 
objective lens was used to obtain an overview of the slide. Following this, an 
automated two-step focusing process took place: coarse focusing at 10X followed by 
fine focusing at 20X. Sequential images were then acquired and stitched 
automatically. Different settings were applied as described in Table 2.5.  
 
 Page | 53 












Chapter 3 DAPI 395 445 100 2 
 GFAP 578 603 100 350 
 Iba-1 650 668 100 360 
Chapter 4 DAPI 395 445 100 1.3 
 Iba-1 650 668 100 375 
 SV2A 650 668 25 72 
Table 2.5: Zeiss Axioscan.Z1 settings for wide field fluorescence microscopy 
showing the different parameters for excitation and emission wavelength along with 
LED strength and exposure time.  
 
2.6.2 Spinning disc confocal microscopy 
The data presented in this thesis was acquired using the Andor Revolution XDi 
system using a Dual Nipkow disk (CSU-W1) which combines two pinholes 25 and 50 
µm.  The Andor Revolution XDi system has 4 lasers: 405nm, 488nm, 561nm, 640nm. 
For experiments in this thesis, we used 488nm (eGFP) and 561nm (mKO2). Light 
from the lasers was directed onto the sample using a dichroic mirror and quad filter. 
A 2x post-magnification lens was placed in front of camera to increase sampling rate. 
The system also contained the Borealis Perfect Illumination Delivery which improves 
the uniformity of the field illumination. Images were acquired using the Olympus 
UplanSAPO 100x oil immersion lens (N.A 1.4) and detection was achieved using the 
Andor iXon Ultra monochrome back-illuminated EMCCD. Acquired images were 
images were 512 x 512 pixel and 16-bit depth. For whole brain acquisition, images 
underwent mosaic tilling across a grid defined by the user. Within this grid, focus 
points were placed by the user which allowed for adaptive focusing throughout the 
imaged sample. No z-stacking was taken in images in this thesis. 
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2.7 IMAGE ANALYSIS 
2.7.1 Semi-quantitative analysis of Amyloid Precursor Protein 
Slides were blinded and then examined using Olympus BX-51 microscope set at 20x. 
A semi-quantitative approach was taken to determine the number of APP-positive 
varicosities within the corpus callosum. An APP-positive varicosity was defined as a 
dark aggregate of staining lying within the corpus callosum as shown in Figure 2.5. 
A total number of varicosities were counted for both the ipsilateral and contralateral 
corpus callosum.  
 
 
Figure 2.5: Amyloid precursor protein aggregates in the corpus callosum as 
indicated with black arrows.  
 
2.7.2 Semi-automated quantification of cellular immunostains 
Images acquired by the Zeiss Axioscan.Z1 were converted from Carl Zeiss Image 
(CZI) format into Tagged Image File Format (TIFF) using the ZEN software. 
Multichannel image were split into their respective channels during the conversion 
process. The TIFF images were then converted into 8-bit images and a threshold was 
applied with the parameters defined in Table 2.6 and then converted into binary 
images (Figure 2.6). ImageJ was then used to apply regions of interest across the 
mouse brain. Finally, a semi-automated particle analysis script was applied to count 
the number of immunostain positive cells with the defined parameters. 
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Table 2.6: ImageJ parameters used for Iba-1 and GFAP particle analysis 
demonstrating the thresholding and particle sizes  
 
Figure 2.6: GFAP analysis using ImageJ demonstrating conversion of TIFF image 
(A) into binary image (B) prior to particle analysis  
 
2.7.3 SV2A field intensity analysis 
Evgenia Rusina performed the image analysis under my supervision. Carl Zeiss 
Image (CZI) formatted images were analyzed using ZEN software. Regions of interest 
(ROI) corresponding to major brain regions were applied and the raw fluorescence 
intensity value measured. To adjust for variation in immunostaining, the fluorescence 
intensity value of the corpus callosum was deducted and then divided by the intensity 




Chapter Stain Threshold Particle size 
Chapter 3 GFAP 0-9 0.008-0.2 
 Iba-1 0-17 0.005-0.1 
Chapter 4 Iba-1 0-17 0.005-0.2 
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2.7.4 Automated synaptic puncta analysis 
2.7.4.1 Mouse brain regions of interest delineation 
Images generated from the SDM were stitched to create a montage image to allow 
delineation. The code to do this was written by Dr. Zhen Qui (Appendix 1). The code 
downsized each image by factor of 16 and stitched tiles side by side using the image 
metadata (Figure 2.7). This whole brain montage image was then saved as a TIFF 
file. Montages were generated for both channels: 488 and 561. Subsequently, the 
polygon selection function in ImageJ was used to delineate regions based upon Allen 
Institute mouse brain atlas. These delineations, which were saved as a ZIP file, would 
be subsequently incorporated in binary function into the automated puncta analysis 
process and used to calculate median values for each metric per region which were 
then plotted. Evgenia Rusina and Jude Milvidaite assisted in generating the mouse 
brain delineations in Chapter 4. 
 
 
Figure 2.7: Pipeline for image analysis of PSD95 and SAP102 synaptome 
demonstrating the conversion of raw puncta data into a stitched montage which 
subsequently was delineated using ImageJ. The raw data then underwent object 
segmentation and stat_sum image generation. Masks created from the delineated file 
were then applied to the stat_sum image and raw puncta data generated in an Excel 
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file. This data was then processed (as described below) to generate spatial heat maps 
for PSD95 and SAP102 puncta density, size and intensity.  
 
2.7.4.2 Puncta detection and segmentation using Ensemble  
A novel detection method using supervised machine learning techniques was 
developed in-house by Dr. Zhen Qui using Matlab and Python. To generate a ‘ground 
truth’ of puncta detection, a series of randomly selected image subsets were analysed 
by independent researchers. Using the ‘cell counter’ plugin for ImageJ, synaptic 
puncta were manually counted for each protein (PSD95 and SAP102). This training 
set was then used to train the machine learning algorithm. The Ensemble method has 
a proven performance in generalization error prediction (Breiman 2001) making it a 
strong candidate for puncta classification from diverse intensities. Once a punctum 
was detected, it was then segmented by generating a ROI around the object. From 
this ROI, three parameters were then calculated: puncta intensity, density and area. 
The puncta density was calculated by averaging the number of puncta per tile. The 
puncta intensity was calculated by averaging the intensity of pixels within the 
punctum. While the puncta area was calculated as the number of pixels within the 
punctum which was then converted into µm2 as detailed below. 
 
2.7.4.3 Generation of LFPI synaptome maps 
Below we describe the image analysis pipeline used to generate the synaptome maps 
for the LFPI experiment: 
 
2.7.4.3.1 Stage 1: Object segmentation 
In stage 1, we used the Ensemble detection and segmentation method as described 
above. To do this, each tile (which was constituted of 512 x 512 pixels) was divided 
into 4 images. The puncta within these images were detected and the segmentation 
parameters described above calculated. This data was saved as a text file with the 
coordinates of the puncta and associated measurements. 
 
2.7.4.3.2 Stage 2: Generation of ‘Stat_Sum’ image 
The data within the text files was then converted into a 3D array containing three 
coordinates: x, y and z. The x and y values represented coordinates of the pixels. The 
z value represented a subset in which each value corresponded to a particular puncta 
parameter. So, different puncta parameters, such as puncta size, is represented at 
 Page | 58 
different z levels. The mean value for each puncta parameter per sub-tile was 
calculated by dividing the sum of the pixel z value and then divided by the number of 
puncta per sub-tile.  
 
2.7.4.3.3 Stage 3: Binary mask generation and regional quantification 
The ROI delineation ZIP files were then converted into binary masks. For each brain, 
there were 222 sub-regions delineated which translated into an equivalent number of 
masks which were applied to the ‘Stat_Sum’ image. For each puncta metric, the 
median value was calculated for each mask which was then complied into a Microsoft 
Excel sheet for further processing as described below. 
 
2.7.4.3.4 Stage 4: LFPI Cohen’s d heatmap generation 
To graphically represent the sub-regional differences between the injury and sham 
mice, we calculated the Cohen’s d effect size (described in statistical analysis section) 
comparing the two cohorts. These values were then mapped onto a 2D coronal image 
of a mouse brain by converting the Cohen’s d value into a colour spectrum value 
(described below) before using the ‘flood fill’ tool in ImageJ to colour the sub-regions.  
 
2.8 STATISTICAL ANALYSIS 
2.8.1 Raw puncta metric calculations 
The Ensemble method generated raw puncta metrics that required adjustment to 
reflect their biological basis. No adjustment was made for the puncta intensity which 
was kept as a raw grey scale value. Pixel dimensions were 84nm x 84nm giving it a 
surface area of 0.007056µm2. To calculate the puncta area in µm2 we multiplied this 
value by the raw number of pixel per puncta provided by Ensemble. For density, 
Ensemble provided the mean number of puncta per a quarter tile. Each full tile was 
composed of 512x512 pixels therefore giving it a surface area of 1849µm2. Therefore, 
to calculate the puncta density /µm2 we used the following equation with ! 
representing the raw Ensemble puncta density:  
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2.8.2 Two-group comparisons 
Two-group comparisons were undertaken using Graphpad Prism 7. Normality was 
tested for using the Shapiro-Wilk Normality test. For unpaired non-parametric data 
the Mann Whitney U test was used while for parametric data the Student’s unpaired 
t-test was utilized. The Chi-square test was used for categorical data. 
 
2.8.3 Correlation 
To look for linear relationships between two variables, a Pearson coefficient was 
calculated using Graphpad Prism 7. The Pearson coefficient varies from -1 to 1 which 
related to perfect negative and positive relationships. The significance of the linear 
relationship was calculated using a two-tailed test.  
 
2.8.4 Multiple group comparison 
For analysis of multiple groups, we used Analysis of Variance (ANOVA) with post-hoc 
multiple comparison with Bonferroni correction. However, for the sub-region analysis 
of the synaptic puncta, we opted to undertake post-hoc multiple t-tests to compare 
the injury and sham cohorts. Due to the number of comparisons (>200) the use of 
statistical correction would be too conservative and lead to false negatives. However, 
not using any correction does increase the likelihood of false positives. To address 
this, we took a two-tiered approach to interpret the significant findings from the 
multiple t-tests. Firstly, we only discussed significant results that clustered 
anatomically together as this was more likely to represent a true biological effect. We 
defined clustering as three or more sub-regions within two or more adjacent brain 
regions. For isolated sub-regions, we then applied a higher significance threshold to 
it ensure that false positives were not discussed. A form of correction is to divide the 
usual p-value threshold (p>0.05) by the number of comparisons. In our study, this 
would be 0.05 divided by 222 giving isolated sub-regions a p-value threshold of 
0.0002.  
 
2.8.5 Cohen’s d effect size 
Cohen’s d measures the difference in effect size between two groups. It is calculated 
as the difference between two means divided by their pooled standard deviation. In 
the case of this thesis, a comparison between the injury cohort mean (x1) would have 
the sham cohort mean (x2) deducted from it and then divided by the pooled standard 
deviation (-): 
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" = 	!. − !0-  
 
The pooled standard deviation (s) is calculated with the below equation where n1 and 
n2 are the numbers for the respective groups. While -1 and -2 are the standard 
deviations for the corresponding groups: 
 
- = 	2(4. − 1)-.6 +	(40 − 1)-06(4. +	40 − 2)
 
 
If the mean value of the injury cohort for a sub-region was less than that of the sham 
cohort the Cohen’s d effect size would be negative. While if the injury cohort had a 
larger mean then the Cohen’s d effect size would be positive.  
 
2.8.6 Colour scheme calculation for heat-map 
To graphically represent the Cohen’s d effect sizes, each sub-regional value was 
converted into a triad of values for conversion into an RGB scale (values of 0-255 for 
each of the three colours: red, green and blue). For negative Cohen’s d effect sizes 
the colour blue was picked and for positive values the colour red. To calculate the 
RGB values, the following equation was used with ! representing the Cohen’s d effect 
size: 
 
9:-;<;=>	?:ℎ>4A-	" = $0.75 − !2) × 	255 
 
E>FG<;=>	?:ℎ>4A-	" = $0.75 + !2) × 	255 
 
For negative Cohen’s d effect size the blue value was set at 255 and the results of 
the above calculation applied to red and green. While for positive results, the red scale 
was set at 255 and then results of the equation applied to blue and green. These RGB 
values were then translated into the ImageJ ‘colour picker’ function following which 
the ‘flood fill’ tool was used to apply the appropriate colour to the sub-region.    








Characterization of mild fluid percussion 
injury model in wildtype mice 
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3.1 INTRODUCTION 
The fluid percussion Injury model is an open skull model that causes a mixed – focal 
and diffuse – injury. The model was first established in cats and was subsequently 
modified to be used in mice by Carbonell (Carbonell et al. 1998). A major benefit of 
using the model in mice is the ability to utilize genetically modified animals to answer 
focused mechanistic questions. However, the surgical preparation of the model with 
mice comes with several technical challenges. A flexible cranium and fragile dura 
pose difficulties in maintaining an intact dura and minimizing brain injury in sham mice 
(which undergo the full surgical procedure except for application of the fluid pulse). 
This coupled to known factors, such as craniectomy location, can lead to variation in 
injury morphology which highlights the importance of robust characterization of the 
model by a new user (Vink et al. 2001). A major benefit of the LFPI is its ability to vary 
the intensity of the fluid percussion pulse to reflect differing severities of human TBI. 
Mild TBI accounts for over 80% of head injuries and can lead to post-concussional 
symptoms that affect patients’ quality of life (Bruns & Hauser 2003; Levin & Diaz-
Arrastia 2015). Several studies have aimed to characterize a mild LFPI in murine 
models. Hylin and colleagues applied LFPIs of 1.0 and 1.5 atm to rats and found 
limited cognitive changes in 1.0 atm cohort but evidence of significant impairment in 
the 1.5 atm cohort associated with a robust neuroinflammatory response and 
evidence of water matter changes shown with Diffusion Tensor Imaging (Hylin et al. 
2013). A study by Spain looking at mild LFPI (0.9±0.1 atm) in mice found moderate 
neuronal damage in the cortex in both the injury and sham mice but minimal neuronal 
injury within the hippocampus (Spain et al. 2010). The same study found evidence of 
progressive diffuse axonal pathology in the injury group in sites distal to the 
percussion site. The aim of this chapter is to establish an experimental protocol for a 
mild LFPI in wildtype C57BL/6 mice. We define this as an injury leading to an 
elongated right reflex with evidence of axonal injury and inflammatory response but 
in the absence of gross disruption of brain architecture such as contusions.  
 
3.2 SUMMARY OF METHODS AND EXPERIMENTAL PIPELINE 
To characterize the LFPI model, 40 male C57BL/6 mice aged between 8-12 weeks 
were included in the study. They were randomly allocated to either injury or sham 
LFPI groups as detailed in Chapter 2. Briefly, the mice were anaesthetized with 
isoflourane and were attached to a stereotactic frame. A circular craniectomy was 
fashioned and a hub secured using glue and dental cement. The mice were then 
 Page | 64 
attached to the fluid percussion device and either underwent a mild fluid pulse (1.1-
1.2) or sham (no release of pendulum) procedure (Figure 3.1, A). Following this, the 
righting time was measured and then the mice were kept in a warm (30oC) chamber 
till they recovered. After the LFPI procedure, the mice were allowed to survive to 24 
hours and then underwent transcardial perfusion and the brains were harvested. After 
post-fixation in a 30% sucrose solution, the brains were embedded in OCT and then 
cryosectioned into 18µm coronal sections (Figure 3.1, B). Sections corresponding to 
approximately -1.94mm from bregma were selected and underwent H+E staining 
alongside immunostaining for APP, Iba-1 and GFAP as detailed in Chapter 2. For the 
analysis, brains were blinded. The Iba-1 and GFAP immunofluorescence staining was 
performed on a single section and then imaged using a wide field fluorescence 
microscope (Figure 3.1, D). The multichannel images were split and ImageJ was 
used to count positive cells within delineated anatomical regions of interest. For H+E 
and APP staining, a semi-quantitative approach was taken using a light microscope 
in which damaged neurons were qualitatively examined and APP positive aggregates 
within the corpus callosum were counted (Figure 3.1, C and E).  
 
 
Figure 3.1: Schematic of mild LFPI characterization experiment methodology. 
Forty mice were randomised to injury or sham LFPI procedures (A). The injury cohort 
underwent a 1.1-1.2 atm fluid percussion injury. After 24 hours, the mice underwent 
transcardial perfusion and the brains were harvested following which they were 
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cryosectioned into 18µm sections (B). Brains sections were stained with APP and the 
number of aggregates in the ipsilateral corpus callosum were quantified (C). GFAP 
and Iba1 immunofluorescence was performed and widefield microscopy used to 
image the sections (D). The GFAP and Iba1 channels were then split and ImageJ 
used to quantify positive cells within 8 major brain regions. H+E staining was 
performed and qualitative analysis of corpus callosum fracturing (black arrows) and 
neuronal injury was performed (E) 
 
3.3 EXPERIMENTAL RESULTS 
A total of twenty-six mice (15 injury and 11 sham) were included in the final analysis 
(Figure 3.2). Fourteen mice were excluded for the following reasons: 11 dural 
ruptures (dural breach at time of fluid percussion), 2 dural tears (dural breach when 
performing craniectomy) and 1 post-injury paralysis. This gave the experiment an 
attrition rate of 35%. The below flow diagram highlights the animal exclusion: 
 
 
Figure 3.2: Flow diagram demonstrating mouse exclusion. A total of 14 mice were 
exclude: 11 dural ruptures (tears due to application of fluid pulse to dura), 2 dural 
tears (dural injury as craniectomy is elevated) and 1 post-injury paralysis (lasting 
greater than 30 minutes) 
 
 Page | 66 
There was no significant difference between the injury (25.4g ± 0.7) and sham (25.1g 
± 0.4) mice weights (p=0.77; student t-test). The injury mice were exposed to a 
percussion amplitude of 1.18±0.03atm.  
 
3.3.1 Injury cohort exhibited increased righting times 
Following application of the fluid percussion pulse or sham procedure, the mice were 
detached from the LFPI device and placed on their back to check their right time (RT) 
– a simple behavioural assay to assess acute brain function disruption (Figure 3.3, 
A). In our experiment, injury mice had a statistically significant higher RT (431.4 ± 
178.2 seconds) compared to sham mice (40.3 ± 57.5 seconds) (p<0.0001; Mann 
Whitney U test) (Figure 3.3, B).  
 
 
Figure 3.3: Mouse righting time following LFPI experiment. A mouse was 
considered righted once it had placed all four paws on the floor (A). In the experiment, 
we found significantly elevated RT for injury mice (n=15) compared to sham mice 
(n=11) (B). The mouse images were taken from Wikimedia Commons. [**** = 
p<0.0001].  
 
3.3.2 Dysmorphic neurons and fractured corpus callosum found in injury cohort 
Haematoxlyin and Eosin (H+E) staining was used to examine for evidence of tissue 
damage and cellular injury (Figure 3.4). For H+E, we analysed 7 mice in the injury 
cohort and 6 mice in the sham cohort. This revealed no significant cortical disruption 
or contusion across both the injury and sham groups. However, more mice in injury 
group (85%) had evidence of ipsilateral corpus callosal fracturing compared to the 
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sham mice (16.7%) (p=0.01; Chi-squared test). Closer inspection of neuronal 
morphology showed that the injury group mice had evidence of neuronal cell injury in 
all the mice in cortical layers 1 and 2/3. Just under half (42.8%) of injury mice had 
evidence of neuronal injury extending down to cortical layer 6a. Conversely, only half 
of the sham mice had injured neurons in cortical layer 1 and a third had injured 
neurons extending into cortical layer 2/3. There was no evidence of visible neuronal 
cell death in the hippocampus across both cohorts. 
 
 
Figure 3.4: Hamatoxylin and Eosin analysis of LFPI experiment. Injury cohort 
(n=7) demonstrated corpus callosal fracturing (A – black arrows) which is not evident 
in sham (n=6) example (B). Magnification of selected region highlights dysmorphic 
injured neurons in injury mice (C – black arrows). Scale bars in A and B (200 µm) in 
C and C (20 µm) 
 
3.3.3 Injury cohort demonstrated evidence of traumatic axonal pathology 
To measure the degree of traumatic axonal pathology, we examined the brain tissue 
with Amyloid Precursor Protein (APP). Injured axons appeared as dark aggregates 
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(Figure 3.5, A) which were semi-quantitatively counted. Using two-way ANOVA, we 
observed statistically significant differences between the injury and sham cohorts 
(F(1,42)=36.94; p<0.0001) and between the ipsilateral and contralateral corpus 
callosum (F(1,42)=34.89; p<0.0001). In post-hoc Bonferroni multiple comparison, the 
ipsilateral corpus callosum in the injury cohort had significantly higher numbers of 
APP positive aggregates (74.1 ± 38.6) compared to both the contralateral corpus 
callosum in the injury mice (1.8 ± 2.1) (p<0.0001) and the ipsilateral corpus callosum 
in the sham mice (0.8 ± 1.0) (p<0.0001) (Figure 3.5, B). There was no significant 
difference between the number of APP positive puncta in the corpus callosum in the 
sham mice (p>0.9999).  
 
 
Figure 3.5: Amyloid precursor protein analysis in LFPI experiment. Image A 
demonstrates APP positive aggregates in ipsilateral corpus callosum in injury mice 
(black arrows) and bar chart highlights differences in aggregate numbers between 
injury and sham mice (B). Scale bar = 20 µm. [**** = p<0.0001] 
 
3.3.4 Inflammatory changes following mild LFPI 
3.3.4.1 Microglia indexed with Iba-1 
We aimed to examine the inflammatory response following LFPI by staining for 
microglia using the antibody Iba-1 (Figure 3.6, A). Using two-way ANOVA, we found 
statistically significant differences between the ipsilateral and contralateral cortical 
Iba-1 numbers (F(1,48)=23.5; p<0.0001) but not between the injury and sham mice 
(F(1,48)=2.95; p=0.092). Post-hoc Bonferroni correction multiple comparisons 
revealed elevated Iba-1 numbers in the ipsilateral cortex in the injury mice (2767 ± 
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1352) compared to the contralateral cortex (1230 ± 642.1) which reached statistical 
significance (p=0.0002) (Figure 3.6, B). There was no statistically significant 
difference in the number of Iba-1 cells in the ipsilateral cortex between the injury (2767 
± 1352) and sham mice (2030 ± 791.3) (p=0.287). In the hippocampus, we observed 
statistically significant difference between the injury and sham cohorts 
(F(1,48)=16.29; p=0.0002) but not between the ipsilateral and contralateral 
hemispheres (F(1,48)=3.97; p=0.0521). Post-hoc Bonferroni test revealed 
significantly elevated numbers of Iba-1 cells within the injury ipsilateral hippocampus 
(1168 ± 575.3) compared to the ipsilateral hippocampus in the sham mice (458.0 ± 
275; p=0.0006) (Figure 3.6, C). There was no difference in the number of Iba-1 
positive cells across the groups in the thalamus and hypothalamus. 
 
 
Figure 3.6: Iba-1 immunostaining and quantification in LFPI experiment. Iba1 
immunofluorescence was imaged using wide-field microscopy and ImageJ utilised for 
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particle analysis (A). Quantification demonstrated elevated Iba1 positive cells in the 
ipsilateral cortex in both injury and sham mice (B). However, significantly elevated 
Iba1 positive cells in the ipsilateral hippocampus in the injury cohort (C). Scale bar = 
100µm. [**** p£0.0001; *** p£0.001; ** p£0.01; * p£0.05; ns p>0.05] 
 
3.3.4.2 Astrocytes indexed with GFAP 
Similar to Iba1, we aimed to examine astrocytic changes following LFPI. To do this, 
we used immunofluorescence staining for GFAP (Figure 3.7, A). Analysis using two-
way ANOVA revealed statistically significant differences between GFAP numbers 
within the cortex in the injury and sham mice (F(1,48)=8.07; p=0.006) and the 
ipsilateral and contralateral hemispheres (F(1,48)=65.39; p<0.0001). Post-hoc 
Bonferroni revealed an elevated number of GFAP positive cells in the ipsilateral cortex 
in the injury mice (1390 ± 424.5) compared to the contralateral cortex in the injury 
mice (505.6 ± 212.8; p<0.0001) and the ipsilateral cortex in the sham mice (963.4 ± 
326.6, p=0.07) (Figure 3.7, B). In the hippocampus, there was significant difference 
between the injury and sham cohorts (F(1,48)=9.08; p=0.004) but not between the 
ipsilateral and contralateral hippocampi (F(1,48)=0.397; p=0.5). Multiple comparisons 
with post-hoc Bonferroni test revealed significantly higher numbers of GFAP positive 
cells in the ipsilateral hippocampus in the injury mice (1195 ± 484.2) compared to the 
ipsilateral hippocampus in the sham mice (638.8 ± 415.2) (p=0.025) (Figure 3.7, C). 
There was no difference in the numbers of GFAP positive cells across the cohorts in 
the thalamus and hypothalamus.  
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Figure 3.7: GFAP immunostaining and quantification in LFPI experiment. GFAP 
immunofluorescence was imaged using wide-field microscopy and ImageJ utilised for 
particle analysis (A). Quantification demonstrated significantly elevated GFAP 
positive cells in the ipsilateral cortex in injury compared to sham mice (B). Similarly, 
we observed significantly elevated GFAP positive cells in the ipsilateral hippocampus 
in the injury cohort (C). Scale bar = 100µm. [**** p£0.0001; *** p£0.001; ** p£0.01; * 
p£0.05; ns p>0.05] 
 
3.4 CHAPTER DISCUSSION AND CONCLUSION 
Mild TBI account for over 80% of all head injuries and lead to a myriad of post-
concussional symptoms which can significantly affect patients (Bruns & Hauser 2003; 
Levin & Diaz-Arrastia 2015). In this chapter, we describe the characterization of a mild 
LFPI model which demonstrated axonal and inflammatory pathology with minimal 
neuronal cell death. One of the defining parameters of mild TBI is a period of loss of 
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consciousness or disorientation. In our study, we used the righting time which is a 
simple behavioural assay to assess for evidence of brain function disruption. We 
found that injury mice had significantly extended righting times compared to sham 
mice. The presence of structural injury (such as contusion or extra-axial collections) 
is not common in mild TBI. A study found that only 14% of patients with GCS 14 and 
above had positive findings on CT (Smits et al. 2007). This was evident in our model 
which failed to have any mice exhibiting significant contusion or cortical disruption. 
Furthermore, H+E examination revealed neuronal injury but no significant neuronal 
cell death. This has been found in other studies characterising mild LFPI (Spain et al. 
2010; Hylin et al. 2013). Axonal injury is believed to be a major pathological finding in 
mild TBI. This has been demonstrated histopathologically in a limited number of mild 
TBI cases (Bumbergs et al. 1995). However, more recently, diffusion MRI has been 
utilised to study white matter tract changes after mild TBI as a proxy of axonal 
integrity. A meta-analysis of studies on the subject concluded that there is evidence 
of white matter tract abnormalities within the corpus callosum of mild TBI patients 
(Aoki et al. 2012). Animal models have been particularly important in investigating 
axonal pathology after a mild injury. This has been demonstrated in a number of 
differing models across different animals including mice, rats and pigs (Spain et al. 
2010; Hylin et al. 2013; Browne et al. 2011). Immunohistochemical examination for 
APP accumulation is currently the gold standard for studying axonal pathology in both 
human and preclinical TBI (Hill et al. 2016). APP is transported through axons and 
mechanical disruption leads impaired transport and subsequent accumulation of the 
protein (Tang-Schomer et al. 2012). In our study, we found evidence of pronounced 
APP expression in the ipsilateral corpus callosum in the injury group at 24 hours. 
Alongside the APP findings, we also observed astroglial activation using Iba1 and 
GFAP to index microglia and astrocytes respectively. Within the cortex, the sham 
mice had evidence of significant astroglial activation in the ipsilateral compared to the 
contralateral cortex. This finding was important in highlighting the sham procedure 
was sufficient to induce an inflammatory response. However, this finding was not 
evident within the hippocampus and significant differences were noted between the 
injury and sham cohorts. This reflects findings from human mild TBI studies which 
has found inflammatory changes using molecular imaging techniques (Coughlin et al. 
2017). Several preclinical studies have demonstrated astroglial activation following a 
single mild TBI (Shultz et al. 2011; Shultz et al. 2012; Lafrenaye et al. 2015). In this 
chapter, we have described the characterization of a mild TBI model utilizing the LFPI 
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device. The model demonstrated axonal and astroglial pathology without overt 
neuronal cell death. These characteristics mirror those seen in human mild TBI and 
are consistent with preclinical findings in the literature. We therefore believe this 
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Mapping changes in the Synaptome map 
following a mild lateral fluid percussion 
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4.1 INTRODUCTION 
Traumatic Brain Injury (TBI) is a critical public health problem, of which, mild TBI is 
the most common injury. A large prospective cohort study found that almost half 
(44%) of patients with a mild TBI had an incomplete functional recovery at 6 months 
(van der Naalt et al. 2017). As described in Chapter 1, a combination of preclinical 
and human imaging studies has provided insights into the neuronal, axonal and 
inflammatory impact of mild TBI. However, there is limited understanding of the effect 
of mild TBI on the synapse. The synapse plays an important role in a range of 
cognitive processes and has been implicated in a number of neurological disorders 
including schizophrenia and Alzheimer’s disease (Nithianantharajah et al. 2013; 
Fromer et al. 2014; S. Hong et al. 2016). In TBI, the synapse is an area of confluence 
for a range of secondary injury processes including inflammation, glutamate 
neurotoxicity and oxidative stress. A number of studies have attempted to examine 
the impact of TBI on the synapse using immunohistochemistry, western blot and 
electron microscopy (Scheff et al. 2005; Gao et al. 2011; Wakade et al. 2010). 
Collectively, these data point towards an early loss of synapses (or synaptic proteins) 
followed by a period of reorganization. However, the approaches used in the 
experiments either provided limited spatial information, focused on single sub-regions 
or utilized antibodies against synaptic proteins which suffer from issues around non-
specificity. To overcome these methodological limitations, we aimed to utilize a strain 
of transgenic mouse with eGFP and mKO2 knocked into PSD95 and SAP102 
respectively. With the use of an in-house developed machine learning algorithm, we 
aimed to create whole brain synaptome maps to examine the temporal-spatial profile 
of PSD95 and SAP102 after a mild TBI. Using the LFPI, an established model of TBI, 
we first characterized the neuronal, axonal and inflammatory impact of a mild injury 
(1-1.5atm) in wildtype mice as described in Chapter 3. This demonstrated evidence 
of significant axonal and inflammatory pathology in the injury group without 
pronounced disruption of the brain architecture. In this chapter, we describe using this 
LFPI procedure to examine the impact of a single mild LFPI injury in the eGFP-PSD95 
mKO2-SAP102 mice across two time-points: 7 and 28 days. We opted for these time-
points for a number of reasons. Firstly, there is evidence of delayed degeneration of 
synapses at 7 days followed by synaptic recovery that peaks at 28 days (Wakade et 
al. 2010; Scheff et al. 2005). We conducted a pilot study that followed mice up to 24 
hours and 7 days after injury which demonstrated more pronounced synapse loss in 
the injury cohort compared to sham at 7 days compared to 24 hours (Appendix 2). 
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Based on this data, we opted to make 7 days our first time-point. Coupled to this, 
there is growing literature on the neurodegenerative and chronic inflammatory 
sequalae of TBI and we were interested to look at the longer-term impact of TBI on 
the synapse (Wilson et al. 2017). We therefore opted to follow the mice up to 28 days 
for this reason and to provide temporal data on synapse change.  
 
In this chapter, we first describe the early behavioural impact of the injury using the 
righting time. Secondly, we compare the areas of the major brain regions between the 
injury and sham mice to assess for differences in architecture that may bias 
observations seen in the synaptome map. Thirdly, using previously described 
markers, we examined the axonal and inflammatory effects between the injury and 
sham groups as a means to validate the observations seen at the synaptic level. 
Fourthly, due to the asymmetrical nature of the LFPI, we then compared the synaptic 
metrics (density, area and intensity) for 6 major brain regions of the left and right 
hemispheres in a group of naïve eGFP-PSD95 mKO2-SAP102 mice.  Following this, 
we examined the two synaptic proteins, starting with PSD95. For each protein, we 
first calculated the synaptic metrics of the whole ipsilateral cortex. From here, we then 
examined the synaptic density of the sub-regions of the cortex. Having focused on 
the cortex, we then calculated the Cohen’s d effect size differences for 222 sub-
regions between the injury and sham map and plotted them on a spatial map. A similar 
approach was used to examine temporal changes after an injury group between 7 
and 28 days. From there, we then examined the relationship between PSD95 and 
SAP102 and how it changed following LFPI. Finally, we assessed the association 
between PSD95 and SAP102 and the presynaptic protein, SV2A, and the microglial 
marker Iba-1.  
 
4.2 SUMMARY OF METHODS AND EXPERIMENTAL PIPELINE 
In order to examine the impact of LFPI on the synaptome, male PSD95-eGFP and 
SAP102-mKO2 knock-in mice aged between 8-16 weeks were randomised to four 
groups: injury or sham at 7 and 28 days (Figure 4.1, A). Briefly, the mice were 
anaesthetised with 5% isoflurane and underwent a right circular craniectomy to which 
a hub was attached. The mice were then attached to the LFPI device and either had 
a mild LFPI pulse (1-1.5 atm) applied or a sham (no pulse). Mice were then recovered 
and followed up to 7 or 28 days. A fifth group of non-randomised naïve mice were 
included within the study as a control. Mice were sacrificed by transcardial perfusion 
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and their brains were collected. Brains were subsequently cryosectioned and coronal 
18µm sections approximately corresponding to approximately -1.94mm from bregma 
according to Franklin and Paxinos were selected (Figure 4.1, B). The Andor 
Revolution XDi system was used to image the sections for which each tile 
corresponded to 512x512 pixels (84nm/pixel). Direct fluorescence from PSD95-eGFP 
was imaged using the 488nm laser line (30% laser intensity; 48ms exposure time; 
250 EMCCD gain) and SAP102-mKO2 was imaged using the 561nm laser line (50% 
laser intensity; 100ms exposure time; 250 EMCCD gain) (Figure 4.1, C). A 
rectangular montage was created and 222 brain sub-regions based on the Allen 
Mouse Brain Atlas were delineated using ImageJ (Figure 4.1, D and E). A key for the 
sub-region nomenclature can be found in Figure 4.2. The Ensemble method was then 
utilised to detect individual puncta and generate three metrics for each of the two 
proteins: puncta density (number of puncta per unit area), puncta area (size of the 
puncta) and puncta intensity (mean grey value of the puncta) (Figure 4.1, F). Median 
puncta metrics were then calculated for the individual brain sub-regions and 
represented visually in spatial heatmaps (Figure 4.1, G).  
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Figure 4.1: Schematic of mild LFPI PSD95-eGFP SAP102-mKO2 mice 
experiment methodology: a mild LFPI or sham was applied to double knock-in 
PSD95-eGFP mKO2-SAP102 mice (A) after follow-up to 7 or 28 days the mice were 
culled and their brain cryosectioned to 18µm sections (B) following which they were 
imaged with the Andor Revolution XDi system (C). Single coronal stitched image 
created per mouse (D) and ImageJ used to delineate 222 sub-regions of interest 
based on Allen Institute Mouse Brain Atlas (E) following which Ensemble method (F) 
used to detect puncta and quantify puncta density, area and intensity which were 
plotted onto regional heat maps (G) 
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Figure 4.2: Delineation map sub-regions of coronal section of mouse brain 
made in accordance with Allen Mouse Brain Atlas. Each hemisphere include 111 sub-
regions for which the complete names for abbreviations are demonstrated in the 
attached table.  
 
4.3 EXPERIMENTAL RESULTS 
A pilot study of 6 mice was performed to provide data to power this experiment 
(Appendix 2). These calculations indicated that a total of 9 should be randomized to 
each cohort, therefore a total of 64 mice were randomized into this experiment. Of 
these mice, 20 had to be excluded for the following reasons: 9 mice developed dural 
ruptures, 6 mice were found to have an incorrect genotype on reanalysis, 4 sustained 
dural tears and 1 mouse died two days post-operatively. Figure 4.3 shows the final 
cohort numbers.  
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Figure 4.3: Flow diagram of mouse cohorts in study demonstrating mouse 
numbers in different cohorts 
 
The mean mouse weight was 26.5±3.2g. A comparison of the cohorts’ weight showed 
that there was no significant variation across the groups. The mean fluid percussion 
intensity was 1.26±0.1atm. There was no significant difference in the intensity of the 
fluid percussion wave between the 7-day (1.27±0.07atm) and 28-day (1.24±0.14atm) 
cohorts (p=0.5; student t-test) (Figure 4.3). From this data, we conclude that there 
was no significant differences in the mice randomized to the different cohorts and that 
the intensity of the percussion pulse did not differ across the time-points.  
 
4.3.1 Injury mice exhibit increased righting times 
To examine whether the fluid percussion led to an early alteration in brain function we 
measured the righting time (RT) of the mice. The injury cohort had an RT of 562.4±271 
seconds compared to the sham cohort for an RT of 79±118.6 seconds was observed 
(p<0.0001; student t test) (Figure 4.4). Using this simple behavioural assay, we 
conclude that application of the fluid pulse led to early alteration in brain function. This 
observation is limited by the fact it was an unblinded test and that it only provides 
information on brain function immediately post-injury.  
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Figure 4.4: Comparison of righting times between injury and sham mice which 
demonstrates significant increase in RT in the injury group compared to the sham 
group. Boxplot represents median and interquartile range. Mouse images taken from 
Wikimedia Commons. [**** p£0.0001; *** p£0.001; ** p£0.01; * p£0.05; ns p>0.05] 
 
4.3.2 No difference in regional architecture between injury and sham mice 
TBI can lead to cerebral oedema and atrophy which can distort the regional 
architecture of the brain. To examine whether this was present in our experimental 
groups, we used area analysis to ascertain whether there were differences between 
the injury and sham groups in 6 major brain regions: cortex, corpus callosum, 
hippocampus, thalamus, striatum and hypothalamus (Figure 4.5). Two-way ANOVA 
was used to compare injury and sham groups for each region (ipsilateral and 
contralateral) across the two time-points. No significant differences were observed 
across any of the regions at either 7 days or 28 days. Therefore, we conclude that 
there are no major differences in gross brain architecture between the injury and sham 
groups. However, this conclusion must be caveated by the fact that our analyses are 
of 2-dimensional area measurements and not full volumetric values and we only 
looked at major regions and not individual sub-regions.  
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Figure 4.5: Comparison of regional area between injury and sham mice. No 
significant differences (p>0.05) were observed between the injury (red) and sham 
(blue) mice in 6 major brain regions (CC: corpus callosum; Cx: cortex; Hip: 
hippocampus; Hyp: hypothalamus; Str: striatum; Th: thalamus) across the ipsilateral 
and contralateral hemispheres for both 7 and 28 days (A-D). Graphs shown are bar 
charts with standard deviations.  
 
4.3.3 Axonal injury observed in corpus callosum of injury mice 
Axonal pathology is a pathological hallmark of TBI. To assess whether this was the 
case in our experiment, Amyloid Precursor protein (APP) was used to examine the 
degree of axonal pathology in the ipsilateral corpus callosum (Figure 4.6, A). Using 
two-way ANOVA, there was statistically significant difference the injury and sham 
cohorts (F(1,35)=15.71; p=0.0003) but not between 7 and 28 days (F(1,35)=2.21; 
p=0.146). In a post-hoc Bonferroni test, the injury cohort was found to have 
significantly elevated numbers of corpus callosal APP aggregates at 7 days 
(44.7±25.4) compared to the sham mice (11.5±18.; p=0.006). At 28 days, the injury 
cohort had 27.6±22.2 aggregates compared to the sham mice which were found to 
have 9.3±10.7 but this did not reach statistical significance (p=0.3) (Figure 4.6, B). 
These data provide evidence of significant axonal pathology in our injury cohorts 
which peaks at 7 days. We conclude that, in the absence of major structural 
differences between the injury and sham groups, axonal injury was induced by 
application of the percussion pulse. This observation is made only within the corpus 
callosum which limits its generalisability to other brain regions.  
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Figure 4.6: Comparison of APP aggregates in the ipsilateral corpus callosum. 
This demonstrated APP aggregates in the corpus callosum of injury mice (A) and 
graph highlighting differences in ipsilateral corpus callosum aggregate counts 
between injury, sham and naïve mice across the two time points (B). Boxplot denote 
the median and interquartile range. Scale bar = 20µm. [**** p£0.0001; *** p£0.001; ** 
p£0.01; * p£0.05; ns p>0.05] 
 
4.3.4 Injury cohort exhibited progressive inflammatory response 
Post-traumatic inflammation is a major secondary injury process after TBI. To 
examine inflammatory changes in our experimental group we stained for Iba-1, a 
marker of microglial activity (Figure 4.7 A). With two-way ANOVA, we observed that 
comparison of injury and sham mice had a statistically significant effect in the 
ipsilateral cortical (F(1,31)=14.57;p=0.0006), contralateral cortical (F(1,31)=6.99; 
p=0.01) and ipsilateral hippocampal (F(1,31)=9.43; p=0.004) and contralateral 
hippocampal (F(1,31)=5.95; p0.02) Iba-1 count. Utilising post-hoc Bonferroni test, we 
found that at 7 days, the number of Iba-1 positive cells were increased in the injury 
cohort’s ipsilateral cortex (1011±386) compared to the sham mice (563.8±251.4; 
p=0.041) (Figure 4.7, B). The number of Iba-1 cells had remained elevated at 28 days 
in the injury cohort’s ipsilateral cortex (837.5±398) compared to the sham cohort 
(434.9±223.5, p=0.09), but this did not reach statistical significance. Within the 
ipsilateral hippocampus there was a statistically significant difference in Iba-1 cell 
count between the injury and sham mice at 7days (p=0.02) (Figure 4.7, C). Within 
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the contralateral hemisphere, there was no significant different in Iba-1 cell count at 
7 days in the cortex between the injury and sham mice (p>0.999) (Figure 4.7, D). 
However, by 28 days the number of Iba-1 positive cells were significantly higher in 
the injury group (1017±473.3) compared to the sham group which had a mean of 
397.6±226.4 cells (p=0.0036). In the contralateral hippocampus there was no 
difference in Iba-1 cell count between injury and sham at 7 days (p=0.627) and 28 
days (p=0.13) (Figure 4.7, E). However, there was a statistically significant temporal 
increase in the number of Iba-1 cells from 7 to 28 days (p=0.038). There were no 
significant differences in the number of Iba-1 positive cells between the injury and 
sham groups and across the two time-points in the thalamus and hypothalamus. From 
this data, we can conclude that in the injury group there was increased microglial 
numbers in the ipsilateral cortex and hippocampus from day 7 post-injury which 
persisted to 28 days post-injury. Interestingly, we observed a delayed increase in 
microglia numbers in the contralateral cortex and hippocampus in the injury group. 
This points towards a progressive inflammatory process that extends well beyond the 
initial injury.  
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Figure 4.7: Comparison of Iba-1 positive cells between injury and sham mice. 
Image demonstrates Iba-1 immunohistochemistry and image J conversion (A) and a 
comparison of Iba-1 positive cell numbers across the ipsilateral and contralateral 
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cortex and hippocampus (B-E). Boxplots denote median and interquartile range. 
Scale bar = 100µm. [**** p£0.0001; *** p£0.001; ** p£0.01; * p£0.05; ns p>0.05] 
 
4.3.5 No left-right asymmetry detected in the PSD95 and SAP102 synaptome 
maps 
Due to the unilateral nature of the fluid percussion model, it was important to ensure 
that there was no inherent asymmetry between the left and right hemispheres in our 
naïve cohort that may bias observations seen between the ipsilateral and contralateral 
hemispheres in both the sham and injury mice (Appendix 3). To do this, we compared 
6 major brain regions (cortex, hippocampus, thalamus, hypothalamus, striatum and 
corpus callosum) between the left and right hemispheres in our naïve cohort. The 
synaptic density, area and intensity for both PSD95 and SAP102 were compared. 
Using two-way ANOVA, we found no significant differences in any of the synaptic 
metrics across both proteins (Figure 4.8). 
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Figure 4.8: Left-Right comparison of major brain regions in naïve mice. No 
significant difference (p>0.05) between right and left hemispheres for major brain 
regions (CC: corpus callosum; Cx: cortex; Hip: hippocampus; Hyp: hypothalamus; St: 
striatum; Th: thalamus) for puncta density, area and intensity in both PSD95 and 
SAP102.  
 
4.3.6 Reorganization of PSD-95 synaptome map following injury 
4.3.6.1 Comparison of PSD95 puncta metrics in ipsilateral cortex  
Due to the focal nature of the LFPI model, we first examined the impact of the LFPI 
on the ipsilateral cortex. A gross examination of the whole ipsilateral cortex was 
undertaken looking at PSD95 puncta density, area and intensity in the three mice 
cohorts (naïve, sham and injury) and across the 2 time-points (7 and 28 days). Two-
way ANOVA revealed that mouse cohort had a statistically significant effect on the 
overall puncta density effect (F(2,43)=11.14; p=0.0001). Multiple comparisons with 
Bonferroni correction revealed that at 7 days there was a significant drop in cortical 
PSD95 density in both the injury (86.4±7.2 per 100µm2; p=0.001) and sham (87.9±7.9 
per 100µm2; p=0.006) mice compared to the naïve cohort (99.7±7.2 per 100µm2) 
(Figure 4.9, A). However, there was no significant difference in cortical PSD95 
density between the injury and sham mice at 7 days (p>0.999). At 28 days, the PSD95 
density in the injury group (90.13±4.8 per 100µm2) remained significantly reduced 
compared to the naïve cohort (p=0.026) which was no longer the case with the sham 
cohort (93.31±4.4 per 100µm2; p=0.219). There were no significant differences 
between the cohorts for both PSD95 puncta area and intensity (Figure 4.9, B and C). 
This data indicates a drop in ipsilateral cortical PSD95 density in both the sham and 
injury groups compared to the naïve cohort with no differences observed in puncta 
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Figure 4.9: Comparison of PSD95 metrics in the ipsilateral cortex between the 
three cohorts (injury, sham and naïve) for PSD95 density (A), puncta area (B) and 
puncta intensity (C) 
 
4.3.6.2 Comparison of PSD95 density in ipsilateral cortical regions 
Given the observed differences in gross ipsilateral cortical PSD95 density, we then 
aimed to compare regional PSD95 density in the ipsilateral cortex in more detail. The 
cortex was subdivided into its major regions including: retrosplenial, motor, 
somatosensory, auditory, temporal association, ectorhinal, perihinal and entorhinal 
areas (Figure 4.10, A). These were plotted from medial to lateral to demonstrate 
regional alterations in PSD95 density (Figure 4.10, B and C). Using two-way ANOVA, 
we observed significant variation between the cohorts (injury, sham and naïve) at 7 
days (F(2,273)=20.56; p<0.0001) and 28 days (F(2,286)=28.5; p<0.0001). With 
multiple testing with Bonferroni correction, we observed significant decreases in 
PSD95 density in both the sham and injury mice compared to the naïve mice within 
the primary motor area (MOp) and trunk somatosensory area (SSp-tr). The injury 
cohort demonstrated further significant decreases in PSD95 density compared to the 
naïve cohort in the secondary motor area (MOs) [82.55±7.5 vs 70.86±7.9 per 100µm2; 
p=0.04] and the barrel field somatosensory area (SSp-bfd) [99.08±9.6 vs 86.56±9.3 
per 100µm2; p=0.02]. At 28 days, there remained a significant reduction in PSD95 
density in both the injury and sham groups compared to the naïve group in MOp and 
SSp-tr. The injury cohort demonstrated persisting reduction in PSD95 density in SSp-
bfd compared to the naïve cohort [99.08±9.6 vs 89.32±5.8 per 100µm2; p=0.008]. 
Alongside this, the injury cohort had significantly reduced PSD95 density in the dorsal 
auditory area (AUDd) compared to the naïve cohort [102.74±7.3 vs 93.59±4.7 per 
100µm2; p=0.01]. There were no significant differences between the injury and sham 
groups across both time-points. These data indicate that the motor and 
somatosensory areas of the mouse cortex were most affected by the LFPI procedure 
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which are situated underneath the craniotomy site. Interestingly, the results highlight 
that the process of the removal of the bone flap led to a comparable reduction in 
PSD95 density in the sham mice. However, it appears that the application of the LFPI 
pulse led to significant reduction in PSD95 puncta density distal to the craniotomy site 
(SSp-bdf and AUDd) in the injury group compared to the naïve mice which was not 
present in the sham cohort.  
 
 
Figure 4.10: Comparison of cortical sub-regional PSD95 density. Representation 
of the cortical regions (A) with line graph of cortex regional PSD95 density at 7 days 
(B) and 28 days (C). Abbreviations: RSPv: Retrospenial area ventral part; RSPd: 
Retrospenial area dorsal part; MOs: Secondary motor area; MOp: Primary motor 
area; SSp-tr: Somatosensory area trunk; SSp-bfd: Somatosensory area barrel field; 
AUDd: Doral auditory area; AUDp: Primary auditory area; AUDv: Ventral auditory 
area; TEa: Temporal association area; ECT: Ectorhinal area; PERI: Perirhinal area; 
ENTI: Entorhinal area.  
  
4.3.6.3 Sub-regional changes in the PSD-95 synaptome map following LFPI 
To investigate the impact of the LFPI model at the sub-regional level across the whole 
synaptome, we then subdivided the brain into 222 sub-regions (111 sub-regions in 
ipsilateral and contralateral hemispheres to the fluid percussion injury) and a Cohen’s 
d value was measured comparing injury with sham for PSD95 puncta density, area 
and intensity (Appendix 4). These effect sizes were then plotted on a spatial heat 
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map of a coronal mouse brain section (Figure 4.11). Two-way ANOVA was used to 
examine the effect of experimental cohort (injury vs sham) on the three PSD95 
metrics. Post-hoc unpaired student t-tests were then utilized to examine the 
significance of differences seen at the sub-regional level. Two-way ANOVA showed 
that there was a significant difference observed between the injury and sham cohort 
for both PSD95 puncta density at 7 days (F(1,3370)=35.09; p<0.0001) and 28 days 
(F(1,3986)=165.1; p<0.0001) and intensity across both 7 days (F(1,3770)=140; 
p<0.0001) and 28 days (F(1,3986)=300.3; p<0.0001). Conversely, there was no 
significant difference (p>0.05) between injury and sham for PSD95 puncta area. 
Using post-hoc t-tests, at 7 days there was evidence of significant sub-regional 
clustering for PSD95 puncta density, size or intensity. There were a number of 
isolated sub-regions with p<0.05 however none of these reached the threshold of 
p<0.0002 and are therefore not considered within the discussion of the results (Figure 
4.11). These findings indicate that there was significant difference in the synaptome 
between injury and sham at 7 days. At 28 days, we observed a reduction in PSD95 
puncta density Cohen’s d effect size in the injury compared to the sham cohort 
(Figure 4.11, A). This was most pronounced within the contralateral hippocampus 
with differences within clustering sub-regions in the CA1, CA3 and the dentate gyrus 
all reaching statistical significance (p<0.05). We also observed reductions in Cohen’s 
d effect size in the injury group in the isocortex bilaterally. This included significant 
differences within the ipsilateral somatosensory barrel-field (SSp-bfd) and dorsal 
auditory areas (AUDd) alongside the contralateral trunk somatosensory trunk (SSp-
tr) and primary auditory areas (AUDp). Conversely, there was a less clear pattern of 
change in PSD95 puncta area (Figure 4.11, B). However, there was no evidence of 
sub-region clustering or isolated sub-regions with p<0.0002. The PSD95 puncta 
intensity revealed a uniform global reduction in Cohen’s d effect size in the injury 
group compared to the sham, however none of these were considered significant 
based on our interpretation thresholds (Figure 4.11, C).  
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Figure 4.11: Sub-regional PSD95 synaptome map comparing injury and sham 
mice across 7 days and 28 days looking at PSD95 puncta density (A), PSD95 puncta 
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area (B) and PSD95 puncta intensity (C). Large black star identifies side of fluid 
percussion. [ * = p<0.05].  
 
To examine the relationship between the PSD95 synapse metric changes seen after 
injury, we calculated the Pearson correlation co-efficient between the Cohen’s d effect 
sizes for each of the metrics across both time points. There was a negative 
relationship between PSD95 density and area at 7 days (r=-0.249; p=0.0002) that 
became more pronounced at 28 days (r=-0.538; p<0.0001) (Figure 4.12, A). 
Similarly, a negative relationship was observed between PSD95 area and intensity at 
both 7 days (r=0.618; p<0.0001) and 28 days (r=-416; p<0.0001) (Figure 4.12, B). 
Conversely, PSD95 density and puncta intensity revealed significant positive 
correlation across both time-points: 7 days (r=0.233; p=0.0005) and 28 days (r=0.574; 
p<0.0001) (Figure 4.12, C). Collectively, this data indicates that the LFPI leads to 
progressive alteration in the synaptome up to a month after a single mild injury. In 
particular, it demonstrated a marked global reduction in both PSD95 puncta density 
in the injury compared to the sham group at 28 days centred around the contralateral 
hippocampus and isocortex bilaterally.  
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Figure 4.12: Correlation between PSD95 metrics Cohen’s d effect size. 
Scatterplots of Cohen d effect sizes for 222 brain sub-regions comparing PSD95 
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4.3.6.4 Temporal changes in PSD95 synaptome map in injury cohort 
To better understand the temporal changes in PSD95 in the injury groups, we mapped 
Cohen’s d effect sizes of the 28-day against the 7-day injury groups across the 222 
brain regions (Figure 4.13). The same statistical approach as described earlier was 
used: two-way ANOVA to examine the impact of time-points (7 days vs 28 days) 
followed by unpaired student t-tests for sub-region analysis. Comparison of the 
temporal cohorts with two-ANOVA showed significant difference between the two 
cohorts (p<0.0001) for all three PSD95 metrics. On comparison of the 222 sub-
regions using post-hoc multiple t-tests, we observed a substantial increase in PSD95 
puncta density Cohen’s d effect size in the ipsilateral cortex at 28 days compared to 
7 days (Figure 4.13, A). This was centred around the primary motor (MOp) and 
somatosensory trunk (SSp-tr) areas. However, despite this increase, PSD95 puncta 
density within the ipsilateral motor and somatosensory cortical regions did not return 
to naïve mice levels. We observed an increase of 6% from 83% of naïve density at 7 
days up to 89% by 28 days. The differences observed in the superficial (layer 1 and 
2/3) of the MOp and deeper layers of SSp-tr (layers 4, 5 and 6a) reached statistical 
significance (p<0.05). This contrasted against relative PSD95 puncta density 
reduction in the contralateral cortex of which the ventral retrosplenial area (RSPv), 
barrel-field somatosensory (SSp-bfd) and auditory areas all demonstrated significant 
reductions in Cohen’s d effect size at 28 days compared to 7 days. A similar pattern 
was observed for PSD95 puncta intensity which revealed small increases in Cohen’s 
d effect size in the ipsilateral cortex mainly within the superficial layers of MOp and 
SSp-tr (Figure 4.13, C). However, none of these observations were statistically 
significant (p>0.05). There was a reduction in Cohen’s d effect size in other brain 
regions distal to the injury site. Sub-regions within the ectorhinal (ECT), perirhinal 
(PERI) and ventral auditory (AUDv) areas showed statistically significant reductions 
in the 28 day versus the 7 day injury cohort. Conversely, PSD95 puncta area 
demonstrated very pronounced statistically significant changes in the ipsilateral 
isocortex and subcortical plate. In the isocortex, we observed statistically significant 
increases in PSD95 puncta areas in the 28 days cohort within the isocortex distal to 
the fluid percussion site (Figure 4.13, B). In particular, the piriform (PIR), entorhinal 
(ENT), perirhinal (PERI), ectorhinal (ECT) and temporal association (TEa) areas saw 
statistically significant changes in Cohen’s d effect size. We also observed similar 
increases in PSD95 puncta area Cohen’s d effect size in the ipsilateral cortical sub-
plate with statistically significant findings within the lateral amygdalar nucleus (LA) 
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and both anterior and posterior parts of the basolateral amygdalar nucleus (BLAp and 
BLAa). To examine the relationship between the PSD95 metrics, we calculated the 
Pearson correlation co-efficient for the Cohen’s d effect sizes across the 222 brain 
sub-regions. This demonstrated a significantly positive relationship between PSD95 
density and puncta intensity (r=0.471; p<0.0001). While PSD95 puncta area and 
density (r=-0.345; p<0.0001) and mean (p=-0.479; p<0.0001) showed significantly 
negative correlations. This data indicates that following LFPI, there is a focal increase 
in PSD95 density and puncta intensity at the site of injury between 7 and 28 days. 
While there is evidence of relative reductions in both metrics at regions distal to the 
injury site. This indicates that the synaptome map following injury is a dynamic entity 
with evidence of both synapse loss and recovery occurring in tandem.  
 
 
Figure 4.13: Subregional PSD95 synaptome map comparing 7 and 28 days in 
injury group looking at PSD95 puncta density including a boxplot graph of ipsilateral 
motor and somatosensory PSD95 at 7 days, 28 days and naïve mice (A), PSD95 
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puncta area (B) and PSD95 puncta intensity (C). Large black star identifies side of 
fluid percussion. [ * = p<0.05]. 
 
4.3.7 Reorganization of SAP102 synaptome map following injury 
4.3.7.1 Comparison of SAP102 puncta metrics in ipsilateral cortex 
Similar to PSD95, we first examined the impact of the LFPI on the synaptic metrics of 
the whole ipsilateral cortex. Using two-way ANOVA, we found that the mouse cohorts 
had a statistically significant impact on the overall effect of puncta intensity 
(F(2,43)=3.96; p=0.026) but not puncta density (F(2,43)=2.38; p=0.1) or size 
(F(2,43)=1.33; p=0.27). Using multiple comparisons with Bonferroni correction, at 7 
days, neither the injury (71.5±12.4 per 100µm2; p=0.377) nor sham (68.7±12.4 per 
100µm2; p=0.203) mice saw significant differences in their SAP102 puncta density 
compared to naïve mice (82.0±17.7 per 100µm2) (Figure 4.14, A). A similar pattern 
was seen at 28 days in both the injury (72.8±9.3 per 100µm2; p=0.544) and sham 
mice (76.7±9.1 per 100µm2; p>0.999) compared to the naïve mice. There were no 
significant differences between the cohorts for both SAP102 puncta area or mean 
intensity in multiple comparison analysis (Figure 4.14, B and C). These data indicate 
that, compared to PSD95, SAP102 appears to less vulnerable to loss following a 
traumatic insult.  
 
 
Figure 4.14: Comparison of SAP102 metrics in the ipsilateral cortex between the 
three cohorts (injury, sham and naïve) for PSD95 density (A), puncta area (B) and 
puncta intensity (C) 
 
4.3.7.2 Comparison of SAP102 density in ipsilateral cortical regions 
To further examine for cortical regional changes in SAP102 puncta density, we 
subdivided the ipsilateral cortex into 13 sub-regions. Using two-way ANOVA, we 
observed a significant effect of the mouse cohorts on puncta density at 7 days 
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(F(2,273)=12.5; p<0.0001) and 28 days (F(2,286)=12.27; p<0.0001). With multiple 
correction with Bonferroni corrections, we observed a reduction in SAP102 puncta 
density in the primary motor area between both the injury (67.9±12.9 100µm2) and 
sham (63.6±11.1 100µm2) cohorts compared to the naïve mice (80.7±20.0 100µm2) 
at 7 days, however these observations did not reach statistical significance (p>0.05) 
(Figure 4.15, B). There were no reductions in SAP102 puncta density in the 
somatosensory areas in both the injury and sham mice. Throughout the cortical 
regions, there were no statistically significant differences observed between the three 
cohorts across both time-points. This highlights SAP102’s limited response to LFPI. 
The reasons for these observations may either be that SAP102 has greater biological 
resistance to traumatic insult compared to PSD95 or our observations are limited by 
detection bias. This latter explanation is plausible particularly given the greater 




Figure 4.15: Comparison of cortical subregional SAP102 density. Representation 
of the cortical regions (A) with line graph of cortex regional SAP102 density at 7 days 
(B) and 28 days (C). Abbreviations: RSPv: Retrospenial area ventral part; RSPd: 
Retrospenial area dorsal part; MOs: Secondary motor area; MOp: Primary motor 
area; SSp-tr: Somatosensory area trunk; SSp-bfd: Somatosensory area barrel field; 
AUDd: Doral auditory area; AUDp: Primary auditory area; AUDv: Ventral auditory 
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area; TEa: Temporal association area; ECT: Ectorhinal area; PERI: Perirhinal area; 
ENTI: Entorhinal area 
 
4.3.7.3 Sub-regional changes in the SAP102 synaptome map following LFPI 
As with PSD95, we subdivided the brain into 222 sub-regions and a Cohen’s d effect 
size was measured comparing injury with sham for SAP102 puncta density, area and 
intensity (Appendix 5). These effect sizes were then plotted on a spatial heat map of 
a coronal mouse brain section (Figure 4.16). Two-way ANOVA was used to examine 
the effect of injury type (injury vs sham) followed by unpaired student t-tests to more 
closely examine the significance of sub-regions. The two-way ANOVAs observed 
significant differences (p<0.0001) across the injury and sham cohorts across all three 
SAP102 metrics across both time-points: puncta density at 7 days (F(1,3770)=44.46; 
p<0.0001) and 28 days (F(1,3986)=149.5; p<0.0001); puncta size at 7 days 
(F(1,3770)=28.50;p<0.0001) and 28 days (F(1,3986)=44.75; p<0.0001); puncta 
intensity at 7 days (F(1,3770)=68.44; p<0.0001) and 28 days (F(1,3986)=232.2; 
p<0.0001). Within the post-hoc multiple t-tests no individual comparison met the 
p<0.0002 threshold and therefore isolated sub-regions are not discussed. At 7 days, 
there was an increase in Cohen’s d effect size of SAP102 puncta area in the 
contralateral primary and ventral auditory areas. Otherwise, there were no other 
significant difference observed for SAP102 synaptic parameters (Figure 4.16). Much 
like PSD95, at 28 days, we observed a reduction in SAP102 puncta density Cohen’s 
d effect size in the injury group contralateral hippocampus including the polymoreph 
layer of the dentate gyrus (Figure 4.16, A). SAP102 puncta area exhibited reductions 
in Cohen’s d effect size within the isocortex bilaterally (Figure 4.16, B). There was 
clustering of statistically significant observations centred around the deeper layers 
(layer 5, 6a and 6b) of the secondary motor area (MOs) and ventral and dorsal 
retrosplenial areas (RSPd and RSPv) within the ipsilateral isocortex. Similar 
reductions were observed within the deep layers of MOp and MOs in the contralateral 
isocortex. SAP102 intensity did not demonstrate any significant findings. 
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Figure 4.16: Sub-regional SAP102 synaptome map comparing injury and sham 
mice across 7 days and 28 days looking at SAP102 puncta density (A), SAP102 
puncta area (B) and SAP102 puncta intensity (C). Large black star identifies side of 
fluid percussion. [ * = p<0.05]. 
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Figure 4.17: Correlation between SAP102 metrics Cohen’s d effect sizes 
Scatterplots of Cohen d effect sizes for 222 brain sub-regions comparing SAP102 
density and area (A); SAP102 area and mean (B) and SAP102 density and mean (C) 
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To examine the relationship between the SAP102 puncta metric changes seen after 
injury, we calculated the Pearson correlation co-efficient between the Cohen’s d effect 
sizes for each of the metrics across both time points (Figure 4.17). Similar to PSD95, 
there was a negative relationship between SAP102 puncta density and size after 
injury. The Pearson R correlation coefficient was -0.536 (p<0.0001) at 7 days and -
0.482 (p<0.0001) at 28 days. Similarly, SAP102 puncta size and intensity had a 
significantly negative relationship at both 7 days (r=-0.527; <0.0001) and 28 days (r=-
0.418; <0.0001). However, the SAP102 puncta density and intensity had a positive 
relationship with a correlation coefficient of 0.585 (p<0.0001) at 7 days and a 
coefficient of 0.445 (p<0.0001). Together these data show that SAP102, much like 
PSD95, showed progressive region-specific decline in puncta density and intensity at 
28 days following injury. These findings along with the correlation analysis show that 
TBI leads to loss of synapse numbers but also the amount of SAP102 protein within 
the remaining synapses at 28 days post-injury.  
 
4.3.7.4 Temporal changes in SAP102 synaptome map in injury cohort 
To better understand the temporal changes in SAP102 in the injury groups, we 
mapped the Cohen’s d effect sizes of the 28-day against the 7-day injury groups 
across the 222 brain regions (Figure 4.18). Two-way ANOVAs demonstrated 
significant differences (p<0.0001) between the time-points for all three SAP102 
puncta metrics. Unlike PSD95, SAP102 puncta density Cohen’s d effect size 
increased modestly in the cortex underlying the fluid percussion site with only layer 1 
of the primary motor cortex (MOp) reaching statistical significance (R=1.1; p=0.02) 
(Figure 4.18, A). Even though the difference between the injury and sham were 
modest, they mirrored PSD95 density changes in the ipsilateral motor and 
somatosensory cortex compared to naïve mice. For SAP102, at 7 days the injury 
density was 85% of naïve increasing up to 89% by 28 days. Areas distal to the 
percussion site [ectorhinal (ECT), perirhinal (PERI) and entorhinal (ENT) areas] in the 
ipsilateral cortex saw statistically significant relative reductions in SAP102 puncta 
density Cohen’s d effect size (Figure 4.18, C). Alongside this, there was a global 
reduction in effect size in other brain regions of which the ipsilateral cortical areas 
distal to the percussion site were statistically significantly affected (ECT, PERI, ENT 
and TEa areas). Conversely, these same regions showed statistically significant 
increases in SAP102 puncta area (Figure 4.18, B). To better examine the relationship 
between the SAP102 puncta metrics, we calculated the Pearson correlation co-
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efficient for the Cohen’s d effect sizes across the 222 brain sub-regions. This 
demonstrated a significantly positive relationship between SAP102 puncta density 
and intensity (r=0.605; p<0.0001). We observed negative relationships between 
SAP102 puncta area and the two metrics: intensity (r=-0.052; p<0.0001) and density 
(r=-0.537; p<0.0001). This data indicates that following LFPI, there are progressive 
changes occurring within the ipsilateral cortical hemisphere. Regions at the 
percussion site demonstrated increases in SAP102 puncta density as more distal 
regions saw reductions in puncta density and intensity coupled with a modest 
increase in puncta size between 7 to 28 days.  
 
 
Figure 4.18: Subregional SAP102 synaptome map comparing 7 and 28 days in 
injury group looking at SAP102 puncta density including a boxplot graph of ipsilateral 
motor and somatosensory PSD95 at 7 days, 28 days and naïve mice (A), SAP102 
puncta area (B) and SAP102 puncta intensity (C). Large black star identifies side of 
fluid percussion. [ * = p<0.05] 
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4.3.8 Correlation between PSD95 and SAP102 following LFPI 
Next, we aimed to examine the relationship between changes observed in PSD95 
and SAP102. To determine this, we first assessed the relationship between SAP102 
and PSD95 in the naïve mice cohort (n=5). We correlated the mean values of PSD95 
and SAP102 across 222 sub-regions (Figure 4.19, A1-3). We found very strong 
statistically significant positive correlation between PSD95 and SAP102 density 
(r=0.963; p<0.0001) and area (r=0.937; p<0.0001). We also observed a positive 
correlation between PSD95 and SAP102 for puncta intensity albeit less strong 
(r=0.474; p<0.0001). We then aimed to examine the relationship between the 
changes seen after LFPI between PSD95 and SAP102. To do this, we correlated the 
Cohen’s d effect sizes for PSD95 and SAP102 puncta parameters across the 7 and 
28-day time-points (Figure 4.19, B). We found that at 7 days there was a strongly 
positive correlation between PSD95 and SAP102 intensity (r=0.9054; p<0.0001). 
There were also statistically significant positive relationships between density 
(r=0.5912; p<0.0001) and size (r=0.627; p<0.0001). At 28 days, density was found to 
have a very strong positive correlation (r=0.8463; p<0.0001) compared to size 
(r=0.6803; p<0.0001) and intensity (r=0.6645; p<0.0001). These findings point 
towards a positive relationship between PSD95 and SAP102 following an LFPI. 
Interestingly, there were differences in the strength of correlation between the time-
points. At 7 days, puncta intensity showed strong correlation (r=0.905) which may 
reflect a close relationship between the changes of the amount of PSD95 and SAP102 
protein within the synapse after injury. The relationship for puncta density at 7 days 
was not as strong (r=0.5912) suggesting differential susceptibility to PSD95 and 
SAP102 dominant synapses. However, by 28 days there was a stronger correlation 
of PSD95 and SAP102 density (r=0.8463) reflecting that the degree of puncta loss for 
the two proteins had become more aligned.  
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Figure 4.19: Correlation between PSD95 and SAP102 puncta parameters. 
Correlation between PSD95 and SAP102 puncta parameters in 222 sub-regions in 
naïve mice (n=5) for puncta density (A1), puncta area (A2) and puncta intensity (A3). 
Alongside this, we examined the relation between the Pearson correlation coefficient 
following LFPI for the three parameters across 7 and 28 days (B) [**** = p<0.0001] 
 
4.3.9 Impact of LFPI on the presynaptic protein SV2A 
To further examine the synaptic effects of LFPI on the synapse, we investigated the 
presynaptic protein SV2A. Given our observation of reduction in PSD95 and SAP102 
density at 28 days, we opted to investigate SV2A at this time-point.  Using a different 
brain section to the one imaged with the SDM, the protein was tagged with an 
immunohistochemistry protocol and then imaged using wide field florescence 
microcopy (Figure 4.20, A). Twelve brain regions (ipsilateral and contralateral cortex, 
hippocampus, thalamus, hypothalamus, subcortical plate and striatum) were 
delineated using ImageJ and a raw florescence intensity measured for SV2A. To help 
address for variation in SV2A intensity across brains, we normalized the value by 
deducting the SV2A intensity of the corpus callosum from the regional value and then 
dividing this by the SV2A intensity value of the whole mouse brain. A two-way ANOVA 
showed a significant difference between the injury and sham groups (p=0.0005). 
There were significant reductions in SV2A value in the injury cohort compared to 
sham in the contralateral cortex (p=0.036), hippocampus (p=0.02) and thalamus 
(p=0.017). We also observed a significant increase in SV2A in the ipsilateral cortex in 
the injury group compared to the sham group (p=0.011). To better understand the 
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relationship between the changes in SV2A and the postsynaptic proteins PSD95 and 
SAP102, we correlated the synapse metrics of the postsynaptic proteins and the 
normalized intensity value of SV2A in 12 mice (injury n=7; sham n=5). We opted to 
examine this relationship in the contralateral hippocampus as it provided insight into 
the relationship between pre- and post-synaptic proteins downstream from axonal 
injury. We found that there were strong positive correlations between SV2A and both 
PSD95 density (r=0.779; p=0.003) and SAP102 (r=0.711; p=0.009) (Figure 4.20, B 
and C). A similar positive, statistically significant relationship was observed between 
SV2A and PSD95 puncta intensity (r=0.787; p=0.002) and SAP102 puncta intensity 
(r=0.713; p=0.009). Interestingly, SV2A was negatively correlated with PSD95 puncta 
area with a Pearson correlation coefficient of -0.648 (p=0.02). SAP102 puncta area 
was also negatively correlated with SV2A (r=-0.567) but this did not reach statistical 
significance (p>0.05). This data shows that following LFPI, the presynaptic protein 
SV2A mirrors changes observed in PSD95 and SAP102. We found evidence of 
significant reductions in SV2A normalized intensity in the contralateral cortex, 
hippocampus and thalamus which we had also seen in the more detailed high-
resolution mapping of PSD95 and SAP102. When we looked more closely at this 
relationship within the contralateral hippocampus we found statistically significant 
relationships between SV2A and both PSD95 and SAP102 density and intensity. This 
is supportive evidence of synaptic loss distal to the injury site at 28 days post-LFPI. 
Interestingly, PSD95 puncta size was negatively correlated with SV2A suggesting that 
loss of presynaptic bouton may occur more within smaller synapses.  
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Figure 4.20: Correlation between PSD95 and SAP102 puncta parameters and 
SV2A. Wide field fluorescence image of three synaptic proteins imaged with 
difference fluorescence wavelengths: SV2A (far red), SAP102 (red) and PSD95 
(green) (A). Correlation between PSD95 (B) and SAP102 (C) puncta density and 
intensity (injury n=7; sham n=5) in the contralateral hippocampus and normalised 
SV2A value [** p£0.01] 
 
4.3.10 Correlation of PSD95 and SAP102 metrics with Iba-1 
Finally, we aimed to examine the relationship between the three puncta metrics and 
Iba1. There is evidence that microglia play a role in removing the synapse in both 
health and disease (Soyon Hong et al. 2016). To determine the relationship between 
PSD95, SAP102 and Iba-1 we looked at the Pearson correlation coefficient between 
each of the proteins’ three metrics and the number of Iba-1 positive cells. As we were 
interested in the role of microglia in synaptic loss in the chronic phase of TBI we 
focused our analysis on the contralateral cortex and hippocampus at 28 days in a 
cohort of 17 mice. This revealed a statistically significant negative correlation between 
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Iba-1 cell count and both PSD95 (r = -0.609; p=0.0001) and SAP102 (r = -0.671; 
p<0.0001) puncta density (Figure 4.21). Interestingly, this was reflected with a 
statistically significant positive correlation between both PSD95 and SAP102 puncta 
area. SAP102 puncta intensity and Iba-1 count had a significant negative correlation 
(r = -0.545; p=0.0009). The observations made in the synaptome map and Iba-1 cell 
counting indicate that at 28 days the contralateral hemisphere undergoes a significant 
increase in microglia numbers alongside a reduction in both PSD95 and SAP102 
puncta density. This relationship is significantly correlated in our dataset. Studies 
within Alzheimer mice models have observed the phagocytic role of microglia in early 
synapse loss (S. Hong et al. 2016). This data shows a negative association between 
synapse and microglia numbers which fits with these observations however does not 
conclude direction causation. Similarly, the positive correlation between Iba-1 and 
puncta size could be explained by the phagocytosis of smaller synapses by the 
microglia.  
 
 Synapse parameters 
 Density Size Intensity 
PSD95 -0.609*** 0.674**** 0.167 (ns) 
SAP102 -0.671**** 0.491** -0.545*** 
 
Figure 4.21: Correlation between PSD95 and SAP102 puncta parameters and 
Iba-1. Correlation between PSD95 and SAP102 puncta parameters in the 
contralateral hippocampus and cortex across 17 mice (both sham and injury) [**** 
p£0.0001; *** p£0.001; ** p£0.01; * p£0.05; ns p>0.05] 
 
4.4 CHAPTER DISCUSSION AND CONCLUSION 
In this chapter, we investigated the impact of a fluid percussion injury on two post-
synaptic density proteins, PSD95 and SAP102, using a transgenic knock-in reporter 
mouse model. Utilizing a machine learning approach, we were able to interrogate 
synaptic changes across a whole coronal mouse brain section and produced 
synaptome maps for both proteins’ puncta density, area and intensity. This provided 
highly detailed spatial and temporal insights into alterations in the synaptic proteins 
PSD95 and SAP102 after a traumatic injury. Our main findings were a progressive 
alteration in the synaptome of the injury mice. This reorganisation was most 
pronounced at 28 days post-injury when we observed reductions in both PSD95 and 
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SAP102 puncta density and intensity. These changes were centred around the 
hippocampus and cortex contralateral to the side of the injury. Our unbiased, whole 
brain approach, highlighted a reduction in both synapse numbers and the number 
PSD95 and SAP102 molecules within the remaining synapses in regions distal to the 
injury site. Coupled to this, we also observed a significant increase in PSD95 puncta 
density in the injury cohort from 7 to 28 days. Underpinning these observations, we 
found no significant differences in the area of the major brain regions between the 
injury and sham mice and evidence of elevated aggregates of APP in the ipsilateral 
cortex that peaked at 7 days. Alongside this, we observed progressive inflammatory 
changes, as index with Iba-1, within the cortex and hippocampus. Collectively, these 
data confirm histopathological findings in keeping with mild TBI and provide a firm 
basis to examine changes in the PSD95 and SAP102 synaptome. Interestingly, our 
data showed a negative correlation between Iba-1 positive cell numbers and both 
PSD95 and SAP102 density within the contralateral hippocampus. This correlation, 
though not evidence of direct causation, fits with other data that have implicated the 
microglia in synaptic pruning in disease processes (S. Hong et al. 2016). Overall, we 
conclude that we validated a model of mild LFPI in a cohort of transgenic knockin 
reporter mice. This model has allowed us to interrogate the impact of a mild traumatic 
injury on the postsynaptic density proteins PSD95 and SAP102. We observed a 
reorganization of the synaptome following injury which was progressive and involved 
brain regions distal from the injury site and also showed evidence of synaptic 
recovery. We will discuss these findings and their implications in greater detail in 
Chapter 5 however they highlight that TBI leads to synatopathy long after the initial 
insult but with evidence of synaptogenesis.  
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5.1 SUMMARY OF FINDINGS 
5.1.1 Wildtype characterization of mild LFPI 
To examine the impact of TBI on the synapse, we first had to develop and validate a 
protocol for a mild fluid percussion injury model. In a cohort of twenty-six mice (15 
injury and 11 sham) we examined the impact of a mild lateral percussion pulse 
(1.18±0.03atm) on righting time, neuronal morphology, axonal injury and inflammatory 
response. We found evidence of a significantly elevated righting time in the injury 
cohort (431.4±178.2 vs 40.3±57.5 seconds; p<0.0001). Coupled to this, H+E staining 
demonstrated altered neuronal morphology in the ipsilateral cortex to the percussion 
pulse in the injury group. We also observed significantly more APP-positive 
aggregates in the ipsilateral corpus callosum in the injury mice compared to the sham 
(74.1±38.6 vs 1.8±2.1; p<0.0001). We then examined inflammatory response after 
the LFPI and found increased numbers of microglia and astrocytes, as indexed with 
Iba-1 and GFAP respectively, in the ipsilateral compared to the contralateral cortex in 
both the injury and sham mice. This highlighted that even the act of performing the 
craniectomy on the sham mice led to an inflammatory response. The application of 
the percussion pulse, did however, lead to a significantly elevated number of both 
microglia and astrocytes in the ipsilateral hippocampus in the injury cohort compared 
to the sham. Taken together, these findings validated a model of mild LFPI in mice 
that led to elevated righting time, altered cortical neuronal morphology and axonal 
pathology in the injury cohort. It also demonstrated that the act of removing the cranial 
bone in the sham mice led to a degree of cortical injury and inflammatory response.  
 
5.1.2 Behavioural, axonal and inflammatory changes in knock-in cohort 
To internally validate our knock-in reporter cohort of mice we examined differences in 
the behavioural, axonal and inflammatory response between the injury and sham 
groups. Much like in the wildtype characterization experiment, we found significantly 
elevated righting time in the injury cohort compared to the sham (562.4±271 vs 
79±118.6 seconds; p<0.0001). We examined later time-points in the knock-in cohort, 
however, found elevated corpus callosum APP-positive aggregates in the injury group 
compared to the sham. These findings were significantly elevated at 7 days 
(44.7±25.4 vs 11.5±18.; p=0.0018) and remained elevated in the injury group at 28 
days, however the difference was no longer statistically significant (27.6±22.2 vs 
9.3±10.7; p=0.07). To investigate inflammatory response, we immunostained for 
microglia and found evidence of elevated iba-1 positive cells at 7 days (1011±386 vs 
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563.8±251.4; p=0.012) and 28 days (837.5±398 vs 434.9±223.5, p=0.001). 
Interestingly, within the contralateral hemisphere to the LFPI there was no significant 
differences in iba-1 cell counts at 7 days been the injury and sham cohort. However, 
at 28 days injury group had significantly elevated microglia in both the cortex 
(1017±473.3 vs 397.6±226.4; p=0.01) and hippocampus (227.5±114.9 vs 125±55; 
p=0.03). These findings highlight that post-LFPI inflammation is a progressive 
process with increased microglial numbers in brain regions distal to the percussion 
site a month after ictus. Overall, these observations of elevated righting time, axonal 
injury and increased microglial activity internally validate the knock-in cohort as a 
precursor to investigating the changes in PSD95 and SAP102.  
 
5.1.3 Temporal and spatial changes in PSD95 following LFPI 
After validating the behavioural and cellular changes in the injury cohort, we then 
investigated the impact of a mild percussion pulse on the postsynaptic protein PSD95. 
Utilizing a knock-in reporter mouse model, confocal microscopy and machine learning 
approaches we quantified PSD95 puncta density, size and intensity. There was no 
difference in PSD95 density within the ipsilateral cortex in the injury cohort compared 
to the sham. A closer investigation of the cortical sub-regions found no statistically 
significant differences between the injury and sham cohorts across both time-points 
and all cortical sub-regions. However, when compared to naïve mice (no surgery), 
both the injury and sham cohorts exhibited significantly reduced PSD95 in the 
ipsilateral motor and somatosensory regions. These findings highlight that the 
craniectomy in the sham group led to a pronounced reduction in PSD95 density in the 
ipsilateral cortex which was comparable to the injury cohort (which experienced both 
a craniectomy and percussion pulse). To further investigate the effect of the 
percussion pulse on PSD95 distal brain regions, we created whole brain synaptome 
maps for PSD95 puncta density, size and intensity across the two time-points (7 and 
28 days). Cohen’s d effect sizes were calculated and spatial heat maps constructed.  
At 7 days, there was no significant differences in the synaptic parameters between 
the injury and sham mice. Conversely, at 28 days, we observed a pronounced and 
statistically significant reduction in PSD95 puncta density spanning regions of the 
cortex bilaterally (somatosensory and auditory regions) and the contralateral 
hippocampus (CA1, CA3 and dentate gyrus). These findings show that synaptic loss 
after a traumatic insult is a progressive process that continues to occur up to a month 
after the initial injury. Coupled to this, synapse loss happens in regions distal to the 
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injury site. We then examined the temporal profile of PSD95 in the injury cohort 
between 7 and 28 days. This demonstrated that PSD95 puncta density increased 
from 7 to 28 days within the ipsilateral motor and somatosensory regions. This 
process of recovery occurred in tandem with reductions in density in the contralateral 
cortex and in the ipsilateral cortex distal to the percussion site. This highlights that the 
PSD95 synaptome is a dynamic entity with both sub-regional recovery and loss 
happening in tandem. Coupled to this finding, we observed a significant increase in 
PSD95 puncta size in the ipsilateral cortex and cortical sub-plate distal to the 
percussion site. Alongside this, there was a significant reduction in PSD95 puncta 
intensity within a similar distribution in the ipsilateral cortex. These findings point 
towards a temporal increase in PSD95 puncta size along with a reduction in density 
and intensity. Together, this data suggests a preferential loss of smaller synapses 
over time and a shift to larger puncta but with an associated reduction in PSD95 
protein within each synapse.  
 
5.1.4 Temporal spatial changes in SAP102 following LFPI 
The SAP102 synaptome demonstrated less observed changes to LFPI compared to 
PSD95. There was no significant reduction in SAP102 density between the injury 
cohort and both the sham and naïve mice within the ipsilateral cortex, as a whole and 
divided into its sub-regions. Much like PSD95, there was limited statistical significance 
between injury and sham miceat 7 days. By 28 days, a similar pattern of puncta 
density was observed in SAP102 compared to PSD95. Significant puncta density loss 
was seen in contralateral hippocampus. Interestingly, SAP102 demonstrated 
reductions in puncta size in a constellation of deep cortical layers in the ipsilateral 
motor and retrosplenial areas. This was mirrored in the contralateral cortex within the 
deep layers of the motor areas. There was a much more muted temporal recovery of 
SAP102 in the ipsilateral cortex compared PSD95. There was however, a much more 
pronounced, pattern of increasing puncta size coupled to reduced puncta intensity 
within the ipsilateral cortex distal to the fluid percussion site. These data, coupled to 
the significant positive correlation between PSD95 and SAP102 Cohen’s d effect 
sizes, suggest that the broad patterns of protein loss and recovery are similar between 
the two proteins. However, SAP102 demonstrated less pronounced density loss 
compared to PSD95 and an equally limited recovery of SAP102 puncta between 7 
and 28 days in the injury cohort. This may suggest that SAP102 is less susceptible to 
traumatic injury when compared to PSD95 or that our ability to measure it was more 
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limited possibly related to the intensity fluorescence from the mKO2 protein which 
was hemizygous compared to PSD95 which was homozygous.  
 
5.1.5 Relationship between SV2A and Iba-1 with post-synaptic density proteins 
To examine the relationship between PSD95 and SAP102 and the presynaptic 
terminal, we stained a series of brain section with SV2A. Within the 28-day cohort, we 
found evidence of SV2A reduction in the contralateral cortex, hippocampus and 
thalamus. Interestingly, when we correlated SV2A and the PSD95 and SAP102 
puncta metrics within the contralateral hippocampus, we found significant positive 
correlations between SV2A and both postsynaptic protein puncta density and 
intensity. This finding suggests that both the pre- and post-synaptic terminals of the 
synapse are lost together. When then examined the relationship between Iba-1 and 
the two synaptic proteins in the contralateral cortex and hippocampus. We found a 
significant negative relationship between PSD95 and SAP102 density and Iba-1 
positive cell count. This association suggests that infiltrating microglia may play a role 
in synaptic pruning post-TBI. Coupled to this, there was a significant positive 
correlation between the synaptic puncta area and number of Iba-1 cells. This 
suggests that as the number of microglia increases there is a shift towards larger 
synapses. This could be explained by microglial preferential pruning of smaller 
synapses. Together, this data provides a useful presynaptic control that reflect 
findings we observed in the postsynaptic proteins. It also provides correlative 
relationships between PSD95 and SAP102 and microglia.  
 
5.2 DISCUSSION OF FINDINGS 
In this thesis, we have described the impact of a LFPI on the synaptome maps of two 
postsynaptic proteins: PSD95 and SAP102. Our findings highlight that the synaptome 
is susceptible to traumatic injury showing temporal spatial patterns of loss up to 28 
days after injury and in sub-regions distal to the injury site. Our findings also 
highlighted synaptic recovery and reorganization between 7 and 28 days in the cortex 
ipsilateral to the injury.  
 
5.2.1 Delayed synapse loss occurs at 28 days after injury 
Our most striking finding was a significant drop in PSD95 and SAP102 puncta density 
at 28 days. This was centred around the contralateral hippocampus and the cortex 
bilaterally. Other studies have looked primarily at early time-points (<7 days), however 
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a number have examined later follow-up times. Scheff and collagues used EM to 
examine the impact of a moderate CCI on the synapses of the ipsilateral CA1 stratum 
radiatum (Scheff et al. 2005). The investigators found a comparative reduction in 
puncta density in the injury group compared to the sham group at 30 days. However, 
they saw an early and dramatic reduction in puncta density at day 2 post-injury which 
slowly recovered at 30 days before plateauing. Semchenko observed a similar pattern 
using a rotatory head model in rats with a reduction in synaptic density measured with 
EM at 7 days followed by an increase in density up to 30 days (Semchenko et al. 
2006). On the other hand, using a blast model of TBI, Meabon found similar levels of 
cerebellar PSD95 in the injury and sham cohorts at day 1 followed by a significant 
reduction in PSD95 levels in the injury group at 30 days (Meabon et al. 2016). These 
differing observations are a product of substantially different TBI models, both in terms 
of the mechanism and severity of the injury and different techniques of synapse 
quantification and sub-regional analysis. However, they do collectively point towards 
a relative reduction in synapses at 30 days after a mechanical trauma which fits with 
our observations. An important finding in our study was that there was a delay in 
synaptic density changes between the injury and sham mice. At 7 days, the puncta 
density between the sham and injury groups showed little significant difference. When 
compared to the naïve sham, there was evidence of reduction in puncta density of the 
ipsilateral cortex in both the injury and sham mice suggesting that the act of 
craniectomy alone was enough of an insult to alter synapse numbers. It also suggests 
that the act of applying the fluid pulse to the injury cohort set in motion a pathological 
process that led to progressive loss of synapses that became evident at 28 days. 
Other studies have observed delayed drops in synapse numbers or protein 
concentrations at differing time-points. Ansari and colleagues examined the impact of 
CCI on a number of synaptic proteins using western blot (Ansari et al., 2008 (1)). The 
investigators found a delayed reduction in PSD95 and Synapsin-I that occurred at 48 
hours while SAP97 reduced at 96 hours compared to sham. Wakade found a similar 
finding with a delayed drop in PSD95 at 7 days following CCI (Wakade et al. 2010). 
These studies found that synaptic proteins reduced at earlier time-points compared 
to our observations. Part of the reason for this is the regions examined were ipsilateral 
to the injury site and the severity of the traumatic injuries were higher. It is important 
to note that compared to the naïve sham mice we observed significant reductions in 
PSD95 density in the ipsilateral cortex at 7 days indicating that our findings are not a 
significant outlier compared to the literature. Collectively, these data suggest that 
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synapse loss is not immediate and can take time to develop highlighting a potential 
window for intervention.  
 
5.2.2 The impact of traumatic axonal pathology on the synapse 
We also examined post-traumatic axonal pathology in our experimental cohort to help 
understand its relationship with our observations in the synapse. Though our 
methodology was limited to the ipsilateral corpus callosum it helped provide important 
data into the state of axonal pathology in our cohort. We found elevated levels of APP 
aggregates at both 7 and 28 days, though this difference was not significant at the 
latter time-point. The application of an external force onto the brain leads to 
deformation of axons. Microtubular failure secondary to calcium influx leads to 
impairment of axonal transport (Douglas H Smith et al. 2013). APP, which is 
transported through the axon, then starts to accumulate leading to the visualised 
varicosities. In severe cases, primary axotomy occurs and Wallerian degeneration 
occur within the distal axon. Using a cortical lesion model, Gilingwater et al found 
evidence of degenerating synapse terminals in the striatum at day 2 post-lesion in 
wildtype mice which peaked at day 3 and had resolved by day 10 (Gillingwater et al. 
2006). Interestingly, when they examined Wallerian Degeneration slow mice model 
(a spontaneous dominant mutation in mice that delays axon degeneration), they found 
delayed and less pronounced synaptic degeneration within the striatum. Their findings 
indicate that axonal pathology is intimately linked with the synapse and that protection 
against axon degeneration delays and limits synapse loss. Diffusion MRI studies in 
humans have demonstrated white matter tract degeneration post-injury which bring 
into question the extent of synapse loss downstream (Aoki et al. 2012). One of the 
strengths of our study, was the whole brain unbiased approach which highlighted that 
the contralateral hippocampus and in particular the dentate gyrus is vulnerable to 
synapse loss after injury. The loss of synapse density in the dentate gyrus had been 
demonstrated earlier by Gao et al after a moderate CCI (Gao et al. 2011). Our 
observation of a reduction in puncta density in the contralateral hippocampus and 
cortex is likely caused by axonal injury within the corpus callosum and hippocampal 
commissure which project onto the contralateral hemisphere (Zhou et al. 2013).  
 
5.2.3 Synapse reorganization and recovery after traumatic injury 
A further key finding was evidence of an increase in the density of synapses between 
7 and 28 days within the ipsilateral cortex. There were significant increases within the 
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somatorsensory and motor regions which underlie the fluid precussion site. It is 
important to note that though the injury did demonstrate an increase in synaptic 
density at 28 compared to 7 days, it still had a lower density compared to naïve mice 
in the primary motor, somatosensory and dorsal auditory areas. Post-deafferentation 
synaptogenesis has been well documented in the past (Anderson et al. 1986). More 
recently, Scheff and colleagues also observed synapse recovery in the stratum 
radiatum of CA1 after a moderate CCI (Scheff et al. 2005). This recovery occurred 
from day 2 before plateauing at day 30 post-injury. Much like our finding, Scheff 
observed that the synapse density did not reach control levels despite following up to 
60 days in his experiment. Investigators have also found similar patterns of recovery 
in GABAergic synapses. Erb and Povlishock examined the dorsal lateral vestibular 
nucleus in cats after a fluid percussion injury (Erb & Povlishock 1991). Using EM and 
light microscopy, they found a reduction in GABAergic puncta up until day 30 followed 
by a period of recovery up to 12 months after the injury. A number of studies have 
looked at the subject of synaptic recovery after TBI and attempted to tease out the 
impact of TBI secondary injury processes on synaptogenesis. To do this, hippocampal 
synaptic recovery was compared between bilateral entorhinal deafferentation (BED) 
alone and BED combined with a fluid percussion injury (FPI). Early findings from this 
approach found that the synaptic recovery observed in the BED model did not occur 
in the combined injury model (Phillips et al. 1994). This suboptimal synaptic recovery 
was termed ‘maladptaive synaptic plasticity’. A focus of research has been Matrix 
Metalloproteinases (MMPs) which are endopeptidases that affect cellular behaviour 
by processing various extracellular matrix molecules (Huntley 2012). Importantly, 
MMPs have been shown to play a role in mediating synaptic plasticity (Huntley 2012). 
However, a series of studies comparing BED with the combined BED and FPI model, 
demonstrated persistent elevates levels of a number of MMPs in the combined model 
suggesting that aberrant MMP elevation contributed to maladaptive synaptic recovery 
(Warren et al. 2012; Kim et al. 2005; Falo et al. 2006). Importantly, these studies found 
evidence of colocalization between MMPs and astrocytes and posited that reactive 
astrocytes may selectively induce MMPs. We found evidence of robust astrocyte 
activation at 24 hours when characterizing our wildtype cohort of mice. Astrocytes 
have been implicated in post-TBI impaired synaptic recovery through a number of 
other mechanisms. Furman et al examined the role of astrocytic calcineurin-
dependent transcription factor Nuclear Factor of Activated T cells (CN/NFAT) 
(Furman et al. 2016). The investigators found blockade of the CN/NFAT pathway 
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using an adeno-associated virus led to a significant increase in the synaptogenic 
molecule Hevin. Similarly, Nikolakopoulou investigated another astrocyte-associated 
pathway involving Ephrin-B1 in a moderate CCI in mice (Nikolakopoulou et al. 2016). 
Following injury, the investigators observed an upregulation of Ephrin-B1 levels in 
hippocampal astrocytes which coincided with a decrease in the presynaptic protein 
VGlut1. The ablation of Ephrin-B1 accelerated the recovery of VGlut1 puncta. Finally, 
the authors then presented evidence that Ephrin-B1 may play a role in post-TBI 
synaptic recovery through STAT3 phosphorylation. This pathway has was also 
investigated by Tyzack et al in an axotomy model which concluded that astrocytic 
STAT3-regulated thrombospondin-1 contributed to post-injury synaptic remodelling 
(Tyzack et al. 2014). Thrombospondins are large astrocyte-secreted oligometric 
extracellular matrix proteins that have been found to promote synaptogenesis 
(Christopherson et al. 2005). Thrombospondins have been found to be elevated in 
both TBI patients and in preclinical models (Tran et al. 2012; Wang et al. 2016).  Tran 
and colleagues found in an in-vitro model of TBI that thrombospondin-1 expression 
was significantly attenuated by a P2 receptor antagonist (Tran et al. 2012). 
Interestingly, addition of ATP (which is released upon traumatic damage of brain 
tissue), led primary culture of astrocytes to phosphorylate STAT3 (Washburn & Neary 
2006). Together these data point towards a common pathway through STAT3 that 
regulates astrocytic thrombospondin release. From our findings and the literature, it 
is clear that synaptic recovery occurs following a traumatic insult to the brain. 
However, this process of remodelling is not complete particularly when compared to 
pure deafferentation models which do not include secondary brain injury processes. 
The astrocyte plays an important role in synaptogenesis and synaptic function in 
health and development (Allen & Eroglu 2017). However, a traumatic insult leads to 
astrocyte upregulation which appears to have a double-edged sword effect on 
synaptic recovery.   
 
5.2.4 Microglia and synaptopathy after traumatic injury 
Microglia are highly motile and are constantly surveying their surroundings 
(Nimmerjahn et al. 2005). There is also evidence that they selectively remove synaptic 
components in development (Paolicelli et al. 2011). The process in which microglia 
interact with synapses has been debated with suggestions that the phagocytosis. 
However, a recent study by Weinhard et al used a combination of imaging techniques 
to interrogate microglial-synapses interactions (Weinhard et al. 2018). They found that 
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microglia partial eliminate or trogocytosise (nibbling) presynaptic boutons and axons. 
We observed a significant increase in the number of Iba-1 positive cells in the injury 
compared to the sham cohort. It is important to note that craniectomy alone led to an 
inflammatory response in the sham cohort. However, we found a significant and 
temporally progressive inflammatory reaction that spread to the contralateral 
hemisphere at 28 days post-injury. Post-TBI inflammation has been well documented 
in human subjects. Both the examination of autopsy tissue and the use of in-vivo 
molecular imaging approaches have demonstrated evidence of chronic inflammation 
(Coughlin et al. 2017; Fujita et al. 2017; Victoria E. Johnson et al. 2013). In animal 
models, recent investigation has focused on understanding the differing phenotypes 
of microglia and their temporal profile. Macrophage polarization states have been  
applied to microglia with a distinction between ‘pro-inflammatory’ M1-like microglia 
and ‘anti-inflammatory’ M2-like microglia (Mosser & Edwards 2008). Jin and 
colleagues found a bimodal response of microglia with a M2-like peak at 7 days 
followed by an M1-like peak at 3 weeks (Jin et al. 2012). This reflected similar findings 
in a spinal cord injury model (Kigerl et al. 2009). A number of studies have suggested 
that chronic M1 microglia impair recovery and leads to neurodegenerative cascades 
(Block et al. 2007; Horn et al. 2008). However, this dichotomous distinction between 
M1 and M2-like microglia has been criticized as over-simplistic and that, in reality, a 
number of complex, overlapping polarization states are likely to be present (Jassam 
et al. 2017). Nonetheless, our finding of persistent microglial activation is in keeping 
with evidence pointing towards chronic inflammation. Interestingly, when we 
correlated the density of PSD95 and SAP102 with microglia numbers in the 
contralateral hemisphere, we found a significant negative correlation. Though this 
finding is an association and does not provide evidence of causation, it may suggest 
that as microglia numbers increased they contributed to the removal or stripping of 
synapses. The question of whether microglia have a role in synapse removal in 
disease states has been examined. In a preclinical model of Alzheimer’s disease, 
Hong and colleagues suggested that an inappropriately activated complement 
pathway led to excessive microglial pruning of synapses (S. Hong et al. 2016). Wake 
et al used two-photon microscopy and found prolonged contact between microglia 
and presynaptic bouton in a model of transient cerebral ischaemia led to synapse loss 
(Wake et al. 2009). How microglia contribute to synaptopathy was looked at by Zhang 
and colleagues in an in-vitro model of inflammation and ischaemia, two important 
process after TBI (Zhang et al. 2014). The authors found that inducing hypoxia and 
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an inflammatory stimulus (lipopolysaccharide) triggered microglial-CR3 activated 
LTD.  
 
5.2.5 Differential patterns PSD95 and SAP102 puncta response to LFPI 
In this thesis, we investigated two synaptic proteins: PSD95 and SAP102. This 
allowed for comparison of the response of the proteins to a traumatic insult. We 
observed broadly similar responses to LFPI which was reflected by the positive 
correlation between the PSD95 and SAP102 Cohen’s d effect size changes across 
all three puncta parameters for both time-points. The strength of this positive 
correlation, however, varied with only moderate positive correlations for puncta size 
(r=~0.6) at both time-points. When comparing the synaptome maps of puncta size, a 
divergence in response between PSD95 and SAP102 was notable at 28 days with a 
significant shift towards smaller SAP102 puncta centred around the motor and 
retrosplenial regions in both cortices. Scheff et al found no difference in synapse size 
in the CA1 after a CCI using EM during periods of denervation and synapse recovery 
(Scheff et al. 2005). Scheff and colleagues also studied CA1 synapses from patients 
with mild Alzheimer’s Disease (AD) (Scheff et al. 2007). Using EM, the group 
observed a shift towards larger synapses in the AD cohort compared to patients with 
no cognitive impairment. This may be due to loss of smaller synapses during the 
neurodegenerative process. In our data set, we observed a temporal shift towards 
significantly larger puncta size (both PSD95 and SAP102) in the injury cohorts 
between 7 and 28 days within the ipsilateral cortex distal to the fluid percussion site. 
This pronounced observation may reflect a similar process of smaller synapse loss. 
We also noted moderate correlation of puncta density changes between the two 
proteins at 7 days (r=0.59). Comparing the heat maps, this is likely due to a reduction 
in PSD95 effect size in the ipsilateral cortex compared to SAP102, which did not 
demonstrate a similar reduction. This finding, along with the greater reductions in 
PSD95 density at 28 days, may suggest that PSD95 is more susceptible to loss 
following traumatic insult compared to SAP102. Coupled to this, we found that 
between 7 and 28 days, PSD95 puncta density showed a more pronounced recovery 
compared to SAP102 puncta. Within our lab, an in-house technique to subtype 
synapses using PSD95 and SAP102 synaptome imaging data identified 37 synaptic 
subtypes (Zhu et al., 2018). This approach revealed a wealth of information about the 
synaptic diversity and that each subtype had a unique distribution across the mouse. 
Based on our data and prior experiments that revealed differences in synaptic protein 
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loss after TBI using Western Blotting (Mubeen A Ansari et al. 2008), we would expect 
the application of synaptic subtyping techniques would reveal differential responses 
to traumatic injury across the differing synapse types.  
 
5.3 METHODOLOGICAL CONSIDERATIONS 
5.3.1 The lateral fluid percussion injury model 
The LFPI is a well-established and comprehensively characterized model of TBI 
(Thompson et al. 2005). Its strengths are its reproducibility, the ability to apply the 
model to mice and that the severity of the injury can be easily modified. The latter two 
strengths were very important for our study which aims to look at a milder injury 
severity and also centred on the use of a knock-in transgenic mouse model. However, 
from our experience the LFPI suffers from two major drawbacks. Firstly, it has a high 
attrition rate which in our main experiment sat at just over a fifth of randomized mice. 
This was an improvement compared to our wildtype characterization experiment 
which had an attrition rate of 35%. The main cause for mouse exclusion was dural 
rupture occurs after the application of the percussion pulse which is an inherent 
complication of the model. This high attrition rate can be very costly particularly in the 
context of expensive genetically modified animals. The second major weakness of 
the model is that the sham mice undergo a degree of brain injury during the process 
of bone flap removal. Despite very careful and meticulous technique, we found that 
we were inducing an inflammatory response in the sham mice and found that there 
was also a reduction in synapse density in their ipsilateral cortex. One of the major 
differentiator between injury and sham was the presence of APP aggregates in the 
corpus callosum which demonstrated that the application of the fluid pulse led to 
axonal injury. The similarity of synapse loss in the ipsilateral cortex of the sham mice 
without axonal pathology is an interesting finding, however it also likely masked the 
extent of the synaptic changes in the injury group when we looked at the Cohen d 
effect sizes between the cohorts.  
 
5.3.2 Experimental design 
We aimed to use robust methodological approaches to ensure our experiment was 
less susceptible to bias. Prior to commencing our main experiment, we undertook a 
pilot study of 6 mice followed up to 7 days to generate data for a power calculation. 
Using PSD95 density data from the ipsilateral cortex, we calculated that we required 
9 mice per cohort to power the experiment. A criticism of this approach was that we 
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did not look at SAP102 and only concentrated on the ipsilateral cortex and puncta 
density. For the main experiment, we randomized the mice in the four cohorts: injury 
and sham across 7 and 28 days. As mice only become eligible for inclusion in the 
study once they were aged between 8-16 weeks, we would randomize small groups 
of mice across the four groups. Our randomization technique used a random number 
generator to ensure that no bias was introduced into the process. Our naïve cohort, 
however, was not randomized and was analyzed after the completion of the main 
experiment. This is important to note as it limits our ability to compare the naïve cohort 
to other groups. Alongside this, we only used the righting reflex as a behavioural test 
in these experiments. The righting reflex is a simple test and can only provide 
information in the acute phase of the injury. There are more robust means of 
examining the longer term effects of TBI on motor and cognitive function in mice such 
as the rota rod, Morris Water Maze and cognitive touch screen testing (Xiong et al. 
2013; Bussey et al. 2012). This means we were unable to correlate functional 
changes to the observations we were making at the level of the synapse. Finally, we 
ensured that the primary investigator (AJ) was blinded to the mice cohort during from 
the tissue processing stage. A research number was applied to the mouse and a 
central register of the mice numbers was held by another member of the lab (SL). For 
logistic and technical reasons, we were unable to blind AJ to the mouse cohort from 
the point of injury. This may have led to bias in measuring the mouse righting time 
however, we felt that the main focus of the experiment was the synaptic analysis for 
which AJ was completely blinded during the stages of tissue processing and image 
analysis.  
 
5.3.3 Unbiased imaging approach 
Prior studies looking at synaptopathy following TBI either focused on specific brain 
regions or homogenised brains losing all spatial information. Both these two 
approaches tend to neglect brain regions and mean that any subtle synaptic changes 
are likely to be missed. As we have detailed in this thesis, TBI leads to global brain 
changes and therefore an approach that characterized synapses at the whole brain 
level is vital to better understanding post-TBI synaptopathy. We believe the high 
throughput and high-resolution approach we have described here is a major step in 
addressing the technical limitation of previous studies. 
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5.4 FUTURE DIRECTIONS 
5.4.1 More detailed statistical analysis 
We have captured a huge amount of data from the LFPI synaptome maps. In this 
thesis, we described a statistical analysis approach comparing the injury and sham 
cohorts using multiple t-tests. This approach is crude and at risk of generating false 
positives, particularly as there are >200 brain sub-regions and we set our p value at 
<0.05. An alternative approach would have been to utilise a two-way ANOVA with 
multiple comparison analysis, however our concern with this approach was that it 
would be too conservative due to the high number of sub-regions and miss potentially 
significant findings. We deemed our approach an appropriate middle ground that 
focused on sub-region clustering and then set a higher p-value threshold for isolated 
sub-regions. One more advanced technique to address these limitations is Bayesian 
inference approaches. Within the Seth Grant lab, Dr. Nathan Skene developed a 
Bayesian model to analyse Dr. Melissa Cizeron’s synaptome dataset. This model 
could be modified to analyse the LFPI synaptome data  
 
5.4.2 Colocalization and synapse subtyping 
In this thesis, we described the analysis of three raw puncta parameters: size, density 
and intensity. Using this base raw data, there are further forms of analysis which can 
be applied to our dataset to gain deeper insights into post-TBI synaptopathy. In the 
first instance, the degree of colocalization between PSD95 and SAP102 can be 
examined to better understand how the relationship between the two proteins is 
affected by a traumatic insult. To further investigate synapse subtypes, Dr. Zhen Qui, 
in the Seth Grant lab, devised an advanced machine learning technique called the 
Weighted Clustering Ensemble method that used PSD95 and SAP102 synaptome 
data to classify individual synapses in an unsupervised manner. This technique 
identified 37 synaptic subtypes: 11 subtypes of PSD95-only Types, 7 subtypes of 
SAP102-only Types, and 19 subtypes of colocalized Types (Zhu et al. 2018). We plan 
on applying this approach to look at more granular detail on synaptic subtype changes 
following TBI. 
 
5.4.3 SV2A molecular imaging 
Recently, a novel PET ligand has been developed that targets SV2A and has been 
shown to measure synaptic density in-vivo (Finnema et al. 2016). During the last year 
of my PhD, we set up a collaboration with UCB Pharma (the company that developed 
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the ligand) and acquired the SV2A precursor in Edinburgh. A focus of future 
investigation will be the use of this ligand to translate our synapse preclinical findings 
in the LFPI model into humans. In the first instance, we aim to use autoradiography 
to assess the efficacy of the ligand on tissue sections from LFPI experiments. From 




In this thesis, we utilized the combination of a knock-in transgenic mouse model, high 
throughput imaging techniques and machine learning approaches to characterize 
whole synaptome reorganisation of the postsynaptic density proteins PSD95 and 
SAP102 following a mild traumatic fluid percussion injury. Our results demonstrated 
that synapse loss is a progressive process that happens up to a month post-injury. 
However, we also observed evidence of synapse recovery in the ipsilateral cortex 
between 7 and 28 suggesting that post-TBI synaptopathy is a dynamic process with 
both loss and recovery happening in tandem. Despite broadly similar patterns of 
change, we observed nuanced differences between SAP102 and PSD95 suggesting 
differences in synaptic subtypes responses to trauma. Finally, we observed a 
negative correlation between microglia numbers and synapse density suggesting a 
potential role for microglia in post-TBI synaptopathy. Collectively, this thesis provides 
one of the most comprehensive insights into synaptopathy following a TBI and lays 
groundwork for more detailed statistical and imaging analysis of the dataset and the 
use of molecular imaging techniques to translate our findings into humans.  
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APPENDIX 
 
Appendix 1: Matlab script used to generate montage images (written by Dr. 
Zhen Qiu) 
function stitching_Melissa 
% SPECIFY THE INPUT DIRECTORY 
root_dir = 'X:\microscopy\2014-04_SAP102KO_PSD95EGFP_Mapping\';  
% SPECIFY THE OUTPUT DIRECTORY 
out_dir = 'X:\users\Melissa\Montages\'; 
% SPECIFY THE MOUSE ID 
Mouse_id = {'GHB29'}; 
% SPECIFY THE SECTION ID 
Section_id = {'HC'}; 
d = dir(root_dir); 
isub = [d(:).isdir]; %# returns logical vector 
name_Folds = {d(isub).name}'; 
name_Folds(ismember(name_Folds,{'.','..'})) = []; 
% temp_path = '/data/project/HBP/Jess/temp/'; 
down_sampling_factor = 16; 
split_char ='\';% for windows 
%% divide the folder name 
Mouse_list = cell(length(name_Folds)-2,1); 
Section_list = cell(length(name_Folds)-2,1); 
parfor i = 1:length(name_Folds) - 2 
    temp_folder_name_split = strsplit(name_Folds{i},'_'); 
    Mouse_list(i) = temp_folder_name_split(1); 
    Section_list(i) = temp_folder_name_split(2); 
end 
%% select the mouse in the Mouse_id and Section_id. 
  
n = 1; 
for i = 1:length(Mouse_id) 
    for j = 1:length(Section_id) 
%         i,j 
        temp_mouse_index = 
intersect(strmatch(Mouse_id{i},Mouse_list),strmatch(Section_id{j},Section_list)); 
        if ~isempty(temp_mouse_index) 
            select_mouse_path{n} = [root_dir,name_Folds{temp_mouse_index(end)}]; 
            n = n +1; 
        end 
    end 
end 
if size(select_mouse_path,1) == 1 
    select_mouse_path = select_mouse_path'; 
end 
  
%% Then reorder the imported data based on the digitsfor i = 1:length(dir1) 
row_num = zeros(length(select_mouse_path),1); 
col_num = zeros(length(select_mouse_path),1); 
for i = 1:length(select_mouse_path) 
    disp(select_mouse_path{i}); 
    %% first get the number of rows and columns from the meta_data 
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    dir_meta = dir([select_mouse_path{i},split_char,'*.txt']); 
    if ~isempty(dir_meta) 
        fid = fopen([select_mouse_path{i},split_char,dir_meta(1).name]); 
        montage_meta = textscan(fid,'%s',10, 'headerlines', 89);%% Number specifies 
the line before the number of raws and columns in the metadata file 
        col_num(i) = str2num(montage_meta{1}{6}); 
        row_num(i) = str2num(montage_meta{1}{8}); 
        fclose(fid); 
        %% then get the image name and re-order the name 
%         tic 
        dir_image{i} = dir([select_mouse_path{i},split_char,'*.tif']); 
%         t = toc; 
        temp_digits = zeros(length(dir_image{i}),1); 
        parfor j = 1:length(dir_image{i}) 
            temp_file_name = strsplit(dir_image{i}(j).name(1:end-4),'_'); 
            temp_digits(j) = str2num(temp_file_name{end}(2:end)); 
        end 
        digits{i} = temp_digits; 
        [~,ind] = sort(temp_digits); 
         
        %% then load the data and save the downsample image in the memory 
         
        pctRunOnAll warning off; 
        % montage = cell(row_num,1); 
        iminfo = imfinfo([select_mouse_path{i},split_char,dir_image{i}(ind(1)).name]); 
%         pctRunOnAll warning off 
%         im = uint16(rand(iminfo.Height/4,iminfo.Width/4,length(dir1))*100); 
        im = 
zeros(iminfo(1).Height/down_sampling_factor,iminfo(1).Width/down_sampling_facto
r,length(temp_digits)); 
        tic 
        parfor j = 1:length(temp_digits) 
%                 tic 
            %     for j = 1:col_num; 
%             j 
            %     montage{i} = [montage{i},imread(dir1(ind).name)]; 
            im(:,:,j) = 
imresize(imread([select_mouse_path{i},split_char,dir_image{i}(ind(j)).name]),1/down
_sampling_factor,'nearest'); 
            %         disp(dir1(ind(i).name)); 
            %     ind = ind +1; 
            %     end 
            %     montage{i} = imresize(montage{i} ,1/down_sampling_factor); 
%                 t = toc 
        end 
        t = toc 
        montage = cell(row_num(i),1); 
        ind = 1; 
        for m = 1:row_num(i) 
            for n = 1:col_num(i) 
                %         i,j 
                %         im(:,:,index) = normaliz(im(:,:,index)); 
                %         ind = (i-1)*col_num+j; 
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                mont = [montage{m},(im(:,:,ind))]; 
                ind = ind +1; 
            end 
        end 
        montage_output = cell2mat(montage); 
        temp_name = strsplit(select_mouse_path{i},split_char); 
         
        imwrite(uint16(montage_output),[out_dir,'Montage_',temp_name{end},'.tif']); 




        %     filename{end} = sprintf('m%.5d',digits); 
        %         filename = [strjoin(filename,'_'),'.tif']; 
        %     end 
        %     movefile(dir1(i).name,[temp_path,filename]); 
        %     end 
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Appendix 2: Pilot LFPI experiment of PSD95-eGFP mKO2-SAP102 KI mice at 24 
hours and 7 days 
A total of male 12 eGFP-PSD95 mKO2-SAP102 mice aged 8-12 weeks were included 
within the pilot study: 24 hours (3 injury and 3 sham); 7 days (4 injury and 2 sham). 
The injury mice were exposed to a percussion amplitude of 1.19±0.03atm. Injury mice 
had a significantly higher righting time (RT) (295 secs) compared to sham mice (89 
secs) (p=0.027). Mice were sacrificed at 24 hours and 7 days and their brains were 
processed as described in the methods section. Imaging of a whole brain mid-
hippocampal coronal section was undertaken using the SDM. Analysis of the density 
of synaptic puncta per tile within the cortices revealed no significant different between 
injury or sham [Figure 1].  
 
Analysis of the density of PSD-95 positive puncta per tile within the cortices revealed 
no significant different between injury or sham. In the ipsilateral cortex at 24 hours, 
the density of PSD-95 puncta in the injury group was 335±4.5 compared to sham at 
329±8.6 (p=0.4). By 7 days, the density of the injury group had dropped to 289±16.1 
compared to sham (323±5) however this did not reach significant (p=0.13) (Figure 1). 
Analysis of SAP102 revealed a reduction in SAP102 puncta in the ipsilateral cortex 
of the injury group (249±4.9) compared to the sham group (263±4.7) (p=0.1). At 7 
days, the ipsilateral cortex in the injury group had a SAP102 density of 253±15.8 
compared to the sham cohort 266±1 (p=0.533). There was no significant differences 
between the two cohorts across the two time points in the contralateral cortex. 
 
Using this data, we performed power calculations for 24 hours and 7 days. We 
attempted a number of different a prior calculations (Table 1). Based upon this, we 
opted for a priori calculation with alpha error=0.05 and power=0.95 which showed that 
we needed a sample size of 71 at 24 hours and 9 at 7 days. Based on these findings, 
we decided to proceed with 7 and 28 days as our primary time-points. Therefore, with 
four cohorts and an approximated attrition rate of 30%, we calculated a minimum of 
47 mice to be randomised. 
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Figure 1: Scatter plot demonstrating cortical PSD-95 and SAP102 cortex puncta 
density  
 
Alpha error Power Sample size 
0.05 0.95 9 
0.05 0.9 7 
0.05 0.85 6 
0.05 0.8 5 
0.01 0.95 13 
0.01 0.9 10 
0.01 0.85 9 
0.01 0.8 8 
Table 1: A priori calculations for 7 day cohort
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Appendix 3: Raw PSD95 and SAP102 data from naïve mice 
 
Table 1: PSD95 puncta parameters for naïve mice 
 
  Density   Size   Intensity   
Region Average SD Average SD Average SD 
contra_amgmed 290.00 36.80 12.71 0.15 11538.43 955.99 
contra_AUDd 455.80 32.09 12.24 0.25 18646.75 1748.31 
contra_AUDd1 565.50 27.75 12.08 0.35 19940.67 1895.11 
contra_AUDd3 494.20 29.81 12.36 0.27 20663.18 1867.96 
contra_AUDd4 486.60 35.02 11.97 0.22 18689.27 2034.83 
contra_AUDd5 419.90 33.02 12.30 0.25 17244.06 1896.09 
contra_AUDd6a 403.40 20.48 12.12 0.26 16241.72 2141.20 
contra_AUDd6b 307.10 39.53 12.40 0.38 12589.13 2395.71 
contra_AUDp 469.70 32.37 12.18 0.23 18862.29 1697.40 
contra_AUDp1 566.20 16.57 12.00 0.19 20407.82 968.62 
contra_AUDp3 504.80 30.64 12.29 0.23 20637.98 1584.23 
contra_AUDp4 498.60 23.96 11.95 0.23 19031.62 1916.66 
contra_AUDp5 437.70 41.50 12.21 0.27 17475.57 1990.58 
contra_AUDp6a 411.10 21.42 12.10 0.27 16379.57 2105.71 
contra_AUDp6b 300.10 51.62 12.35 0.35 12880.48 2504.32 
contra_AUDv 482.20 30.76 12.11 0.25 18784.89 1767.59 
contra_AUDv1 568.10 31.89 11.98 0.30 19957.26 1775.18 
contra_AUDv3 511.70 26.72 12.18 0.20 20308.89 1533.74 
contra_AUDv4 517.20 34.80 11.93 0.25 19075.87 1887.65 
contra_AUDv5 460.20 38.50 12.11 0.27 17756.28 2050.29 
contra_AUDv6a 408.30 22.97 12.13 0.26 16621.04 2161.69 
contra_AUDv6b 294.10 40.39 12.48 0.40 12504.69 2461.27 
contra_BLAa 443.10 26.25 11.97 0.39 14649.98 1851.75 
contra_BLAp 457.10 32.82 12.18 0.33 17087.92 1961.48 
contra_BLAv 372.50 42.22 12.25 0.21 12831.57 1847.02 
contra_BMAp 348.50 35.26 12.31 0.22 12407.22 1442.40 
contra_CA1slm 502.10 16.90 12.11 0.44 13306.25 1872.96 
contra_CA1so 654.90 45.90 11.52 0.46 14844.00 1797.70 
contra_CA1sp 147.40 13.71 12.51 0.20 9409.77 1146.33 
contra_CA1sr 655.50 50.03 11.63 0.46 16532.64 1968.97 
contra_CA2slm 530.00 12.66 11.45 0.40 9453.96 1165.36 
contra_CA2so 513.80 12.02 11.44 0.41 9608.00 1060.54 
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contra_CA2sp 65.50 26.62 14.79 0.96 7090.51 696.60 
contra_CA2sr 478.50 22.88 11.76 0.51 9394.61 1025.47 
contra_CA3slm 540.00 28.85 11.85 0.44 9724.69 1203.54 
contra_CA3slu 264.20 19.07 14.76 0.50 11932.09 1449.86 
contra_CA3so 462.40 28.46 12.07 0.53 9341.14 864.33 
contra_CA3sp 121.20 29.16 15.34 0.68 9305.54 1124.85 
contra_CA3sr 514.80 25.63 12.21 0.55 10845.94 1184.28 
contra_CC 11.60 5.78 13.09 0.22 7861.25 1351.30 
contra_cing 82.70 37.28 13.20 0.41 8887.29 1908.10 
contra_COApl 359.80 23.64 12.43 0.23 12794.32 1407.97 
contra_COApl1 388.60 22.15 12.23 0.21 13212.16 1093.95 
contra_COApl2 346.50 37.83 12.54 0.30 12503.99 1649.23 
contra_COApl3 345.10 14.46 12.49 0.15 12764.00 1557.23 
contra_cortex 454.60 27.21 12.21 0.29 17983.41 2162.02 
contra_CP 390.20 17.65 12.02 0.27 14554.62 1817.83 
contra_cpd 14.00 9.14 13.69 0.39 7482.86 1030.89 
contra_DG 657.20 42.64 11.59 0.52 13688.57 1625.69 
contra_DGinf 656.40 39.63 11.62 0.51 13352.37 1747.04 
contra_DGpo 220.90 18.10 14.75 0.43 9737.74 1145.91 
contra_DGsg 45.90 11.83 15.12 0.25 6928.48 508.24 
contra_DGsup 660.10 46.62 11.57 0.53 13917.17 1628.70 
contra_ECT 512.50 27.28 11.96 0.29 18921.88 1845.06 
contra_ECT1 606.00 37.47 11.82 0.28 20550.97 1806.88 
contra_ECT3 536.50 17.22 12.02 0.26 19837.71 1872.91 
contra_ECT5 476.30 29.77 11.96 0.31 17508.27 1868.62 
contra_ECT6a 442.70 32.68 11.89 0.36 16556.67 1718.32 
contra_ECT6b 325.30 46.58 12.17 0.44 12622.67 1965.85 
contra_ENTI 478.60 21.28 11.83 0.33 17055.64 1806.84 
contra_ENTl1 603.60 25.38 11.59 0.29 18669.31 2025.11 
contra_ENTl3 499.00 23.79 11.94 0.30 17796.98 2066.18 
contra_ENTl5 465.00 22.71 11.97 0.41 16541.05 1670.18 
contra_ENTl6a 440.30 13.76 11.62 0.36 14013.17 1392.76 
contra_ENTl6b 378.00 37.11 11.77 0.27 12214.01 1383.33 
contra_FC 264.80 25.96 11.97 0.47 7479.49 1169.66 
contra_hip 538.60 20.03 11.82 0.48 12498.46 1631.24 
contra_hyp 123.20 7.63 13.89 0.05 9828.62 1112.02 
contra_LA 454.20 26.44 12.03 0.33 16479.95 2137.54 
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contra_lay1 565.10 29.92 12.04 0.33 19846.77 2045.53 
contra_lay2 297.90 30.47 12.60 0.38 12741.38 2550.48 
contra_lay3 491.00 26.75 12.26 0.28 19969.51 2005.96 
contra_lay4 486.70 29.86 12.01 0.26 18402.76 2165.19 
contra_lay5 422.50 24.59 12.31 0.30 16894.89 2140.26 
contra_lay6a 399.40 19.03 12.12 0.32 15544.63 2337.01 
contra_lay6b 304.80 35.06 12.37 0.36 12237.21 2149.91 
contra_MOp 483.40 31.78 12.17 0.40 18141.69 2883.78 
contra_MOp1 582.20 52.52 12.08 0.45 19925.05 3288.75 
contra_MOp3 512.20 39.87 12.16 0.40 19373.88 2997.05 
contra_MOp5 467.70 34.71 12.24 0.38 17244.13 2817.74 
contra_MOp6a 402.60 22.40 12.15 0.37 14927.54 2612.06 
contra_MOp6b 303.00 36.57 12.36 0.39 12303.70 2625.08 
contra_MOs 409.30 18.56 12.46 0.39 17230.71 3015.15 
contra_MOs1 540.60 38.32 12.32 0.40 20547.80 3617.58 
contra_MOs3 437.10 20.39 12.46 0.38 18325.53 3055.87 
contra_MOs5 368.20 12.86 12.59 0.42 15415.76 2755.05 
contra_MOs6a 337.90 24.01 12.40 0.41 13306.66 2656.58 
contra_MOs6b 271.40 34.47 12.51 0.29 11264.70 2318.04 
contra_PAA 387.70 21.19 12.28 0.18 13090.09 915.79 
contra_PAA1 394.40 12.47 12.22 0.19 13072.57 1062.64 
contra_PAA2 387.60 28.05 12.32 0.21 12913.77 945.03 
contra_PAA3 381.40 25.71 12.33 0.17 13110.12 1007.26 
contra_PERI 509.70 28.78 11.84 0.33 18119.81 1906.13 
contra_PERI1 625.80 50.53 11.61 0.37 19753.32 2292.41 
contra_PERI3 536.10 27.22 11.89 0.34 18749.52 1956.64 
contra_PERI5 474.60 23.27 11.93 0.32 17413.03 1905.30 
contra_PERI6a 454.00 29.87 11.76 0.33 15748.85 1685.66 
contra_PERI6b 350.70 23.40 11.96 0.25 12248.25 1546.63 
contra_PIR 435.00 30.08 11.97 0.23 14515.50 1519.27 
contra_PIR1 484.90 40.64 11.92 0.23 15205.68 1217.43 
contra_PIR2 390.10 32.50 11.98 0.16 13706.97 1307.72 
contra_PIR3 434.70 25.05 11.99 0.25 14566.21 1693.48 
contra_RSPd 353.40 13.87 12.66 0.33 16097.02 3178.33 
contra_RSPd1 484.70 48.08 12.57 0.31 19808.56 4047.25 
contra_RSPd3 389.00 20.03 12.62 0.28 17123.62 3359.66 
contra_RSPd5 314.40 19.13 12.96 0.36 13930.67 2749.73 
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contra_RSPd6a 298.70 28.07 12.56 0.34 12154.33 2556.65 
contra_RSPd6b 233.40 38.13 12.56 0.32 10898.82 2458.80 
contra_RSPv 340.30 18.38 12.61 0.32 14550.58 2922.16 
contra_RSPv1 377.70 14.66 12.73 0.37 15659.89 3153.96 
contra_RSPv2 299.60 31.11 12.59 0.38 12766.19 2569.66 
contra_RSPv3 383.60 16.19 12.34 0.29 15503.81 3073.68 
contra_RSPv5 312.80 25.98 12.86 0.24 13763.00 2535.43 
contra_RSPv6a 270.30 27.04 12.80 0.33 11752.34 2386.84 
contra_RSPv6b 215.30 46.79 12.68 0.41 10844.37 2576.53 
contra_SSp-bfd 440.90 34.73 12.28 0.28 17968.92 2186.84 
contra_SSp-
bfd1 563.60 38.19 12.07 0.29 20549.24 2069.99 
contra_SSp-
bfd3 482.60 38.70 12.37 0.27 20627.00 2061.30 
contra_SSp-
bfd4 469.80 36.87 12.05 0.27 17878.33 2180.31 
contra_SSp-
bfd5 408.20 28.73 12.40 0.29 16666.18 2199.85 
contra_SSp-
bfd6a 393.10 23.47 12.16 0.32 15482.61 2422.80 
contra_SSp-
bfd6b 297.40 55.06 12.42 0.39 12273.04 2338.81 
contra_SSP-tr 467.80 28.81 12.18 0.32 18413.92 2541.67 
contra_SSp-tr1 599.30 46.72 11.94 0.37 20844.78 2686.64 
contra_SSp-tr3 517.40 31.08 12.23 0.32 20904.66 2608.89 
contra_SSp-tr4 481.70 31.75 12.04 0.28 18147.72 2456.83 
contra_SSp-tr5 424.40 25.54 12.39 0.30 16664.10 2413.25 
contra_SSp-
tr6a 404.10 17.60 12.09 0.33 15503.94 2470.58 
contra_SSp-
tr6b 307.50 36.50 12.34 0.40 12460.47 2370.15 
contra_TEa 497.60 31.73 12.04 0.25 18817.64 1764.80 
contra_TEa1 589.90 19.52 11.91 0.21 19990.52 1344.70 
contra_TEa3 532.40 25.73 12.09 0.22 20120.48 1705.28 
contra_TEa4 526.30 36.55 11.99 0.32 19435.70 2136.46 
contra_TEa5 474.10 30.68 12.02 0.24 17860.28 1978.35 
contra_TEa6a 426.80 37.72 12.05 0.29 16983.96 2350.69 
contra_TEa6b 309.80 34.45 12.38 0.39 12582.87 2424.77 
contra_th 317.10 25.89 11.73 0.27 9265.30 1151.64 
ips_amgmed 290.00 35.34 12.68 0.16 11285.16 1806.20 
ips_AUDd 474.90 30.05 12.30 0.45 18126.34 4155.08 
ips_AUDd1 575.50 75.52 12.17 0.57 20249.76 4971.44 
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ips_AUDd3 507.60 43.17 12.39 0.47 20234.62 4733.64 
ips_AUDd4 496.60 32.07 12.07 0.42 17792.93 4031.95 
ips_AUDd5 436.80 18.83 12.34 0.41 16377.92 3822.66 
ips_AUDd6a 415.30 19.38 12.16 0.41 15458.47 3639.75 
ips_AUDd6b 299.00 37.25 12.52 0.37 12182.26 2871.52 
ips_AUDp 480.40 28.54 12.25 0.41 17961.10 3877.89 
ips_AUDp1 564.50 68.37 12.18 0.50 19587.58 4199.40 
ips_AUDp3 510.60 43.14 12.31 0.42 19622.64 4352.63 
ips_AUDp4 496.80 26.93 12.17 0.44 17778.09 3964.71 
ips_AUDp5 455.50 29.33 12.24 0.39 16401.52 3681.50 
ips_AUDp6a 414.20 8.09 12.19 0.39 15469.32 3611.93 
ips_AUDp6b 304.40 14.44 12.49 0.33 11915.56 2730.04 
ips_AUDv 489.50 31.38 12.19 0.42 17764.46 3716.13 
ips_AUDv1 568.10 64.06 12.13 0.49 19336.97 3957.59 
ips_AUDv3 518.30 33.09 12.22 0.40 19265.76 4075.51 
ips_AUDv4 507.00 37.10 12.14 0.49 17707.19 3852.00 
ips_AUDv5 464.30 32.76 12.12 0.42 16402.14 3720.51 
ips_AUDv6a 419.00 23.27 12.24 0.43 15321.20 3664.50 
ips_AUDv6b 291.00 39.07 12.55 0.45 11509.99 2616.48 
ips_BLAa 436.50 28.37 12.17 0.50 13904.70 2545.69 
ips_BLAp 447.75 16.47 12.36 0.43 15522.56 2838.90 
ips_BLAv 383.90 50.49 12.23 0.28 12402.86 2459.46 
ips_BMAp 346.30 44.86 12.34 0.23 11973.72 2181.43 
ips_CA1slm 495.20 32.89 12.20 0.55 13125.35 2467.54 
ips_CA1so 655.10 75.04 11.63 0.65 14584.36 2677.95 
ips_CA1sp 154.70 40.52 12.47 0.45 9414.53 1743.45 
ips_CA1sr 653.80 73.08 11.76 0.61 16248.03 2711.45 
ips_CA2slm 510.20 65.18 11.65 0.72 9296.23 1789.68 
ips_CA2so 464.60 66.01 11.82 0.76 9143.67 1751.28 
ips_CA2sp 53.80 35.61 16.27 2.09 6777.55 1133.56 
ips_CA2sr 427.60 92.65 12.20 0.89 9266.44 1856.75 
ips_CA3slm 493.40 96.51 12.11 0.80 9366.07 1706.46 
ips_CA3slu 254.90 37.02 15.13 0.74 11486.93 2360.34 
ips_CA3so 425.40 86.39 12.43 0.92 9282.07 1609.19 
ips_CA3sp 117.10 25.64 15.63 0.98 9307.75 1824.54 
ips_CA3sr 474.60 89.11 12.57 0.90 10734.08 1943.02 
ips_CC 10.20 5.56 13.11 0.16 7670.50 1721.07 
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ips_cing 55.90 24.80 13.38 0.47 8572.56 2103.79 
ips_COApl 345.80 31.11 12.48 0.25 12282.83 2132.79 
ips_COApl1 368.10 33.02 12.33 0.29 12681.87 2089.39 
ips_COApl2 332.10 38.76 12.54 0.32 12092.36 2166.66 
ips_COApl3 341.40 28.18 12.55 0.20 12229.55 2129.89 
ips_cortex 461.20 29.80 12.30 0.44 17442.39 3944.19 
ips_CP 377.20 19.80 12.20 0.34 13392.68 2592.20 
ips_cpd 11.00 8.69 13.67 0.30 7318.46 1102.74 
ips_DG 652.00 68.63 11.70 0.69 13594.19 2185.88 
ips_DGinf 651.90 57.54 11.70 0.67 13319.36 2032.48 
ips_DGpo 211.00 27.84 14.90 0.72 9596.04 1597.13 
ips_DGsg 43.60 22.81 15.15 0.40 6763.70 771.94 
ips_DGsup 652.80 74.73 11.70 0.70 13720.00 2267.09 
ips_ECT 496.60 26.17 12.07 0.39 17289.60 3388.55 
ips_ECT1 556.90 44.61 11.99 0.46 18276.86 3348.78 
ips_ECT3 508.70 24.95 12.10 0.39 18125.17 3400.93 
ips_ECT5 460.30 16.74 12.05 0.38 15829.63 3128.64 
ips_ECT6a 446.70 23.11 12.03 0.40 14608.13 3177.95 
ips_ECT6b 297.00 15.98 12.45 0.35 10847.47 2322.77 
ips_ENTI 459.30 22.21 12.04 0.36 15490.56 2666.71 
ips_ENTl1 520.10 49.29 11.89 0.42 16518.93 2304.99 
ips_ENTl3 453.90 25.10 12.14 0.36 15992.78 2616.68 
ips_ENTl5 454.00 21.60 12.03 0.41 14818.00 3202.04 
ips_ENTl6a 413.75 15.47 11.82 0.42 12221.76 2930.17 
ips_ENTl6b 342.63 36.50 12.12 0.29 10742.64 2520.15 
ips_FC 242.90 57.46 11.96 0.44 7277.07 1208.83 
ips_hip 519.60 64.80 11.97 0.68 12373.44 2391.73 
ips_hyp 120.60 9.77 13.91 0.03 9703.72 1282.66 
ips_LA 449.60 22.73 12.10 0.46 15059.52 2784.05 
ips_lay1 550.80 56.06 12.19 0.52 19306.85 4109.94 
ips_lay2 298.40 33.17 12.62 0.34 12720.47 2747.93 
ips_lay3 487.00 37.08 12.35 0.43 19223.74 4304.56 
ips_lay4 490.80 36.71 12.13 0.45 17700.30 4276.19 
ips_lay5 428.10 24.05 12.36 0.41 16178.90 3928.62 
ips_lay6a 398.20 27.37 12.21 0.45 15037.56 3898.90 
ips_lay6b 292.80 44.62 12.47 0.45 11896.27 3156.56 
ips_MOp 474.70 45.64 12.28 0.51 17752.58 4205.71 
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ips_MOp1 557.70 72.13 12.22 0.52 19431.40 4451.29 
ips_MOp3 501.20 57.10 12.29 0.52 18827.53 4416.16 
ips_MOp5 451.30 36.94 12.32 0.47 16801.68 3952.26 
ips_MOp6a 395.20 45.42 12.20 0.53 14727.34 3898.38 
ips_MOp6b 289.30 55.18 12.48 0.49 11803.58 3373.11 
ips_MOs 381.60 31.08 12.59 0.42 16772.05 4101.74 
ips_MOs1 523.60 49.97 12.44 0.38 20455.61 4149.95 
ips_MOs3 411.80 28.86 12.63 0.43 17843.34 4292.56 
ips_MOs5 342.30 32.19 12.63 0.43 14241.33 3583.15 
ips_MOs6a 299.10 46.92 12.55 0.41 12252.94 3231.06 
ips_MOs6b 231.60 47.16 12.64 0.36 10707.72 2752.04 
ips_PAA 377.40 37.32 12.35 0.27 12523.60 2419.31 
ips_PAA1 385.50 71.13 12.28 0.33 12394.21 2445.96 
ips_PAA2 371.60 32.81 12.35 0.26 12345.83 2194.99 
ips_PAA3 371.90 31.56 12.41 0.29 12568.93 2488.26 
ips_PERI 484.80 24.26 12.01 0.36 16422.21 2841.99 
ips_PERI1 563.40 48.94 11.80 0.38 17878.51 2733.09 
ips_PERI3 487.80 24.53 12.07 0.36 17044.18 2704.07 
ips_PERI5 466.40 30.43 12.09 0.39 15621.15 3046.08 
ips_PERI6a 427.63 12.55 11.93 0.39 13728.93 3314.32 
ips_PERI6b 327.88 10.47 12.23 0.32 10940.17 2522.37 
ips_PIR 443.40 36.55 12.03 0.29 14038.19 2253.83 
ips_PIR1 475.80 50.99 12.02 0.43 14524.46 2212.89 
ips_PIR2 395.20 32.24 12.05 0.25 13384.60 1991.58 
ips_PIR3 444.40 33.52 12.05 0.27 14106.96 2367.23 
ips_RSPd 354.90 12.08 12.68 0.35 16321.90 3715.40 
ips_RSPd1 481.20 44.94 12.58 0.38 20106.84 4442.74 
ips_RSPd3 387.60 23.29 12.64 0.34 17043.43 4014.44 
ips_RSPd5 308.60 20.75 12.98 0.38 13988.60 3540.01 
ips_RSPd6a 293.70 33.51 12.62 0.39 12215.81 3146.79 
ips_RSPd6b 214.60 21.33 12.53 0.21 10909.78 2530.55 
ips_RSPv 336.70 27.89 12.61 0.34 14596.41 3317.41 
ips_RSPv1 386.40 27.58 12.68 0.38 16087.89 3561.47 
ips_RSPv2 297.60 32.96 12.63 0.34 12708.88 2743.77 
ips_RSPv3 372.30 19.79 12.35 0.31 15263.44 3349.12 
ips_RSPv5 295.40 29.53 12.85 0.34 13404.12 2937.61 
ips_RSPv6a 268.40 25.94 12.64 0.33 11553.10 2692.05 
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ips_RSPv6b 191.50 33.33 12.72 0.35 10491.59 2515.48 
ips_SSp-bfd 458.00 39.77 12.33 0.44 17687.44 4593.16 
ips_SSp-bfd1 575.30 82.49 12.19 0.57 20497.79 5172.91 
ips_SSp-bfd3 490.20 48.52 12.43 0.43 20327.13 5176.40 
ips_SSp-bfd4 483.90 38.40 12.11 0.44 17552.74 4442.97 
ips_SSp-bfd5 421.50 34.10 12.40 0.39 16294.29 4229.88 
ips_SSp-bfd6a 401.60 33.14 12.19 0.44 15326.79 4016.52 
ips_SSp-bfd6b 299.40 43.65 12.45 0.46 12239.30 3252.37 
ips_SSp-tr 470.20 40.97 12.31 0.51 18083.66 4575.80 
ips_SSp-tr1 579.20 77.19 12.16 0.57 20208.81 5283.17 
ips_SSp-tr3 505.40 51.87 12.36 0.49 20262.00 5187.29 
ips_SSp-tr4 486.00 44.70 12.13 0.50 17721.14 4597.08 
ips_SSp-tr5 426.10 34.30 12.48 0.49 16492.42 4478.79 
ips_SSp-tr6a 397.70 46.42 12.20 0.54 15474.80 4561.80 
ips_SSp-tr6b 290.80 64.41 12.53 0.62 12487.01 3826.83 
ips_TEa 496.40 29.18 12.14 0.42 17521.72 3528.21 
ips_TEa1 565.00 49.46 12.05 0.50 18629.08 3735.33 
ips_TEa3 516.90 31.66 12.18 0.40 18791.63 3675.59 
ips_TEa4 499.50 28.23 12.17 0.38 17547.39 3526.36 
ips_TEa5 477.90 23.35 12.05 0.37 16272.52 3406.42 
ips_TEa6a 428.60 43.42 12.19 0.47 15307.66 3483.91 
ips_TEa6b 303.60 53.00 12.41 0.60 11365.17 2895.59 
ips_th 310.00 26.92 11.78 0.29 9124.41 1575.68 
 
 
Table 2: SAP102 puncta parameters for naïve mice 
 
  Density   Size   Intensity   
Region Average SD Average SD Average SD 
contra_amgmed 249.00 24.48 14.70 0.26 72.11 102.49 
contra_AUDd 403.80 27.59 14.39 0.34 111.53 169.02 
contra_AUDd1 489.13 25.61 13.85 0.32 132.23 206.25 
contra_AUDd3 433.90 30.68 14.62 0.41 119.90 181.60 
contra_AUDd4 408.60 27.86 14.01 0.18 112.66 171.14 
contra_AUDd5 368.40 26.31 14.33 0.34 102.34 153.88 
contra_AUDd6a 374.10 23.01 14.28 0.26 102.91 156.78 
contra_AUDd6b 278.40 48.11 14.43 0.40 85.34 112.81 
contra_AUDp 417.30 26.76 14.23 0.30 114.65 174.99 
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contra_AUDp1 492.70 6.17 13.85 0.25 128.24 210.47 
contra_AUDp3 446.40 28.29 14.44 0.34 122.37 187.34 
contra_AUDp4 420.10 20.14 13.90 0.23 113.59 177.11 
contra_AUDp5 386.00 36.11 14.21 0.32 109.16 160.34 
contra_AUDp6a 383.50 29.51 14.16 0.22 106.85 160.06 
contra_AUDp6b 286.60 53.74 14.28 0.36 88.74 115.90 
contra_AUDv 425.80 26.39 14.12 0.27 116.64 178.73 
contra_AUDv1 490.70 24.49 13.81 0.29 132.32 207.09 
contra_AUDv3 452.90 20.13 14.30 0.30 121.91 191.24 
contra_AUDv4 439.20 31.56 13.81 0.23 121.20 183.93 
contra_AUDv5 406.30 32.01 14.10 0.29 113.18 169.61 
contra_AUDv6a 384.70 29.60 14.15 0.24 107.17 160.57 
contra_AUDv6b 273.40 47.99 14.33 0.25 83.99 110.72 
contra_BLAa 433.20 30.14 13.70 0.26 119.33 181.52 
contra_BLAp 448.00 29.40 13.77 0.24 122.85 188.01 
contra_BLAv 345.40 45.50 13.99 0.21 101.28 141.90 
contra_BMAp 315.20 44.55 14.20 0.26 93.55 128.97 
contra_CA1slm 387.00 42.38 14.85 0.44 111.17 159.96 
contra_CA1so 558.20 46.42 13.58 0.49 154.67 233.58 
contra_CA1sp 178.40 26.38 16.45 0.57 55.45 71.58 
contra_CA1sr 585.60 47.06 13.98 0.40 161.76 245.29 
contra_CA2slm 518.10 16.56 13.11 0.31 137.02 220.10 
contra_CA2so 525.60 19.90 12.97 0.22 139.67 222.93 
contra_CA2sp 124.50 30.98 17.77 1.15 43.60 47.89 
contra_CA2sr 482.30 21.48 13.47 0.22 129.37 203.91 
contra_CA3slm 544.60 36.92 13.40 0.36 148.82 228.88 
contra_CA3slu 209.10 20.81 19.45 0.14 62.38 85.10 
contra_CA3so 461.00 21.45 13.46 0.44 124.09 194.66 
contra_CA3sp 130.30 26.05 19.28 0.20 43.96 50.74 
contra_CA3sr 544.00 32.53 13.72 0.43 147.67 229.10 
contra_CC 26.40 11.36 15.94 0.60 13.57 9.27 
contra_cing 90.30 29.14 15.21 0.54 33.80 34.15 
contra_COApl 319.20 39.91 14.20 0.26 93.39 131.14 
contra_COApl1 349.60 39.33 13.80 0.18 100.73 144.37 
contra_COApl2 310.00 45.12 14.38 0.33 92.46 126.64 
contra_COApl3 301.70 24.07 14.36 0.23 85.09 125.35 
contra_cortex 394.80 32.00 14.30 0.27 110.34 164.62 
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contra_CP 353.00 34.12 14.19 0.32 100.41 146.33 
contra_cpd 31.60 15.58 17.42 0.93 16.38 10.87 
contra_DG 661.80 19.70 13.82 0.39 173.93 281.76 
contra_DGinf 656.00 16.26 13.83 0.35 171.61 279.73 
contra_DGpo 196.50 14.75 17.85 0.48 57.39 80.58 
contra_DGsg 120.80 14.26 20.11 1.24 39.10 47.66 
contra_DGsup 667.90 24.88 13.82 0.43 176.76 283.69 
contra_ECT 462.80 26.07 13.83 0.23 125.73 194.82 
contra_ECT1 535.50 34.53 13.49 0.20 145.93 225.25 
contra_ECT3 471.80 21.17 13.94 0.16 126.77 199.35 
contra_ECT5 439.50 31.97 13.79 0.30 121.39 184.00 
contra_ECT6a 419.50 33.22 13.89 0.26 116.72 175.20 
contra_ECT6b 306.60 45.46 14.07 0.32 91.62 125.20 
contra_ENTI 468.40 22.47 13.64 0.21 126.18 197.74 
contra_ENTl1 575.20 38.36 13.21 0.24 156.75 241.98 
contra_ENTl3 486.70 26.13 13.73 0.26 131.71 205.16 
contra_ENTl5 449.80 18.40 13.62 0.22 120.51 190.23 
contra_ENTl6a 430.70 18.60 13.73 0.19 115.80 181.93 
contra_ENTl6b 347.80 36.93 14.02 0.31 99.76 143.80 
contra_FC 302.10 15.22 13.81 0.28 82.85 126.72 
contra_hip 511.60 28.02 14.02 0.37 138.50 215.63 
contra_hyp 121.30 11.35 15.77 0.20 37.16 48.91 
contra_LA 423.30 26.79 13.88 0.37 116.09 177.62 
contra_lay1 486.20 32.01 13.89 0.32 133.11 204.17 
contra_lay2 255.40 43.61 14.97 0.33 78.58 103.27 
contra_lay3 424.90 28.99 14.49 0.30 117.17 177.96 
contra_lay4 404.50 29.91 14.02 0.22 112.16 169.11 
contra_lay5 359.20 32.01 14.29 0.26 101.44 149.24 
contra_lay6a 361.60 35.51 14.25 0.26 102.90 149.89 
contra_lay6b 268.60 39.90 14.33 0.26 80.77 109.37 
contra_MOp 392.80 51.61 14.26 0.45 114.78 161.60 
contra_MOp1 486.00 56.55 13.89 0.54 139.25 201.26 
contra_MOp3 417.80 52.18 14.43 0.50 121.23 172.27 
contra_MOp5 373.30 54.43 14.18 0.46 110.59 152.97 
contra_MOp6a 345.00 46.30 14.28 0.37 101.49 141.57 
contra_MOp6b 256.60 43.28 14.40 0.28 78.64 103.91 
contra_MOs 331.20 43.19 14.56 0.42 97.34 135.89 
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contra_MOs1 448.60 50.85 14.23 0.49 128.54 185.70 
contra_MOs3 356.90 41.67 14.72 0.45 103.44 147.08 
contra_MOs5 298.40 48.08 14.50 0.42 90.35 121.36 
contra_MOs6a 287.10 45.39 14.45 0.37 86.83 116.77 
contra_MOs6b 229.00 42.99 14.41 0.27 71.67 92.13 
contra_PAA 359.60 24.66 13.92 0.11 99.57 150.38 
contra_PAA1 361.00 11.70 13.69 0.10 96.62 152.73 
contra_PAA2 363.10 28.41 14.02 0.08 101.40 151.42 
contra_PAA3 356.20 30.32 13.99 0.15 100.17 148.21 
contra_PERI 474.30 30.73 13.65 0.25 129.73 199.23 
contra_PERI1 560.30 50.57 13.33 0.34 156.13 234.07 
contra_PERI3 489.80 28.46 13.74 0.28 133.07 206.20 
contra_PERI5 449.40 30.28 13.67 0.24 123.40 188.52 
contra_PERI6a 435.90 29.81 13.67 0.20 119.89 182.75 
contra_PERI6b 325.30 35.49 13.93 0.36 93.77 134.26 
contra_PIR 436.20 25.17 13.62 0.15 118.79 183.47 
contra_PIR1 490.60 30.39 13.17 0.20 133.59 206.40 
contra_PIR2 401.90 31.57 14.13 0.22 111.96 167.77 
contra_PIR3 426.30 22.93 13.66 0.16 115.76 179.47 
contra_RSPd 285.20 42.28 14.69 0.34 85.63 116.21 
contra_RSPd1 404.10 52.42 14.48 0.40 117.85 166.36 
contra_RSPd3 306.30 44.49 14.74 0.38 91.48 125.04 
contra_RSPd5 245.70 39.14 14.83 0.37 75.01 99.52 
contra_RSPd6a 249.70 42.54 14.61 0.30 76.79 100.98 
contra_RSPd6b 194.10 39.35 14.40 0.50 62.09 77.48 
contra_RSPv 275.40 41.57 14.71 0.30 82.99 112.07 
contra_RSPv1 313.10 40.77 14.66 0.31 92.21 128.35 
contra_RSPv2 255.80 44.02 14.96 0.34 78.78 103.41 
contra_RSPv3 295.40 40.94 14.45 0.35 87.79 120.75 
contra_RSPv5 243.90 37.28 14.91 0.27 74.09 98.92 
contra_RSPv6a 223.30 36.41 14.81 0.49 68.75 90.14 
contra_RSPv6b 182.20 42.27 14.68 0.50 59.91 72.18 
contra_SSp-bfd 384.60 32.03 14.49 0.32 107.86 160.17 
contra_SSp-
bfd1 487.60 33.12 13.97 0.28 133.74 204.63 
contra_SSp-
bfd3 417.60 31.38 14.73 0.37 116.02 174.46 
contra_SSp-
bfd4 393.80 31.87 14.09 0.23 110.00 164.24 
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contra_SSp-
bfd5 346.00 31.04 14.52 0.33 97.97 143.61 
contra_SSp-
bfd6a 355.40 38.87 14.38 0.30 102.24 146.81 
contra_SSp-
bfd6b 264.00 49.81 14.39 0.34 82.13 106.54 
contra_SSP-tr 391.40 40.49 14.35 0.30 111.64 162.16 
contra_SSp-tr1 512.10 49.09 13.77 0.44 143.85 213.35 
contra_SSp-tr3 437.00 42.30 14.58 0.33 123.55 181.60 
contra_SSp-tr4 387.20 41.22 14.21 0.33 110.74 160.29 
contra_SSp-tr5 343.00 38.65 14.34 0.24 99.06 141.51 
contra_SSp-
tr6a 352.80 39.44 14.29 0.26 101.70 145.65 
contra_SSp-
tr6b 266.40 41.07 14.36 0.24 80.52 108.32 
contra_TEa 443.50 30.09 14.00 0.18 121.94 185.95 
contra_TEa1 511.10 19.20 13.67 0.17 136.03 216.65 
contra_TEa3 473.60 22.75 14.15 0.16 127.66 199.89 
contra_TEa4 457.70 27.56 13.71 0.20 124.79 192.45 
contra_TEa5 418.30 29.72 14.01 0.25 115.57 175.09 
contra_TEa6a 403.00 40.75 14.08 0.23 114.51 167.19 
contra_TEa6b 288.70 50.36 14.35 0.27 88.42 117.06 
contra_th 305.80 12.22 13.25 0.25 82.88 128.80 
ips_amgmed 243.40 32.27 14.73 0.17 72.64 99.24 
ips_AUDd 396.80 71.88 14.50 0.48 120.91 161.51 
ips_AUDd1 484.70 102.03 14.02 0.72 150.37 196.91 
ips_AUDd3 424.30 81.43 14.67 0.56 130.24 172.50 
ips_AUDd4 398.50 69.00 14.19 0.47 120.54 162.52 
ips_AUDd5 358.10 63.23 14.53 0.37 109.06 145.66 
ips_AUDd6a 364.70 59.78 14.42 0.45 109.84 148.77 
ips_AUDd6b 262.50 44.52 14.50 0.25 80.44 106.32 
ips_AUDp 404.60 66.22 14.39 0.50 121.43 165.31 
ips_AUDp1 476.00 88.47 14.09 0.60 144.79 194.13 
ips_AUDp3 427.00 79.05 14.61 0.57 130.30 173.83 
ips_AUDp4 405.20 64.23 14.10 0.39 120.98 165.81 
ips_AUDp5 376.50 62.69 14.39 0.49 113.52 153.58 
ips_AUDp6a 366.20 52.02 14.33 0.35 108.23 150.14 
ips_AUDp6b 263.30 36.30 14.48 0.24 78.58 107.42 
ips_AUDv 418.70 61.82 14.29 0.47 123.82 171.76 
ips_AUDv1 479.90 80.57 14.02 0.59 143.77 196.41 
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ips_AUDv3 442.50 68.64 14.44 0.49 131.52 181.34 
ips_AUDv4 423.40 64.87 14.08 0.52 125.72 173.53 
ips_AUDv5 391.40 68.07 14.28 0.49 118.56 159.53 
ips_AUDv6a 377.10 55.29 14.24 0.39 111.76 154.52 
ips_AUDv6b 264.10 45.25 14.40 0.29 81.01 106.95 
ips_BLAa 421.50 38.20 13.98 0.36 118.51 175.46 
ips_BLAp 435.50 24.23 13.94 0.31 118.50 183.22 
ips_BLAv 349.20 57.85 14.00 0.30 105.34 142.39 
ips_BMAp 308.30 61.38 14.31 0.38 96.09 124.59 
ips_CA1slm 373.70 65.99 14.93 0.53 113.79 152.02 
ips_CA1so 534.70 96.55 13.74 0.76 161.44 218.61 
ips_CA1sp 179.30 51.62 16.10 0.46 61.87 70.29 
ips_CA1sr 561.50 90.53 14.15 0.61 166.70 230.50 
ips_CA2slm 514.50 55.66 13.30 0.62 146.02 213.72 
ips_CA2so 497.60 30.37 13.21 0.47 135.41 209.38 
ips_CA2sp 107.40 47.02 18.27 1.18 43.47 40.38 
ips_CA2sr 458.40 52.14 13.76 0.62 131.23 189.84 
ips_CA3slm 517.00 90.82 13.70 0.79 155.58 211.49 
ips_CA3slu 193.50 47.55 19.95 0.55 65.39 75.83 
ips_CA3so 430.80 71.79 13.80 0.80 129.29 176.11 
ips_CA3sp 125.70 33.91 19.66 0.53 44.95 48.10 
ips_CA3sr 511.00 86.64 14.06 0.89 153.15 209.17 
ips_CC 27.10 13.92 15.99 0.91 14.48 9.30 
ips_cing 74.20 27.15 15.51 0.75 29.40 27.50 
ips_COApl 300.20 44.80 14.29 0.30 89.90 122.48 
ips_COApl1 322.40 49.38 13.90 0.33 96.51 131.64 
ips_COApl2 292.80 47.53 14.40 0.36 88.77 119.03 
ips_COApl3 293.90 45.06 14.43 0.31 88.43 119.73 
ips_cortex 379.20 73.14 14.46 0.47 116.82 153.92 
ips_CP 323.00 45.57 14.33 0.26 95.79 132.20 
ips_cpd 31.20 18.65 17.45 1.19 17.12 10.66 
ips_DG 650.00 41.54 13.94 0.51 176.50 273.78 
ips_DGinf 649.00 30.36 13.92 0.47 173.44 274.77 
ips_DGpo 188.80 20.76 18.04 0.69 57.07 76.44 
ips_DGsg 117.60 31.56 20.22 1.23 42.65 44.61 
ips_DGsup 651.00 51.08 13.97 0.54 179.15 273.05 
ips_ECT 440.30 52.26 14.03 0.45 126.76 182.02 
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ips_ECT1 490.60 60.42 13.82 0.52 141.34 202.87 
ips_ECT3 444.60 50.88 14.11 0.46 127.51 184.00 
ips_ECT5 416.50 54.41 14.10 0.47 121.37 171.54 
ips_ECT6a 405.70 50.82 14.00 0.38 117.73 167.28 
ips_ECT6b 266.63 18.06 14.31 0.08 74.77 110.97 
ips_ENTI 447.20 30.60 13.84 0.29 122.98 187.49 
ips_ENTl1 503.90 47.05 13.62 0.56 141.28 210.04 
ips_ENTl3 452.70 25.31 13.87 0.22 123.03 190.54 
ips_ENTl5 434.50 39.41 13.89 0.24 122.01 180.96 
ips_ENTl6a 379.63 44.87 13.99 0.27 109.69 156.68 
ips_ENTl6b 312.63 51.83 14.33 0.28 94.77 127.18 
ips_FC 291.80 20.89 13.81 0.30 81.70 121.53 
ips_hip 491.40 74.90 14.20 0.60 145.28 201.78 
ips_hyp 118.60 12.88 15.82 0.24 36.89 47.54 
ips_LA 406.30 45.45 13.94 0.37 116.51 168.11 
ips_lay1 459.00 83.45 14.11 0.64 139.30 187.23 
ips_lay2 257.80 50.90 15.05 0.42 81.04 103.69 
ips_lay3 402.00 78.55 14.66 0.51 123.93 163.21 
ips_lay4 386.60 78.62 14.18 0.48 119.97 156.74 
ips_lay5 343.80 71.59 14.44 0.41 107.56 138.98 
ips_lay6a 341.90 72.10 14.42 0.42 107.21 138.14 
ips_lay6b 252.10 60.03 14.52 0.33 81.74 100.80 
ips_MOp 373.10 82.77 14.41 0.65 117.73 150.68 
ips_MOp1 449.90 93.02 14.14 0.74 139.45 182.67 
ips_MOp3 396.90 87.92 14.63 0.72 125.04 160.42 
ips_MOp5 347.60 78.10 14.31 0.57 110.14 140.18 
ips_MOp6a 328.20 82.50 14.33 0.56 106.40 131.76 
ips_MOp6b 244.60 67.50 14.51 0.40 81.75 97.29 
ips_MOs 301.10 64.27 14.71 0.45 95.13 121.25 
ips_MOs1 427.60 59.64 14.37 0.56 125.54 175.76 
ips_MOs3 326.90 63.39 14.87 0.46 101.40 132.26 
ips_MOs5 276.10 60.33 14.58 0.43 87.86 110.91 
ips_MOs6a 246.80 63.39 14.70 0.42 81.33 98.35 
ips_MOs6b 202.30 51.73 14.74 0.42 67.30 80.16 
ips_PAA 335.50 52.76 14.13 0.26 100.66 136.94 
ips_PAA1 337.30 80.12 13.86 0.40 107.92 135.83 
ips_PAA2 332.60 42.41 14.30 0.15 97.37 136.66 
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ips_PAA3 334.80 46.80 14.19 0.31 99.02 137.17 
ips_PERI 449.70 37.04 13.89 0.39 125.26 187.78 
ips_PERI1 510.20 52.19 13.65 0.50 144.14 212.20 
ips_PERI3 453.30 28.74 13.95 0.42 124.10 190.33 
ips_PERI5 439.00 41.32 13.94 0.38 123.66 182.66 
ips_PERI6a 394.88 41.95 14.03 0.22 112.77 163.57 
ips_PERI6b 297.88 29.20 14.47 0.18 85.43 123.08 
ips_PIR 434.60 36.73 13.74 0.29 121.34 181.33 
ips_PIR1 475.00 46.00 13.39 0.40 133.70 197.75 
ips_PIR2 406.40 26.96 14.27 0.31 111.99 170.24 
ips_PIR3 428.00 35.66 13.75 0.27 119.42 178.61 
ips_RSPd 281.80 50.14 14.77 0.31 86.76 114.06 
ips_RSPd1 396.80 58.87 14.44 0.44 117.64 162.61 
ips_RSPd3 300.40 57.66 14.82 0.35 93.31 121.41 
ips_RSPd5 244.50 48.69 14.89 0.29 77.09 98.23 
ips_RSPd6a 240.60 54.69 14.71 0.36 77.59 96.20 
ips_RSPd6b 181.90 29.88 14.78 0.42 56.74 73.01 
ips_RSPv 273.10 50.29 14.74 0.34 84.62 110.33 
ips_RSPv1 316.20 51.99 14.60 0.35 95.78 128.65 
ips_RSPv2 257.30 50.88 15.04 0.43 80.91 103.48 
ips_RSPv3 286.10 48.21 14.51 0.36 87.29 116.09 
ips_RSPv5 226.70 43.65 14.89 0.35 71.40 91.01 
ips_RSPv6a 222.70 45.51 14.75 0.30 70.82 89.20 
ips_RSPv6b 164.50 39.85 15.06 0.89 55.07 64.70 
ips_SSp-bfd 374.00 85.51 14.61 0.48 118.65 150.91 
ips_SSp-bfd1 475.80 115.14 14.15 0.77 151.47 192.40 
ips_SSp-bfd3 400.80 94.85 14.84 0.52 127.75 161.69 
ips_SSp-bfd4 378.50 81.89 14.17 0.44 118.75 153.10 
ips_SSp-bfd5 336.60 76.69 14.61 0.43 107.09 135.58 
ips_SSp-bfd6a 343.10 73.44 14.53 0.43 107.87 138.54 
ips_SSp-bfd6b 259.50 61.20 14.53 0.37 83.90 103.85 
ips_SSp-tr 370.10 90.14 14.56 0.57 118.84 149.01 
ips_SSp-tr1 474.40 101.99 14.09 0.76 147.81 192.53 
ips_SSp-tr3 404.90 95.68 14.82 0.61 129.00 163.37 
ips_SSp-tr4 366.20 92.40 14.33 0.55 118.37 147.31 
ips_SSp-tr5 325.20 84.82 14.51 0.48 106.25 130.39 
ips_SSp-tr6a 332.90 93.34 14.53 0.51 110.32 133.29 
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ips_SSp-tr6b 249.40 80.16 14.58 0.47 86.15 98.93 
ips_TEa 428.40 57.36 14.18 0.47 125.10 176.36 
ips_TEa1 486.00 63.21 13.92 0.56 140.92 200.59 
ips_TEa3 443.70 59.17 14.34 0.49 129.42 182.74 
ips_TEa4 426.00 51.34 14.01 0.42 122.94 175.96 
ips_TEa5 412.00 61.57 14.18 0.51 122.07 168.92 
ips_TEa6a 389.00 67.92 14.19 0.57 117.92 158.52 
ips_TEa6b 279.20 54.57 14.29 0.26 87.08 112.70 
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Appendix 4: Raw PSD95 from LFPI experiment at 7 and 28 days 
 
Table 1: PSD95 puncta density at 7 days 
 
  Injury   Sham   
region Average SD Average SD 
contra_amgmed 315.36 34.25 307.00 30.49 
contra_AUDd 471.09 38.70 456.50 43.31 
contra_AUDd1 572.36 70.12 547.50 54.92 
contra_AUDd3 513.45 44.53 498.50 51.80 
contra_AUDd4 493.91 41.12 478.56 39.82 
contra_AUDd5 440.05 30.33 423.19 51.61 
contra_AUDd6a 417.64 21.72 398.56 40.12 
contra_AUDd6b 246.50 69.91 234.31 75.80 
contra_AUDp 478.64 37.98 460.19 44.50 
contra_AUDp1 570.32 61.37 560.81 66.55 
contra_AUDp3 517.23 46.28 503.38 53.31 
contra_AUDp4 504.18 36.54 487.13 43.41 
contra_AUDp5 458.09 36.26 437.38 50.78 
contra_AUDp6a 425.55 31.91 398.13 33.53 
contra_AUDp6b 254.73 74.55 220.06 73.94 
contra_AUDv 498.55 46.30 481.50 45.56 
contra_AUDv1 586.86 70.94 579.19 66.39 
contra_AUDv3 540.00 52.31 523.94 48.66 
contra_AUDv4 527.86 43.30 510.63 57.83 
contra_AUDv5 487.68 44.50 467.25 54.68 
contra_AUDv6a 431.09 40.55 407.31 32.12 
contra_AUDv6b 281.68 48.98 264.50 67.41 
contra_BLAa 461.50 40.15 444.63 37.02 
contra_BLAp 483.77 51.14 462.19 37.60 
contra_BLAv 402.64 45.95 384.06 37.13 
contra_BMAp 367.09 55.23 347.00 20.51 
contra_CA1slm 512.77 47.19 497.63 25.07 
contra_CA1so 662.05 62.26 635.81 52.60 
contra_CA1sp 172.05 31.81 149.25 26.38 
contra_CA1sr 694.36 62.42 671.19 49.26 
contra_CA2slm 552.32 43.85 545.06 12.74 
contra_CA2so 518.64 33.35 507.19 23.98 
 Page | 165 
contra_CA2sp 69.18 22.23 54.75 17.25 
contra_CA2sr 477.82 37.10 477.44 31.42 
contra_CA3slm 575.36 50.66 558.00 23.26 
contra_CA3slu 272.86 29.17 261.75 14.73 
contra_CA3so 484.09 41.28 473.69 27.24 
contra_CA3sp 97.00 27.04 108.06 18.97 
contra_CA3sr 536.27 48.67 531.50 18.78 
contra_CC 6.82 3.57 8.00 3.12 
contra_cing 76.14 25.20 59.13 16.56 
contra_COApl 364.50 46.12 349.31 24.73 
contra_COApl1 399.00 39.33 383.06 22.89 
contra_COApl2 361.09 44.73 347.50 36.72 
contra_COApl3 358.59 54.35 339.38 22.03 
contra_cortex 455.36 32.27 441.88 41.92 
contra_CP 385.68 34.69 373.63 19.01 
contra_cpd 12.36 8.15 12.25 7.57 
contra_DG 698.73 64.19 669.31 46.91 
contra_DGinf 699.55 60.12 670.94 47.82 
contra_DGpo 229.50 26.69 226.63 16.97 
contra_DGsg 53.68 21.20 48.63 10.35 
contra_DGsup 699.82 68.52 669.00 46.97 
contra_ECT 510.05 53.13 500.25 42.06 
contra_ECT1 587.41 88.03 579.69 59.10 
contra_ECT3 541.68 57.00 527.69 43.19 
contra_ECT5 491.77 46.02 475.31 44.42 
contra_ECT6a 443.95 40.83 423.06 34.89 
contra_ECT6b 289.00 52.68 300.19 43.87 
contra_ENTI 482.50 56.90 463.31 38.23 
contra_ENTl1 572.55 80.11 561.56 63.75 
contra_ENTl3 504.82 64.36 490.75 50.30 
contra_ENTl5 466.64 55.42 443.81 36.78 
contra_ENTl6a 437.27 43.47 417.63 25.20 
contra_ENTl6b 325.41 59.20 334.19 48.72 
contra_FC 295.41 59.40 284.88 57.10 
contra_hip 564.55 47.13 544.31 29.27 
contra_hyp 128.64 19.50 124.25 16.19 
contra_LA 469.59 40.36 451.81 41.86 
 Page | 166 
contra_lay1 549.18 47.31 544.63 58.26 
contra_lay2 306.14 32.14 294.00 22.60 
contra_lay3 491.64 37.90 479.38 48.80 
contra_lay4 485.68 34.57 470.06 42.31 
contra_lay5 431.32 30.27 417.00 43.12 
contra_lay6a 400.36 24.87 387.06 32.25 
contra_lay6b 264.59 47.76 271.31 42.15 
contra_MOp 457.05 37.33 444.13 53.17 
contra_MOp1 552.50 57.31 547.31 81.35 
contra_MOp3 491.59 41.78 484.50 62.38 
contra_MOp5 451.32 43.58 448.31 59.03 
contra_MOp6a 391.05 40.01 385.50 41.60 
contra_MOp6b 281.32 65.62 289.63 27.79 
contra_MOs 388.86 25.02 379.44 46.47 
contra_MOs1 515.14 51.67 504.75 78.45 
contra_MOs3 416.55 31.80 421.88 52.48 
contra_MOs5 356.14 28.40 348.88 36.44 
contra_MOs6a 318.82 34.86 307.13 35.00 
contra_MOs6b 241.64 59.54 229.13 53.63 
contra_PAA 389.14 37.42 380.31 35.72 
contra_PAA1 410.20 50.92 392.00 34.57 
contra_PAA2 394.50 41.06 383.75 52.51 
contra_PAA3 383.95 35.46 374.75 27.20 
contra_PERI 504.82 54.94 489.13 44.87 
contra_PERI1 582.86 85.41 581.81 69.59 
contra_PERI3 526.45 62.15 512.88 45.47 
contra_PERI5 490.23 49.04 468.75 44.38 
contra_PERI6a 446.32 42.50 432.44 35.23 
contra_PERI6b 291.36 58.04 296.38 42.14 
contra_PIR 465.36 38.50 443.75 27.67 
contra_PIR1 516.55 60.89 493.25 40.87 
contra_PIR2 402.95 48.00 399.44 14.35 
contra_PIR3 461.36 35.71 441.63 27.78 
contra_RSPd 352.82 21.83 355.25 34.80 
contra_RSPd1 477.77 63.20 481.69 59.92 
contra_RSPd3 385.77 27.00 385.44 45.25 
contra_RSPd5 310.91 23.81 315.75 26.21 
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contra_RSPd6a 300.50 24.29 291.63 29.96 
contra_RSPd6b 221.68 56.86 237.75 49.67 
contra_RSPv 339.77 21.71 335.94 22.74 
contra_RSPv1 391.82 32.17 381.81 39.90 
contra_RSPv2 306.59 31.51 293.38 21.67 
contra_RSPv3 378.50 27.29 380.69 36.40 
contra_RSPv5 316.64 27.73 324.25 26.83 
contra_RSPv6a 282.45 29.94 276.56 24.72 
contra_RSPv6b 232.95 48.05 216.63 50.29 
contra_SSp-bfd 444.64 31.29 426.63 46.22 
contra_SSp-
bfd1 564.09 52.50 545.19 65.07 
contra_SSp-
bfd3 484.91 40.31 462.88 56.89 
contra_SSp-
bfd4 464.50 32.24 448.31 42.81 
contra_SSp-
bfd5 414.73 28.10 396.13 43.00 
contra_SSp-
bfd6a 397.32 22.64 381.94 33.21 
contra_SSp-
bfd6b 257.55 60.50 264.38 61.83 
contra_SSP-tr 458.09 34.06 448.88 44.14 
contra_SSp-tr1 560.59 48.67 563.94 61.32 
contra_SSp-tr3 502.14 41.19 493.69 52.24 
contra_SSp-tr4 475.41 37.18 461.94 46.35 
contra_SSp-tr5 425.36 37.12 419.25 44.35 
contra_SSp-
tr6a 392.14 29.17 393.25 34.48 
contra_SSp-
tr6b 245.32 60.25 267.50 47.13 
contra_TEa 516.23 53.70 495.50 40.56 
contra_TEa1 595.95 81.37 580.56 63.29 
contra_TEa3 553.18 54.20 532.31 51.80 
contra_TEa4 538.77 50.17 520.00 43.75 
contra_TEa5 499.73 53.40 480.19 46.53 
contra_TEa6a 439.32 42.35 414.50 37.29 
contra_TEa6b 281.36 46.95 306.69 37.66 
contra_th 320.55 30.80 308.50 25.08 
ips_amgmed 298.27 38.37 285.19 20.74 
ips_AUDd 432.86 40.18 428.19 36.78 
ips_AUDd1 518.41 80.29 505.44 70.26 
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ips_AUDd3 469.95 52.77 462.13 46.08 
ips_AUDd4 454.82 39.00 452.81 35.85 
ips_AUDd5 396.86 34.76 400.00 33.43 
ips_AUDd6a 378.86 32.31 381.75 25.14 
ips_AUDd6b 228.36 66.95 279.00 47.64 
ips_AUDp 449.14 41.21 439.75 41.89 
ips_AUDp1 549.59 73.78 515.50 66.92 
ips_AUDp3 488.50 51.72 477.06 48.19 
ips_AUDp4 475.00 45.90 462.31 45.60 
ips_AUDp5 417.77 33.78 417.56 41.09 
ips_AUDp6a 378.23 37.27 389.44 30.30 
ips_AUDp6b 221.55 65.63 239.56 67.96 
ips_AUDv 472.18 44.69 455.75 44.93 
ips_AUDv1 588.00 57.44 536.56 63.03 
ips_AUDv3 519.55 48.02 491.94 38.74 
ips_AUDv4 485.00 47.57 463.94 36.34 
ips_AUDv5 442.82 38.82 439.88 47.32 
ips_AUDv6a 390.36 41.34 382.13 43.12 
ips_AUDv6b 258.50 46.40 261.25 69.96 
ips_BLAa 444.27 32.30 438.44 25.04 
ips_BLAp 461.50 37.24 445.56 38.96 
ips_BLAv 376.50 63.62 377.31 57.81 
ips_BMAp 344.05 58.90 331.56 35.79 
ips_CA1slm 515.68 42.99 493.06 19.66 
ips_CA1so 666.86 60.91 632.06 51.30 
ips_CA1sp 166.64 42.06 136.38 18.48 
ips_CA1sr 704.91 61.67 670.38 57.97 
ips_CA2slm 544.41 38.20 545.63 28.30 
ips_CA2so 504.27 37.12 500.38 26.62 
ips_CA2sp 62.00 31.94 37.00 12.03 
ips_CA2sr 481.14 38.00 469.38 39.78 
ips_CA3slm 547.23 44.04 539.94 43.56 
ips_CA3slu 269.45 29.19 260.75 28.40 
ips_CA3so 474.05 47.59 460.50 43.77 
ips_CA3sp 105.45 21.89 85.25 28.76 
ips_CA3sr 527.18 41.94 516.50 41.12 
ips_CC 6.41 4.10 7.38 2.72 
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ips_cing 75.41 31.06 44.06 17.54 
ips_COApl 360.45 58.72 327.00 23.44 
ips_COApl1 403.86 65.60 358.06 27.55 
ips_COApl2 350.91 65.06 318.69 28.82 
ips_COApl3 350.14 57.56 319.63 28.22 
ips_cortex 399.27 33.35 406.13 36.62 
ips_CP 352.18 37.30 355.13 23.25 
ips_cpd 9.82 5.33 11.75 8.21 
ips_DG 703.36 57.84 663.31 48.77 
ips_DGinf 697.77 54.42 665.44 47.89 
ips_DGpo 227.36 27.78 218.50 24.17 
ips_DGsg 60.18 19.72 43.75 15.42 
ips_DGsup 707.45 60.86 663.19 49.79 
ips_ECT 486.91 43.84 480.81 48.32 
ips_ECT1 570.23 76.77 554.19 78.11 
ips_ECT3 516.23 50.46 511.06 53.30 
ips_ECT5 465.32 39.36 455.94 43.31 
ips_ECT6a 417.41 40.53 405.75 47.41 
ips_ECT6b 266.09 65.90 271.25 63.75 
ips_ENTI 460.14 57.83 452.06 49.38 
ips_ENTl1 579.27 92.58 558.31 77.28 
ips_ENTl3 479.95 74.17 475.63 64.71 
ips_ENTl5 435.32 49.12 437.31 40.86 
ips_ENTl6a 390.00 45.92 403.31 46.85 
ips_ENTl6b 297.23 53.58 334.06 64.70 
ips_FC 281.64 38.34 262.44 40.11 
ips_hip 559.18 39.94 543.88 29.36 
ips_hyp 128.64 16.37 124.25 16.16 
ips_LA 428.32 31.15 425.56 32.97 
ips_lay1 477.55 59.94 485.00 59.02 
ips_lay2 286.64 39.52 278.25 20.17 
ips_lay3 433.86 42.60 435.75 45.41 
ips_lay4 430.95 39.80 429.06 39.47 
ips_lay5 378.09 29.16 387.50 32.51 
ips_lay6a 345.23 40.90 355.69 32.71 
ips_lay6b 229.86 52.97 240.69 50.33 
ips_MOp 378.45 44.08 378.31 33.08 
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ips_MOp1 415.36 74.29 439.57 59.82 
ips_MOp3 401.27 54.98 403.44 38.86 
ips_MOp5 388.55 42.99 384.81 36.78 
ips_MOp6a 336.82 49.52 322.00 54.35 
ips_MOp6b 218.23 85.12 200.50 59.97 
ips_MOs 327.55 36.93 334.81 24.52 
ips_MOs1 404.65 64.29 429.94 52.83 
ips_MOs3 357.95 44.25 369.31 32.27 
ips_MOs5 310.32 38.89 314.25 27.84 
ips_MOs6a 276.45 44.29 261.63 37.29 
ips_MOs6b 231.18 50.66 189.94 34.18 
ips_PAA 366.23 40.28 366.88 52.44 
ips_PAA1 388.64 53.32 370.31 62.77 
ips_PAA2 363.73 42.44 361.00 31.06 
ips_PAA3 359.77 43.85 368.00 60.61 
ips_PERI 484.68 47.89 476.63 53.50 
ips_PERI1 601.95 74.49 560.88 79.94 
ips_PERI3 514.59 54.03 490.81 50.37 
ips_PERI5 454.95 43.07 460.38 53.27 
ips_PERI6a 413.18 48.70 424.81 50.71 
ips_PERI6b 283.59 60.03 276.13 71.03 
ips_PIR 436.64 43.54 421.31 42.49 
ips_PIR1 501.27 64.19 472.75 67.52 
ips_PIR2 380.77 64.55 376.38 36.19 
ips_PIR3 429.82 38.30 418.94 38.17 
ips_RSPd 321.45 26.47 334.25 23.74 
ips_RSPd1 408.95 53.37 420.06 41.21 
ips_RSPd3 352.09 35.92 359.56 24.65 
ips_RSPd5 289.50 30.46 299.94 35.33 
ips_RSPd6a 273.86 36.60 271.38 26.51 
ips_RSPd6b 237.18 51.38 214.06 40.09 
ips_RSPv 321.00 26.63 322.25 22.94 
ips_RSPv1 363.09 38.55 355.81 15.82 
ips_RSPv2 286.59 39.38 277.19 20.87 
ips_RSPv3 364.64 30.47 361.88 25.83 
ips_RSPv5 302.55 22.12 310.69 32.00 
ips_RSPv6a 261.50 32.01 254.25 31.05 
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ips_RSPv6b 235.86 55.75 204.81 32.84 
ips_SSp-bfd 400.14 42.88 410.50 45.41 
ips_SSp-bfd1 498.23 80.04 513.31 55.30 
ips_SSp-bfd3 438.59 57.64 450.13 58.95 
ips_SSp-bfd4 426.64 43.96 431.06 42.78 
ips_SSp-bfd5 371.32 34.46 381.75 40.22 
ips_SSp-bfd6a 352.41 39.92 368.81 33.84 
ips_SSp-bfd6b 232.27 66.49 264.00 55.93 
ips_SSp-tr 378.86 34.83 394.63 39.56 
ips_SSp-tr1 460.91 69.96 475.19 67.78 
ips_SSp-tr3 408.77 46.21 418.38 52.91 
ips_SSp-tr4 397.00 36.26 406.81 39.89 
ips_SSp-tr5 359.00 27.30 378.25 34.57 
ips_SSp-tr6a 328.18 53.75 343.06 37.64 
ips_SSp-tr6b 201.14 65.53 216.88 56.78 
ips_TEa 485.91 43.03 476.00 48.08 
ips_TEa1 576.68 71.69 560.25 62.17 
ips_TEa3 523.91 51.86 508.81 47.18 
ips_TEa4 494.95 49.53 480.88 51.17 
ips_TEa5 467.77 39.46 456.75 43.85 
ips_TEa6a 396.14 36.26 397.75 46.87 
ips_TEa6b 253.64 47.99 260.44 71.17 
ips_th 309.82 30.51 296.75 28.23 
 
 
Table 2: PSD95 puncta size at 7 days 
 
  Injury   Sham   
region Average SD Average SD 
contra_amgmed 12.47 0.17 12.44 0.14 
contra_AUDd 12.23 0.16 12.15 0.13 
contra_AUDd1 12.12 0.21 12.02 0.14 
contra_AUDd3 12.38 0.14 12.28 0.12 
contra_AUDd4 12.06 0.20 11.95 0.16 
contra_AUDd5 12.25 0.18 12.17 0.16 
contra_AUDd6a 12.06 0.17 12.01 0.09 
contra_AUDd6b 12.62 0.29 12.52 0.36 
contra_AUDp 12.19 0.18 12.11 0.15 
 Page | 172 
contra_AUDp1 12.11 0.22 11.98 0.15 
contra_AUDp3 12.32 0.18 12.22 0.16 
contra_AUDp4 12.04 0.15 11.93 0.13 
contra_AUDp5 12.17 0.17 12.10 0.16 
ontra_AUDp6a 12.06 0.22 12.01 0.12 
contra_AUDp6b 12.52 0.33 12.56 0.29 
contra_AUDv 12.09 0.21 11.98 0.20 
contra_AUDv1 12.05 0.25 11.89 0.20 
contra_AUDv3 12.19 0.18 12.06 0.24 
contra_AUDv4 12.00 0.16 11.84 0.15 
contra_AUDv5 12.01 0.21 11.96 0.22 
contra_AUDv6a 12.07 0.28 11.99 0.15 
contra_AUDv6b 12.45 0.30 12.43 0.27 
contra_BLAa 11.93 0.32 11.78 0.19 
contra_BLAp 11.99 0.34 11.88 0.18 
contra_BLAv 12.07 0.25 11.99 0.21 
contra_BMAp 12.21 0.27 12.20 0.22 
contra_CA1slm 11.92 0.20 11.93 0.16 
contra_CA1so 11.30 0.22 11.35 0.19 
contra_CA1sp 12.43 0.24 12.47 0.25 
contra_CA1sr 11.41 0.20 11.44 0.18 
contra_CA2slm 11.19 0.22 11.21 0.09 
contra_CA2so 11.24 0.19 11.26 0.08 
contra_CA2sp 14.40 0.68 15.09 0.79 
contra_CA2sr 11.50 0.23 11.53 0.15 
contra_CA3slm 11.55 0.28 11.63 0.18 
contra_CA3slu 14.47 0.44 14.43 0.42 
contra_CA3so 11.73 0.34 11.74 0.15 
contra_CA3sp 15.41 0.71 15.26 0.33 
contra_CA3sr 11.92 0.38 11.92 0.18 
contra_CC 13.28 0.45 13.06 0.22 
contra_cing 13.26 0.26 13.12 0.23 
contra_COApl 12.29 0.28 12.26 0.22 
contra_COApl1 12.08 0.25 12.07 0.23 
contra_COApl2 12.33 0.29 12.30 0.31 
contra_COApl3 12.35 0.31 12.33 0.17 
contra_cortex 12.19 0.14 12.14 0.14 
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contra_CP 12.02 0.25 11.98 0.15 
contra_cpd 13.99 0.75 13.89 0.39 
contra_DG 11.27 0.26 11.30 0.15 
contra_DGinf 11.30 0.28 11.31 0.11 
contra_DGpo 14.39 0.28 14.49 0.23 
contra_DGsg 15.13 0.33 14.87 0.38 
contra_DGsup 11.25 0.25 11.29 0.18 
contra_ECT 11.99 0.22 11.87 0.17 
contra_ECT1 11.96 0.25 11.77 0.20 
contra_ECT3 12.03 0.19 11.92 0.17 
contra_ECT5 11.91 0.25 11.82 0.17 
contra_ECT6a 11.93 0.24 11.83 0.24 
contra_ECT6b 12.46 0.42 12.30 0.27 
contra_ENTI 11.85 0.27 11.74 0.22 
contra_ENTl1 11.72 0.26 11.64 0.36 
contra_ENTl3 11.91 0.26 11.79 0.23 
contra_ENTl5 11.98 0.30 11.84 0.16 
contra_ENTl6a 11.70 0.26 11.59 0.24 
contra_ENTl6b 12.01 0.37 11.88 0.28 
contra_FC 11.70 0.14 11.68 0.16 
contra_hip 11.56 0.24 11.59 0.15 
contra_hyp 13.92 0.11 13.88 0.18 
contra_LA 11.88 0.30 11.81 0.21 
contra_lay1 12.10 0.16 12.01 0.16 
contra_lay2 12.50 0.11 12.60 0.15 
contra_lay3 12.27 0.13 12.22 0.15 
contra_lay4 12.04 0.14 11.94 0.13 
contra_lay5 12.23 0.16 12.19 0.14 
contra_lay6a 12.09 0.17 12.05 0.13 
contra_lay6b 12.48 0.22 12.39 0.20 
contra_MOp 12.10 0.14 12.15 0.19 
contra_MOp1 12.03 0.19 12.08 0.27 
contra_MOp3 12.09 0.14 12.14 0.20 
contra_MOp5 12.14 0.15 12.15 0.17 
contra_MOp6a 12.08 0.15 12.17 0.18 
contra_MOp6b 12.45 0.34 12.30 0.11 
contra_MOs 12.46 0.15 12.51 0.21 
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contra_MOs1 12.39 0.17 12.38 0.24 
contra_MOs3 12.48 0.14 12.51 0.22 
contra_MOs5 12.57 0.17 12.70 0.22 
contra_MOs6a 12.38 0.18 12.44 0.20 
contra_MOs6b 12.53 0.22 12.52 0.27 
contra_PAA 12.10 0.22 12.03 0.28 
contra_PAA1 11.95 0.26 11.96 0.26 
contra_PAA2 12.05 0.23 12.01 0.35 
contra_PAA3 12.18 0.20 12.09 0.26 
contra_PERI 11.90 0.25 11.80 0.24 
contra_PERI1 11.81 0.28 11.69 0.33 
contra_PERI3 11.94 0.22 11.83 0.24 
contra_PERI5 11.93 0.29 11.83 0.18 
contra_PERI6a 11.78 0.28 11.70 0.29 
contra_PERI6b 12.32 0.47 12.18 0.27 
contra_PIR 11.80 0.25 11.74 0.15 
contra_PIR1 11.68 0.25 11.63 0.16 
contra_PIR2 11.86 0.25 11.79 0.15 
contra_PIR3 11.83 0.25 11.76 0.15 
contra_RSPd 12.65 0.13 12.66 0.17 
contra_RSPd1 12.57 0.24 12.53 0.16 
contra_RSPd3 12.59 0.11 12.56 0.19 
contra_RSPd5 13.00 0.17 13.03 0.24 
contra_RSPd6a 12.54 0.14 12.67 0.20 
contra_RSPd6b 12.57 0.15 12.51 0.15 
contra_RSPv 12.52 0.12 12.58 0.15 
contra_RSPv1 12.53 0.12 12.62 0.20 
contra_RSPv2 12.50 0.11 12.60 0.15 
contra_RSPv3 12.26 0.12 12.31 0.13 
contra_RSPv5 12.77 0.16 12.73 0.13 
contra_RSPv6a 12.70 0.16 12.82 0.18 
contra_RSPv6b 12.54 0.31 12.52 0.17 
contra_SSp-bfd 12.27 0.15 12.22 0.16 
contra_SSp-
bfd1 12.12 0.18 12.05 0.17 
contra_SSp-
bfd3 12.40 0.15 12.38 0.20 
contra_SSp-
bfd4 12.06 0.18 11.95 0.14 
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contra_SSp-
bfd5 12.31 0.18 12.30 0.13 
contra_SSp-
bfd6a 12.10 0.18 12.03 0.12 
contra_SSp-
bfd6b 12.58 0.29 12.43 0.24 
contra_SSP-tr 12.19 0.11 12.13 0.13 
contra_SSp-tr1 12.02 0.13 11.93 0.16 
contra_SSp-tr3 12.27 0.12 12.21 0.14 
contra_SSp-tr4 12.04 0.12 11.98 0.14 
contra_SSp-tr5 12.30 0.17 12.24 0.13 
contra_SSp-
tr6a 12.09 0.15 12.05 0.13 
contra_SSp-
tr6b 12.53 0.26 12.42 0.17 
contra_TEa 12.03 0.23 11.92 0.17 
contra_TEa1 11.99 0.28 11.84 0.22 
contra_TEa3 12.12 0.19 11.96 0.17 
contra_TEa4 11.98 0.20 11.84 0.12 
contra_TEa5 11.93 0.21 11.86 0.18 
contra_TEa6a 12.05 0.31 12.00 0.17 
contra_TEa6b 12.44 0.32 12.23 0.24 
contra_th 11.66 0.17 11.67 0.12 
ips_amgmed 12.54 0.20 12.61 0.12 
ips_AUDd 12.27 0.19 12.25 0.16 
ips_AUDd1 12.21 0.24 12.24 0.28 
ips_AUDd3 12.37 0.23 12.29 0.21 
ips_AUDd4 12.13 0.20 12.11 0.14 
ips_AUDd5 12.32 0.20 12.32 0.13 
ips_AUDd6a 12.07 0.19 12.09 0.14 
ips_AUDd6b 12.72 0.29 12.50 0.31 
ips_AUDp 12.15 0.18 12.18 0.19 
ips_AUDp1 12.05 0.21 12.16 0.24 
ips_AUDp3 12.18 0.18 12.19 0.27 
ips_AUDp4 12.02 0.19 12.09 0.18 
ips_AUDp5 12.19 0.18 12.22 0.17 
ips_AUDp6a 12.11 0.24 12.10 0.17 
ips_AUDp6b 12.77 0.26 12.71 0.31 
ips_AUDv 11.97 0.13 12.03 0.20 
ips_AUDv1 11.88 0.12 12.02 0.27 
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ips_AUDv3 11.95 0.11 11.98 0.23 
ips_AUDv4 11.98 0.17 12.03 0.16 
ips_AUDv5 11.95 0.17 12.02 0.21 
ips_AUDv6a 12.03 0.24 12.11 0.19 
ips_AUDv6b 12.65 0.18 12.58 0.32 
ips_BLAa 11.84 0.22 11.88 0.21 
ips_BLAp 11.91 0.22 11.97 0.22 
ips_BLAv 12.18 0.29 12.21 0.35 
ips_BMAp 12.37 0.31 12.39 0.39 
ips_CA1slm 11.88 0.24 11.95 0.18 
ips_CA1so 11.22 0.26 11.38 0.21 
ips_CA1sp 12.47 0.24 12.55 0.22 
ips_CA1sr 11.33 0.23 11.44 0.22 
ips_CA2slm 11.21 0.27 11.33 0.20 
ips_CA2so 11.28 0.21 11.38 0.15 
ips_CA2sp 15.09 1.20 15.70 1.32 
ips_CA2sr 11.53 0.31 11.70 0.26 
ips_CA3slm 11.63 0.35 11.80 0.33 
ips_CA3slu 14.48 0.41 14.65 0.37 
ips_CA3so 11.75 0.40 11.96 0.28 
ips_CA3sp 15.28 0.40 15.75 0.80 
ips_CA3sr 11.91 0.41 12.11 0.28 
ips_CC 13.29 0.44 13.06 0.23 
ips_cing 13.18 0.25 13.09 0.35 
ips_COApl 12.37 0.35 12.49 0.21 
ips_COApl1 12.17 0.32 12.28 0.20 
ips_COApl2 12.42 0.38 12.53 0.28 
ips_COApl3 12.44 0.36 12.56 0.23 
ips_cortex 12.29 0.18 12.28 0.16 
ips_CP 12.10 0.23 12.12 0.18 
ips_cpd 13.99 0.64 13.83 0.63 
ips_DG 11.20 0.28 11.35 0.21 
ips_DGinf 11.22 0.27 11.35 0.18 
ips_DGpo 14.39 0.30 14.52 0.24 
ips_DGsg 15.05 0.37 15.05 0.58 
ips_DGsup 11.18 0.29 11.35 0.24 
ips_ECT 11.88 0.15 11.92 0.19 
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ips_ECT1 11.88 0.24 11.87 0.18 
ips_ECT3 11.91 0.16 11.94 0.18 
ips_ECT5 11.77 0.14 11.82 0.16 
ips_ECT6a 11.87 0.16 11.93 0.30 
ips_ECT6b 12.42 0.33 12.48 0.41 
ips_ENTI 11.81 0.21 11.82 0.20 
ips_ENTl1 11.56 0.23 11.56 0.24 
ips_ENTl3 11.81 0.25 11.83 0.22 
ips_ENTl5 11.95 0.21 11.94 0.25 
ips_ENTl6a 11.79 0.19 11.77 0.21 
ips_ENTl6b 12.12 0.26 12.01 0.34 
ips_FC 11.80 0.16 11.77 0.08 
ips_hip 11.51 0.26 11.65 0.22 
ips_hyp 13.92 0.10 13.88 0.20 
ips_LA 11.90 0.22 11.93 0.22 
ips_lay1 12.24 0.20 12.22 0.18 
ips_lay2 12.56 0.16 12.61 0.13 
ips_lay3 12.31 0.18 12.30 0.16 
ips_lay4 12.18 0.23 12.19 0.17 
ips_lay5 12.34 0.15 12.35 0.15 
ips_lay6a 12.18 0.19 12.19 0.15 
ips_lay6b 12.64 0.20 12.55 0.25 
ips_MOp 12.31 0.26 12.41 0.19 
ips_MOp1 12.41 0.39 12.44 0.24 
ips_MOp3 12.35 0.33 12.48 0.20 
ips_MOp5 12.26 0.24 12.35 0.16 
ips_MOp6a 12.24 0.22 12.35 0.17 
ips_MOp6b 12.58 0.29 12.69 0.37 
ips_MOs 12.73 0.23 12.72 0.18 
ips_MOs1 12.73 0.30 12.70 0.25 
ips_MOs3 12.79 0.27 12.79 0.21 
ips_MOs5 12.83 0.26 12.84 0.13 
ips_MOs6a 12.51 0.12 12.58 0.19 
ips_MOs6b 12.57 0.15 12.64 0.21 
ips_PAA 12.33 0.24 12.30 0.36 
ips_PAA1 12.22 0.29 12.25 0.36 
ips_PAA2 12.34 0.27 12.29 0.36 
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ips_PAA3 12.35 0.22 12.34 0.38 
ips_PERI 11.78 0.16 11.84 0.20 
ips_PERI1 11.65 0.19 11.69 0.21 
ips_PERI3 11.80 0.14 11.87 0.19 
ips_PERI5 11.84 0.21 11.88 0.21 
ips_PERI6a 11.76 0.24 11.78 0.26 
ips_PERI6b 12.31 0.44 12.41 0.49 
ips_PIR 11.85 0.21 11.90 0.22 
ips_PIR1 11.80 0.27 11.82 0.28 
ips_PIR2 11.98 0.34 12.03 0.29 
ips_PIR3 11.83 0.17 11.90 0.20 
ips_RSPd 12.80 0.16 12.76 0.18 
ips_RSPd1 12.80 0.24 12.70 0.18 
ips_RSPd3 12.75 0.17 12.71 0.19 
ips_RSPd5 13.07 0.14 13.02 0.21 
ips_RSPd6a 12.65 0.18 12.71 0.09 
ips_RSPd6b 12.46 0.18 12.48 0.18 
ips_RSPv 12.61 0.15 12.63 0.12 
ips_RSPv1 12.71 0.18 12.71 0.11 
ips_RSPv2 12.56 0.16 12.61 0.14 
ips_RSPv3 12.33 0.16 12.35 0.14 
ips_RSPv5 12.79 0.15 12.76 0.21 
ips_RSPv6a 12.69 0.20 12.81 0.11 
ips_RSPv6b 12.56 0.19 12.47 0.28 
ips_SSp-bfd 12.36 0.24 12.27 0.19 
ips_SSp-bfd1 12.24 0.26 12.12 0.24 
ips_SSp-bfd3 12.45 0.28 12.30 0.22 
ips_SSp-bfd4 12.25 0.28 12.18 0.18 
ips_SSp-bfd5 12.45 0.19 12.44 0.21 
ips_SSp-bfd6a 12.18 0.22 12.12 0.18 
ips_SSp-bfd6b 12.71 0.29 12.47 0.21 
ips_SSp-tr 12.38 0.19 12.37 0.18 
ips_SSp-tr1 12.26 0.27 12.25 0.20 
ips_SSp-tr3 12.44 0.22 12.44 0.21 
ips_SSp-tr4 12.27 0.24 12.32 0.21 
ips_SSp-tr5 12.47 0.15 12.46 0.15 
ips_SSp-tr6a 12.24 0.25 12.22 0.16 
 Page | 179 
ips_SSp-tr6b 12.80 0.35 12.62 0.28 
ips_TEa 11.92 0.15 11.93 0.19 
ips_TEa1 11.90 0.20 11.85 0.18 
ips_TEa3 11.90 0.16 11.91 0.21 
ips_TEa4 11.97 0.15 11.98 0.21 
ips_TEa5 11.79 0.14 11.87 0.17 
ips_TEa6a 12.03 0.22 12.07 0.27 
ips_TEa6b 12.55 0.26 12.53 0.37 
ips_th 11.84 0.19 11.82 0.17 
 
Table 3: PSD95 puncta intensity at 7 days 
 
  Injury   Sham   
region Average SD Average SD 
contra_amgmed 12995.74 2966.05 12691.52 2394.19 
contra_AUDd 19984.26 4269.30 19658.92 2756.98 
contra_AUDd1 21654.19 4454.66 20812.08 2656.84 
contra_AUDd3 22387.37 4674.55 21953.59 2896.94 
contra_AUDd4 20134.59 4483.84 19711.07 3102.17 
contra_AUDd5 18449.34 4047.57 18310.46 2945.41 
contra_AUDd6a 17211.65 3883.18 16955.50 2784.05 
contra_AUDd6b 12463.08 3278.44 12119.61 1909.13 
contra_AUDp 19973.43 4309.67 19612.72 2894.11 
contra_AUDp1 21394.86 4334.89 21085.31 3215.65 
contra_AUDp3 22088.33 4672.71 21902.58 3220.05 
contra_AUDp4 20301.61 4492.15 19889.97 3066.53 
contra_AUDp5 18843.38 4184.86 18427.54 2972.79 
ontra_AUDp6a 17376.81 4147.87 17047.40 2714.34 
contra_AUDp6b 12399.45 3634.64 11902.12 1730.60 
contra_AUDv 20033.72 4501.86 19617.16 2943.45 
contra_AUDv1 21627.34 4831.26 21356.96 3185.38 
contra_AUDv3 22075.43 4993.20 21780.14 3309.07 
contra_AUDv4 20627.55 4608.29 20245.74 3403.68 
contra_AUDv5 19037.84 4456.16 18561.95 3113.91 
contra_AUDv6a 17513.66 4263.90 17040.50 2747.98 
contra_AUDv6b 12810.86 3607.02 12513.11 2178.76 
contra_BLAa 15997.54 3904.58 15416.02 2769.13 
contra_BLAp 17241.96 4085.05 17101.43 2759.16 
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contra_BLAv 14582.16 3620.79 14149.48 2611.59 
contra_BMAp 13708.62 3306.74 13249.68 2497.65 
contra_CA1slm 15039.23 3156.36 13374.91 1772.15 
contra_CA1so 16258.74 3192.62 14732.51 2219.87 
contra_CA1sp 10776.94 2046.65 9688.88 1165.42 
contra_CA1sr 18604.79 3311.09 16705.59 2530.92 
contra_CA2slm 10778.78 2329.72 9929.08 1395.45 
contra_CA2so 10651.33 2358.28 9835.44 1647.22 
contra_CA2sp 7865.82 1296.54 7486.41 643.97 
contra_CA2sr 10484.76 2247.10 9886.53 1610.64 
contra_CA3slm 10704.42 2167.39 9878.58 1503.35 
contra_CA3slu 13240.39 3068.84 12350.96 1756.64 
contra_CA3so 10502.24 2211.63 9774.85 1575.88 
contra_CA3sp 9561.69 1794.43 9118.41 669.69 
contra_CA3sr 11817.58 2356.87 11005.11 1716.32 
contra_CC 7996.47 1343.41 7856.79 460.58 
contra_cing 9820.15 1699.90 8874.05 1160.28 
contra_COApl 13926.44 3103.83 13710.61 2950.79 
contra_COApl1 14544.70 3191.90 14477.10 3099.89 
contra_COApl2 13788.95 3015.08 13636.78 3117.84 
contra_COApl3 13908.92 3163.48 13611.18 2830.52 
contra_cortex 18951.25 3746.67 18372.02 2774.57 
contra_CP 15007.94 3465.22 14629.89 2436.74 
contra_cpd 7666.12 1291.34 7881.45 922.36 
contra_DG 15072.98 2691.06 13462.39 1758.84 
contra_DGinf 14564.32 2374.37 13068.83 1801.67 
contra_DGpo 10563.30 1810.84 9851.01 1177.13 
contra_DGsg 7301.77 894.61 6857.01 325.79 
contra_DGsup 15363.37 2898.79 13695.90 1760.28 
contra_ECT 19775.04 4664.05 19371.20 2987.72 
contra_ECT1 21236.38 5007.87 20791.06 3360.84 
contra_ECT3 21177.16 4961.62 20791.10 3365.96 
contra_ECT5 18570.10 4523.21 17964.55 2937.80 
contra_ECT6a 17359.06 4389.50 16831.13 2700.59 
contra_ECT6b 12807.41 3404.43 12732.70 2022.40 
contra_ENTI 17350.93 4592.71 16964.02 3006.13 
contra_ENTl1 18729.70 4218.80 17949.82 3045.55 
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contra_ENTl3 18294.20 4552.14 17786.39 3213.47 
contra_ENTl5 17072.57 4617.16 16724.56 3142.67 
contra_ENTl6a 14836.85 4255.32 14259.34 2284.29 
contra_ENTl6b 12343.84 3253.60 12303.43 2284.65 
contra_FC 8531.22 1724.34 7179.72 761.82 
contra_hip 14062.48 2712.94 12585.90 1882.41 
contra_hyp 10833.81 2068.31 10603.23 1793.99 
contra_LA 16837.86 3981.70 16686.36 3006.12 
contra_lay1 20391.18 3806.68 19851.68 3158.57 
contra_lay2 14655.17 3196.52 12483.85 2112.65 
contra_lay3 21038.48 4102.85 20307.55 3188.96 
contra_lay4 19818.00 4163.10 19097.96 2973.23 
contra_lay5 18200.91 3870.16 17558.12 2790.63 
contra_lay6a 16471.83 3726.08 15806.27 2579.32 
contra_lay6b 12392.50 2958.66 12032.60 1817.54 
contra_MOp 18621.56 3359.68 17427.91 2958.14 
contra_MOp1 19931.29 3577.65 19534.72 3769.52 
contra_MOp3 19802.91 3602.14 18801.68 3488.96 
contra_MOp5 18498.02 3665.28 17239.58 2970.93 
contra_MOp6a 15984.73 3610.83 14376.48 2492.22 
contra_MOp6b 12642.51 3052.67 11415.42 1644.91 
contra_MOs 18558.38 3141.31 17159.62 3046.10 
contra_MOs1 21877.06 4334.53 20628.60 3856.76 
contra_MOs3 19682.62 3427.09 18711.95 3291.27 
contra_MOs5 16901.53 3571.76 15525.74 2881.04 
contra_MOs6a 14333.23 3244.86 12754.48 2351.87 
contra_MOs6b 11974.40 2699.40 10702.77 2040.77 
contra_PAA 14010.84 3147.67 14201.60 2640.32 
contra_PAA1 14041.21 3437.44 14095.38 2646.14 
contra_PAA2 13975.68 3194.32 14178.72 2709.21 
contra_PAA3 14180.91 3162.18 14274.70 2648.24 
contra_PERI 18722.54 4566.73 18371.67 2996.13 
contra_PERI1 20027.27 4831.12 19746.43 3199.95 
contra_PERI3 19742.87 4842.20 19419.76 3239.86 
contra_PERI5 18050.39 4491.77 17503.94 3178.20 
contra_PERI6a 16228.15 4328.62 15740.42 2378.86 
contra_PERI6b 12440.65 3375.51 12200.93 1860.48 
 Page | 182 
contra_PIR 15523.77 3541.86 15077.78 2561.45 
contra_PIR1 15897.22 3496.15 15512.03 2677.42 
contra_PIR2 14645.16 3499.78 14272.59 2449.51 
contra_PIR3 15650.76 3556.59 15203.21 2577.16 
contra_RSPd 18036.39 3448.88 16654.21 2791.83 
contra_RSPd1 21633.70 4738.12 20531.89 3743.91 
contra_RSPd3 18985.33 3580.46 17682.70 3155.17 
contra_RSPd5 16224.51 3612.51 14810.05 2329.50 
contra_RSPd6a 14048.04 2973.97 12524.85 2176.64 
contra_RSPd6b 12161.13 2688.61 10955.96 2015.51 
contra_RSPv 16381.21 3253.98 14340.36 2496.80 
contra_RSPv1 18469.70 3737.10 16054.49 3043.32 
contra_RSPv2 14657.42 3182.48 12496.62 2071.30 
contra_RSPv3 17358.88 3324.98 15385.41 2840.59 
contra_RSPv5 15793.06 3373.60 14267.48 2282.10 
contra_RSPv6a 13383.31 2849.27 12108.43 1935.19 
contra_RSPv6b 12622.55 2568.38 10951.72 2007.18 
contra_SSp-bfd 19265.36 4089.16 18628.16 2916.66 
contra_SSp-
bfd1 21471.57 4235.56 19930.24 3429.01 
contra_SSp-
bfd3 21875.01 4592.29 20654.58 3243.12 
contra_SSp-
bfd4 19411.84 4291.02 18552.15 2892.29 
contra_SSp-
bfd5 18167.52 3960.16 17540.34 2761.27 
contra_SSp-
bfd6a 16745.82 3858.78 16337.97 2798.11 
contra_SSp-
bfd6b 12382.78 2791.82 12413.50 2191.05 
contra_SSP-tr 19044.90 3625.69 18192.10 2728.89 
contra_SSp-tr1 19933.49 3882.10 19555.59 3199.03 
contra_SSp-tr3 21214.59 4195.05 20085.29 3179.75 
contra_SSp-tr4 19526.48 3935.29 18379.49 2859.95 
contra_SSp-tr5 18175.66 3659.12 17301.71 2638.97 
contra_SSp-
tr6a 16401.53 3640.51 15482.64 2662.52 
contra_SSp-
tr6b 12423.54 3159.15 11980.80 2122.20 
contra_TEa 20211.95 4730.58 19619.59 2964.24 
contra_TEa1 21628.72 4934.73 20991.24 3326.99 
contra_TEa3 22009.35 5059.88 21467.90 3229.73 
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contra_TEa4 20824.57 4804.51 20333.61 3314.18 
contra_TEa5 18948.11 4514.74 18460.16 2877.69 
contra_TEa6a 17581.36 4265.14 17373.06 2823.52 
contra_TEa6b 12703.70 3478.39 12905.91 2121.86 
contra_th 10610.20 2182.54 9679.39 1414.98 
ips_amgmed 12668.97 2131.28 11859.26 2165.96 
ips_AUDd 19495.64 4150.24 17331.15 3292.57 
ips_AUDd1 21199.38 4534.17 18384.96 3697.85 
ips_AUDd3 21594.47 4615.12 18962.34 3585.40 
ips_AUDd4 19582.83 3878.65 17572.80 3336.30 
ips_AUDd5 17781.41 3722.12 15954.34 3305.54 
ips_AUDd6a 16303.68 3546.50 14673.81 3356.53 
ips_AUDd6b 12137.74 2828.27 11570.45 2521.64 
ips_AUDp 20036.33 3902.62 17425.22 3206.04 
ips_AUDp1 21973.55 4089.35 18309.35 3116.71 
ips_AUDp3 22020.60 4170.89 19084.12 3397.54 
ips_AUDp4 20191.79 3865.82 17757.87 3253.50 
ips_AUDp5 18443.62 3753.73 16259.24 3265.66 
ips_AUDp6a 16681.10 3644.88 14905.75 3367.01 
ips_AUDp6b 12032.40 2653.37 10978.96 2051.35 
ips_AUDv 20154.84 3799.93 17484.19 3202.56 
ips_AUDv1 22572.42 3653.45 18758.76 3071.17 
ips_AUDv3 22090.67 3949.40 19101.48 3400.87 
ips_AUDv4 20283.07 3921.71 17741.71 3348.57 
ips_AUDv5 18462.71 3675.63 16329.30 3290.29 
ips_AUDv6a 16830.80 3678.25 15042.74 3423.64 
ips_AUDv6b 12497.80 2715.91 11280.70 2619.34 
ips_BLAa 16120.67 2824.90 14945.42 3026.37 
ips_BLAp 17287.75 2826.48 16037.80 3231.75 
ips_BLAv 14979.16 3227.61 13674.05 2770.48 
ips_BMAp 13941.65 2627.63 12904.76 2721.63 
ips_CA1slm 15054.25 3091.60 12904.33 2130.06 
ips_CA1so 16307.48 3035.32 14167.89 2262.50 
ips_CA1sp 10656.25 2001.05 9069.21 1270.80 
ips_CA1sr 18682.10 3324.58 16300.39 2749.00 
ips_CA2slm 10714.28 2023.86 9526.66 1684.91 
ips_CA2so 10615.82 2038.57 9318.34 1664.21 
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ips_CA2sp 7648.18 1039.77 6871.13 839.21 
ips_CA2sr 10406.51 1852.56 9385.08 1761.42 
ips_CA3slm 10434.36 1808.78 9578.94 1589.29 
ips_CA3slu 12907.10 2210.07 11613.57 2202.74 
ips_CA3so 10267.89 1798.47 9270.12 1634.98 
ips_CA3sp 9424.49 1361.60 8335.50 1077.48 
ips_CA3sr 11564.87 1879.14 10662.61 1930.32 
ips_CC 7994.56 1429.40 7397.54 777.78 
ips_cing 9765.70 1774.40 8247.48 1203.72 
ips_COApl 14426.59 2804.88 12773.78 2527.50 
ips_COApl1 15082.42 2870.29 13195.79 2837.44 
ips_COApl2 14232.22 2883.40 12534.25 2378.33 
ips_COApl3 14356.08 2724.10 12831.69 2593.39 
ips_cortex 17496.41 3625.73 15669.78 2880.90 
ips_CP 13903.49 2573.91 12848.80 2639.64 
ips_cpd 7619.60 968.40 7591.94 1069.25 
ips_DG 15096.10 2550.50 13151.69 1941.37 
ips_DGinf 14528.48 2323.34 12737.41 1850.85 
ips_DGpo 10770.73 1732.11 9525.59 1340.51 
ips_DGsg 7458.69 837.95 6728.92 552.09 
ips_DGsup 15402.51 2688.19 13362.33 1990.51 
ips_ECT 19950.01 3817.65 17882.82 3506.72 
ips_ECT1 21420.93 4198.79 19035.15 3967.37 
ips_ECT3 21309.93 4102.06 19095.27 3772.69 
ips_ECT5 18155.29 3566.75 16442.67 3417.34 
ips_ECT6a 16602.36 3712.20 15063.62 3607.55 
ips_ECT6b 12638.59 2822.04 11812.51 2880.12 
ips_ENTI 17919.08 4065.97 16614.89 3461.95 
ips_ENTl1 19837.15 4470.94 17665.87 3793.34 
ips_ENTl3 18904.54 4414.46 17402.32 3774.28 
ips_ENTl5 16946.06 3779.10 16050.66 3504.23 
ips_ENTl6a 13991.29 3330.68 13207.56 3594.19 
ips_ENTl6b 11975.41 2069.65 11653.82 2723.63 
ips_FC 8331.78 1447.94 7151.21 863.09 
ips_hip 14049.86 2517.95 12182.30 2015.12 
ips_hyp 10881.09 1710.19 10578.84 1807.96 
ips_LA 16397.47 2832.49 15467.90 3103.73 
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ips_lay1 19270.39 3962.03 17053.47 2672.29 
ips_lay2 13785.90 3460.46 11714.79 1400.62 
ips_lay3 19420.08 4184.67 17358.83 3149.02 
ips_lay4 18427.70 4072.84 16459.87 3338.07 
ips_lay5 16789.52 3676.10 15048.85 3042.62 
ips_lay6a 14858.35 3594.70 13213.63 2918.89 
ips_lay6b 11723.17 2563.57 10504.45 2195.13 
ips_MOp 15836.02 3597.63 14083.49 2288.04 
ips_MOp1 16754.51 3497.13 15286.36 2043.26 
ips_MOp3 16456.14 3750.48 14942.44 2366.13 
ips_MOp5 16134.44 3787.08 14157.22 2606.20 
ips_MOp6a 14224.84 3615.29 11899.84 2439.20 
ips_MOp6b 11394.33 2822.97 9584.82 1865.02 
ips_MOs 16200.91 3773.86 14733.47 2230.64 
ips_MOs1 18417.08 3896.37 17552.56 2191.79 
ips_MOs3 17193.06 4039.47 15853.40 2308.18 
ips_MOs5 15547.67 3834.48 13444.39 2424.77 
ips_MOs6a 13139.52 3240.88 11066.31 1968.77 
ips_MOs6b 11571.21 2734.66 9322.43 1471.14 
ips_PAA 14355.53 3007.83 13275.20 2664.71 
ips_PAA1 14342.77 3070.86 13037.14 2760.76 
ips_PAA2 14140.20 3184.67 13135.46 2469.71 
ips_PAA3 14571.25 2874.89 13524.24 2787.86 
ips_PERI 19210.91 3613.49 17371.30 3448.44 
ips_PERI1 21433.28 4303.22 18637.37 3713.42 
ips_PERI3 20319.39 4027.57 18140.03 3490.17 
ips_PERI5 17800.31 3419.33 16468.01 3465.12 
ips_PERI6a 15305.83 3572.09 14431.97 3652.29 
ips_PERI6b 12618.14 2734.95 11547.33 2699.75 
ips_PIR 16053.50 3384.04 14511.99 2808.59 
ips_PIR1 16888.76 3393.57 14959.99 2882.81 
ips_PIR2 15957.22 3696.61 14206.58 2846.12 
ips_PIR3 15811.70 3279.66 14457.89 2811.80 
ips_RSPd 16730.82 3717.33 15074.54 1989.05 
ips_RSPd1 19486.60 4320.04 17923.45 1821.42 
ips_RSPd3 17474.74 3938.23 15708.32 1998.47 
ips_RSPd5 15359.28 3595.04 13796.31 2265.32 
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ips_RSPd6a 13212.45 3043.60 11392.38 1832.58 
ips_RSPd6b 11805.78 2897.11 10128.47 1630.62 
ips_RSPv 15681.65 3490.08 13429.94 2008.36 
ips_RSPv1 17282.32 4054.31 14629.32 1916.70 
ips_RSPv2 13743.45 3406.59 11719.95 1400.85 
ips_RSPv3 16934.89 3546.31 14389.32 2295.48 
ips_RSPv5 15173.24 3046.20 13464.08 2192.16 
ips_RSPv6a 12949.62 2829.93 11005.46 1825.62 
ips_RSPv6b 12084.29 2820.74 10174.55 1723.11 
ips_SSp-bfd 18262.19 4205.43 16385.74 3728.01 
ips_SSp-bfd1 20207.85 5069.35 18205.64 3349.26 
ips_SSp-bfd3 20340.96 4915.34 18603.03 3939.73 
ips_SSp-bfd4 18561.31 4132.82 16754.06 3766.31 
ips_SSp-bfd5 17058.82 3816.62 15448.87 3476.21 
ips_SSp-bfd6a 15434.60 3669.46 14030.27 3507.43 
ips_SSp-bfd6b 11920.87 2648.22 11062.48 2752.70 
ips_SSp-tr 16616.98 3621.75 14767.28 3069.98 
ips_SSp-tr1 17979.62 3915.34 15830.82 2965.09 
ips_SSp-tr3 17876.25 4035.35 15867.71 3359.07 
ips_SSp-tr4 16970.89 3673.89 15136.89 3048.84 
ips_SSp-tr5 15930.37 3557.33 14282.08 3117.46 
ips_SSp-tr6a 14178.83 3609.15 12565.28 2960.22 
ips_SSp-tr6b 11191.33 2588.87 10012.18 2210.18 
ips_TEa 20203.56 3676.00 17916.24 3518.49 
ips_TEa1 21800.00 4062.88 19398.63 3544.80 
ips_TEa3 21907.93 4078.74 19385.10 3636.63 
ips_TEa4 20309.29 3917.66 18113.53 3711.91 
ips_TEa5 18434.48 3496.77 16629.04 3436.62 
ips_TEa6a 16984.97 3491.54 15551.04 3552.84 
ips_TEa6b 12472.37 2509.15 11517.49 2751.87 
ips_th 10821.45 1924.80 9655.73 1695.91 
 
Table 4: PSD95 puncta density at 28 days 
 
   Injury    Sham   
region Average SD Average SD 
contra_amgmed 294.25 29.77 318.00 32.54 
contra_AUDd 449.35 30.87 460.70 16.26 
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contra_AUDd1 533.55 53.19 558.90 32.10 
contra_AUDd3 481.70 37.49 492.90 26.68 
contra_AUDd4 481.15 36.57 490.10 26.53 
contra_AUDd5 419.05 27.26 427.40 22.36 
contra_AUDd6a 396.30 24.19 403.90 13.78 
contra_AUDd6b 258.40 58.12 268.75 73.29 
contra_AUDp 450.40 28.90 469.65 16.78 
contra_AUDp1 533.65 42.96 560.85 24.18 
contra_AUDp3 479.10 33.64 503.90 22.34 
contra_AUDp4 483.20 27.25 495.00 18.33 
contra_AUDp5 430.20 27.47 454.15 21.31 
contra_AUDp6a 402.85 22.67 414.50 16.23 
contra_AUDp6b 249.90 65.49 279.80 62.04 
contra_AUDv 470.75 30.00 488.80 17.63 
contra_AUDv1 550.65 49.29 569.00 29.48 
contra_AUDv3 508.10 34.27 523.20 21.23 
contra_AUDv4 500.90 32.80 515.70 15.62 
contra_AUDv5 456.35 30.39 475.60 22.99 
contra_AUDv6a 402.00 27.30 422.80 18.77 
contra_AUDv6b 257.75 51.14 269.05 58.08 
contra_BLAa 430.20 31.85 456.10 35.83 
contra_BLAp 451.80 35.18 474.05 50.76 
contra_BLAv 377.35 59.43 422.83 50.79 
contra_BMAp 340.20 43.17 386.67 55.64 
contra_CA1slm 490.25 28.53 525.20 34.15 
contra_CA1so 630.00 35.99 668.75 40.14 
contra_CA1sp 167.45 18.40 163.05 23.72 
contra_CA1sr 665.15 46.28 696.60 42.18 
contra_CA2slm 537.25 30.28 554.50 29.65 
contra_CA2so 487.50 31.05 501.70 17.95 
contra_CA2sp 63.60 19.30 62.45 21.73 
contra_CA2sr 464.15 37.93 474.85 25.85 
contra_CA3slm 537.75 31.98 568.90 26.78 
contra_CA3slu 257.40 29.16 269.00 13.28 
contra_CA3so 455.75 37.20 472.45 25.12 
contra_CA3sp 79.30 13.59 101.45 22.79 
contra_CA3sr 511.90 35.44 534.25 25.51 
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contra_CC 5.85 2.33 9.00 2.49 
contra_cing 64.85 14.07 80.65 27.26 
contra_COApl 346.85 48.32 398.72 79.48 
contra_COApl1 389.28 61.29 413.50 50.59 
contra_COApl2 337.70 56.49 403.72 85.88 
contra_COApl3 339.25 43.76 390.00 86.32 
contra_cortex 430.20 24.46 442.60 12.18 
contra_CP 368.00 17.26 372.50 10.36 
contra_cpd 10.40 5.64 13.40 6.90 
contra_DG 674.60 49.21 717.60 54.01 
contra_DGinf 674.35 54.40 718.65 55.00 
contra_DGpo 213.60 22.22 236.55 16.33 
contra_DGsg 53.90 9.68 66.55 21.76 
contra_DGsup 675.40 47.02 716.55 53.60 
contra_ECT 487.95 37.03 500.65 27.80 
contra_ECT1 564.95 62.57 578.35 45.74 
contra_ECT3 514.20 39.45 522.15 35.33 
contra_ECT5 467.75 31.36 483.30 28.41 
contra_ECT6a 414.40 21.72 433.75 36.67 
contra_ECT6b 274.61 43.54 289.60 55.39 
contra_ENTI 466.20 42.93 477.50 32.53 
contra_ENTl1 570.80 64.40 550.70 59.83 
contra_ENTl3 487.20 44.59 496.50 47.34 
contra_ENTl5 447.80 40.61 462.40 29.68 
contra_ENTl6a 418.15 43.29 430.40 34.16 
contra_ENTl6b 335.80 45.05 330.10 46.69 
contra_FC 289.30 41.56 308.35 46.38 
contra_hip 535.30 31.82 565.70 25.01 
contra_hyp 116.80 15.13 126.30 10.27 
contra_LA 441.60 33.47 465.45 35.23 
contra_lay1 524.30 37.78 537.70 22.55 
contra_lay2 287.25 23.29 298.10 19.60 
contra_lay3 463.40 29.67 472.40 18.51 
contra_lay4 465.60 31.36 474.20 11.66 
contra_lay5 405.75 20.26 420.40 13.48 
contra_lay6a 377.80 16.42 388.50 8.09 
contra_lay6b 251.15 27.89 275.10 25.48 
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contra_MOp 437.05 37.64 451.10 31.97 
contra_MOp1 540.85 59.97 555.05 52.55 
contra_MOp3 471.10 49.54 490.20 38.05 
contra_MOp5 431.95 32.03 443.55 37.89 
contra_MOp6a 374.00 24.47 380.60 22.35 
contra_MOp6b 255.60 46.93 290.80 32.52 
contra_MOs 361.25 33.08 371.90 24.45 
contra_MOs1 486.70 48.19 503.95 48.48 
contra_MOs3 394.20 37.03 407.60 29.10 
contra_MOs5 338.20 28.09 340.50 24.40 
contra_MOs6a 307.90 29.99 307.65 20.10 
contra_MOs6b 246.50 44.14 229.25 35.02 
contra_PAA 386.50 55.33 420.50 63.54 
contra_PAA1 398.20 52.82 417.83 77.83 
contra_PAA2 388.70 73.17 427.00 54.93 
contra_PAA3 380.60 52.06 413.89 61.28 
contra_PERI 487.05 40.08 491.35 29.81 
contra_PERI1 572.00 69.58 553.85 43.39 
contra_PERI3 506.55 44.50 504.00 36.38 
contra_PERI5 466.15 34.22 470.15 40.18 
contra_PERI6a 430.60 40.61 449.20 26.71 
contra_PERI6b 263.00 38.85 322.25 44.39 
contra_PIR 437.00 38.28 458.25 42.67 
contra_PIR1 485.05 55.04 502.50 56.49 
contra_PIR2 391.50 33.56 401.00 45.82 
contra_PIR3 433.00 37.28 457.95 41.98 
contra_RSPd 331.55 25.37 345.45 20.50 
contra_RSPd1 448.65 39.41 457.65 51.82 
contra_RSPd3 358.75 25.83 382.15 31.29 
contra_RSPd5 299.35 24.66 309.05 17.28 
contra_RSPd6a 286.05 28.08 297.10 19.14 
contra_RSPd6b 226.10 47.49 244.20 36.79 
contra_RSPv 322.50 20.42 329.20 14.89 
contra_RSPv1 354.20 16.77 369.05 33.45 
contra_RSPv2 288.15 23.78 298.65 19.44 
contra_RSPv3 356.30 15.42 366.90 22.27 
contra_RSPv5 304.65 28.69 319.60 29.76 
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contra_RSPv6a 264.55 29.15 278.60 22.08 
contra_RSPv6b 222.45 68.06 241.55 48.32 
contra_SSp-bfd 420.40 26.44 422.20 14.83 
contra_SSp-
bfd1 544.70 54.02 532.20 33.57 
contra_SSp-
bfd3 452.60 34.52 452.30 22.69 
contra_SSp-
bfd4 450.05 37.64 449.90 18.55 
contra_SSp-
bfd5 388.70 19.68 394.95 16.12 
contra_SSp-
bfd6a 378.15 15.60 380.20 10.81 
contra_SSp-
bfd6b 247.05 43.80 256.95 46.04 
contra_SSP-tr 435.20 29.43 449.50 18.56 
contra_SSp-tr1 544.70 53.33 559.50 33.29 
contra_SSp-tr3 474.90 35.23 488.90 25.86 
contra_SSp-tr4 449.15 28.92 467.60 23.93 
contra_SSp-tr5 402.10 21.01 423.25 19.51 
contra_SSp-
tr6a 377.10 18.98 388.45 17.23 
contra_SSp-
tr6b 231.80 39.70 272.15 26.19 
contra_TEa 483.55 33.86 497.25 25.31 
contra_TEa1 560.90 63.94 591.65 57.80 
contra_TEa3 515.90 40.63 521.45 37.36 
contra_TEa4 514.85 44.65 528.40 36.17 
contra_TEa5 471.25 35.55 489.20 30.68 
contra_TEa6a 403.90 28.49 425.55 27.00 
contra_TEa6b 273.55 47.95 295.00 44.13 
contra_th 307.00 26.35 322.90 10.82 
ips_amgmed 289.80 26.69 295.70 24.53 
ips_AUDd 432.60 21.64 452.75 25.90 
ips_AUDd1 507.65 45.24 544.10 41.32 
ips_AUDd3 457.40 25.92 489.90 24.02 
ips_AUDd4 459.25 27.87 476.60 22.21 
ips_AUDd5 404.25 18.57 416.70 26.14 
ips_AUDd6a 394.80 22.58 398.55 16.97 
ips_AUDd6b 253.00 55.37 281.60 38.14 
ips_AUDp 449.50 27.72 458.45 29.71 
ips_AUDp1 535.95 44.85 538.30 62.63 
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ips_AUDp3 480.10 30.69 496.85 38.16 
ips_AUDp4 474.80 35.32 487.40 25.22 
ips_AUDp5 416.40 25.84 431.85 30.86 
ips_AUDp6a 391.75 28.26 394.60 13.78 
ips_AUDp6b 219.80 57.70 260.75 46.70 
ips_AUDv 466.65 34.94 471.30 25.63 
ips_AUDv1 548.00 58.20 556.65 45.65 
ips_AUDv3 501.40 41.50 507.25 29.34 
ips_AUDv4 481.40 28.98 493.55 26.64 
ips_AUDv5 440.30 29.00 448.40 29.59 
ips_AUDv6a 381.05 30.91 392.70 12.66 
ips_AUDv6b 243.15 38.59 262.70 47.36 
ips_BLAa 435.95 30.21 436.70 26.51 
ips_BLAp 449.05 43.53 462.55 37.36 
ips_BLAv 375.25 49.31 392.75 46.46 
ips_BMAp 341.10 40.22 366.95 32.62 
ips_CA1slm 490.95 24.06 514.85 35.63 
ips_CA1so 650.00 41.71 662.05 44.73 
ips_CA1sp 165.10 20.03 155.55 36.94 
ips_CA1sr 678.40 46.62 692.45 48.30 
ips_CA2slm 548.15 34.55 553.25 17.22 
ips_CA2so 510.75 38.49 510.65 16.69 
ips_CA2sp 65.30 24.97 55.15 14.74 
ips_CA2sr 474.80 33.55 476.65 26.72 
ips_CA3slm 540.20 39.68 561.25 25.93 
ips_CA3slu 256.65 23.44 265.85 21.87 
ips_CA3so 462.80 40.01 475.95 17.06 
ips_CA3sp 78.60 17.85 87.60 26.85 
ips_CA3sr 510.65 26.03 530.45 28.78 
ips_CC 6.20 1.69 6.50 1.65 
ips_cing 65.85 17.94 62.40 24.69 
ips_COApl 346.10 40.24 373.95 59.75 
ips_COApl1 372.25 30.50 385.80 53.41 
ips_COApl2 339.40 44.17 375.10 65.81 
ips_COApl3 338.90 43.85 367.85 58.54 
ips_cortex 416.60 22.49 431.30 21.14 
ips_CP 358.95 25.78 368.10 24.44 
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ips_cpd 8.30 5.40 9.10 7.58 
ips_DG 683.35 50.01 703.80 58.53 
ips_DGinf 679.60 54.70 701.60 50.74 
ips_DGpo 210.10 24.33 233.25 16.76 
ips_DGsg 53.00 10.99 60.45 21.27 
ips_DGsup 686.90 47.84 706.95 63.86 
ips_ECT 471.05 26.84 487.00 16.57 
ips_ECT1 515.25 39.69 563.40 25.49 
ips_ECT3 489.50 28.64 507.95 17.21 
ips_ECT5 449.70 20.63 466.45 19.07 
ips_ECT6a 396.55 31.16 423.70 26.05 
ips_ECT6b 284.90 50.11 288.20 42.42 
ips_ENTI 454.05 38.22 451.00 23.02 
ips_ENTl1 516.50 47.19 519.25 31.15 
ips_ENTl3 469.40 51.74 459.10 21.48 
ips_ENTl5 439.35 33.58 443.65 22.30 
ips_ENTl6a 404.50 31.02 420.75 26.15 
ips_ENTl6b 288.20 64.40 315.10 29.96 
ips_FC 278.10 54.53 300.20 60.83 
ips_hip 544.10 28.42 560.50 28.49 
ips_hyp 115.70 17.24 123.10 11.14 
ips_LA 436.45 29.38 454.35 35.49 
ips_lay1 497.60 34.78 522.85 23.74 
ips_lay2 279.55 21.40 289.40 19.46 
ips_lay3 445.25 27.14 463.80 23.44 
ips_lay4 446.70 28.85 461.20 24.84 
ips_lay5 395.80 19.11 408.05 17.51 
ips_lay6a 369.60 15.40 378.30 12.26 
ips_lay6b 247.40 25.24 257.60 28.76 
ips_MOp 422.00 27.95 418.85 17.65 
ips_MOp1 502.30 48.05 515.35 31.69 
ips_MOp3 451.95 32.60 445.15 24.43 
ips_MOp5 420.60 31.63 412.55 19.59 
ips_MOp6a 368.85 27.71 354.65 23.51 
ips_MOp6b 254.20 45.54 230.95 50.37 
ips_MOs 352.85 26.91 348.10 14.60 
ips_MOs1 462.10 58.95 463.95 39.83 
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ips_MOs3 393.25 34.20 390.00 27.82 
ips_MOs5 334.15 30.47 324.95 13.01 
ips_MOs6a 300.30 39.98 281.60 29.88 
ips_MOs6b 246.05 32.58 219.35 53.80 
ips_PAA 377.35 41.62 385.95 48.88 
ips_PAA1 387.90 44.49 390.90 63.93 
ips_PAA2 377.95 44.77 383.50 38.32 
ips_PAA3 369.90 44.47 384.95 49.76 
ips_PERI 466.50 28.11 481.25 16.62 
ips_PERI1 518.75 51.11 567.05 43.94 
ips_PERI3 487.00 30.93 502.50 20.43 
ips_PERI5 448.35 23.71 456.90 16.21 
ips_PERI6a 404.35 26.26 418.35 20.66 
ips_PERI6b 273.15 50.69 290.90 47.88 
ips_PIR 420.40 27.48 436.50 27.86 
ips_PIR1 456.90 37.70 486.85 45.37 
ips_PIR2 385.80 27.22 389.10 28.42 
ips_PIR3 417.75 28.60 434.20 25.11 
ips_RSPd 328.55 20.58 338.10 15.58 
ips_RSPd1 432.95 35.45 445.80 38.42 
ips_RSPd3 359.30 23.52 369.60 22.18 
ips_RSPd5 292.10 25.24 303.35 15.92 
ips_RSPd6a 277.85 31.34 284.65 21.99 
ips_RSPd6b 234.30 36.82 245.50 39.46 
ips_RSPv 317.60 22.27 321.70 12.45 
ips_RSPv1 351.15 20.44 354.35 14.95 
ips_RSPv2 279.70 21.12 289.70 20.04 
ips_RSPv3 356.30 19.56 366.25 14.17 
ips_RSPv5 297.70 38.11 309.90 20.75 
ips_RSPv6a 262.45 25.97 270.35 26.19 
ips_RSPv6b 244.65 31.96 237.15 65.91 
ips_SSp-bfd 412.90 26.84 431.55 24.71 
ips_SSp-bfd1 501.35 41.68 547.90 31.96 
ips_SSp-bfd3 440.30 33.03 471.10 29.95 
ips_SSp-bfd4 440.65 30.56 456.05 27.41 
ips_SSp-bfd5 385.70 21.70 402.45 18.11 
ips_SSp-bfd6a 375.50 20.28 386.30 17.51 
 Page | 194 
ips_SSp-bfd6b 249.45 31.62 279.10 38.89 
ips_SSp-tr 411.45 25.85 430.40 26.48 
ips_SSp-tr1 503.30 37.68 530.20 26.40 
ips_SSp-tr3 440.75 33.51 462.20 31.42 
ips_SSp-tr4 431.00 34.17 445.45 28.08 
ips_SSp-tr5 390.45 22.99 404.20 23.36 
ips_SSp-tr6a 368.70 16.85 375.50 14.65 
ips_SSp-tr6b 224.45 47.25 216.60 60.94 
ips_TEa 471.95 31.99 478.40 19.92 
ips_TEa1 541.00 59.78 561.15 28.52 
ips_TEa3 500.30 39.77 513.35 24.64 
ips_TEa4 478.30 28.35 496.60 20.50 
ips_TEa5 453.25 28.58 459.80 25.80 
ips_TEa6a 384.00 30.52 402.85 18.15 
ips_TEa6b 275.40 25.89 273.55 37.43 
ips_th 303.60 30.65 313.50 17.08 
 
Table 5: PSD95 puncta size at 28 days 
 
   Injury    Sham   
region Average SD Average SD 
contra_amgmed 12.63 0.23 12.52 0.30 
contra_AUDd 12.30 0.26 12.24 0.22 
contra_AUDd1 12.24 0.33 12.16 0.18 
contra_AUDd3 12.43 0.28 12.40 0.20 
contra_AUDd4 11.99 0.21 11.97 0.21 
contra_AUDd5 12.29 0.26 12.22 0.23 
contra_AUDd6a 12.13 0.24 12.09 0.27 
contra_AUDd6b 12.54 0.32 12.58 0.46 
contra_AUDp 12.26 0.29 12.20 0.23 
contra_AUDp1 12.22 0.33 12.14 0.26 
contra_AUDp3 12.40 0.31 12.36 0.23 
contra_AUDp4 12.00 0.25 11.98 0.23 
contra_AUDp5 12.24 0.27 12.14 0.24 
contra_AUDp6a 12.12 0.26 12.05 0.22 
contra_AUDp6b 12.60 0.35 12.40 0.34 
contra_AUDv 12.11 0.31 12.08 0.23 
contra_AUDv1 12.08 0.38 12.04 0.24 
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contra_AUDv3 12.17 0.33 12.19 0.22 
contra_AUDv4 11.91 0.27 11.89 0.22 
contra_AUDv5 12.06 0.31 12.01 0.27 
contra_AUDv6a 12.12 0.27 12.02 0.24 
contra_AUDv6b 12.48 0.29 12.43 0.31 
contra_BLAa 12.01 0.47 11.90 0.35 
contra_BLAp 12.13 0.48 11.99 0.37 
contra_BLAv 12.17 0.39 12.02 0.27 
contra_BMAp 12.31 0.33 12.17 0.34 
contra_CA1slm 11.97 0.22 11.86 0.31 
contra_CA1so 11.35 0.25 11.26 0.30 
contra_CA1sp 12.25 0.21 12.52 0.23 
contra_CA1sr 11.42 0.24 11.38 0.31 
contra_CA2slm 11.33 0.27 11.24 0.43 
contra_CA2so 11.39 0.24 11.33 0.30 
contra_CA2sp 15.00 1.10 15.38 1.52 
contra_CA2sr 11.64 0.32 11.54 0.40 
contra_CA3slm 11.73 0.33 11.58 0.47 
contra_CA3slu 14.76 0.54 14.73 0.60 
contra_CA3so 11.95 0.38 11.76 0.45 
contra_CA3sp 15.79 0.80 15.58 0.58 
contra_CA3sr 12.07 0.39 11.87 0.51 
contra_CC 13.03 0.34 13.25 0.38 
contra_cing 13.13 0.30 13.24 0.25 
contra_COApl 12.43 0.38 12.16 0.46 
contra_COApl1 12.23 0.47 12.03 0.38 
contra_COApl2 12.46 0.45 12.15 0.46 
contra_COApl3 12.50 0.35 12.26 0.49 
contra_cortex 12.26 0.24 12.22 0.20 
contra_CP 12.09 0.29 12.03 0.24 
contra_cpd 13.74 0.44 14.22 0.70 
contra_DG 11.30 0.23 11.25 0.37 
contra_DGinf 11.34 0.22 11.28 0.35 
contra_DGpo 14.56 0.38 14.52 0.46 
contra_DGsg 14.95 0.42 15.12 0.48 
contra_DGsup 11.28 0.23 11.22 0.38 
contra_ECT 12.04 0.38 12.00 0.24 
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contra_ECT1 12.05 0.44 12.00 0.24 
contra_ECT3 12.09 0.39 12.06 0.24 
contra_ECT5 11.95 0.38 11.87 0.21 
contra_ECT6a 11.97 0.31 11.93 0.27 
contra_ECT6b 12.41 0.23 12.25 0.41 
contra_ENTI 11.90 0.42 11.84 0.28 
contra_ENTl1 11.74 0.54 11.75 0.32 
contra_ENTl3 11.97 0.43 11.91 0.31 
contra_ENTl5 12.02 0.40 11.90 0.25 
contra_ENTl6a 11.69 0.42 11.63 0.26 
contra_ENTl6b 12.00 0.38 12.02 0.42 
contra_FC 11.80 0.23 11.74 0.25 
contra_hip 11.62 0.26 11.54 0.34 
contra_hyp 13.96 0.18 14.01 0.19 
contra_LA 12.11 0.50 11.86 0.37 
contra_lay1 12.19 0.27 12.15 0.21 
contra_lay2 12.61 0.18 12.63 0.20 
contra_lay3 12.34 0.26 12.32 0.21 
contra_lay4 12.02 0.22 11.98 0.20 
contra_lay5 12.31 0.23 12.23 0.19 
contra_lay6a 12.15 0.23 12.09 0.21 
contra_lay6b 12.52 0.21 12.48 0.21 
contra_MOp 12.15 0.24 12.19 0.23 
contra_MOp1 12.07 0.28 12.13 0.27 
contra_MOp3 12.15 0.25 12.18 0.25 
contra_MOp5 12.20 0.23 12.22 0.23 
contra_MOp6a 12.13 0.18 12.18 0.21 
contra_MOp6b 12.43 0.20 12.47 0.22 
contra_MOs 12.56 0.26 12.63 0.24 
contra_MOs1 12.51 0.29 12.58 0.30 
contra_MOs3 12.58 0.28 12.63 0.26 
contra_MOs5 12.66 0.28 12.76 0.28 
contra_MOs6a 12.47 0.23 12.55 0.20 
contra_MOs6b 12.47 0.23 12.69 0.16 
contra_PAA 12.23 0.45 12.03 0.36 
contra_PAA1 12.14 0.44 11.98 0.39 
contra_PAA2 12.22 0.54 11.97 0.40 
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contra_PAA3 12.29 0.43 12.12 0.36 
contra_PERI 11.94 0.39 11.92 0.25 
contra_PERI1 11.87 0.46 11.93 0.26 
contra_PERI3 11.98 0.40 11.99 0.26 
contra_PERI5 11.96 0.38 11.92 0.26 
contra_PERI6a 11.79 0.34 11.73 0.25 
contra_PERI6b 12.35 0.25 12.16 0.36 
contra_PIR 12.00 0.43 11.87 0.28 
contra_PIR1 11.94 0.51 11.78 0.33 
contra_PIR2 12.03 0.41 11.94 0.25 
contra_PIR3 12.01 0.42 11.88 0.27 
contra_RSPd 12.74 0.25 12.75 0.25 
contra_RSPd1 12.67 0.26 12.73 0.27 
contra_RSPd3 12.69 0.25 12.65 0.28 
contra_RSPd5 13.15 0.27 13.13 0.24 
contra_RSPd6a 12.62 0.21 12.70 0.19 
contra_RSPd6b 12.56 0.23 12.63 0.19 
contra_RSPv 12.63 0.19 12.67 0.21 
contra_RSPv1 12.71 0.20 12.78 0.24 
contra_RSPv2 12.61 0.18 12.63 0.20 
contra_RSPv3 12.34 0.19 12.36 0.23 
contra_RSPv5 12.80 0.21 12.79 0.29 
contra_RSPv6a 12.77 0.19 12.84 0.22 
contra_RSPv6b 12.60 0.39 12.59 0.29 
contra_SSp-bfd 12.32 0.24 12.30 0.21 
contra_SSp-
bfd1 12.18 0.27 12.18 0.22 
contra_SSp-
bfd3 12.45 0.26 12.46 0.21 
contra_SSp-
bfd4 12.03 0.23 12.01 0.19 
contra_SSp-
bfd5 12.39 0.21 12.35 0.21 
contra_SSp-
bfd6a 12.14 0.24 12.10 0.23 
contra_SSp-
bfd6b 12.58 0.27 12.62 0.31 
contra_SSP-tr 12.23 0.22 12.19 0.20 
contra_SSp-tr1 12.06 0.24 12.05 0.22 
contra_SSp-tr3 12.30 0.24 12.27 0.22 
contra_SSp-tr4 12.07 0.19 12.01 0.22 
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contra_SSp-tr5 12.36 0.22 12.28 0.17 
contra_SSp-
tr6a 12.12 0.20 12.09 0.20 
contra_SSp-
tr6b 12.60 0.25 12.50 0.19 
contra_TEa 12.06 0.35 12.00 0.23 
contra_TEa1 12.02 0.38 11.99 0.24 
contra_TEa3 12.10 0.37 12.10 0.20 
contra_TEa4 11.99 0.34 11.91 0.28 
contra_TEa5 11.97 0.34 11.90 0.25 
contra_TEa6a 12.13 0.34 12.00 0.30 
contra_TEa6b 12.42 0.30 12.33 0.32 
contra_th 11.70 0.21 11.71 0.19 
ips_amgmed 12.67 0.16 12.73 0.10 
ips_AUDd 12.34 0.16 12.33 0.20 
ips_AUDd1 12.32 0.21 12.31 0.23 
ips_AUDd3 12.44 0.16 12.42 0.21 
ips_AUDd4 12.09 0.17 12.10 0.17 
ips_AUDd5 12.34 0.16 12.35 0.22 
ips_AUDd6a 12.20 0.17 12.19 0.21 
ips_AUDd6b 12.62 0.29 12.60 0.27 
ips_AUDp 12.27 0.17 12.26 0.21 
ips_AUDp1 12.23 0.20 12.22 0.21 
ips_AUDp3 12.32 0.16 12.31 0.24 
ips_AUDp4 12.09 0.20 12.06 0.20 
ips_AUDp5 12.27 0.18 12.26 0.22 
ips_AUDp6a 12.23 0.18 12.22 0.22 
ips_AUDp6b 12.82 0.28 12.76 0.21 
ips_AUDv 12.17 0.19 12.16 0.20 
ips_AUDv1 12.14 0.25 12.11 0.21 
ips_AUDv3 12.17 0.19 12.18 0.22 
ips_AUDv4 12.10 0.17 12.09 0.20 
ips_AUDv5 12.10 0.18 12.13 0.25 
ips_AUDv6a 12.29 0.22 12.21 0.21 
ips_AUDv6b 12.59 0.26 12.65 0.22 
ips_BLAa 12.10 0.28 12.06 0.29 
ips_BLAp 12.18 0.29 12.10 0.31 
ips_BLAv 12.30 0.25 12.24 0.24 
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ips_BMAp 12.42 0.25 12.29 0.31 
ips_CA1slm 11.98 0.20 11.90 0.28 
ips_CA1so 11.31 0.23 11.28 0.25 
ips_CA1sp 12.27 0.23 12.53 0.24 
ips_CA1sr 11.41 0.21 11.38 0.26 
ips_CA2slm 11.30 0.19 11.23 0.21 
ips_CA2so 11.28 0.19 11.32 0.14 
ips_CA2sp 14.28 0.67 15.85 0.91 
ips_CA2sr 11.59 0.20 11.61 0.22 
ips_CA3slm 11.70 0.25 11.60 0.27 
ips_CA3slu 14.73 0.28 14.75 0.42 
ips_CA3so 11.89 0.22 11.84 0.30 
ips_CA3sp 15.71 0.43 15.86 0.73 
ips_CA3sr 12.05 0.23 11.97 0.36 
ips_CC 13.20 0.45 13.22 0.33 
ips_cing 13.11 0.32 13.23 0.31 
ips_COApl 12.52 0.32 12.43 0.30 
ips_COApl1 12.37 0.32 12.27 0.24 
ips_COApl2 12.54 0.36 12.40 0.39 
ips_COApl3 12.62 0.31 12.51 0.30 
ips_cortex 12.35 0.18 12.33 0.17 
ips_CP 12.14 0.17 12.12 0.25 
ips_cpd 13.56 0.80 13.86 1.12 
ips_DG 11.28 0.19 11.26 0.31 
ips_DGinf 11.32 0.19 11.29 0.31 
ips_DGpo 14.54 0.25 14.60 0.41 
ips_DGsg 15.01 0.32 15.15 0.26 
ips_DGsup 11.25 0.19 11.23 0.32 
ips_ECT 12.13 0.18 12.05 0.23 
ips_ECT1 12.15 0.18 11.95 0.26 
ips_ECT3 12.16 0.19 12.09 0.24 
ips_ECT5 11.99 0.18 11.98 0.18 
ips_ECT6a 12.14 0.26 12.02 0.30 
ips_ECT6b 12.51 0.31 12.50 0.33 
ips_ENTI 12.02 0.16 11.98 0.21 
ips_ENTl1 11.91 0.17 11.88 0.25 
ips_ENTl3 12.08 0.14 12.07 0.19 
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ips_ENTl5 12.02 0.23 11.98 0.25 
ips_ENTl6a 11.86 0.24 11.76 0.24 
ips_ENTl6b 12.37 0.40 12.21 0.29 
ips_FC 11.77 0.28 11.75 0.30 
ips_hip 11.60 0.21 11.57 0.27 
ips_hyp 13.97 0.18 14.02 0.19 
ips_LA 12.11 0.24 12.02 0.34 
ips_lay1 12.32 0.20 12.30 0.15 
ips_lay2 12.67 0.23 12.70 0.20 
ips_lay3 12.41 0.19 12.39 0.17 
ips_lay4 12.17 0.19 12.14 0.17 
ips_lay5 12.36 0.17 12.35 0.17 
ips_lay6a 12.23 0.18 12.22 0.19 
ips_lay6b 12.59 0.19 12.61 0.17 
ips_MOp 12.35 0.26 12.39 0.22 
ips_MOp1 12.42 0.34 12.41 0.28 
ips_MOp3 12.40 0.28 12.44 0.25 
ips_MOp5 12.31 0.23 12.34 0.20 
ips_MOp6a 12.22 0.24 12.32 0.21 
ips_MOp6b 12.49 0.20 12.64 0.19 
ips_MOs 12.73 0.33 12.74 0.22 
ips_MOs1 12.81 0.38 12.72 0.28 
ips_MOs3 12.79 0.37 12.75 0.23 
ips_MOs5 12.76 0.28 12.86 0.28 
ips_MOs6a 12.54 0.26 12.65 0.24 
ips_MOs6b 12.51 0.21 12.70 0.21 
ips_PAA 12.37 0.31 12.30 0.27 
ips_PAA1 12.28 0.34 12.18 0.32 
ips_PAA2 12.36 0.35 12.25 0.30 
ips_PAA3 12.45 0.31 12.42 0.24 
ips_PERI 12.05 0.18 11.99 0.22 
ips_PERI1 12.05 0.23 11.87 0.31 
ips_PERI3 12.08 0.18 12.04 0.22 
ips_PERI5 11.98 0.18 11.98 0.18 
ips_PERI6a 11.96 0.25 11.88 0.21 
ips_PERI6b 12.43 0.31 12.41 0.41 
ips_PIR 12.19 0.23 12.08 0.19 
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ips_PIR1 12.12 0.27 11.97 0.25 
ips_PIR2 12.24 0.20 12.19 0.20 
ips_PIR3 12.19 0.22 12.09 0.18 
ips_RSPd 12.80 0.28 12.78 0.23 
ips_RSPd1 12.73 0.30 12.74 0.26 
ips_RSPd3 12.76 0.29 12.69 0.24 
ips_RSPd5 13.15 0.24 13.09 0.22 
ips_RSPd6a 12.65 0.22 12.77 0.23 
ips_RSPd6b 12.60 0.31 12.56 0.24 
ips_RSPv 12.68 0.23 12.70 0.19 
ips_RSPv1 12.76 0.26 12.80 0.23 
ips_RSPv2 12.66 0.24 12.70 0.20 
ips_RSPv3 12.35 0.22 12.38 0.20 
ips_RSPv5 12.85 0.32 12.82 0.20 
ips_RSPv6a 12.84 0.19 12.87 0.18 
ips_RSPv6b 12.50 0.24 12.56 0.22 
ips_SSp-bfd 12.37 0.17 12.34 0.16 
ips_SSp-bfd1 12.31 0.19 12.25 0.18 
ips_SSp-bfd3 12.47 0.17 12.44 0.16 
ips_SSp-bfd4 12.14 0.19 12.13 0.17 
ips_SSp-bfd5 12.42 0.17 12.40 0.17 
ips_SSp-bfd6a 12.19 0.17 12.17 0.18 
ips_SSp-bfd6b 12.65 0.23 12.56 0.22 
ips_SSp-tr 12.39 0.22 12.37 0.19 
ips_SSp-tr1 12.32 0.27 12.33 0.18 
ips_SSp-tr3 12.50 0.22 12.47 0.21 
ips_SSp-tr4 12.24 0.21 12.22 0.23 
ips_SSp-tr5 12.44 0.19 12.41 0.20 
ips_SSp-tr6a 12.19 0.19 12.19 0.21 
ips_SSp-tr6b 12.59 0.22 12.72 0.22 
ips_TEa 12.16 0.22 12.12 0.17 
ips_TEa1 12.13 0.27 12.02 0.17 
ips_TEa3 12.18 0.21 12.14 0.19 
ips_TEa4 12.15 0.23 12.11 0.19 
ips_TEa5 12.02 0.21 12.04 0.20 
ips_TEa6a 12.30 0.29 12.21 0.21 
ips_TEa6b 12.64 0.26 12.61 0.26 
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ips_th 11.72 0.20 11.74 0.15 
 
Table 6: PSD95 puncta intensity at 28 days 
 
   Injury    Sham   
region Average SD Average SD 
contra_amgmed 12012.71 2499.64 13690.88 2835.38 
contra_AUDd 18203.25 2833.02 20217.44 2820.59 
contra_AUDd1 19381.81 2992.54 21407.20 2829.69 
contra_AUDd3 20001.92 3039.45 22085.35 3121.87 
contra_AUDd4 18026.81 2755.48 20249.88 2957.90 
contra_AUDd5 16920.57 2671.03 18861.13 2808.15 
contra_AUDd6a 15806.43 2573.68 17444.72 2603.58 
contra_AUDd6b 11317.67 2435.11 12539.29 1779.66 
contra_AUDp 18115.12 2922.62 20352.87 2924.34 
contra_AUDp1 19506.59 3101.71 21839.46 3022.60 
contra_AUDp3 20058.99 3212.36 22410.66 2974.49 
contra_AUDp4 18150.74 2735.24 20556.59 2951.87 
contra_AUDp5 17125.63 2841.90 19364.97 2943.69 
contra_AUDp6a 16018.81 2864.39 17906.93 2808.99 
contra_AUDp6b 11311.19 2694.64 13306.66 2701.49 
contra_AUDv 18389.50 3231.20 20269.69 2966.34 
contra_AUDv1 20048.92 3636.86 21655.29 2817.06 
contra_AUDv3 20328.31 3498.00 21953.95 3117.65 
contra_AUDv4 18628.56 3235.41 20703.74 3099.18 
contra_AUDv5 17329.73 2955.59 19480.46 3037.99 
contra_AUDv6a 16027.37 3068.28 18147.08 2912.82 
contra_AUDv6b 11449.43 2463.17 13076.70 2204.35 
contra_BLAa 14702.99 2877.27 16872.11 3394.74 
contra_BLAp 16162.81 3536.37 18170.18 3710.21 
contra_BLAv 13163.23 3762.55 16168.85 3517.22 
contra_BMAp 12540.86 3158.73 15204.43 3202.05 
contra_CA1slm 14262.79 1166.96 15233.53 2589.37 
contra_CA1so 15323.54 1259.60 16669.41 2411.56 
contra_CA1sp 10456.19 895.80 11153.64 1676.18 
contra_CA1sr 17621.65 1291.15 18857.55 2653.11 
contra_CA2slm 10069.19 958.70 11095.74 1572.04 
contra_CA2so 9772.03 1099.08 11011.70 1668.75 
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contra_CA2sp 7479.43 627.82 8068.09 989.73 
contra_CA2sr 9795.56 930.61 10728.87 1479.73 
contra_CA3slm 10050.74 989.75 11156.37 1405.65 
contra_CA3slu 12473.62 1326.59 13575.54 1734.64 
contra_CA3so 9792.32 858.02 10617.97 1339.44 
contra_CA3sp 8879.48 1006.70 10114.46 1391.00 
contra_CA3sr 11300.68 1116.74 12113.55 1425.07 
contra_CC 7414.91 907.42 8459.33 845.24 
contra_cing 9233.77 990.35 9908.54 1465.49 
contra_COApl 13107.97 3620.15 15854.75 3223.63 
contra_COApl1 13918.22 4035.08 16146.44 3072.24 
contra_COApl2 13010.80 3683.26 16008.39 3398.30 
contra_COApl3 13018.75 3473.76 15697.78 3144.20 
contra_cortex 17547.50 2332.69 19110.79 2709.84 
contra_CP 13844.25 2427.34 15475.25 2668.29 
contra_cpd 7448.26 990.61 7821.20 1141.29 
contra_DG 14770.19 1252.44 15728.07 2396.92 
contra_DGinf 14447.93 1410.60 15439.93 2333.38 
contra_DGpo 10176.12 773.03 11166.45 1383.78 
contra_DGsg 7199.59 351.17 7658.01 866.56 
contra_DGsup 14910.71 1211.04 15861.24 2417.25 
contra_ECT 18303.20 3544.28 19930.54 3368.68 
contra_ECT1 20039.83 4364.81 21219.34 4338.25 
contra_ECT3 19593.38 3944.97 20952.46 3691.95 
contra_ECT5 17017.58 3297.48 18921.46 3246.21 
contra_ECT6a 15906.92 3072.12 18028.53 3302.04 
contra_ECT6b 11960.14 1804.75 13567.48 2636.81 
contra_ENTI 16505.04 3828.18 17988.88 3451.95 
contra_ENTl1 17839.79 4436.87 18632.05 3594.50 
contra_ENTl3 17417.74 4126.12 18763.32 3627.89 
contra_ENTl5 16085.09 3618.29 18026.93 3381.93 
contra_ENTl6a 13757.64 3149.58 15611.09 3374.83 
contra_ENTl6b 11828.04 2603.64 13287.92 2326.61 
contra_FC 7738.57 893.72 9049.06 1917.96 
contra_hip 13513.55 1170.75 14531.85 2150.11 
contra_hyp 9999.20 1792.49 11053.87 2001.92 
contra_LA 16012.17 3218.58 17896.20 3327.46 
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contra_lay1 19108.59 2527.05 20310.99 2602.30 
contra_lay2 13002.31 1508.65 14079.72 2675.96 
contra_lay3 19320.73 2552.09 20804.82 2855.51 
contra_lay4 17819.15 2511.44 19704.19 2814.47 
contra_lay5 16589.37 2299.65 18430.77 2732.22 
contra_lay6a 15034.08 2204.68 16774.01 2579.56 
contra_lay6b 11223.91 1676.23 12747.97 1845.61 
contra_MOp 18118.48 2380.57 19151.53 3082.13 
contra_MOp1 19948.42 3042.89 21035.14 3747.54 
contra_MOp3 19244.47 2743.67 20400.53 3401.64 
contra_MOp5 17633.07 2011.58 18762.82 2940.43 
contra_MOp6a 15084.75 1712.06 16120.23 2650.05 
contra_MOp6b 11883.49 1523.08 12835.13 2394.32 
contra_MOs 17277.84 2251.45 18819.88 3140.98 
contra_MOs1 20610.05 2790.50 22448.94 4035.03 
contra_MOs3 18477.08 2488.13 20158.76 3468.49 
contra_MOs5 15763.22 1840.32 17059.58 2775.46 
contra_MOs6a 13169.01 1414.94 14027.60 2487.06 
contra_MOs6b 11302.27 1254.92 11932.16 2142.44 
contra_PAA 13593.05 4076.60 15918.10 3330.10 
contra_PAA1 13487.23 3891.44 15411.71 3077.05 
contra_PAA2 13514.47 4179.29 15805.61 3475.87 
contra_PAA3 13663.08 4069.14 16213.98 3378.57 
contra_PERI 17556.08 3837.01 18773.67 3155.21 
contra_PERI1 18953.72 4581.97 19419.37 3363.90 
contra_PERI3 18430.63 4073.17 19538.15 3393.65 
contra_PERI5 16848.80 3398.94 18089.72 3106.91 
contra_PERI6a 14877.96 3154.67 16988.01 3272.59 
contra_PERI6b 11307.31 2086.01 13659.50 2604.69 
contra_PIR 14632.35 3717.80 16416.23 3564.83 
contra_PIR1 15167.45 3876.81 16773.99 3460.70 
contra_PIR2 13916.94 3639.89 15511.97 3317.51 
contra_PIR3 14684.64 3671.76 16594.97 3642.83 
contra_RSPd 16726.93 1943.05 17950.26 3316.55 
contra_RSPd1 20611.67 2554.61 21510.91 4004.25 
contra_RSPd3 17677.07 2127.14 19034.54 3497.48 
contra_RSPd5 15039.76 1714.14 16296.24 2720.27 
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contra_RSPd6a 12859.12 1409.05 13946.33 2469.39 
contra_RSPd6b 11239.29 1384.28 12276.09 2100.08 
contra_RSPv 14827.07 1621.57 15797.82 2912.19 
contra_RSPv1 16622.72 1970.65 17241.86 3377.79 
contra_RSPv2 13057.79 1544.87 14106.66 2707.64 
contra_RSPv3 15899.43 1648.43 16882.35 2992.95 
contra_RSPv5 14488.40 1803.22 15745.74 2810.39 
contra_RSPv6a 12355.78 1424.47 13416.59 2368.72 
contra_RSPv6b 11496.84 1521.34 12476.25 2524.77 
contra_SSp-bfd 17424.68 2301.49 19090.64 2691.99 
contra_SSp-
bfd1 19502.02 2786.30 20410.94 2590.88 
contra_SSp-
bfd3 19485.27 2479.38 20883.40 2756.40 
contra_SSp-
bfd4 17383.50 2334.31 19093.56 2844.75 
contra_SSp-
bfd5 16406.68 2228.12 18173.24 2704.41 
contra_SSp-
bfd6a 15191.11 2338.66 16857.36 2570.71 
contra_SSp-
bfd6b 11085.51 1780.89 12545.68 1770.09 
contra_SSP-tr 18028.54 2225.57 19276.35 2805.24 
contra_SSp-tr1 19695.73 3016.10 20337.85 2568.03 
contra_SSp-tr3 19854.62 2665.07 20979.00 2989.63 
contra_SSp-tr4 17893.97 2110.87 19415.62 3030.82 
contra_SSp-tr5 16753.40 1906.67 18515.35 2782.99 
contra_SSp-
tr6a 15125.07 1875.63 16639.05 2572.53 
contra_SSp-
tr6b 11259.10 1415.65 12704.12 1827.79 
contra_TEa 18564.99 3386.20 19978.21 3287.45 
contra_TEa1 20425.06 4240.90 21757.02 4313.59 
contra_TEa3 20347.67 3959.29 21386.67 3677.48 
contra_TEa4 18876.35 3388.41 20705.41 3530.90 
contra_TEa5 17292.17 3196.20 19155.83 3159.29 
contra_TEa6a 16214.70 3171.99 18149.47 3214.02 
contra_TEa6b 11776.40 2354.12 13436.20 2337.96 
contra_th 9634.41 1163.00 10673.47 1870.98 
ips_amgmed 11562.35 2162.10 12986.71 2252.66 
ips_AUDd 17014.54 2813.68 18999.33 3109.57 
ips_AUDd1 18482.29 3123.29 20507.33 3513.79 
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ips_AUDd3 18677.50 2768.34 20910.32 3231.80 
ips_AUDd4 16860.95 2798.34 18910.45 3126.94 
ips_AUDd5 15890.18 2771.39 17508.11 2912.57 
ips_AUDd6a 15017.27 2933.07 16263.19 2933.98 
ips_AUDd6b 10922.17 2163.84 12393.59 2236.13 
ips_AUDp 17427.95 3017.86 18802.60 3030.66 
ips_AUDp1 19096.12 3151.45 20162.89 2980.91 
ips_AUDp3 19034.95 3082.44 20626.88 3266.47 
ips_AUDp4 17364.95 2969.13 19056.02 3166.95 
ips_AUDp5 16186.71 2868.65 17622.25 3008.31 
ips_AUDp6a 15094.73 3249.13 16207.88 2807.20 
ips_AUDp6b 10623.41 2217.03 11826.00 1430.61 
ips_AUDv 17420.19 3104.91 18822.26 2900.07 
ips_AUDv1 18947.34 3514.04 20380.68 3287.42 
ips_AUDv3 18840.86 3271.01 20555.38 3252.78 
ips_AUDv4 17599.35 2863.67 19128.01 3114.61 
ips_AUDv5 16255.11 2953.86 17531.76 2857.84 
ips_AUDv6a 14946.60 3169.30 16272.40 2703.69 
ips_AUDv6b 10806.85 2174.50 11813.12 1878.70 
ips_BLAa 14480.38 2933.57 16162.12 2949.64 
ips_BLAp 15697.91 3194.13 17720.72 3197.18 
ips_BLAv 12964.03 3149.26 15092.39 3119.00 
ips_BMAp 12389.00 2603.67 14305.13 2739.76 
ips_CA1slm 14034.20 1452.16 14690.28 2660.09 
ips_CA1so 15493.41 1532.03 16225.45 2510.38 
ips_CA1sp 10331.24 948.08 10718.53 1815.50 
ips_CA1sr 17725.08 1668.88 18416.58 2724.32 
ips_CA2slm 10056.56 1374.39 10657.90 1634.98 
ips_CA2so 10312.59 1828.83 10376.68 1554.44 
ips_CA2sp 7358.46 998.24 7778.99 921.69 
ips_CA2sr 9813.68 1467.33 10273.37 1685.82 
ips_CA3slm 9952.64 1340.60 10586.43 1523.47 
ips_CA3slu 12343.23 1709.41 12860.59 2103.28 
ips_CA3so 9735.86 1372.32 10244.14 1453.34 
ips_CA3sp 8600.04 1044.54 9463.80 1550.36 
ips_CA3sr 11057.87 1355.90 11703.55 1648.19 
ips_CC 7558.74 684.04 7968.09 1128.48 
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ips_cing 9061.67 1033.20 9486.12 1799.87 
ips_COApl 12428.16 2600.27 14848.03 3201.81 
ips_COApl1 12587.01 2636.85 15118.73 3177.93 
ips_COApl2 12172.78 2573.53 14881.34 3303.08 
ips_COApl3 12522.94 2659.72 14762.88 3099.61 
ips_cortex 16629.93 2392.32 17980.89 2881.27 
ips_CP 12899.73 2352.79 14061.84 2514.51 
ips_cpd 7021.19 1216.74 7263.81 1365.42 
ips_DG 14666.92 1662.03 15184.23 2397.73 
ips_DGinf 14328.02 1730.68 14847.61 2190.73 
ips_DGpo 10076.44 992.08 10800.27 1491.92 
ips_DGsg 7079.02 448.89 7512.48 976.83 
ips_DGsup 14866.96 1619.00 15378.73 2513.80 
ips_ECT 17029.45 2781.34 18613.28 2562.34 
ips_ECT1 17939.94 2976.32 19916.03 2287.94 
ips_ECT3 17986.30 2865.19 19616.88 2611.62 
ips_ECT5 15928.40 2760.05 17419.97 2850.35 
ips_ECT6a 14499.80 2921.25 16109.95 2980.81 
ips_ECT6b 11145.79 2444.30 12253.68 1981.38 
ips_ENTI 15793.28 2789.54 16986.71 2722.36 
ips_ENTl1 16446.48 2850.16 17788.42 2550.54 
ips_ENTl3 16606.40 2991.23 17741.16 2742.18 
ips_ENTl5 15317.23 2866.64 16567.41 2917.51 
ips_ENTl6a 12875.22 3091.80 14310.83 3057.30 
ips_ENTl6b 10919.76 2537.75 12539.47 2445.50 
ips_FC 7912.76 1016.02 8753.01 1668.69 
ips_hip 13517.49 1511.10 14011.37 2145.46 
ips_hyp 9910.37 1740.38 10949.89 1981.41 
ips_LA 15389.99 2896.13 16972.06 3168.45 
ips_lay1 18008.44 2358.83 19362.30 2726.84 
ips_lay2 12761.57 1266.20 13724.17 2644.23 
ips_lay3 17977.17 2460.83 19587.70 3101.65 
ips_lay4 16879.72 2545.61 18428.97 3100.27 
ips_lay5 15734.00 2392.60 17148.96 2847.45 
ips_lay6a 14086.20 2115.99 15328.96 2866.31 
ips_lay6b 10774.89 1560.47 11751.59 2084.12 
ips_MOp 16728.56 1902.58 17778.35 2887.65 
 Page | 208 
ips_MOp1 17956.17 2118.41 19637.15 3347.33 
ips_MOp3 17534.33 1939.19 18693.71 3041.10 
ips_MOp5 16674.69 2020.00 17375.28 2846.74 
ips_MOp6a 14126.79 1714.81 14729.23 2928.49 
ips_MOp6b 11162.18 1090.31 11571.53 2277.75 
ips_MOs 16481.05 2055.14 17621.01 3252.91 
ips_MOs1 19379.30 3005.22 20743.15 3427.34 
ips_MOs3 17768.32 2429.29 19166.28 3471.43 
ips_MOs5 15259.54 2162.18 16268.48 3242.30 
ips_MOs6a 12528.72 1387.36 13119.56 2662.01 
ips_MOs6b 10846.45 1199.32 11441.79 2451.92 
ips_PAA 12922.04 3270.93 14812.23 2915.34 
ips_PAA1 12600.93 3228.42 14675.32 2986.93 
ips_PAA2 12807.82 3169.50 14703.82 2737.56 
ips_PAA3 13177.48 3354.61 15051.00 3114.96 
ips_PERI 16406.96 2662.23 18103.20 2691.03 
ips_PERI1 17354.47 2870.39 19168.62 2550.72 
ips_PERI3 17254.88 2809.48 19064.80 2864.41 
ips_PERI5 15552.82 2677.72 17133.92 2755.85 
ips_PERI6a 13532.28 2680.78 15236.51 2910.84 
ips_PERI6b 10888.05 2344.40 12072.01 2235.24 
ips_PIR 14269.39 2804.54 16396.47 2764.87 
ips_PIR1 14714.33 2667.06 16973.66 2723.20 
ips_PIR2 14123.74 2631.48 16207.92 2873.83 
ips_PIR3 14191.67 2931.16 16287.36 2791.36 
ips_RSPd 16307.65 1948.56 17658.25 3480.49 
ips_RSPd1 19608.35 2309.93 21180.26 3408.10 
ips_RSPd3 17210.00 2008.54 18617.78 3437.07 
ips_RSPd5 14495.94 1554.17 15802.12 3121.43 
ips_RSPd6a 12374.50 1291.52 13463.32 2647.82 
ips_RSPd6b 11103.64 1142.86 12097.46 2701.39 
ips_RSPv 14522.46 1502.08 15488.53 2949.32 
ips_RSPv1 16200.88 1566.43 16744.87 3202.37 
ips_RSPv2 12767.35 1263.66 13705.53 2626.76 
ips_RSPv3 15637.77 1619.33 16632.16 3190.73 
ips_RSPv5 14131.07 1644.63 15293.92 2825.30 
ips_RSPv6a 12100.08 1288.74 13107.47 2715.21 
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ips_RSPv6b 11258.70 1451.38 12053.20 2620.16 
ips_SSp-bfd 16723.32 2708.37 18384.02 3130.92 
ips_SSp-bfd1 18182.53 2487.75 20528.28 3512.13 
ips_SSp-bfd3 18469.10 2847.65 20709.70 3606.19 
ips_SSp-bfd4 16726.58 2671.35 18438.12 3240.09 
ips_SSp-bfd5 15796.18 2660.35 17306.63 2953.45 
ips_SSp-bfd6a 14550.41 2584.47 15826.67 2947.37 
ips_SSp-bfd6b 10890.38 1709.09 12184.02 2364.98 
ips_SSp-tr 16703.41 2151.07 17655.42 2913.31 
ips_SSp-tr1 18102.49 2410.67 18755.22 2818.24 
ips_SSp-tr3 18115.80 2444.86 19001.11 3250.86 
ips_SSp-tr4 16802.02 2098.26 17749.88 2983.39 
ips_SSp-tr5 15759.08 2105.34 16941.75 2845.55 
ips_SSp-tr6a 13991.76 1909.26 15015.36 2866.09 
ips_SSp-tr6b 10574.82 1266.10 11201.67 2036.15 
ips_TEa 17271.34 3033.95 18914.27 2801.91 
ips_TEa1 18401.13 3439.23 20387.42 2796.59 
ips_TEa3 18528.66 3257.07 20383.35 2958.00 
ips_TEa4 17386.43 2922.87 19102.60 2876.40 
ips_TEa5 16077.38 2846.69 17566.31 2771.14 
ips_TEa6a 14999.14 2833.52 16479.44 2797.27 
ips_TEa6b 11070.04 1805.23 11962.40 1678.88 
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Appendix 5: Raw SAP102 from LFPI experiment at 7 and 28 days 
 
Table 1: SAP102 puncta density at 7 days 
 
   Injury    Sham   
region Average SD Average SD 
contra_amgmed 266.45 46.69 257.38 39.12 
contra_AUDd 391.91 56.59 391.63 48.56 
contra_AUDd1 465.41 78.75 455.81 55.20 
contra_AUDd3 423.59 66.61 423.56 54.96 
contra_AUDd4 395.00 56.45 391.94 44.99 
contra_AUDd5 361.55 53.26 360.13 55.15 
contra_AUDd6a 363.77 47.87 361.00 44.63 
contra_AUDd6b 219.45 68.02 211.44 63.89 
contra_AUDp 401.73 57.83 399.13 47.86 
contra_AUDp1 470.68 70.24 477.00 62.55 
contra_AUDp3 435.82 69.05 437.25 58.91 
contra_AUDp4 406.14 55.87 407.50 48.46 
contra_AUDp5 377.91 57.40 371.00 51.92 
contra_AUDp6a 370.77 58.18 362.44 42.72 
contra_AUDp6b 223.23 70.39 199.00 65.34 
contra_AUDv 420.55 63.39 418.13 48.05 
contra_AUDv1 479.55 81.95 490.06 66.09 
contra_AUDv3 453.86 75.84 458.75 54.62 
contra_AUDv4 428.59 60.32 427.19 55.90 
contra_AUDv5 403.86 61.68 398.88 56.76 
contra_AUDv6a 376.64 62.28 372.94 38.52 
contra_AUDv6b 243.59 59.44 237.50 61.93 
contra_BLAa 430.00 50.22 424.25 46.88 
contra_BLAp 453.91 52.06 448.44 33.55 
contra_BLAv 362.23 56.76 351.88 53.05 
contra_BMAp 324.55 66.32 301.94 34.61 
contra_CA1slm 378.95 74.82 365.00 39.87 
contra_CA1so 544.50 60.21 531.56 50.48 
contra_CA1sp 189.68 46.01 163.94 27.59 
contra_CA1sr 598.73 62.74 580.81 52.88 
contra_CA2slm 523.55 41.25 521.63 20.82 
contra_CA2so 508.86 24.43 504.13 29.87 
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contra_CA2sp 119.32 34.29 101.56 21.27 
contra_CA2sr 470.50 29.99 464.75 29.19 
contra_CA3slm 554.64 53.99 550.44 34.00 
contra_CA3slu 208.95 48.27 198.31 27.90 
contra_CA3so 466.64 46.00 457.44 39.23 
contra_CA3sp 113.77 33.77 113.50 18.41 
contra_CA3sr 538.05 54.81 541.50 29.61 
contra_CC 22.73 14.53 17.88 5.44 
contra_cing 82.27 24.35 65.69 18.70 
contra_COApl 317.59 61.75 302.63 43.63 
contra_COApl1 341.36 57.11 327.00 45.28 
contra_COApl2 321.00 58.78 303.50 51.39 
contra_COApl3 311.05 67.34 292.06 42.24 
contra_cortex 375.55 51.07 371.25 48.54 
contra_CP 337.18 61.94 330.63 42.77 
contra_cpd 37.00 23.52 31.13 15.32 
contra_DG 667.32 40.64 656.88 27.84 
contra_DGinf 659.27 37.29 651.38 25.92 
contra_DGpo 197.23 23.95 192.94 14.58 
contra_DGsg 120.64 29.21 116.94 12.00 
contra_DGsup 672.50 43.90 661.31 31.15 
contra_ECT 440.95 60.02 439.50 52.05 
contra_ECT1 497.50 84.44 499.44 68.52 
contra_ECT3 462.14 65.01 457.13 53.59 
contra_ECT5 425.64 55.74 423.13 54.98 
contra_ECT6a 395.18 59.40 393.25 50.94 
contra_ECT6b 255.00 63.48 271.25 42.83 
contra_ENTI 443.68 57.43 435.19 47.44 
contra_ENTl1 516.23 61.13 513.81 75.89 
contra_ENTl3 469.50 50.56 459.38 56.72 
contra_ENTl5 431.05 56.73 421.50 48.08 
contra_ENTl6a 399.95 61.40 393.69 36.66 
contra_ENTl6b 299.86 72.76 306.56 52.66 
contra_FC 317.23 40.74 321.25 33.40 
contra_hip 515.05 50.09 503.63 36.70 
contra_hyp 123.27 24.05 119.81 25.70 
contra_LA 415.50 53.97 414.13 47.05 
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contra_lay1 444.18 54.55 448.88 59.12 
contra_lay2 262.68 50.63 234.50 36.46 
contra_lay3 404.27 57.09 400.44 54.62 
contra_lay4 384.14 53.95 377.44 48.28 
contra_lay5 347.82 49.55 343.75 50.12 
contra_lay6a 344.82 49.45 338.88 43.97 
contra_lay6b 228.14 50.35 232.88 39.71 
contra_MOp 371.14 51.26 357.75 56.58 
contra_MOp1 443.73 64.94 440.06 84.55 
contra_MOp3 398.36 56.72 387.69 66.89 
contra_MOp5 355.95 54.14 349.75 59.71 
contra_MOp6a 331.23 53.80 319.69 51.98 
contra_MOp6b 234.68 65.09 236.00 28.48 
contra_MOs 309.45 44.88 291.69 57.98 
contra_MOs1 409.59 64.29 399.25 79.18 
contra_MOs3 330.09 52.45 324.00 61.83 
contra_MOs5 274.50 45.15 257.19 55.05 
contra_MOs6a 269.50 48.40 248.38 51.08 
contra_MOs6b 208.27 56.34 191.50 51.05 
contra_PAA 347.18 55.42 345.19 54.38 
contra_PAA1 361.90 69.94 348.25 58.30 
contra_PAA2 355.14 58.67 352.50 67.18 
contra_PAA3 340.41 50.16 338.13 46.79 
contra_PERI 449.73 54.17 442.13 56.94 
contra_PERI1 501.45 77.54 505.94 72.72 
contra_PERI3 468.91 55.33 454.13 61.27 
contra_PERI5 442.23 44.83 427.56 58.68 
contra_PERI6a 407.77 57.57 406.88 46.49 
contra_PERI6b 260.32 66.50 272.50 38.97 
contra_PIR 440.50 44.60 434.19 29.78 
contra_PIR1 493.64 56.86 485.19 29.24 
contra_PIR2 407.18 52.02 408.56 18.79 
contra_PIR3 429.55 42.72 423.38 32.78 
contra_RSPd 283.59 44.90 269.56 48.03 
contra_RSPd1 385.41 75.73 383.00 61.24 
contra_RSPd3 307.23 51.78 297.19 50.45 
contra_RSPd5 239.86 42.52 223.13 47.34 
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contra_RSPd6a 250.41 39.71 228.81 51.61 
contra_RSPd6b 190.14 54.03 193.88 51.44 
contra_RSPv 273.68 46.46 253.56 42.02 
contra_RSPv1 322.23 53.88 301.06 48.49 
contra_RSPv2 262.91 50.07 234.50 35.54 
contra_RSPv3 294.27 47.08 277.75 45.52 
contra_RSPv5 241.95 45.08 230.81 38.78 
contra_RSPv6a 231.23 41.08 210.13 40.58 
contra_RSPv6b 195.60 45.49 180.31 52.17 
contra_SSp-bfd 362.36 57.42 357.50 52.99 
contra_SSp-
bfd1 451.32 68.01 445.63 61.87 
contra_SSp-
bfd3 391.91 68.09 383.63 60.59 
contra_SSp-
bfd4 369.41 52.38 363.56 47.23 
contra_SSp-
bfd5 330.27 54.25 324.38 50.25 
contra_SSp-
bfd6a 340.23 52.23 335.63 44.59 
contra_SSp-
bfd6b 220.32 56.84 229.94 55.58 
contra_SSP-tr 365.36 53.19 361.00 49.91 
contra_SSp-tr1 444.91 59.47 456.31 59.19 
contra_SSp-tr3 401.45 62.00 396.25 58.53 
contra_SSp-tr4 364.36 58.72 356.19 50.36 
contra_SSp-tr5 332.36 51.18 328.50 50.75 
contra_SSp-
tr6a 331.32 51.33 331.13 47.33 
contra_SSp-
tr6b 213.77 58.78 228.38 43.92 
contra_TEa 436.32 65.68 431.56 48.99 
contra_TEa1 493.41 88.11 491.75 68.09 
contra_TEa3 468.36 74.18 462.88 56.40 
contra_TEa4 446.95 62.72 435.13 50.39 
contra_TEa5 420.00 64.74 416.44 54.06 
contra_TEa6a 387.77 63.59 382.06 43.83 
contra_TEa6b 248.59 56.57 271.94 42.90 
contra_th 294.73 18.07 286.13 17.45 
ips_amgmed 256.82 42.13 236.88 30.16 
ips_AUDd 361.18 62.16 335.25 67.50 
ips_AUDd1 423.68 85.10 383.75 81.63 
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ips_AUDd3 387.23 75.62 349.06 76.33 
ips_AUDd4 372.68 55.68 357.19 48.56 
ips_AUDd5 332.05 57.05 313.56 64.34 
ips_AUDd6a 330.95 52.09 315.75 62.98 
ips_AUDd6b 208.09 58.86 236.25 53.73 
ips_AUDp 379.18 58.56 356.06 63.81 
ips_AUDp1 453.55 80.52 407.31 73.82 
ips_AUDp3 410.27 70.52 378.69 65.25 
ips_AUDp4 395.73 50.43 365.19 52.64 
ips_AUDp5 350.14 52.06 333.81 63.34 
ips_AUDp6a 336.77 52.20 328.88 64.15 
ips_AUDp6b 202.27 61.08 205.75 58.15 
ips_AUDv 403.73 53.61 373.06 61.98 
ips_AUDv1 492.68 61.32 429.38 68.41 
ips_AUDv3 437.55 59.16 398.06 55.42 
ips_AUDv4 409.18 49.59 372.56 51.00 
ips_AUDv5 376.27 51.95 359.69 67.25 
ips_AUDv6a 351.77 53.75 329.31 67.44 
ips_AUDv6b 230.95 45.46 228.13 62.66 
ips_BLAa 425.73 44.31 420.50 31.72 
ips_BLAp 442.73 39.55 432.19 36.85 
ips_BLAv 352.55 68.19 337.88 64.48 
ips_BMAp 308.14 68.44 285.44 55.65 
ips_CA1slm 383.45 73.57 348.06 54.70 
ips_CA1so 547.55 63.41 510.81 62.97 
ips_CA1sp 188.14 48.09 153.00 30.17 
ips_CA1sr 607.36 62.07 567.75 67.74 
ips_CA2slm 514.55 41.88 516.44 36.99 
ips_CA2so 499.82 29.31 500.88 27.80 
ips_CA2sp 106.95 33.21 83.50 28.91 
ips_CA2sr 471.05 32.45 468.81 32.20 
ips_CA3slm 530.36 55.39 524.19 53.99 
ips_CA3slu 206.18 43.94 184.50 47.97 
ips_CA3so 454.00 52.11 443.44 52.85 
ips_CA3sp 115.86 27.43 97.13 28.65 
ips_CA3sr 530.50 56.03 520.38 54.84 
ips_CC 21.86 14.12 14.75 5.01 
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ips_cing 82.41 27.20 50.63 18.85 
ips_COApl 320.27 72.34 272.00 40.72 
ips_COApl1 356.36 77.84 301.44 46.70 
ips_COApl2 318.18 74.51 270.56 42.14 
ips_COApl3 307.64 70.36 265.50 42.37 
ips_cortex 330.64 57.08 317.63 57.47 
ips_CP 316.55 44.92 303.06 40.78 
ips_cpd 35.14 20.34 31.13 21.34 
ips_DG 664.14 40.52 643.06 43.42 
ips_DGinf 656.68 36.97 637.25 39.78 
ips_DGpo 192.09 22.44 187.38 19.06 
ips_DGsg 126.23 28.72 110.81 19.10 
ips_DGsup 670.18 45.41 648.94 45.96 
ips_ECT 428.09 46.72 412.06 52.71 
ips_ECT1 485.36 73.00 458.69 70.24 
ips_ECT3 445.32 47.61 431.44 55.13 
ips_ECT5 413.32 47.62 394.88 51.56 
ips_ECT6a 381.77 48.54 361.38 64.83 
ips_ECT6b 253.55 68.92 245.56 68.27 
ips_ENTI 429.77 56.17 426.75 47.98 
ips_ENTl1 537.18 74.13 520.56 68.50 
ips_ENTl3 452.86 64.89 446.13 51.24 
ips_ENTl5 408.82 51.47 413.13 43.97 
ips_ENTl6a 363.68 55.59 369.81 55.91 
ips_ENTl6b 279.41 58.00 306.13 68.90 
ips_FC 293.32 32.72 295.88 34.05 
ips_hip 510.64 48.99 493.75 48.33 
ips_hyp 122.82 21.54 120.25 24.79 
ips_LA 392.73 40.41 385.81 40.87 
ips_lay1 385.95 68.10 379.44 61.55 
ips_lay2 238.45 59.45 213.13 26.23 
ips_lay3 355.18 64.36 338.44 60.91 
ips_lay4 350.32 57.63 332.25 52.17 
ips_lay5 311.45 53.85 298.50 58.14 
ips_lay6a 298.36 60.34 287.25 59.90 
ips_lay6b 205.23 49.79 203.94 49.94 
ips_MOp 313.95 59.85 294.13 51.13 
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ips_MOp1 329.91 82.99 336.00 60.97 
ips_MOp3 334.77 67.40 319.00 47.83 
ips_MOp5 318.86 58.75 295.69 56.09 
ips_MOp6a 287.77 63.81 259.56 63.07 
ips_MOp6b 193.41 71.24 171.94 53.12 
ips_MOs 262.09 57.51 246.00 45.40 
ips_MOs1 311.10 71.25 325.56 52.89 
ips_MOs3 284.77 61.97 274.56 46.65 
ips_MOs5 245.23 56.25 225.63 41.24 
ips_MOs6a 234.41 54.36 204.56 48.81 
ips_MOs6b 205.00 48.73 156.38 39.59 
ips_PAA 337.14 54.57 326.31 64.76 
ips_PAA1 361.23 70.90 327.44 78.46 
ips_PAA2 335.77 54.38 327.06 50.04 
ips_PAA3 329.64 53.84 323.69 67.44 
ips_PERI 440.64 44.08 428.44 51.73 
ips_PERI1 529.73 63.77 490.69 65.19 
ips_PERI3 459.27 45.65 437.94 45.05 
ips_PERI5 418.05 43.86 419.06 56.97 
ips_PERI6a 384.86 57.42 387.56 59.72 
ips_PERI6b 268.00 62.64 251.75 70.42 
ips_PIR 423.91 46.53 408.88 46.13 
ips_PIR1 490.14 55.88 468.44 62.05 
ips_PIR2 387.32 72.34 375.75 49.27 
ips_PIR3 410.91 42.04 398.00 40.77 
ips_RSPd 255.23 49.25 242.69 34.11 
ips_RSPd1 324.41 63.07 323.13 41.28 
ips_RSPd3 276.23 56.59 265.69 31.99 
ips_RSPd5 219.64 43.22 207.19 43.33 
ips_RSPd6a 223.36 48.39 199.25 39.92 
ips_RSPd6b 197.23 57.30 162.75 37.88 
ips_RSPv 253.68 50.27 234.19 35.38 
ips_RSPv1 289.95 59.49 269.75 28.81 
ips_RSPv2 238.59 59.07 212.94 26.38 
ips_RSPv3 278.82 49.27 257.88 41.55 
ips_RSPv5 228.91 43.18 212.38 40.55 
ips_RSPv6a 210.77 44.73 186.81 43.11 
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ips_RSPv6b 195.64 59.01 157.69 37.23 
ips_SSp-bfd 329.05 65.92 311.38 74.20 
ips_SSp-bfd1 397.05 90.97 391.13 69.50 
ips_SSp-bfd3 352.73 77.56 328.88 82.99 
ips_SSp-bfd4 346.73 60.22 329.38 64.32 
ips_SSp-bfd5 303.86 57.16 287.56 70.10 
ips_SSp-bfd6a 303.00 63.07 295.13 70.58 
ips_SSp-bfd6b 204.77 54.06 219.56 60.56 
ips_SSp-tr 304.36 58.40 299.00 58.67 
ips_SSp-tr1 361.27 71.88 368.44 70.02 
ips_SSp-tr3 322.82 65.45 317.63 64.28 
ips_SSp-tr4 316.55 54.75 307.00 51.36 
ips_SSp-tr5 288.36 52.23 281.75 56.58 
ips_SSp-tr6a 277.77 69.25 270.31 60.07 
ips_SSp-tr6b 181.91 53.50 184.00 52.66 
ips_TEa 419.27 49.50 397.13 59.49 
ips_TEa1 486.86 69.70 455.13 70.55 
ips_TEa3 445.95 56.67 417.94 54.71 
ips_TEa4 421.14 50.50 400.69 57.48 
ips_TEa5 405.36 51.25 383.88 61.79 
ips_TEa6a 359.27 49.50 351.44 66.51 
ips_TEa6b 232.95 46.48 232.06 63.43 
ips_th 280.18 22.28 274.75 19.65 
 
Table 2: SAP102 puncta size at 7 days 
 
   Injury    Sham   
region Average SD Average SD 
contra_amgmed 14.66 0.21 14.53 0.21 
contra_AUDd 14.42 0.25 14.29 0.27 
contra_AUDd1 13.96 0.30 13.83 0.20 
contra_AUDd3 14.75 0.30 14.66 0.32 
contra_AUDd4 14.08 0.29 13.88 0.20 
contra_AUDd5 14.36 0.30 14.16 0.33 
contra_AUDd6a 14.26 0.26 14.16 0.24 
contra_AUDd6b 14.56 0.40 14.40 0.39 
contra_AUDp 14.34 0.20 14.20 0.22 
contra_AUDp1 14.03 0.26 13.73 0.18 
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contra_AUDp3 14.64 0.22 14.53 0.31 
contra_AUDp4 14.08 0.30 13.80 0.12 
contra_AUDp5 14.21 0.27 14.08 0.22 
contra_AUDp6a 14.27 0.20 14.12 0.20 
contra_AUDp6b 14.40 0.21 14.42 0.32 
contra_AUDv 14.21 0.28 14.05 0.20 
contra_AUDv1 13.98 0.41 13.69 0.27 
contra_AUDv3 14.51 0.30 14.35 0.24 
contra_AUDv4 13.95 0.28 13.76 0.15 
contra_AUDv5 14.08 0.28 13.97 0.20 
contra_AUDv6a 14.19 0.27 14.07 0.21 
contra_AUDv6b 14.34 0.19 14.13 0.19 
contra_BLAa 13.67 0.22 13.49 0.16 
contra_BLAp 13.64 0.29 13.49 0.10 
contra_BLAv 13.87 0.26 13.73 0.29 
contra_BMAp 14.18 0.39 14.10 0.24 
contra_CA1slm 14.70 0.34 14.65 0.42 
contra_CA1so 13.29 0.21 13.27 0.31 
contra_CA1sp 16.33 0.59 16.45 0.48 
contra_CA1sr 13.74 0.24 13.76 0.40 
contra_CA2slm 12.95 0.14 12.87 0.13 
contra_CA2so 12.85 0.11 12.77 0.12 
contra_CA2sp 18.05 1.05 18.57 0.86 
contra_CA2sr 13.27 0.19 13.20 0.17 
contra_CA3slm 13.20 0.23 13.11 0.16 
contra_CA3slu 19.66 0.66 19.47 0.52 
contra_CA3so 13.21 0.23 13.10 0.16 
contra_CA3sp 20.07 0.79 19.81 0.39 
contra_CA3sr 13.45 0.20 13.31 0.14 
contra_CC 16.24 1.11 15.88 0.66 
contra_cing 15.44 0.71 15.11 0.46 
contra_COApl 14.31 0.32 14.22 0.21 
contra_COApl1 13.85 0.24 13.80 0.28 
contra_COApl2 14.49 0.41 14.34 0.31 
contra_COApl3 14.40 0.35 14.35 0.17 
contra_cortex 14.32 0.20 14.24 0.22 
contra_CP 14.22 0.16 14.13 0.18 
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contra_cpd 17.58 1.40 17.65 1.09 
contra_DG 13.72 0.27 13.78 0.37 
contra_DGinf 13.78 0.29 13.80 0.27 
contra_DGpo 17.44 0.34 17.47 0.29 
contra_DGsg 20.56 0.64 20.59 0.78 
contra_DGsup 13.69 0.30 13.78 0.45 
contra_ECT 13.98 0.25 13.79 0.17 
contra_ECT1 13.76 0.36 13.48 0.19 
contra_ECT3 14.04 0.27 13.91 0.22 
contra_ECT5 13.91 0.30 13.73 0.14 
contra_ECT6a 13.99 0.30 13.82 0.23 
contra_ECT6b 14.33 0.37 14.16 0.20 
contra_ENTI 13.69 0.24 13.59 0.21 
contra_ENTl1 13.45 0.30 13.32 0.44 
contra_ENTl3 13.76 0.25 13.64 0.22 
contra_ENTl5 13.68 0.25 13.59 0.21 
contra_ENTl6a 13.75 0.27 13.68 0.17 
contra_ENTl6b 13.94 0.21 13.91 0.31 
contra_FC 13.64 0.25 13.54 0.21 
contra_hip 13.83 0.23 13.84 0.34 
contra_hyp 15.96 0.41 15.85 0.43 
contra_LA 13.69 0.23 13.56 0.14 
contra_lay1 14.00 0.19 13.84 0.18 
contra_lay2 15.02 0.34 15.01 0.27 
contra_lay3 14.60 0.22 14.56 0.27 
contra_lay4 14.12 0.21 13.96 0.22 
contra_lay5 14.21 0.24 14.10 0.24 
contra_lay6a 14.23 0.23 14.16 0.26 
contra_lay6b 14.40 0.28 14.26 0.27 
contra_MOp 14.14 0.24 14.11 0.27 
contra_MOp1 13.91 0.31 13.93 0.41 
contra_MOp3 14.35 0.26 14.38 0.36 
contra_MOp5 13.97 0.23 13.94 0.24 
contra_MOp6a 14.09 0.26 14.09 0.29 
contra_MOp6b 14.33 0.39 14.16 0.25 
contra_MOs 14.56 0.23 14.53 0.28 
contra_MOs1 14.33 0.18 14.27 0.37 
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contra_MOs3 14.77 0.22 14.73 0.26 
contra_MOs5 14.44 0.35 14.43 0.36 
contra_MOs6a 14.43 0.35 14.42 0.32 
contra_MOs6b 14.52 0.38 14.44 0.66 
contra_PAA 13.99 0.24 13.83 0.31 
contra_PAA1 13.50 0.21 13.45 0.39 
contra_PAA2 14.06 0.31 14.06 0.35 
contra_PAA3 14.13 0.24 13.92 0.27 
contra_PERI 13.77 0.24 13.66 0.24 
contra_PERI1 13.59 0.31 13.44 0.49 
contra_PERI3 13.83 0.26 13.70 0.26 
contra_PERI5 13.72 0.26 13.67 0.18 
contra_PERI6a 13.81 0.27 13.65 0.19 
contra_PERI6b 14.19 0.33 14.15 0.33 
contra_PIR 13.61 0.21 13.49 0.09 
contra_PIR1 13.15 0.27 13.04 0.14 
contra_PIR2 14.29 0.26 14.11 0.12 
contra_PIR3 13.64 0.21 13.51 0.09 
contra_RSPd 14.72 0.24 14.59 0.27 
contra_RSPd1 14.41 0.27 14.36 0.19 
contra_RSPd3 14.78 0.28 14.65 0.30 
contra_RSPd5 14.86 0.33 14.71 0.38 
contra_RSPd6a 14.68 0.34 14.53 0.39 
contra_RSPd6b 14.64 0.43 14.41 0.39 
contra_RSPv 14.69 0.26 14.61 0.24 
contra_RSPv1 14.56 0.18 14.53 0.29 
contra_RSPv2 15.01 0.34 15.00 0.27 
contra_RSPv3 14.32 0.25 14.20 0.21 
contra_RSPv5 14.86 0.35 14.66 0.27 
contra_RSPv6a 14.86 0.41 14.71 0.43 
contra_RSPv6b 14.89 0.65 14.65 0.51 
contra_SSp-bfd 14.54 0.29 14.48 0.31 
contra_SSp-
bfd1 14.07 0.25 13.92 0.22 
contra_SSp-
bfd3 14.89 0.31 14.86 0.36 
contra_SSp-
bfd4 14.21 0.26 14.02 0.23 
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contra_SSp-
bfd5 14.47 0.37 14.29 0.31 
contra_SSp-
bfd6a 14.38 0.28 14.32 0.32 
contra_SSp-
bfd6b 14.55 0.43 14.40 0.41 
contra_SSP-tr 14.33 0.23 14.27 0.26 
contra_SSp-tr1 13.90 0.26 13.78 0.16 
contra_SSp-tr3 14.71 0.31 14.66 0.31 
contra_SSp-tr4 14.20 0.24 14.15 0.31 
contra_SSp-tr5 14.13 0.21 14.09 0.31 
contra_SSp-
tr6a 14.24 0.22 14.16 0.32 
contra_SSp-
tr6b 14.45 0.35 14.29 0.31 
contra_TEa 14.09 0.29 13.92 0.21 
contra_TEa1 13.89 0.40 13.65 0.28 
contra_TEa3 14.37 0.34 14.20 0.31 
contra_TEa4 13.84 0.25 13.66 0.14 
contra_TEa5 13.97 0.34 13.83 0.20 
contra_TEa6a 14.10 0.30 13.97 0.20 
contra_TEa6b 14.36 0.31 14.10 0.22 
contra_th 13.13 0.13 13.08 0.18 
ips_amgmed 14.61 0.23 14.55 0.20 
ips_AUDd 14.37 0.17 14.47 0.40 
ips_AUDd1 13.98 0.28 14.18 0.35 
ips_AUDd3 14.56 0.24 14.77 0.50 
ips_AUDd4 14.01 0.17 14.01 0.24 
ips_AUDd5 14.38 0.22 14.34 0.46 
ips_AUDd6a 14.32 0.23 14.35 0.39 
ips_AUDd6b 14.73 0.28 14.47 0.41 
ips_AUDp 14.24 0.15 14.35 0.36 
ips_AUDp1 13.83 0.25 14.11 0.39 
ips_AUDp3 14.37 0.17 14.56 0.41 
ips_AUDp4 13.89 0.20 14.00 0.25 
ips_AUDp5 14.27 0.23 14.29 0.42 
ips_AUDp6a 14.33 0.22 14.27 0.40 
ips_AUDp6b 14.61 0.36 14.58 0.37 
ips_AUDv 14.04 0.11 14.19 0.34 
ips_AUDv1 13.59 0.16 13.92 0.41 
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ips_AUDv3 14.12 0.12 14.34 0.38 
ips_AUDv4 13.87 0.13 14.02 0.26 
ips_AUDv5 14.05 0.20 14.09 0.37 
ips_AUDv6a 14.19 0.18 14.27 0.45 
ips_AUDv6b 14.56 0.32 14.40 0.33 
ips_BLAa 13.64 0.15 13.62 0.17 
ips_BLAp 13.67 0.14 13.67 0.21 
ips_BLAv 13.93 0.22 13.88 0.31 
ips_BMAp 14.27 0.47 14.12 0.36 
ips_CA1slm 14.66 0.26 14.71 0.46 
ips_CA1so 13.25 0.27 13.39 0.36 
ips_CA1sp 16.37 0.49 16.70 0.61 
ips_CA1sr 13.64 0.26 13.83 0.44 
ips_CA2slm 13.00 0.20 13.02 0.22 
ips_CA2so 12.93 0.11 12.89 0.12 
ips_CA2sp 18.39 1.02 19.01 1.35 
ips_CA2sr 13.26 0.21 13.28 0.18 
ips_CA3slm 13.26 0.34 13.32 0.28 
ips_CA3slu 19.67 0.55 19.69 0.26 
ips_CA3so 13.21 0.27 13.29 0.25 
ips_CA3sp 19.96 0.42 20.08 0.91 
ips_CA3sr 13.48 0.30 13.52 0.23 
ips_CC 16.38 1.05 15.50 0.80 
ips_cing 15.34 0.85 15.08 0.67 
ips_COApl 14.33 0.44 14.32 0.21 
ips_COApl1 13.79 0.34 13.85 0.17 
ips_COApl2 14.58 0.55 14.50 0.27 
ips_COApl3 14.43 0.47 14.46 0.31 
ips_cortex 14.31 0.15 14.31 0.24 
ips_CP 14.17 0.24 14.11 0.21 
ips_cpd 17.75 1.36 17.37 1.19 
ips_DG 13.68 0.29 13.91 0.59 
ips_DGinf 13.73 0.29 13.95 0.56 
ips_DGpo 17.56 0.38 17.44 0.34 
ips_DGsg 20.53 0.62 20.60 0.83 
ips_DGsup 13.64 0.30 13.88 0.62 
ips_ECT 13.83 0.11 13.91 0.29 
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ips_ECT1 13.61 0.25 13.72 0.32 
ips_ECT3 13.86 0.14 13.93 0.25 
ips_ECT5 13.76 0.13 13.84 0.34 
ips_ECT6a 13.88 0.19 14.06 0.49 
ips_ECT6b 14.43 0.26 14.33 0.41 
ips_ENTI 13.68 0.12 13.65 0.22 
ips_ENTl1 13.25 0.12 13.31 0.23 
ips_ENTl3 13.68 0.16 13.68 0.19 
ips_ENTl5 13.72 0.15 13.61 0.25 
ips_ENTl6a 13.90 0.20 13.84 0.34 
ips_ENTl6b 14.29 0.32 14.03 0.35 
ips_FC 13.79 0.24 13.56 0.20 
ips_hip 13.78 0.24 13.91 0.41 
ips_hyp 15.97 0.41 15.85 0.44 
ips_LA 13.76 0.12 13.76 0.19 
ips_lay1 14.08 0.28 14.08 0.17 
ips_lay2 15.16 0.32 15.08 0.35 
ips_lay3 14.46 0.16 14.52 0.22 
ips_lay4 14.06 0.12 14.08 0.20 
ips_lay5 14.26 0.17 14.21 0.26 
ips_lay6a 14.25 0.19 14.23 0.30 
ips_lay6b 14.58 0.30 14.38 0.31 
ips_MOp 14.19 0.18 14.21 0.26 
ips_MOp1 14.30 0.56 14.31 0.27 
ips_MOp3 14.38 0.30 14.43 0.26 
ips_MOp5 13.99 0.14 13.98 0.29 
ips_MOp6a 14.01 0.17 14.07 0.28 
ips_MOp6b 14.43 0.39 14.34 0.35 
ips_MOs 14.64 0.20 14.56 0.27 
ips_MOs1 14.64 0.33 14.57 0.35 
ips_MOs3 14.80 0.21 14.73 0.24 
ips_MOs5 14.53 0.22 14.46 0.31 
ips_MOs6a 14.43 0.38 14.40 0.34 
ips_MOs6b 14.53 0.49 14.31 0.42 
ips_PAA 14.16 0.28 13.95 0.35 
ips_PAA1 13.74 0.29 13.59 0.34 
ips_PAA2 14.41 0.27 14.20 0.27 
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ips_PAA3 14.29 0.32 14.06 0.38 
ips_PERI 13.65 0.08 13.72 0.25 
ips_PERI1 13.33 0.16 13.45 0.26 
ips_PERI3 13.68 0.09 13.76 0.24 
ips_PERI5 13.68 0.16 13.71 0.30 
ips_PERI6a 13.73 0.13 13.81 0.35 
ips_PERI6b 14.31 0.34 14.37 0.39 
ips_PIR 13.68 0.11 13.64 0.19 
ips_PIR1 13.24 0.20 13.21 0.26 
ips_PIR2 14.33 0.15 14.25 0.23 
ips_PIR3 13.67 0.12 13.64 0.18 
ips_RSPd 14.78 0.32 14.66 0.25 
ips_RSPd1 14.62 0.23 14.48 0.16 
ips_RSPd3 14.81 0.31 14.69 0.22 
ips_RSPd5 14.92 0.43 14.77 0.38 
ips_RSPd6a 14.73 0.48 14.65 0.37 
ips_RSPd6b 14.62 0.51 14.39 0.53 
ips_RSPv 14.75 0.30 14.63 0.29 
ips_RSPv1 14.69 0.25 14.58 0.23 
ips_RSPv2 15.15 0.32 15.09 0.37 
ips_RSPv3 14.37 0.29 14.25 0.24 
ips_RSPv5 14.88 0.40 14.67 0.36 
ips_RSPv6a 14.89 0.45 14.85 0.38 
ips_RSPv6b 14.65 0.73 14.87 1.03 
ips_SSp-bfd 14.48 0.22 14.47 0.30 
ips_SSp-bfd1 14.10 0.35 14.05 0.24 
ips_SSp-bfd3 14.67 0.25 14.75 0.35 
ips_SSp-bfd4 14.14 0.16 14.12 0.24 
ips_SSp-bfd5 14.49 0.25 14.44 0.35 
ips_SSp-bfd6a 14.38 0.24 14.34 0.31 
ips_SSp-bfd6b 14.63 0.36 14.39 0.29 
ips_SSp-tr 14.39 0.17 14.30 0.22 
ips_SSp-tr1 14.18 0.44 14.08 0.21 
ips_SSp-tr3 14.64 0.21 14.59 0.21 
ips_SSp-tr4 14.15 0.18 14.12 0.23 
ips_SSp-tr5 14.23 0.17 14.14 0.24 
ips_SSp-tr6a 14.23 0.16 14.15 0.26 
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ips_SSp-tr6b 14.70 0.38 14.36 0.31 
ips_TEa 13.94 0.11 14.01 0.31 
ips_TEa1 13.63 0.24 13.67 0.30 
ips_TEa3 14.00 0.13 14.13 0.33 
ips_TEa4 13.79 0.14 13.85 0.28 
ips_TEa5 13.86 0.18 13.96 0.35 
ips_TEa6a 14.20 0.22 14.14 0.49 
ips_TEa6b 14.50 0.35 14.44 0.40 
ips_th 13.31 0.13 13.23 0.23 
 
Table 3: SAP102 puncta intensity at 7 days 
 
   Injury   Sham    
region Average SD Average SD 
contra_amgmed 12678.02 2385.72 12564.75 2665.01 
contra_AUDd 13287.69 2394.93 13077.69 2406.78 
contra_AUDd1 13174.40 2616.21 12830.27 2581.44 
contra_AUDd3 13668.30 2445.38 13477.44 2588.42 
contra_AUDd4 13425.20 2461.81 13194.51 2305.14 
contra_AUDd5 13053.72 2376.52 12883.25 2402.56 
contra_AUDd6a 13043.67 2369.26 12952.25 2449.88 
contra_AUDd6b 11205.07 2144.41 11248.86 1773.58 
contra_AUDp 13459.53 2485.62 13377.10 2495.10 
contra_AUDp1 13280.62 2472.81 13478.99 2743.48 
contra_AUDp3 14066.69 2568.03 14025.62 2745.63 
contra_AUDp4 13537.08 2527.23 13471.87 2486.13 
contra_AUDp5 13237.44 2460.07 13103.07 2456.38 
contra_AUDp6a 13155.79 2534.99 13030.71 2418.07 
contra_AUDp6b 11293.25 2679.50 10766.03 1710.59 
contra_AUDv 13650.92 2631.28 13591.15 2601.88 
contra_AUDv1 13561.35 2854.22 13635.73 2838.20 
contra_AUDv3 14352.27 2930.31 14280.75 2957.59 
contra_AUDv4 13772.81 2596.62 13664.26 2609.10 
contra_AUDv5 13487.21 2528.91 13371.64 2600.21 
contra_AUDv6a 13281.41 2618.67 13200.91 2429.02 
contra_AUDv6b 11608.85 2569.64 11440.69 2073.87 
contra_BLAa 15729.22 3283.96 15450.63 3258.43 
contra_BLAp 16086.54 3299.69 15828.50 3172.42 
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contra_BLAv 14364.87 2961.90 14307.77 2763.31 
contra_BMAp 13863.53 2839.59 13671.58 2750.39 
contra_CA1slm 12810.76 2334.43 11829.43 1441.66 
contra_CA1so 14006.66 2367.25 13117.99 2161.91 
contra_CA1sp 12615.81 1944.45 11756.74 1501.86 
contra_CA1sr 15025.80 2493.51 13792.57 2152.51 
contra_CA2slm 14731.10 2746.57 13753.75 1935.34 
contra_CA2so 16958.46 2999.95 16394.05 2510.63 
contra_CA2sp 12933.76 1807.28 12576.27 1406.24 
contra_CA2sr 15562.37 2970.49 14725.96 2241.06 
contra_CA3slm 13800.86 2470.51 12765.43 1984.66 
contra_CA3slu 11748.56 2025.08 11285.93 1859.87 
contra_CA3so 12140.97 2306.20 11424.22 1709.50 
contra_CA3sp 11037.01 1622.98 10602.94 1282.63 
contra_CA3sr 13386.66 2338.36 12745.50 1799.09 
contra_CC 6959.60 448.62 7219.61 420.91 
contra_cing 9009.43 1251.46 8542.38 1137.11 
contra_COApl 13595.85 2510.30 13601.07 3061.59 
contra_COApl1 13044.39 2426.60 13438.84 2856.76 
contra_COApl2 13990.39 2574.89 13903.71 3272.47 
contra_COApl3 13677.01 2589.09 13486.82 2995.18 
contra_cortex 13065.55 2237.64 12800.42 2526.69 
contra_CP 12058.47 2215.41 11751.20 2173.24 
contra_cpd 6670.20 467.10 6752.29 622.03 
contra_DG 19359.89 3187.83 17673.32 2652.56 
contra_DGinf 18708.93 2894.35 17096.75 2539.29 
contra_DGpo 12267.46 1919.96 11374.52 1495.48 
contra_DGsg 13574.06 1729.39 12650.14 871.95 
contra_DGsup 19755.46 3435.41 18063.48 2713.00 
contra_ECT 14360.87 2861.12 14126.65 2863.56 
contra_ECT1 14388.05 3145.61 14183.04 3025.35 
contra_ECT3 14889.17 3067.48 14509.62 2977.42 
contra_ECT5 14262.36 2788.99 14031.36 2834.95 
contra_ECT6a 13866.55 2762.93 13650.64 2769.97 
contra_ECT6b 12225.09 2572.60 12323.86 2038.01 
contra_ENTI 15221.62 2785.66 15090.19 3459.46 
contra_ENTl1 15145.03 2534.33 14727.77 3859.73 
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contra_ENTl3 15989.89 2687.19 15788.73 3811.98 
contra_ENTl5 15368.08 3075.05 15255.20 3444.58 
contra_ENTl6a 14154.88 2908.01 13946.31 2860.85 
contra_ENTl6b 12819.44 2585.13 12963.75 2621.70 
contra_FC 15237.53 2605.19 13409.40 2026.84 
contra_hip 14238.54 2442.87 13292.75 1941.88 
contra_hyp 10921.93 1747.21 10823.64 2127.42 
contra_LA 14184.15 2839.26 14110.55 2903.55 
contra_lay1 12982.01 2179.37 12920.21 2796.16 
contra_lay2 12878.91 2209.44 11983.90 2248.05 
contra_lay3 13484.40 2316.25 13164.05 2732.95 
contra_lay4 13301.97 2348.93 13040.59 2477.76 
contra_lay5 12942.91 2225.84 12695.60 2452.86 
contra_lay6a 12796.04 2274.78 12537.72 2419.95 
contra_lay6b 11283.25 2103.26 11218.49 1939.42 
contra_MOp 12840.39 2076.98 12356.74 2745.86 
contra_MOp1 12788.32 2204.78 12837.11 3546.49 
contra_MOp3 13339.58 2160.66 13117.26 3215.86 
contra_MOp5 12801.50 2131.94 12264.77 2606.33 
contra_MOp6a 12511.30 2150.04 11774.98 2331.58 
contra_MOp6b 11411.49 2076.95 10792.77 1873.18 
contra_MOs 12393.20 1869.58 11900.40 2700.05 
contra_MOs1 12976.24 2411.13 12713.78 3617.81 
contra_MOs3 12786.78 1952.99 12555.71 3071.77 
contra_MOs5 12054.93 1817.37 11562.37 2342.24 
contra_MOs6a 11676.80 1984.68 10976.68 2221.55 
contra_MOs6b 10616.49 1869.37 10085.18 1864.23 
contra_PAA 13811.19 2719.12 14130.09 2730.93 
contra_PAA1 13100.57 2797.68 13117.27 2492.34 
contra_PAA2 14225.63 2978.27 14472.78 2812.61 
contra_PAA3 13963.67 2687.39 14321.94 2790.26 
contra_PERI 14702.83 2729.96 14483.43 3170.32 
contra_PERI1 14463.63 2945.12 14127.81 3121.63 
contra_PERI3 15098.91 2809.63 14981.42 3449.50 
contra_PERI5 14753.32 2742.56 14602.59 3210.27 
contra_PERI6a 14100.55 2719.79 13924.43 2789.36 
contra_PERI6b 12567.13 2630.96 12530.58 2266.55 
 Page | 228 
contra_PIR 15487.68 3026.64 15290.71 2929.69 
contra_PIR1 15040.62 3091.35 14826.47 3048.05 
contra_PIR2 16462.88 3213.72 16255.58 3107.79 
contra_PIR3 15222.29 2983.48 15004.20 2864.05 
contra_RSPd 12430.22 1967.46 12027.03 2467.65 
contra_RSPd1 13195.00 2682.15 13000.18 3155.10 
contra_RSPd3 12771.01 2061.85 12490.95 2699.42 
contra_RSPd5 11988.31 1796.91 11499.48 2156.02 
contra_RSPd6a 11743.77 1906.88 11124.24 2139.46 
contra_RSPd6b 10536.93 1796.08 10082.35 1894.02 
contra_RSPv 12460.11 2004.07 11641.87 2086.40 
contra_RSPv1 13076.31 2432.00 12181.52 2524.97 
contra_RSPv2 12879.06 2209.70 11947.32 2208.20 
contra_RSPv3 12564.48 2008.12 11772.68 2126.76 
contra_RSPv5 11926.04 1787.42 11265.11 1932.95 
contra_RSPv6a 11589.77 1887.08 10936.91 1996.51 
contra_RSPv6b 11006.45 1792.16 10246.65 1896.43 
contra_SSp-bfd 12958.21 2367.14 12543.25 2411.22 
contra_SSp-
bfd1 12988.96 2535.48 12107.93 2536.83 
contra_SSp-
bfd3 13254.13 2489.02 12594.43 2490.52 
contra_SSp-
bfd4 13242.51 2410.62 12973.34 2371.38 
contra_SSp-
bfd5 12774.32 2295.27 12572.44 2330.10 
contra_SSp-
bfd6a 12667.20 2276.72 12576.85 2482.26 
contra_SSp-
bfd6b 11022.48 1900.57 11223.42 2050.28 
contra_SSP-tr 12628.35 2236.15 12450.75 2626.28 
contra_SSp-tr1 12410.80 2339.37 12701.31 3035.58 
contra_SSp-tr3 13009.55 2427.76 12813.82 2908.99 
contra_SSp-tr4 12784.02 2234.00 12507.68 2609.74 
contra_SSp-tr5 12593.50 2223.76 12324.07 2508.21 
contra_SSp-
tr6a 12460.78 2217.10 12164.50 2440.72 
contra_SSp-
tr6b 11073.92 2022.73 11070.30 2063.85 
contra_TEa 14062.69 2825.26 13864.77 2777.57 
contra_TEa1 14012.14 3109.20 13745.74 3016.73 
contra_TEa3 14623.36 3055.67 14489.61 3001.92 
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contra_TEa4 14264.37 2775.91 14077.51 2826.52 
contra_TEa5 13913.61 2749.70 13727.12 2767.86 
contra_TEa6a 13583.82 2723.92 13460.24 2623.03 
contra_TEa6b 11917.30 2522.14 11970.23 1930.25 
contra_th 13591.10 2555.95 12836.64 1955.72 
ips_amgmed 12885.53 1908.79 11900.93 2277.18 
ips_AUDd 12759.51 2293.65 11907.13 2332.46 
ips_AUDd1 12722.79 2671.19 11447.84 2459.21 
ips_AUDd3 13070.93 2550.26 11959.71 2424.00 
ips_AUDd4 13350.00 2401.23 12422.99 2220.64 
ips_AUDd5 12595.02 2180.31 11901.35 2271.82 
ips_AUDd6a 12399.28 2119.17 11831.44 2405.86 
ips_AUDd6b 11073.57 1940.26 10841.31 2159.53 
ips_AUDp 13229.36 2244.93 12178.51 2276.81 
ips_AUDp1 13390.19 2648.47 11692.07 2260.88 
ips_AUDp3 13664.93 2397.73 12370.11 2323.60 
ips_AUDp4 13716.87 2286.80 12599.42 2199.05 
ips_AUDp5 12927.53 2233.70 12166.27 2298.72 
ips_AUDp6a 12640.47 2104.57 12053.50 2496.86 
ips_AUDp6b 11117.20 2146.26 10505.06 1921.40 
ips_AUDv 13665.13 2214.78 12470.38 2380.37 
ips_AUDv1 14084.12 2299.73 12091.27 2218.19 
ips_AUDv3 14117.92 2364.62 12715.67 2360.07 
ips_AUDv4 14024.37 2243.82 12765.07 2432.62 
ips_AUDv5 13267.48 2195.50 12439.40 2465.47 
ips_AUDv6a 12991.46 2111.14 12334.68 2685.62 
ips_AUDv6b 11502.40 2017.22 11007.80 2311.83 
ips_BLAa 16088.26 2490.25 15121.59 3177.61 
ips_BLAp 16300.48 2644.91 15292.69 3209.57 
ips_BLAv 14895.32 2655.88 13842.60 2889.92 
ips_BMAp 13970.55 2413.52 13121.54 3028.86 
ips_CA1slm 12887.88 2156.06 11635.35 1602.14 
ips_CA1so 14195.56 2201.19 12680.41 2106.26 
ips_CA1sp 12695.92 1820.86 11417.67 1517.96 
ips_CA1sr 15283.09 2375.43 13659.53 2326.34 
ips_CA2slm 14549.93 2363.74 13258.71 2259.86 
ips_CA2so 17061.65 2471.83 15637.06 2413.80 
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ips_CA2sp 12959.71 1480.79 11937.43 1375.62 
ips_CA2sr 15418.39 2387.04 13961.02 2486.91 
ips_CA3slm 13375.81 2209.73 12437.19 2153.23 
ips_CA3slu 11729.36 1700.09 10872.16 1987.06 
ips_CA3so 12003.41 1987.76 11028.39 1843.88 
ips_CA3sp 11124.98 1453.64 10387.16 1394.01 
ips_CA3sr 13245.19 2038.39 12354.44 2034.97 
ips_CC 6867.72 552.51 6944.63 439.27 
ips_cing 8886.26 1345.26 7906.38 1115.39 
ips_COApl 14433.84 2932.30 12425.10 2774.33 
ips_COApl1 14113.94 2907.93 12161.51 3040.27 
ips_COApl2 14884.48 3064.84 12609.83 2855.08 
ips_COApl3 14337.71 2930.40 12456.07 2750.67 
ips_cortex 12134.14 2158.23 11433.01 2150.77 
ips_CP 12052.53 1693.79 11361.83 2185.18 
ips_cpd 6624.89 403.90 6834.62 669.02 
ips_DG 18991.39 2991.11 17276.16 2850.54 
ips_DGinf 18350.92 2858.49 16604.49 2683.85 
ips_DGpo 12302.75 1919.58 11118.80 1543.27 
ips_DGsg 13625.96 1717.29 12404.98 1020.89 
ips_DGsup 19396.55 3084.34 17698.10 2956.78 
ips_ECT 14592.43 2400.13 13626.30 2887.17 
ips_ECT1 14421.49 2924.00 13352.89 3154.47 
ips_ECT3 15044.53 2535.93 13924.67 2887.48 
ips_ECT5 14329.61 2354.89 13606.70 2871.57 
ips_ECT6a 13836.81 2134.79 13176.13 2916.31 
ips_ECT6b 12444.98 2081.63 12012.90 2770.21 
ips_ENTI 16130.40 2820.10 15413.34 3135.23 
ips_ENTl1 16893.28 3215.58 15579.83 3447.06 
ips_ENTl3 17087.82 3049.03 16142.21 3280.30 
ips_ENTl5 15483.09 2848.98 15204.15 3271.08 
ips_ENTl6a 14047.18 2303.21 13873.20 3201.83 
ips_ENTl6b 12921.32 1945.25 12902.72 2989.13 
ips_FC 14645.84 2279.53 12872.05 1657.85 
ips_hip 14373.42 2175.36 13020.02 2052.18 
ips_hyp 11045.59 1497.21 10860.87 2046.87 
ips_LA 14259.19 2090.45 13608.61 2823.74 
 Page | 231 
ips_lay1 12061.05 2354.19 11202.80 2086.85 
ips_lay2 12132.63 2368.24 11210.41 1682.10 
ips_lay3 12400.50 2274.43 11614.89 2215.62 
ips_lay4 12720.36 2336.01 11912.48 2224.54 
ips_lay5 12136.82 2101.34 11518.97 2157.82 
ips_lay6a 11779.54 2154.99 11144.04 2167.18 
ips_lay6b 10766.55 1967.91 10278.64 1999.83 
ips_MOp 11534.16 2145.48 10760.39 1854.84 
ips_MOp1 10727.91 2195.81 9888.73 1976.71 
ips_MOp3 11684.86 2213.63 11071.16 1876.99 
ips_MOp5 11823.30 2183.35 10963.77 1841.02 
ips_MOp6a 11505.42 2240.06 10430.70 1926.53 
ips_MOp6b 10472.71 2115.24 9678.39 1782.01 
ips_MOs 11178.55 2091.04 10558.01 1674.65 
ips_MOs1 11033.78 2223.39 10562.95 1818.90 
ips_MOs3 11382.49 2197.62 10906.99 1698.50 
ips_MOs5 11245.43 2082.28 10492.75 1665.71 
ips_MOs6a 10879.43 2029.29 9928.86 1748.51 
ips_MOs6b 10336.04 1869.68 9147.67 1603.22 
ips_PAA 14307.76 2855.41 13387.52 3359.85 
ips_PAA1 13684.53 3059.68 12463.56 3395.77 
ips_PAA2 14789.13 3261.23 13687.63 3554.90 
ips_PAA3 14381.52 2673.39 13737.74 3298.51 
ips_PERI 15359.94 2388.79 14376.20 2993.00 
ips_PERI1 15712.26 2920.92 14284.31 3163.29 
ips_PERI3 16056.52 2559.78 14805.36 3040.35 
ips_PERI5 14993.24 2301.84 14404.75 3133.96 
ips_PERI6a 14049.96 2235.73 13557.97 3001.08 
ips_PERI6b 12921.66 2046.79 12281.40 2795.35 
ips_PIR 15957.59 3003.55 14825.09 3101.71 
ips_PIR1 16218.37 3225.79 14809.83 3258.86 
ips_PIR2 16820.54 3405.30 15385.35 3235.26 
ips_PIR3 15527.27 2753.96 14571.48 3052.19 
ips_RSPd 11552.99 2082.87 11037.51 1614.15 
ips_RSPd1 11613.36 2558.94 11240.29 1784.71 
ips_RSPd3 11837.33 2173.27 11303.00 1590.63 
ips_RSPd5 11423.04 1897.32 10869.72 1630.79 
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ips_RSPd6a 11137.01 1911.75 10361.43 1705.94 
ips_RSPd6b 10267.53 1909.86 9435.11 1543.58 
ips_RSPv 11896.26 2077.10 11019.75 1716.57 
ips_RSPv1 12289.69 2663.38 11263.10 1736.27 
ips_RSPv2 12131.73 2370.45 11214.18 1683.99 
ips_RSPv3 12234.94 2059.88 11169.51 1710.46 
ips_RSPv5 11504.66 1825.34 10746.86 1730.47 
ips_RSPv6a 11067.18 1869.36 10213.88 1691.82 
ips_RSPv6b 10484.15 1821.31 9429.89 1438.31 
ips_SSp-bfd 12163.90 2308.76 11555.18 2391.78 
ips_SSp-bfd1 12219.16 2841.08 11425.14 2406.77 
ips_SSp-bfd3 12296.09 2491.12 11636.09 2457.22 
ips_SSp-bfd4 12763.03 2327.06 12104.27 2315.28 
ips_SSp-bfd5 12098.95 2095.26 11605.94 2311.28 
ips_SSp-bfd6a 11816.57 2145.53 11349.09 2430.43 
ips_SSp-bfd6b 10758.93 1922.61 10390.41 2259.80 
ips_SSp-tr 11247.08 2025.07 10714.87 2182.15 
ips_SSp-tr1 10964.73 2251.78 10213.45 2278.84 
ips_SSp-tr3 11159.18 2097.72 10740.09 2341.76 
ips_SSp-tr4 11716.01 2106.72 10971.17 1988.58 
ips_SSp-tr5 11511.74 2012.12 11000.25 2198.33 
ips_SSp-tr6a 11113.49 2185.57 10631.03 2133.88 
ips_SSp-tr6b 10247.01 2081.57 9815.54 1984.66 
ips_TEa 14024.67 2250.32 13133.55 2762.58 
ips_TEa1 13998.52 2510.46 13101.88 2893.01 
ips_TEa3 14397.28 2464.58 13346.95 2709.27 
ips_TEa4 14584.79 2297.36 13503.71 2723.93 
ips_TEa5 13760.44 2189.24 13074.28 2787.52 
ips_TEa6a 13317.39 2094.77 12819.68 2873.99 
ips_TEa6b 11901.11 1991.17 11414.49 2595.00 
ips_th 13549.35 2342.16 12530.27 2141.95 
 
Table 4: SAP102 puncta density at 28 days 
 
  Injury   Sham   
region Average SD Average SD 
contra_amgmed 237.80 37.99 270.40 45.36 
contra_AUDd 364.30 45.42 384.75 40.31 
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contra_AUDd1 423.55 57.33 450.95 39.29 
contra_AUDd3 385.15 53.11 408.05 49.25 
contra_AUDd4 371.30 48.82 388.60 46.78 
contra_AUDd5 337.75 42.19 354.35 45.89 
contra_AUDd6a 341.00 39.05 357.15 36.59 
contra_AUDd6b 218.05 57.48 229.30 62.77 
contra_AUDp 369.85 45.05 397.40 37.68 
contra_AUDp1 430.90 51.07 462.15 38.07 
contra_AUDp3 393.95 52.10 424.95 41.54 
contra_AUDp4 375.55 41.61 394.70 37.46 
contra_AUDp5 347.55 43.41 377.95 40.14 
contra_AUDp6a 348.90 41.55 369.30 34.37 
contra_AUDp6b 211.85 63.88 251.40 60.58 
contra_AUDv 384.60 51.15 410.45 40.44 
contra_AUDv1 439.20 61.57 465.90 51.50 
contra_AUDv3 413.55 57.75 438.40 47.00 
contra_AUDv4 392.55 52.64 415.80 42.78 
contra_AUDv5 368.75 51.08 393.00 44.48 
contra_AUDv6a 348.40 46.99 378.55 34.40 
contra_AUDv6b 219.50 53.45 240.50 52.53 
contra_BLAa 398.20 47.36 428.20 40.63 
contra_BLAp 420.75 51.85 441.90 55.36 
contra_BLAv 328.95 74.49 383.56 55.23 
contra_BMAp 291.75 58.64 346.44 61.59 
contra_CA1slm 370.95 40.84 395.75 68.88 
contra_CA1so 526.10 39.72 552.40 50.17 
contra_CA1sp 182.70 24.75 191.00 36.63 
contra_CA1sr 578.75 47.55 597.15 54.13 
contra_CA2slm 512.15 37.46 532.40 37.50 
contra_CA2so 488.00 33.31 498.50 17.94 
contra_CA2sp 103.80 23.27 115.45 34.27 
contra_CA2sr 454.50 34.39 468.50 19.07 
contra_CA3slm 529.45 41.92 554.45 47.94 
contra_CA3slu 186.35 32.87 207.25 36.50 
contra_CA3so 434.35 37.87 455.60 36.30 
contra_CA3sp 91.35 19.39 118.20 22.10 
contra_CA3sr 520.70 46.61 541.10 37.48 
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contra_CC 14.30 6.38 25.20 10.03 
contra_cing 67.70 13.03 83.80 23.26 
contra_COApl 291.35 64.05 358.83 84.38 
contra_COApl1 317.56 74.73 365.72 60.48 
contra_COApl2 293.65 70.96 370.28 86.83 
contra_COApl3 281.95 58.61 351.17 90.80 
contra_cortex 347.20 39.34 365.70 38.18 
contra_CP 302.65 49.48 325.90 42.45 
contra_cpd 23.35 15.44 38.00 20.14 
contra_DG 657.15 33.86 670.50 42.26 
contra_DGinf 650.40 39.06 666.85 39.51 
contra_DGpo 181.40 17.91 201.00 14.51 
contra_DGsg 119.55 14.83 137.90 30.39 
contra_DGsup 663.05 31.27 673.45 43.93 
contra_ECT 409.50 57.26 426.35 40.76 
contra_ECT1 461.60 78.45 472.85 47.18 
contra_ECT3 427.35 62.47 438.65 49.67 
contra_ECT5 394.85 55.27 414.35 36.94 
contra_ECT6a 365.80 46.15 397.00 39.17 
contra_ECT6b 238.39 41.23 258.95 58.67 
contra_ENTI 428.45 53.18 439.00 37.06 
contra_ENTl1 508.65 77.27 491.95 58.72 
contra_ENTl3 452.95 47.03 455.75 39.25 
contra_ENTl5 413.25 55.19 430.20 33.05 
contra_ENTl6a 379.45 67.63 397.45 53.73 
contra_ENTl6b 292.85 54.36 299.45 51.86 
contra_FC 313.70 32.69 323.15 37.90 
contra_hip 495.90 39.49 515.05 39.48 
contra_hyp 108.40 19.69 121.40 17.27 
contra_LA 388.60 58.33 415.45 45.01 
contra_lay1 415.45 47.80 434.60 37.17 
contra_lay2 237.95 29.99 250.50 41.94 
contra_lay3 369.30 44.82 388.10 42.49 
contra_lay4 355.25 42.66 371.80 41.95 
contra_lay5 321.80 37.17 341.50 38.91 
contra_lay6a 318.95 33.96 338.70 38.88 
contra_lay6b 209.45 29.25 231.05 28.25 
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contra_MOp 350.10 47.73 361.10 52.05 
contra_MOp1 427.75 66.61 435.95 67.32 
contra_MOp3 373.70 56.75 389.05 63.83 
contra_MOp5 336.65 44.04 347.55 54.93 
contra_MOp6a 313.55 35.29 318.30 44.49 
contra_MOp6b 210.25 42.36 236.35 42.21 
contra_MOs 285.10 47.36 292.35 48.86 
contra_MOs1 381.95 56.67 400.90 63.66 
contra_MOs3 304.10 49.98 321.30 58.97 
contra_MOs5 258.15 41.49 257.55 44.90 
contra_MOs6a 248.85 35.07 249.75 41.49 
contra_MOs6b 199.75 33.96 188.85 37.09 
contra_PAA 335.40 74.60 383.00 68.04 
contra_PAA1 340.60 74.11 376.00 82.76 
contra_PAA2 340.90 88.63 393.22 67.46 
contra_PAA3 330.45 69.70 377.17 66.22 
contra_PERI 422.80 54.31 429.65 37.49 
contra_PERI1 476.80 81.60 463.00 50.65 
contra_PERI3 436.85 55.54 434.75 44.34 
contra_PERI5 413.40 48.68 418.65 41.09 
contra_PERI6a 381.10 58.64 410.60 39.34 
contra_PERI6b 225.90 37.88 287.80 56.60 
contra_PIR 411.85 51.45 434.60 44.41 
contra_PIR1 463.60 60.07 480.90 52.59 
contra_PIR2 389.25 48.66 400.80 45.94 
contra_PIR3 398.60 51.31 426.30 45.32 
contra_RSPd 255.80 37.37 272.90 48.11 
contra_RSPd1 353.80 52.91 371.65 66.69 
contra_RSPd3 276.30 40.76 301.70 56.55 
contra_RSPd5 213.50 34.39 225.80 43.93 
contra_RSPd6a 225.65 30.57 237.35 40.26 
contra_RSPd6b 185.70 42.44 197.15 40.47 
contra_RSPv 253.35 29.01 264.50 38.92 
contra_RSPv1 292.10 31.92 299.35 49.33 
contra_RSPv2 238.00 29.67 250.90 42.53 
contra_RSPv3 275.70 28.46 287.30 37.82 
contra_RSPv5 223.80 30.85 243.70 43.76 
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contra_RSPv6a 209.50 28.31 220.15 35.44 
contra_RSPv6b 176.95 53.65 201.05 48.13 
contra_SSp-bfd 334.10 40.72 345.95 44.61 
contra_SSp-
bfd1 427.65 58.14 427.15 49.76 
contra_SSp-
bfd3 352.80 47.67 365.60 48.02 
contra_SSp-
bfd4 343.80 44.23 355.00 43.42 
contra_SSp-
bfd5 303.85 35.14 317.20 43.46 
contra_SSp-
bfd6a 316.45 35.69 328.80 43.09 
contra_SSp-
bfd6b 203.50 37.53 217.05 38.65 
contra_SSP-tr 343.15 41.68 357.80 47.58 
contra_SSp-tr1 429.20 59.54 441.55 46.47 
contra_SSp-tr3 371.80 47.42 389.45 53.81 
contra_SSp-tr4 339.60 41.65 355.90 52.71 
contra_SSp-tr5 309.85 38.01 329.25 45.36 
contra_SSp-
tr6a 311.45 34.89 325.90 42.38 
contra_SSp-
tr6b 193.70 31.22 224.50 29.20 
contra_TEa 401.00 55.91 418.95 44.63 
contra_TEa1 453.20 80.18 480.20 62.80 
contra_TEa3 426.15 65.89 437.45 53.30 
contra_TEa4 411.35 58.93 430.70 53.06 
contra_TEa5 390.15 57.62 408.20 46.75 
contra_TEa6a 354.20 48.82 386.20 39.91 
contra_TEa6b 235.05 46.86 265.45 45.11 
contra_th 289.45 17.95 295.20 7.28 
ips_amgmed 230.50 35.78 240.30 37.11 
ips_AUDd 354.30 49.96 376.45 46.41 
ips_AUDd1 408.50 66.72 446.10 57.20 
ips_AUDd3 367.40 53.08 403.05 49.65 
ips_AUDd4 364.35 46.41 378.20 48.27 
ips_AUDd5 331.85 47.25 344.60 40.69 
ips_AUDd6a 338.25 49.68 343.95 44.08 
ips_AUDd6b 217.65 49.66 239.85 33.59 
ips_AUDp 368.40 53.15 381.25 47.28 
ips_AUDp1 432.45 64.54 443.45 61.22 
 Page | 237 
ips_AUDp3 386.70 55.92 409.05 54.47 
ips_AUDp4 375.40 52.02 389.35 52.40 
ips_AUDp5 341.35 53.86 358.35 50.15 
ips_AUDp6a 337.20 53.69 346.15 39.56 
ips_AUDp6b 192.45 49.72 217.45 23.07 
ips_AUDv 377.10 62.08 391.45 47.48 
ips_AUDv1 433.60 85.14 449.90 54.59 
ips_AUDv3 396.85 67.56 414.40 52.22 
ips_AUDv4 380.05 50.76 396.05 49.11 
ips_AUDv5 363.20 58.55 374.60 54.53 
ips_AUDv6a 329.75 50.83 345.15 38.69 
ips_AUDv6b 208.65 37.73 224.90 31.58 
ips_BLAa 405.60 44.39 409.55 36.46 
ips_BLAp 420.30 48.31 434.25 40.55 
ips_BLAv 324.55 67.90 355.75 54.14 
ips_BMAp 288.35 59.98 321.45 47.03 
ips_CA1slm 367.55 46.09 384.65 75.87 
ips_CA1so 537.20 53.30 548.05 45.64 
ips_CA1sp 179.80 25.10 180.20 45.03 
ips_CA1sr 585.30 51.71 592.70 53.75 
ips_CA2slm 524.85 40.34 526.80 31.14 
ips_CA2so 507.25 32.74 502.65 17.18 
ips_CA2sp 112.35 29.47 104.45 21.60 
ips_CA2sr 462.65 29.26 468.25 22.24 
ips_CA3slm 531.85 48.34 548.25 39.51 
ips_CA3slu 185.75 34.12 200.65 36.81 
ips_CA3so 440.00 44.46 456.30 26.57 
ips_CA3sp 92.10 19.83 103.70 25.84 
ips_CA3sr 512.95 40.35 534.90 40.99 
ips_CC 14.20 6.16 20.70 11.36 
ips_cing 69.65 17.14 71.55 26.13 
ips_COApl 289.20 57.91 319.55 65.14 
ips_COApl1 303.35 53.23 329.95 63.30 
ips_COApl2 288.40 55.17 325.60 72.02 
ips_COApl3 280.60 60.09 315.40 63.62 
ips_cortex 336.30 44.38 354.50 42.18 
ips_CP 285.00 48.91 305.55 49.82 
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ips_cpd 20.10 17.37 30.60 18.08 
ips_DG 658.85 36.55 663.90 35.86 
ips_DGinf 646.70 39.38 657.85 30.51 
ips_DGpo 179.50 17.48 196.80 15.68 
ips_DGsg 117.15 18.32 128.00 27.69 
ips_DGsup 667.35 34.88 668.55 40.26 
ips_ECT 391.20 47.76 416.85 42.25 
ips_ECT1 419.00 57.24 472.75 45.82 
ips_ECT3 398.80 50.21 424.05 44.88 
ips_ECT5 386.75 42.87 407.20 44.08 
ips_ECT6a 352.10 49.92 381.10 44.58 
ips_ECT6b 246.95 49.76 250.60 42.60 
ips_ENTI 410.30 45.71 417.05 29.64 
ips_ENTl1 452.50 63.21 473.95 37.15 
ips_ENTl3 422.70 50.79 424.35 30.05 
ips_ENTl5 406.50 41.30 413.60 27.40 
ips_ENTl6a 357.70 50.10 383.55 38.93 
ips_ENTl6b 253.10 69.87 280.00 36.73 
ips_FC 300.55 43.13 307.10 50.04 
ips_hip 502.60 42.22 511.30 36.30 
ips_hyp 107.50 20.13 118.90 16.96 
ips_LA 378.25 43.86 396.15 55.09 
ips_lay1 401.35 49.21 428.50 36.69 
ips_lay2 230.00 29.79 242.60 41.24 
ips_lay3 352.60 48.87 377.50 43.45 
ips_lay4 347.80 48.57 363.20 48.53 
ips_lay5 316.80 42.40 331.50 40.01 
ips_lay6a 308.55 37.44 321.60 42.41 
ips_lay6b 207.10 26.98 215.40 29.73 
ips_MOp 339.85 44.79 335.50 39.18 
ips_MOp1 407.75 59.57 413.05 48.26 
ips_MOp3 354.45 47.23 352.85 42.19 
ips_MOp5 332.85 45.41 326.80 38.49 
ips_MOp6a 307.75 40.48 294.20 43.63 
ips_MOp6b 207.35 36.64 192.35 43.01 
ips_MOs 276.95 45.45 270.60 41.92 
ips_MOs1 371.65 64.08 365.60 49.57 
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ips_MOs3 302.35 54.58 303.80 49.26 
ips_MOs5 253.25 37.81 246.25 39.96 
ips_MOs6a 243.00 41.73 229.70 42.57 
ips_MOs6b 202.65 31.56 186.10 48.64 
ips_PAA 325.20 68.50 344.35 56.87 
ips_PAA1 329.25 74.73 351.20 73.20 
ips_PAA2 329.65 69.61 345.90 49.41 
ips_PAA3 316.25 66.66 340.80 52.21 
ips_PERI 399.95 47.14 427.45 39.30 
ips_PERI1 427.40 68.85 486.00 66.28 
ips_PERI3 411.80 49.13 437.30 46.48 
ips_PERI5 398.65 41.26 416.90 35.20 
ips_PERI6a 362.35 42.80 384.35 37.05 
ips_PERI6b 235.05 52.08 256.25 48.93 
ips_PIR 383.00 38.65 408.30 30.44 
ips_PIR1 429.10 41.44 456.55 40.86 
ips_PIR2 356.00 37.16 370.00 33.60 
ips_PIR3 376.20 39.88 401.40 29.74 
ips_RSPd 251.55 36.59 265.90 48.10 
ips_RSPd1 347.95 45.41 364.70 52.01 
ips_RSPd3 275.05 40.32 293.30 50.42 
ips_RSPd5 211.25 32.76 226.25 42.93 
ips_RSPd6a 223.85 32.10 226.05 42.37 
ips_RSPd6b 193.00 37.98 200.30 46.29 
ips_RSPv 247.55 29.93 256.75 38.89 
ips_RSPv1 287.25 29.14 288.95 36.89 
ips_RSPv2 230.15 29.68 242.75 41.42 
ips_RSPv3 271.75 32.03 283.80 43.17 
ips_RSPv5 221.30 37.78 234.60 41.56 
ips_RSPv6a 204.15 28.86 210.95 42.44 
ips_RSPv6b 195.00 37.38 197.70 60.62 
ips_SSp-bfd 331.70 50.48 352.55 46.51 
ips_SSp-bfd1 398.25 52.80 440.95 48.23 
ips_SSp-bfd3 343.60 55.70 378.55 49.79 
ips_SSp-bfd4 344.30 50.86 358.35 53.62 
ips_SSp-bfd5 307.70 49.53 324.80 41.46 
ips_SSp-bfd6a 315.75 44.78 327.90 44.00 
 Page | 240 
ips_SSp-bfd6b 208.95 28.68 233.55 35.88 
ips_SSp-tr 324.70 41.68 344.90 44.70 
ips_SSp-tr1 407.45 45.15 436.35 28.88 
ips_SSp-tr3 342.90 49.38 369.00 47.42 
ips_SSp-tr4 327.55 46.86 345.25 47.87 
ips_SSp-tr5 302.25 39.04 320.20 42.50 
ips_SSp-tr6a 300.70 37.72 311.30 42.67 
ips_SSp-tr6b 188.15 35.30 185.05 49.30 
ips_TEa 384.20 60.17 400.95 42.84 
ips_TEa1 427.20 79.35 461.25 40.87 
ips_TEa3 400.35 67.83 420.65 49.43 
ips_TEa4 382.85 53.31 406.90 44.90 
ips_TEa5 376.35 56.74 390.10 44.72 
ips_TEa6a 336.95 48.60 358.65 41.76 
ips_TEa6b 228.90 29.37 235.15 32.41 
ips_th 287.70 19.15 289.60 7.66 
 
Table 5: SAP102 puncta size at 28 days 
 
  Injury   Sham   
region Average SD Average SD 
contra_amgmed 14.67 0.22 14.64 0.19 
contra_AUDd 14.40 0.24 14.45 0.34 
contra_AUDd1 14.22 0.33 13.99 0.37 
contra_AUDd3 14.76 0.24 14.81 0.45 
contra_AUDd4 13.92 0.29 13.99 0.31 
contra_AUDd5 14.24 0.26 14.30 0.33 
contra_AUDd6a 14.22 0.22 14.38 0.31 
contra_AUDd6b 14.32 0.27 14.60 0.37 
contra_AUDp 14.34 0.25 14.36 0.32 
contra_AUDp1 14.12 0.40 13.96 0.40 
contra_AUDp3 14.71 0.25 14.72 0.39 
contra_AUDp4 13.96 0.34 14.06 0.28 
contra_AUDp5 14.17 0.26 14.15 0.32 
contra_AUDp6a 14.19 0.22 14.28 0.23 
contra_AUDp6b 14.30 0.24 14.33 0.25 
contra_AUDv 14.22 0.30 14.26 0.35 
contra_AUDv1 14.05 0.45 13.98 0.43 
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contra_AUDv3 14.50 0.34 14.60 0.40 
contra_AUDv4 13.86 0.36 13.90 0.32 
contra_AUDv5 14.08 0.32 14.04 0.43 
contra_AUDv6a 14.20 0.18 14.18 0.23 
contra_AUDv6b 14.23 0.24 14.35 0.19 
contra_BLAa 13.79 0.49 13.67 0.31 
contra_BLAp 13.80 0.47 13.67 0.26 
contra_BLAv 13.96 0.36 13.78 0.32 
contra_BMAp 14.11 0.36 14.09 0.39 
contra_CA1slm 14.47 0.25 14.58 0.48 
contra_CA1so 13.22 0.25 13.28 0.43 
contra_CA1sp 15.83 0.63 16.54 0.56 
contra_CA1sr 13.62 0.23 13.77 0.48 
contra_CA2slm 13.00 0.23 12.98 0.53 
contra_CA2so 12.94 0.20 12.92 0.24 
contra_CA2sp 18.27 1.38 18.61 1.25 
contra_CA2sr 13.30 0.20 13.39 0.38 
contra_CA3slm 13.24 0.25 13.19 0.58 
contra_CA3slu 19.83 0.71 19.74 0.86 
contra_CA3so 13.31 0.29 13.20 0.52 
contra_CA3sp 20.41 0.98 19.95 0.65 
contra_CA3sr 13.53 0.30 13.46 0.53 
contra_CC 15.62 0.92 16.25 0.91 
contra_cing 14.89 0.63 15.31 0.55 
contra_COApl 14.33 0.28 14.12 0.51 
contra_COApl1 13.92 0.43 13.71 0.50 
contra_COApl2 14.47 0.30 14.17 0.60 
contra_COApl3 14.42 0.30 14.32 0.55 
contra_cortex 14.28 0.17 14.40 0.28 
contra_CP 14.24 0.26 14.30 0.29 
contra_cpd 16.88 1.28 17.64 1.28 
contra_DG 13.69 0.27 13.83 0.56 
contra_DGinf 13.80 0.26 13.79 0.54 
contra_DGpo 17.69 0.44 17.65 0.58 
contra_DGsg 20.38 0.80 20.45 0.59 
contra_DGsup 13.62 0.26 13.88 0.61 
contra_ECT 14.05 0.40 14.04 0.34 
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contra_ECT1 13.93 0.51 13.85 0.45 
contra_ECT3 14.12 0.42 14.19 0.37 
contra_ECT5 13.92 0.42 13.92 0.32 
contra_ECT6a 14.11 0.37 13.97 0.28 
contra_ECT6b 14.19 0.33 14.26 0.25 
contra_ENTI 13.78 0.33 13.73 0.33 
contra_ENTl1 13.52 0.47 13.55 0.48 
contra_ENTl3 13.84 0.35 13.80 0.33 
contra_ENTl5 13.78 0.33 13.64 0.31 
contra_ENTl6a 13.76 0.37 13.79 0.37 
contra_ENTl6b 14.05 0.39 14.13 0.37 
contra_FC 13.56 0.28 13.59 0.35 
contra_hip 13.76 0.19 13.86 0.47 
contra_hyp 15.73 0.42 15.98 0.38 
contra_LA 13.83 0.41 13.72 0.33 
contra_lay1 14.06 0.22 14.04 0.35 
contra_lay2 14.87 0.39 15.09 0.28 
contra_lay3 14.58 0.17 14.71 0.34 
contra_lay4 13.96 0.23 14.11 0.27 
contra_lay5 14.15 0.19 14.26 0.26 
contra_lay6a 14.16 0.18 14.30 0.26 
contra_lay6b 14.24 0.23 14.42 0.20 
contra_MOp 14.05 0.26 14.28 0.34 
contra_MOp1 13.85 0.35 13.95 0.43 
contra_MOp3 14.27 0.29 14.48 0.40 
contra_MOp5 13.90 0.23 14.13 0.31 
contra_MOp6a 13.94 0.25 14.27 0.31 
contra_MOp6b 14.19 0.31 14.41 0.27 
contra_MOs 14.41 0.27 14.68 0.21 
contra_MOs1 14.27 0.25 14.39 0.33 
contra_MOs3 14.65 0.30 14.85 0.25 
contra_MOs5 14.26 0.30 14.60 0.20 
contra_MOs6a 14.22 0.33 14.64 0.32 
contra_MOs6b 14.26 0.32 14.55 0.35 
contra_PAA 13.99 0.38 13.87 0.41 
contra_PAA1 13.63 0.50 13.53 0.44 
contra_PAA2 14.19 0.40 13.98 0.38 
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contra_PAA3 14.12 0.36 14.01 0.43 
contra_PERI 13.87 0.41 13.89 0.34 
contra_PERI1 13.78 0.56 13.80 0.48 
contra_PERI3 13.93 0.43 14.02 0.35 
contra_PERI5 13.79 0.38 13.81 0.34 
contra_PERI6a 13.84 0.37 13.77 0.28 
contra_PERI6b 14.10 0.28 14.12 0.27 
contra_PIR 13.77 0.35 13.66 0.26 
contra_PIR1 13.36 0.56 13.19 0.35 
contra_PIR2 14.33 0.24 14.31 0.28 
contra_PIR3 13.77 0.33 13.68 0.25 
contra_RSPd 14.59 0.31 14.76 0.19 
contra_RSPd1 14.41 0.25 14.52 0.30 
contra_RSPd3 14.70 0.32 14.78 0.22 
contra_RSPd5 14.67 0.39 14.96 0.27 
contra_RSPd6a 14.43 0.36 14.73 0.33 
contra_RSPd6b 14.42 0.43 14.67 0.46 
contra_RSPv 14.52 0.30 14.74 0.17 
contra_RSPv1 14.51 0.25 14.65 0.24 
contra_RSPv2 14.86 0.38 15.09 0.28 
contra_RSPv3 14.17 0.27 14.35 0.19 
contra_RSPv5 14.64 0.38 14.78 0.21 
contra_RSPv6a 14.63 0.44 14.89 0.28 
contra_RSPv6b 14.51 0.72 14.64 0.44 
contra_SSp-bfd 14.44 0.22 14.66 0.35 
contra_SSp-
bfd1 14.07 0.34 14.08 0.36 
contra_SSp-
bfd3 14.80 0.23 15.03 0.42 
contra_SSp-
bfd4 13.96 0.18 14.19 0.25 
contra_SSp-
bfd5 14.32 0.22 14.54 0.32 
contra_SSp-
bfd6a 14.25 0.23 14.48 0.33 
contra_SSp-
bfd6b 14.36 0.26 14.60 0.30 
contra_SSP-tr 14.23 0.20 14.41 0.30 
contra_SSp-tr1 13.94 0.23 13.94 0.45 
contra_SSp-tr3 14.60 0.26 14.77 0.37 
contra_SSp-tr4 14.01 0.25 14.26 0.30 
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contra_SSp-tr5 14.05 0.23 14.23 0.24 
contra_SSp-
tr6a 14.08 0.21 14.32 0.29 
contra_SSp-
tr6b 14.27 0.29 14.45 0.27 
contra_TEa 14.13 0.37 14.12 0.32 
contra_TEa1 13.87 0.49 13.93 0.47 
contra_TEa3 14.36 0.42 14.49 0.35 
contra_TEa4 13.85 0.44 13.82 0.34 
contra_TEa5 13.99 0.36 13.94 0.39 
contra_TEa6a 14.24 0.28 14.07 0.28 
contra_TEa6b 14.18 0.25 14.19 0.17 
contra_th 13.14 0.20 13.19 0.23 
ips_amgmed 14.59 0.18 14.79 0.17 
ips_AUDd 14.28 0.23 14.35 0.24 
ips_AUDd1 14.02 0.38 13.98 0.29 
ips_AUDd3 14.57 0.31 14.62 0.30 
ips_AUDd4 13.82 0.19 13.98 0.24 
ips_AUDd5 14.18 0.23 14.28 0.25 
ips_AUDd6a 14.12 0.23 14.28 0.25 
ips_AUDd6b 14.32 0.29 14.41 0.17 
ips_AUDp 14.23 0.24 14.27 0.25 
ips_AUDp1 14.01 0.24 13.96 0.35 
ips_AUDp3 14.46 0.26 14.49 0.34 
ips_AUDp4 13.87 0.20 13.96 0.25 
ips_AUDp5 14.17 0.26 14.24 0.23 
ips_AUDp6a 14.11 0.24 14.22 0.27 
ips_AUDp6b 14.42 0.45 14.40 0.12 
ips_AUDv 14.16 0.24 14.20 0.30 
ips_AUDv1 14.02 0.37 13.88 0.37 
ips_AUDv3 14.36 0.31 14.38 0.38 
ips_AUDv4 13.93 0.24 13.95 0.22 
ips_AUDv5 14.07 0.26 14.21 0.36 
ips_AUDv6a 14.15 0.27 14.23 0.23 
ips_AUDv6b 14.28 0.43 14.41 0.18 
ips_BLAa 13.71 0.26 13.77 0.29 
ips_BLAp 13.81 0.25 13.78 0.29 
ips_BLAv 14.01 0.25 13.93 0.25 
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ips_BMAp 14.19 0.26 14.06 0.33 
ips_CA1slm 14.47 0.28 14.47 0.44 
ips_CA1so 13.21 0.28 13.26 0.34 
ips_CA1sp 15.86 0.61 16.48 0.75 
ips_CA1sr 13.59 0.30 13.66 0.45 
ips_CA2slm 12.98 0.20 13.00 0.26 
ips_CA2so 12.84 0.14 12.90 0.13 
ips_CA2sp 17.43 0.58 18.66 0.90 
ips_CA2sr 13.22 0.18 13.33 0.20 
ips_CA3slm 13.25 0.26 13.24 0.40 
ips_CA3slu 19.62 0.63 19.63 0.73 
ips_CA3so 13.25 0.20 13.23 0.30 
ips_CA3sp 20.18 0.66 20.24 0.69 
ips_CA3sr 13.48 0.20 13.50 0.32 
ips_CC 15.70 0.98 16.05 0.89 
ips_cing 14.83 0.59 15.37 0.53 
ips_COApl 14.33 0.25 14.21 0.35 
ips_COApl1 13.89 0.30 13.86 0.30 
ips_COApl2 14.54 0.25 14.33 0.45 
ips_COApl3 14.49 0.29 14.33 0.36 
ips_cortex 14.26 0.24 14.33 0.17 
ips_CP 14.17 0.24 14.20 0.24 
ips_cpd 16.56 1.48 17.50 1.38 
ips_DG 13.72 0.36 13.72 0.53 
ips_DGinf 13.81 0.35 13.73 0.52 
ips_DGpo 17.64 0.43 17.63 0.46 
ips_DGsg 20.61 0.86 20.35 0.77 
ips_DGsup 13.66 0.37 13.73 0.58 
ips_ECT 14.03 0.25 13.99 0.26 
ips_ECT1 13.99 0.35 13.70 0.30 
ips_ECT3 14.10 0.23 14.09 0.30 
ips_ECT5 13.91 0.28 13.89 0.27 
ips_ECT6a 14.01 0.28 14.02 0.28 
ips_ECT6b 14.18 0.47 14.30 0.21 
ips_ENTI 13.80 0.21 13.79 0.22 
ips_ENTl1 13.61 0.27 13.46 0.34 
ips_ENTl3 13.87 0.22 13.89 0.26 
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ips_ENTl5 13.77 0.26 13.72 0.18 
ips_ENTl6a 13.80 0.26 13.86 0.26 
ips_ENTl6b 13.99 0.27 14.11 0.28 
ips_FC 13.68 0.30 13.58 0.31 
ips_hip 13.75 0.28 13.78 0.41 
ips_hyp 15.71 0.43 15.97 0.37 
ips_LA 13.83 0.22 13.85 0.31 
ips_lay1 14.08 0.26 14.03 0.20 
ips_lay2 14.98 0.44 15.19 0.32 
ips_lay3 14.51 0.28 14.57 0.23 
ips_lay4 13.92 0.20 14.03 0.17 
ips_lay5 14.12 0.23 14.22 0.16 
ips_lay6a 14.11 0.24 14.25 0.17 
ips_lay6b 14.24 0.33 14.41 0.14 
ips_MOp 14.13 0.33 14.30 0.22 
ips_MOp1 14.08 0.43 14.11 0.25 
ips_MOp3 14.38 0.35 14.57 0.33 
ips_MOp5 13.93 0.29 14.10 0.22 
ips_MOp6a 13.95 0.30 14.18 0.19 
ips_MOp6b 14.16 0.36 14.45 0.29 
ips_MOs 14.49 0.38 14.66 0.22 
ips_MOs1 14.50 0.37 14.46 0.28 
ips_MOs3 14.71 0.38 14.80 0.24 
ips_MOs5 14.31 0.39 14.64 0.24 
ips_MOs6a 14.27 0.39 14.59 0.26 
ips_MOs6b 14.24 0.38 14.72 0.27 
ips_PAA 14.12 0.25 14.09 0.28 
ips_PAA1 13.69 0.34 13.65 0.35 
ips_PAA2 14.37 0.25 14.32 0.24 
ips_PAA3 14.29 0.23 14.23 0.29 
ips_PERI 13.89 0.27 13.86 0.25 
ips_PERI1 13.83 0.40 13.58 0.40 
ips_PERI3 13.95 0.25 13.97 0.34 
ips_PERI5 13.83 0.28 13.80 0.19 
ips_PERI6a 13.85 0.26 13.83 0.16 
ips_PERI6b 14.10 0.35 14.22 0.22 
ips_PIR 13.88 0.18 13.80 0.22 
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ips_PIR1 13.46 0.23 13.33 0.29 
ips_PIR2 14.36 0.30 14.42 0.28 
ips_PIR3 13.89 0.18 13.82 0.19 
ips_RSPd 14.61 0.33 14.72 0.17 
ips_RSPd1 14.42 0.27 14.39 0.26 
ips_RSPd3 14.71 0.32 14.80 0.21 
ips_RSPd5 14.70 0.35 14.84 0.23 
ips_RSPd6a 14.48 0.42 14.70 0.34 
ips_RSPd6b 14.35 0.45 14.71 0.25 
ips_RSPv 14.58 0.33 14.75 0.22 
ips_RSPv1 14.52 0.27 14.66 0.25 
ips_RSPv2 14.97 0.44 15.18 0.32 
ips_RSPv3 14.24 0.30 14.34 0.22 
ips_RSPv5 14.65 0.47 14.86 0.29 
ips_RSPv6a 14.67 0.36 14.89 0.29 
ips_RSPv6b 14.35 0.34 14.76 0.49 
ips_SSp-bfd 14.34 0.27 14.43 0.23 
ips_SSp-bfd1 14.05 0.30 13.97 0.29 
ips_SSp-bfd3 14.64 0.32 14.72 0.33 
ips_SSp-bfd4 13.90 0.22 14.06 0.27 
ips_SSp-bfd5 14.28 0.30 14.37 0.24 
ips_SSp-bfd6a 14.17 0.25 14.33 0.22 
ips_SSp-bfd6b 14.31 0.34 14.35 0.17 
ips_SSp-tr 14.27 0.27 14.35 0.17 
ips_SSp-tr1 14.05 0.28 14.04 0.17 
ips_SSp-tr3 14.66 0.30 14.70 0.27 
ips_SSp-tr4 13.98 0.24 14.10 0.18 
ips_SSp-tr5 14.05 0.25 14.15 0.17 
ips_SSp-tr6a 14.06 0.24 14.21 0.16 
ips_SSp-tr6b 14.23 0.37 14.48 0.26 
ips_TEa 14.13 0.30 14.11 0.28 
ips_TEa1 14.01 0.51 13.82 0.25 
ips_TEa3 14.35 0.39 14.27 0.36 
ips_TEa4 13.90 0.21 13.90 0.20 
ips_TEa5 14.02 0.30 14.08 0.39 
ips_TEa6a 14.13 0.28 14.16 0.25 
ips_TEa6b 14.21 0.44 14.41 0.23 
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ips_th 13.14 0.21 13.19 0.17 
 
Table 6: SAP102 puncta intensity at 28 days 
 
  Injury   Sham   
region Average SD Average SD 
contra_amgmed 11801.18 2257.54 13485.10 2669.58 
contra_AUDd 12048.69 1863.23 13139.68 1838.90 
contra_AUDd1 11571.48 1942.98 12780.61 1940.43 
contra_AUDd3 12208.38 1941.69 13444.63 2002.76 
contra_AUDd4 12193.08 1883.42 13275.66 1952.62 
contra_AUDd5 11981.11 1851.47 13021.45 1816.29 
contra_AUDd6a 12194.67 1822.28 12945.07 1737.57 
contra_AUDd6b 10595.57 1767.22 11235.07 1256.96 
contra_AUDp 12273.37 1926.37 13509.97 1970.32 
contra_AUDp1 11875.85 1953.48 13282.52 2008.52 
contra_AUDp3 12592.44 2045.97 13969.25 1993.31 
contra_AUDp4 12263.06 1868.48 13512.51 1987.54 
contra_AUDp5 12164.10 1879.12 13393.65 1997.07 
contra_AUDp6a 12318.67 1892.90 13283.63 1939.00 
contra_AUDp6b 10548.58 1926.23 11618.98 1787.86 
contra_AUDv 12550.00 2061.49 13586.85 2065.30 
contra_AUDv1 12186.53 2240.57 13272.68 2126.02 
contra_AUDv3 12931.46 2149.98 13912.81 2128.29 
contra_AUDv4 12590.68 2097.26 13601.77 2139.67 
contra_AUDv5 12466.74 1974.51 13607.02 2095.73 
contra_AUDv6a 12444.42 2042.21 13560.46 2150.35 
contra_AUDv6b 10711.03 2002.56 11749.72 1929.43 
contra_BLAa 14109.76 2680.33 16003.06 3287.81 
contra_BLAp 14578.82 2971.45 16231.93 3524.91 
contra_BLAv 13219.45 3240.98 15655.88 2955.31 
contra_BMAp 12893.13 2900.65 15390.03 3043.74 
contra_CA1slm 12730.88 1169.10 13302.22 1959.62 
contra_CA1so 13495.87 1351.44 14141.64 1665.69 
contra_CA1sp 12481.69 1136.63 12945.69 1398.68 
contra_CA1sr 14648.48 1291.15 15164.49 1880.02 
contra_CA2slm 13934.32 1381.78 14895.93 2036.75 
contra_CA2so 16154.28 1815.46 17012.05 2368.54 
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contra_CA2sp 12944.95 1074.70 13227.39 1332.66 
contra_CA2sr 14690.13 1395.76 15789.29 2171.88 
contra_CA3slm 13080.54 1170.32 13958.23 1723.87 
contra_CA3slu 11262.71 963.96 11697.16 1485.46 
contra_CA3so 11569.16 933.21 12137.33 1490.97 
contra_CA3sp 10917.84 860.27 11294.25 1243.67 
contra_CA3sr 12939.43 1194.12 13805.41 1641.87 
contra_CC 6912.07 404.47 7000.87 415.10 
contra_cing 8519.63 741.17 8817.68 1079.04 
contra_COApl 12719.00 3187.48 15533.27 3009.57 
contra_COApl1 12674.08 3286.75 14320.49 2422.22 
contra_COApl2 13070.30 3352.36 15731.78 2702.90 
contra_COApl3 12682.05 3068.16 15743.94 3252.84 
contra_cortex 11893.44 1715.45 12774.65 1686.07 
contra_CP 11123.12 1705.92 12092.41 1798.49 
contra_cpd 6829.18 487.70 7005.13 641.45 
contra_DG 18991.84 1650.39 19624.50 2708.69 
contra_DGinf 18815.93 1699.37 19490.36 2787.93 
contra_DGpo 12119.83 846.32 12691.91 1554.26 
contra_DGsg 13947.38 813.64 14374.01 1579.07 
contra_DGsup 19133.62 1650.92 19740.49 2668.46 
contra_ECT 13204.16 2354.14 13951.64 2553.91 
contra_ECT1 13041.76 2661.29 13609.24 3277.31 
contra_ECT3 13462.74 2572.72 14104.22 2630.45 
contra_ECT5 13169.36 2256.95 14177.02 2504.32 
contra_ECT6a 13022.13 2128.10 14017.62 2450.78 
contra_ECT6b 11718.68 1403.63 12438.72 2150.66 
contra_ENTI 14286.94 2958.19 15212.32 2840.44 
contra_ENTl1 13983.60 3407.47 14304.06 3052.19 
contra_ENTl3 14984.82 3404.94 15804.32 2969.39 
contra_ENTl5 14311.37 2770.76 15645.72 2990.55 
contra_ENTl6a 13303.07 2458.04 14424.82 2711.07 
contra_ENTl6b 12214.28 2157.80 13077.82 2235.09 
contra_FC 14352.91 1653.18 16141.66 3122.24 
contra_hip 13830.61 1249.07 14489.97 1775.01 
contra_hyp 10324.96 1638.56 11347.02 1966.93 
contra_LA 13219.39 2511.07 14511.01 2835.91 
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contra_lay1 11865.62 1745.48 12532.86 1639.87 
contra_lay2 11926.28 1552.70 12492.31 1949.82 
contra_lay3 12106.49 1846.93 12986.02 1691.89 
contra_lay4 12078.14 1798.31 12991.34 1758.48 
contra_lay5 11811.84 1654.91 12805.59 1736.80 
contra_lay6a 11833.61 1618.49 12716.20 1726.87 
contra_lay6b 10483.50 1413.79 11291.39 1398.20 
contra_MOp 11918.78 1813.32 12582.82 1991.61 
contra_MOp1 12112.60 2168.21 12758.39 2392.49 
contra_MOp3 12397.35 2071.13 13105.56 2201.82 
contra_MOp5 11718.93 1636.56 12495.51 1908.25 
contra_MOp6a 11613.53 1466.37 12215.42 1739.72 
contra_MOp6b 10449.49 1185.84 11106.18 1632.44 
contra_MOs 11313.53 1670.18 12071.73 1912.87 
contra_MOs1 11804.73 1926.05 12681.76 2329.26 
contra_MOs3 11620.45 1873.14 12574.95 2086.47 
contra_MOs5 11044.39 1512.48 11709.81 1723.39 
contra_MOs6a 10778.00 1285.99 11200.61 1595.36 
contra_MOs6b 10019.32 1051.48 10340.80 1611.52 
contra_PAA 12999.16 3567.72 15718.27 3221.14 
contra_PAA1 12035.65 3398.77 14303.40 2937.71 
contra_PAA2 13438.16 3934.99 16246.73 3480.68 
contra_PAA3 13167.31 3474.70 15958.16 3308.40 
contra_PERI 13559.74 2625.08 14072.07 2599.02 
contra_PERI1 13164.92 2903.60 13102.94 2789.49 
contra_PERI3 13908.18 2960.91 14218.83 2701.82 
contra_PERI5 13735.53 2514.70 14352.81 2714.69 
contra_PERI6a 13175.26 2206.63 14320.21 2546.16 
contra_PERI6b 11606.66 1843.10 13009.83 2400.54 
contra_PIR 14042.40 3277.43 15769.44 3418.41 
contra_PIR1 13568.71 3423.83 15220.54 3406.49 
contra_PIR2 14799.11 3667.69 16586.33 3611.29 
contra_PIR3 13841.96 3069.38 15595.95 3407.50 
contra_RSPd 11355.82 1585.93 12164.84 1836.48 
contra_RSPd1 11998.30 1961.93 12607.33 2117.86 
contra_RSPd3 11660.30 1723.27 12549.22 1982.71 
contra_RSPd5 11000.78 1474.82 11809.88 1763.16 
 Page | 251 
contra_RSPd6a 10821.35 1294.17 11560.84 1679.80 
contra_RSPd6b 9896.74 1151.05 10546.04 1549.79 
contra_RSPv 11607.72 1450.06 12185.89 1859.91 
contra_RSPv1 12096.85 1651.38 12443.28 2022.02 
contra_RSPv2 11936.47 1570.72 12482.73 1943.63 
contra_RSPv3 11704.29 1424.65 12338.62 1825.88 
contra_RSPv5 11148.74 1339.23 11862.18 1715.51 
contra_RSPv6a 10792.93 1186.03 11495.24 1744.99 
contra_RSPv6b 10002.12 1219.14 10763.44 1760.38 
contra_SSp-bfd 11716.17 1668.33 12465.61 1625.36 
contra_SSp-
bfd1 11589.46 1885.30 11981.35 1685.67 
contra_SSp-
bfd3 11765.15 1744.80 12451.90 1607.19 
contra_SSp-
bfd4 12031.24 1789.14 12887.84 1748.52 
contra_SSp-
bfd5 11693.27 1604.52 12606.49 1681.59 
contra_SSp-
bfd6a 11804.92 1614.65 12544.31 1654.73 
contra_SSp-
bfd6b 10316.84 1416.89 11036.15 1358.53 
contra_SSP-tr 11703.19 1769.98 12407.97 1593.93 
contra_SSp-tr1 11822.35 2130.28 12272.86 1396.12 
contra_SSp-tr3 11933.43 1979.99 12652.63 1651.29 
contra_SSp-tr4 11773.70 1757.98 12443.66 1643.86 
contra_SSp-tr5 11530.58 1577.20 12398.97 1659.30 
contra_SSp-
tr6a 11578.14 1570.27 12335.19 1601.25 
contra_SSp-
tr6b 10279.00 1192.66 11109.16 1421.46 
contra_TEa 13000.42 2195.83 13716.53 2406.13 
contra_TEa1 12863.42 2601.03 13630.60 3118.81 
contra_TEa3 13415.69 2389.78 13847.85 2613.18 
contra_TEa4 13184.37 2212.37 13961.78 2398.71 
contra_TEa5 12863.87 2076.67 13805.13 2391.94 
contra_TEa6a 12679.56 2038.74 13772.77 2333.84 
contra_TEa6b 11213.72 1822.84 12381.68 1994.94 
contra_th 13049.53 1554.33 13898.85 2353.80 
ips_amgmed 11390.67 1842.22 12700.15 2274.92 
ips_AUDd 12045.50 2161.93 12968.53 2145.85 
ips_AUDd1 11757.47 2287.86 12707.29 2266.69 
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ips_AUDd3 12183.61 2169.11 13352.41 2271.67 
ips_AUDd4 12187.17 2278.94 13082.04 2190.15 
ips_AUDd5 12002.22 2172.42 12759.29 2030.79 
ips_AUDd6a 12146.60 2272.38 12745.50 2057.07 
ips_AUDd6b 10586.76 1816.47 11482.27 1848.00 
ips_AUDp 12243.82 2129.31 13033.07 2022.69 
ips_AUDp1 12097.39 2100.51 12671.33 1899.05 
ips_AUDp3 12533.82 2174.38 13399.78 2196.69 
ips_AUDp4 12307.18 2066.44 13183.54 2148.24 
ips_AUDp5 12089.42 2080.04 12875.08 2035.81 
ips_AUDp6a 12177.34 2280.13 12896.16 1983.62 
ips_AUDp6b 10159.09 1865.45 11096.08 1338.63 
ips_AUDv 12152.37 2083.33 13144.23 2023.20 
ips_AUDv1 11791.07 2267.89 12830.11 2106.41 
ips_AUDv3 12273.04 2097.80 13455.45 2122.62 
ips_AUDv4 12367.28 1991.64 13327.70 2095.00 
ips_AUDv5 12238.76 2043.99 13145.91 2033.47 
ips_AUDv6a 12115.83 2115.66 13024.87 1989.63 
ips_AUDv6b 10467.35 1822.53 11265.99 1649.48 
ips_BLAa 13885.35 2519.07 15289.66 2665.71 
ips_BLAp 14077.62 2582.03 15683.66 2738.33 
ips_BLAv 12640.73 2603.84 14552.96 2556.44 
ips_BMAp 12368.21 2520.26 14206.07 2679.19 
ips_CA1slm 12621.89 1345.05 13125.58 2126.78 
ips_CA1so 13653.28 1545.13 13909.25 1802.18 
ips_CA1sp 12453.17 1271.49 12689.06 1650.05 
ips_CA1sr 14705.78 1556.81 15049.96 2061.55 
ips_CA2slm 13902.01 1903.42 14431.59 2158.30 
ips_CA2so 16493.17 2700.28 16483.65 2251.63 
ips_CA2sp 12626.39 1696.63 12921.78 1235.77 
ips_CA2sr 14957.59 2162.26 15291.67 2156.09 
ips_CA3slm 13183.40 1684.79 13540.06 1824.52 
ips_CA3slu 11322.05 1374.53 11778.44 1742.73 
ips_CA3so 11588.72 1474.19 12047.02 1618.20 
ips_CA3sp 10871.70 1104.86 11294.32 1395.47 
ips_CA3sr 12958.62 1601.34 13480.97 1811.83 
ips_CC 7054.24 430.42 6826.42 423.86 
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ips_cing 8479.67 761.02 8486.49 1334.15 
ips_COApl 11959.51 2189.62 14282.62 3083.39 
ips_COApl1 11338.15 2046.12 13666.31 2805.12 
ips_COApl2 12250.89 2300.61 14719.18 3342.95 
ips_COApl3 12038.11 2223.85 14245.08 3136.86 
ips_cortex 11633.63 1712.33 12485.90 1949.25 
ips_CP 10846.04 1680.07 11699.16 1743.89 
ips_cpd 6669.41 470.21 6529.83 808.26 
ips_DG 18915.63 2094.70 19329.05 2904.51 
ips_DGinf 18528.86 2090.66 18943.05 2706.78 
ips_DGpo 11953.43 954.53 12544.66 1542.54 
ips_DGsg 13675.51 883.18 14132.85 1613.45 
ips_DGsup 19164.80 2088.27 19564.46 3034.79 
ips_ECT 12479.77 2050.76 13767.11 1863.91 
ips_ECT1 11913.34 2125.69 13412.68 1495.09 
ips_ECT3 12588.14 2094.40 13984.95 1873.59 
ips_ECT5 12635.67 2060.94 13898.18 2045.97 
ips_ECT6a 12516.49 2193.75 13668.31 2184.81 
ips_ECT6b 11199.92 2007.16 12037.01 1774.73 
ips_ENTI 13463.17 2299.53 15005.12 2333.75 
ips_ENTl1 13041.97 2124.65 14649.88 2133.45 
ips_ENTl3 13845.60 2412.79 15678.60 2648.63 
ips_ENTl5 13676.82 2437.53 14953.63 2405.91 
ips_ENTl6a 12682.60 2457.87 13937.96 2417.34 
ips_ENTl6b 11514.29 2179.80 12814.55 2034.91 
ips_FC 14172.34 1763.70 15480.05 2720.53 
ips_hip 13895.91 1537.59 14285.23 1947.32 
ips_hyp 10265.28 1506.43 11255.93 1959.17 
ips_LA 12631.56 2235.22 13873.35 2469.93 
ips_lay1 11601.71 1653.49 12384.10 1731.29 
ips_lay2 11640.25 1369.80 12410.50 2035.31 
ips_lay3 11757.69 1777.56 12736.20 1966.03 
ips_lay4 11933.99 1935.63 12785.83 2079.09 
ips_lay5 11622.61 1686.75 12437.76 1957.14 
ips_lay6a 11518.38 1660.31 12277.69 2042.38 
ips_lay6b 10267.69 1382.60 10876.72 1747.61 
ips_MOp 11279.17 1387.99 11920.81 1851.70 
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ips_MOp1 11305.89 1642.73 12055.00 2160.49 
ips_MOp3 11417.97 1466.99 12122.10 1799.08 
ips_MOp5 11371.35 1421.62 11984.25 1920.68 
ips_MOp6a 11141.36 1273.69 11566.64 1899.04 
ips_MOp6b 10184.86 1075.84 10428.47 1696.02 
ips_MOs 10905.40 1388.05 11690.19 1796.23 
ips_MOs1 11445.95 1744.57 11896.96 1677.93 
ips_MOs3 11158.39 1617.26 12198.57 1923.66 
ips_MOs5 10802.99 1289.32 11555.52 1846.82 
ips_MOs6a 10565.65 1126.12 10942.93 1786.82 
ips_MOs6b 9791.72 910.70 10107.86 1670.47 
ips_PAA 12299.94 2798.00 14415.91 3577.51 
ips_PAA1 11373.22 2859.25 13654.63 3759.98 
ips_PAA2 12771.04 3049.19 14829.69 3901.29 
ips_PAA3 12527.72 2644.88 14433.44 3172.07 
ips_PERI 12771.99 2001.85 14328.97 2198.16 
ips_PERI1 12135.89 1885.21 13986.91 2249.32 
ips_PERI3 12993.59 2087.75 14745.75 2469.63 
ips_PERI5 13083.95 2164.80 14517.04 2254.17 
ips_PERI6a 12564.98 2156.42 13773.95 2108.58 
ips_PERI6b 11241.24 2123.06 12544.61 1955.76 
ips_PIR 13004.13 2341.10 14742.23 2571.46 
ips_PIR1 12607.04 2257.90 14481.88 2640.71 
ips_PIR2 13287.43 2235.47 15176.43 2712.13 
ips_PIR3 13021.99 2433.17 14674.98 2553.06 
ips_RSPd 11142.18 1419.92 12186.58 1927.44 
ips_RSPd1 11580.02 1658.09 12729.99 1960.74 
ips_RSPd3 11336.48 1535.28 12551.44 1943.76 
ips_RSPd5 10855.76 1292.73 11726.12 1847.07 
ips_RSPd6a 10715.04 1142.51 11498.24 1930.01 
ips_RSPd6b 9920.94 891.74 10610.97 1903.41 
ips_RSPv 11415.28 1330.08 12102.35 1929.70 
ips_RSPv1 11855.72 1473.07 12305.73 1965.27 
ips_RSPv2 11651.33 1378.44 12405.19 2027.65 
ips_RSPv3 11542.24 1361.90 12288.94 1938.09 
ips_RSPv5 10937.27 1252.76 11703.14 1785.91 
ips_RSPv6a 10633.31 1151.09 11332.34 1933.90 
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ips_RSPv6b 9976.79 1219.63 10399.96 2037.34 
ips_SSp-bfd 11671.56 2021.72 12648.20 2147.13 
ips_SSp-bfd1 11241.20 1816.14 12521.66 2166.43 
ips_SSp-bfd3 11674.34 2031.16 12916.76 2264.58 
ips_SSp-bfd4 11997.81 2139.93 12984.71 2263.90 
ips_SSp-bfd5 11757.94 2091.54 12530.90 2043.90 
ips_SSp-bfd6a 11771.54 2057.31 12455.10 2088.33 
ips_SSp-bfd6b 10348.51 1545.91 11071.02 1907.84 
ips_SSp-tr 11294.44 1545.64 11868.45 1881.25 
ips_SSp-tr1 11548.56 1570.53 11871.84 1736.79 
ips_SSp-tr3 11388.06 1697.18 11977.84 1938.87 
ips_SSp-tr4 11452.22 1614.89 11978.22 1964.14 
ips_SSp-tr5 11289.04 1501.16 11920.61 1851.38 
ips_SSp-tr6a 11180.88 1449.71 11738.44 1940.27 
ips_SSp-tr6b 9933.66 1129.88 10326.82 1728.68 
ips_TEa 12222.51 2118.51 13451.77 1852.11 
ips_TEa1 11800.08 2218.85 13288.13 1681.21 
ips_TEa3 12286.52 2209.67 13606.16 1799.78 
ips_TEa4 12565.65 2077.21 13719.38 2007.95 
ips_TEa5 12399.17 2065.92 13546.12 2049.44 
ips_TEa6a 12253.12 2120.64 13334.19 2022.40 
ips_TEa6b 10776.75 1713.99 11525.00 1708.82 
ips_th 12971.74 1505.91 13665.45 2305.78 
 
 
